
<html lang="en"     class="pb-page"  data-request-id="ca38de35-e657-4ea6-b89d-7e1ac90b0dad"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.0c01530;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-1;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Peptide–Drug Conjugates with Different Linkers for Cancer Therapy" /></meta><meta name="dc.Creator" content="Mona  Alas" /></meta><meta name="dc.Creator" content="Azam  Saghaeidehkordi" /></meta><meta name="dc.Creator" content="Kamaljit  Kaur" /></meta><meta name="dc.Description" content="Drug conjugates are chemotherapeutic or cytotoxic agents covalently linked to targeting ligands such as an antibody or a peptide via a linker. While antibody–drug conjugates (ADCs) are now clinical..." /></meta><meta name="Description" content="Drug conjugates are chemotherapeutic or cytotoxic agents covalently linked to targeting ligands such as an antibody or a peptide via a linker. While antibody–drug conjugates (ADCs) are now clinical..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 31, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01530" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01530" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01530" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01530" /></link>
        
    
    

<title>Peptide–Drug Conjugates with Different Linkers for Cancer Therapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01530" /></meta><meta property="og:title" content="Peptide–Drug Conjugates with Different Linkers for Cancer Therapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0013.jpeg" /></meta><meta property="og:description" content="Drug conjugates are chemotherapeutic or cytotoxic agents covalently linked to targeting ligands such as an antibody or a peptide via a linker. While antibody–drug conjugates (ADCs) are now clinically established for cancer therapy, peptide–drug conjugates (PDCs) are gaining recognition as a new modality for targeted drug delivery with improved efficacy and reduced side effects for cancer treatment. The linker in a drug conjugate plays a key role in the circulation time of the conjugate and release of the drug for full activity at the target site. Herein, we highlight the main linker chemistries utilized in the design of PDCs and discuss representative examples of PDCs with different linker chemistries with the related outcome in cell and animal studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01530"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01530">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01530&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01530&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01530&amp;href=/doi/10.1021/acs.jmedchem.0c01530" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 216-232</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01507" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01627" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Peptide–Drug Conjugates with Different Linkers for Cancer Therapy</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Mona Alas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mona Alas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, California 92618-1908, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mona++Alas">Mona Alas</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Azam Saghaeidehkordi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Azam Saghaeidehkordi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, California 92618-1908, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Azam++Saghaeidehkordi">Azam Saghaeidehkordi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Kamaljit Kaur</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kamaljit Kaur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, California 92618-1908, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 714-516-5494; Email: <a href="/cdn-cgi/l/email-protection#395252584c4b795a515849545857175c5d4c"><span class="__cf_email__" data-cfemail="dcb7b7bda9ae9cbfb4bdacb1bdb2f2b9b8a9">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kamaljit++Kaur">Kamaljit Kaur</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8190-5658" title="Orcid link">http://orcid.org/0000-0002-8190-5658</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01530&amp;href=/doi/10.1021%2Facs.jmedchem.0c01530" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 216–232</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 31, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 September 2020</li><li><span class="item_label"><b>Published</b> online</span>31 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01530" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01530</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D216%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMona%2BAlas%252C%2BAzam%2BSaghaeidehkordi%252C%2BKamaljit%2BKaur%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D1%26contentID%3Dacs.jmedchem.0c01530%26title%3DPeptide%25E2%2580%2593Drug%2BConjugates%2Bwith%2BDifferent%2BLinkers%2Bfor%2BCancer%2BTherapy%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D232%26publicationDate%3DJanuary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01530"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3786</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01530" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Peptide–Drug Conjugates with Different Linkers for Cancer Therapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mona&quot;,&quot;last_name&quot;:&quot;Alas&quot;},{&quot;first_name&quot;:&quot;Azam&quot;,&quot;last_name&quot;:&quot;Saghaeidehkordi&quot;},{&quot;first_name&quot;:&quot;Kamaljit&quot;,&quot;last_name&quot;:&quot;Kaur&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;216-232&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01530&quot;},&quot;abstract&quot;:&quot;Drug conjugates are chemotherapeutic or cytotoxic agents covalently linked to targeting ligands such as an antibody or a peptide via a linker. While antibody–drug conjugates (ADCs) are now clinically established for cancer therapy, peptide–drug conjugates (PDCs) are gaining recognition as a new modality for targeted drug delivery with improved efficacy and reduced side effects for cancer treatment. The linker in a drug conjugate plays a key role in the circulation time of the conjugate and release of the drug for full activity at the target site. Herein, we highlight the main linker chemistries utilized in the design of PDCs and discuss representative examples of PDCs with different linker chemistries with the related outcome in cell and animal studies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01530&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01530" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01530&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01530" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01530&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01530" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01530&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01530&amp;href=/doi/10.1021/acs.jmedchem.0c01530" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01530" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01530" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01530%26sid%3Dliteratum%253Aachs%26pmid%3D33382619%26genre%3Darticle%26aulast%3DAlas%26date%3D2021%26atitle%3DPeptide%25E2%2580%2593Drug%2BConjugates%2Bwith%2BDifferent%2BLinkers%2Bfor%2BCancer%2BTherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D1%26spage%3D216%26epage%3D232%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/jmcmar.2021.64.issue-1/20210114/jmcmar.2021.64.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Drug conjugates are chemotherapeutic or cytotoxic agents covalently linked to targeting ligands such as an antibody or a peptide via a linker. While antibody–drug conjugates (ADCs) are now clinically established for cancer therapy, peptide–drug conjugates (PDCs) are gaining recognition as a new modality for targeted drug delivery with improved efficacy and reduced side effects for cancer treatment. The linker in a drug conjugate plays a key role in the circulation time of the conjugate and release of the drug for full activity at the target site. Herein, we highlight the main linker chemistries utilized in the design of PDCs and discuss representative examples of PDCs with different linker chemistries with the related outcome in cell and animal studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Conventional chemotherapy is still a major way to treat many cancers.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Chemotherapeutics (CTs) such as doxorubicin, paclitaxel, gemcitabine, and camptothecin are highly potent agents that utilize different mechanisms to display cytotoxicity. The toxicity, however, is nonspecific, leading to reduced efficacy. Different strategies are used to increase the therapeutic efficacy of CT agents and reduce their toxic side effects during cancer treatment. One popular strategy involves the use of targeting ligands for the delivery of CT agents (or the cytotoxic payload/drug) to the cancer site, sparing nonmalignant cells and tissues.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Active targeting using a ligand allows a higher concentration of the drug to reach the tumor by targeting a specific cell-surface receptor or biomarker at the tumor site. The targeting ligands, such as antibodies or peptides, can be covalently conjugated to the drug or to the surface of a drug carrier system like liposomes, micelles, etc. for site-specific delivery. The covalent conjugation of an antibody or a peptide to a drug via a linker gives an antibody–drug conjugate (ADC) or a peptide–drug conjugate (PDC). Both ADC and PDC are promising therapeutic modalities that are rapidly emerging for cancer treatment.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3−7)</a> As of now, at least eight ADCs have been FDA approved to treat various cancers, highlighting the potential of upcoming ADCs and PDCs that are currently in clinical or preclinical stages.<a onclick="showRef(event, 'ref3 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref3 ref8 ref9 ref10">(3,8−10)</a></div><div class="NLM_p">There are a few key differences between an ADC and a PDC. First, the size of an antibody is much larger than the size of a peptide. An antibody (IgG) is typically >1000 amino acids (∼150 kDa), whereas a peptide used for cancer cell targeting ranges from 5 to 25 amino acids in length.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The large size of the antibody and the resulting ADC leads to differences such as uptake by the cells, plasma half-life, immunogenicity, manufacturing costs, and stability. Second, the conjugation of an antibody to a drug via a linker leads to heterogeneous mixtures where the site of conjugation and the number of conjugated drugs per antibody molecule vary. ADCs typically contain final products where the drug to antibody ratio ranges between 3 and 8.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> This can cause batch-to-batch variation, and the exact characterization of species present in the dosage can be tedious leading to complex pharmacokinetics (PK) after systemic administration. PDCs being small in size, ranging in molecular weight 2–5 kDa, can be easily synthesized as single homogeneous entities that are well-characterized for precise large-scale production and can provide improved PK. An additional benefit of small-sized PDCs is their ability to cross the BBB as several cancer types tend to metastasize to the brain. Another difference is the high specificity of an antibody toward the target protein/receptor compared to a smaller peptide.</div><div class="NLM_p">The goal of both the ADC and PDC is to increase the efficacy of the CT agent and overcome the challenges of short circulation half-life and off-target side effects of the CT agent. ADCs have been extensively reviewed elsewhere; therefore, they will be briefly touched upon here.<a onclick="showRef(event, 'ref3 ref5 ref9 ref10 ref13'); return false;" href="javascript:void(0);" class="ref ref3 ref5 ref9 ref10 ref13">(3,5,9,10,13)</a> The three main components of a conjugate are the targeting ligand, cytotoxic drug, and the linker. The targeting ligand or the peptide in a PDC must be highly specific, which leads to receptor-mediated endocytosis of the conjugate by the target cells only. The use of a highly toxic drug, such as maytansine, camptothecin derivatives, auristatin, or doxorubicin with IC<sub>50</sub> values in the subnanomolar range, is recommended in the conjugates. Finally, the linker chemistry is selected to allow sufficient circulation time for the conjugate to reach its target cell. Overall, the PDC should be stable enough so that the peptide, linker, and the drug do not get cleaved or metabolized before reaching the target cell, and sufficient concentration of the PDC reaches the target cell to increase the efficacy of the drug for tumor killing.</div><div class="NLM_p">A perfect linker would release the drug only after intracellular uptake of the conjugate by the cancer cells for selective killing. However, most linkers start getting cleaved the moment they are in the system (upon systemic administration of the PDC), starting with the plasma (blood) and followed by the extracellular milieu of cancer cells. Whatever remains (intact PDC) is then taken up by the cancer cells for the drug’s intracellular delivery. During the synthesis of a drug conjugate, the linker makes two chemical bonds, one between the peptide and the linker and the second between the drug and the linker (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). When the conjugate is administered systemically, one of these bonds is generally more susceptible to cleavage, or there could be a third bond (functional group) present in the linker that may lead to peptide drug separation. Ideally, the bond between the drug and the linker should be cleaved to release the unmodified drug at the target site. Also, the bond between the peptide and linker should not influence the affinity of the peptide for its receptor. The common functional groups that are found in the linker region can be broadly divided into four groups: enzyme cleavable (ester, amide, and carbamate), acid cleavable (hydrazone and carbonate), reducible disulfide, and noncleavable (thioether, oxime, and triazole) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). This classification is based on how these functional groups behave after cellular uptake or under in vivo conditions. The linker chemistry plays a major role in the success of a PDC for improving efficacy. This review aims to provide an overview of the linker chemistries used in the design and development of PDCs and the related outcomes in cell and animal studies. The PDCs discussed here are categorized by the bond between the drug and the linker. The lability of this bond is most important for the release of the unmodified drug.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic of a PDC. The chemical structures of different linker chemistries are shown with the plausible method of release of the drug from PDC after cellular uptake or under in vivo conditions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Enzyme Cleavable Linker Chemistries</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48382" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48382" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Enzyme cleavable ester or amide bonds have gained popularity as linkers because they can be designed for selective cleavage in the tumor microenvironment or in the lysosomes. The intracellular compartments like endosomes and lysosomes of cancer cells are rich in esterases and amidases, and upregulation of such enzymes is exploited for the targeted release of the CT inside the cancer cell. Simple ester or amide bonds or more specific amino acid sequences recognized by enzymes like cathepsin B and matrix metalloproteinases have been utilized as linkers. Carbamate linker that gets cleaved by a family of enzymes has also been utilized for PDC development.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> However, it is important to note that these linker chemistries are not infallible due to cleavage that occurs prior to reaching the target site. For instance, some cleavage and release of the drug can occur in plasma after systemic administration. Proper manipulation of the linker ensures the stability of much of the conjugate until it reaches the cancer site. The following representative PDCs that utilize ester, amide, or carbamate bond linkages to deliver the drug to the target cancer site highlight the potential of these linker chemistries.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Ester and Amide</h3><div class="NLM_p">A study conducted by Karampelas et al. utilized an ester bond to attach gemcitabine with a glutaryl linker, which is further attached to the peptide ([<span class="smallcaps smallerCapital">d</span>-Lys<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a>]-GnRH) via an amide bond (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The overall hypothesis was that the conjugate would be a suitable substrate for the targeted delivery of gemcitabine to tumor cells that overexpress gonadotropin-releasing hormone-receptor (GnRH-R) on the cell surface. This is because the peptide has a high affinity for the cell surface GnRH-R. Various conjugates varying in length of the linker (4 or 5 carbons utilizing succinyl or glutaryl moiety) and the conjugation site on the drug were synthesized and compared. The gemcitabine structure includes a primary 5′–OH and secondary 3′–OH, which enabled the conjugation of the targeting peptide at either functional group. Evaluation of the antiproliferative effect on two prostate cancer cell lines (DU145 and PC3) showed that the GSG conjugate (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) had the greatest potency and sustained gemcitabine levels and was chosen for subsequent analyses. GSG was characterized by the 4-carbon linker attached to the primary 5′–OH of gemcitabine. When tested in a GnRH-R positive prostate cancer xenograft animal model, mice treated with GSG showed a significant inhibitory effect on tumor growth when compared to control (saline) and equimolar doses of gemcitabine or the peptide alone. A much higher dose of gemcitabine (454.5 μmol/kg) was required to achieve similar tumor reduction efficacy when compared to the GSG dose of choice (18.8 μmol/kg). GSG was also associated with a “slow-down” of gemcitabine inactivation or formation of the inactive metabolite of gemcitabine, resulting in sustained levels of gemcitabine. However, the presence of high levels of gemcitabine following GSG administration in mice suggests that the conjugate was rapidly cleaved at the ester site releasing the free drug from the peptide-linker moiety. Overall, the GSG conjugate allowed higher and sustained levels of gemcitabine in blood for a longer time compared to the direct administration of gemcitabine in mice. The study concluded that the exact mechanism of action for efficacy was not fully determined; however, the conjugate with the ester/amide linkage proved beneficial in inhibiting the tumor growth in mice.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PDCs with an ester and/or an amide as linkers. The peptide is shown in red, the linker in blue, and the drug in black. <span class="smallcaps smallerCapital">d</span>-Amino acids are shown in lower case.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">You et al. developed a unique approach for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> A peptide fragment from the heavy chain 3 of the full-length antibody trastuzumab was obtained and termed AHNP. The 12-mer AHNP binds the extracellular domain of HER2 with high affinity and displays similar potency as trastuzumab. The peptide mimetic AHNP was then conjugated via an MMP-2 sensitive linker with doxorubicin (Dox) to form MAHNP-Dox conjugate essentially using ester/amide bonds (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Conjugate MAHNP-Dox was compared to Dox using HER2 positive breast cancer cell lines BT474 and SKBR3. Cellular toxicity analysis showed that MAHNP-Dox was more potent than free Dox, as indicated by lower IC<sub>50</sub> values for both cell lines. The BT474 and SKBR3 cell lines had an IC<sub>50</sub> of 746.8 ± 81.5 and 110.1 ± 12.7 nM for MAHNP-DOX and 2075.0 ± 368.0 and 172.9 ± 19.2 nM for Dox, respectively.</div><div class="NLM_p">The combination of MAHNP-Dox appeared to be more effective than either agent alone and was potentially synergistic. TUNEL assay was then used to determine the effects of MAHNP-Dox on apoptosis and DNA damage. BT474 and SKBR3 cells had a greater number of apoptotic cells after treatment with MAHNP-Dox compared to free Dox. Data also indicated that Dox is released from the peptide via a specific MMP-2 dependent mechanism but shared similar intracellular distribution to free Dox. The conjugate is mainly cleaved by the MMP-2, which is present in large amounts around tumor cells. In vivo studies were then carried out with the BT474 xenografted mice treated with MAHNP-Dox, free Dox, or saline. MAHP-Dox reduced tumor growth by 74.7 ± 5.1% on day 25 after treatment, whereas free Dox resulted in a reduction of 53.4 ± 6.6%. Tumor weight inhibition was also analyzed. Conjugate MAHNP-Dox treated mice resulted in significant tumor weight inhibition that was 45.4 ± 11.2% higher than free Dox, and the weight loss was less for MAHNP-Dox treated mice. In vivo results paralleled in vitro studies, with more apoptosis at the tumor site and reduced off-target effects associated with MAHNP-Dox administration. Lastly, drug concentration profiles in plasma portrayed that MAHNP-Dox had a longer half-life (17.6 h versus 7.7 h) and slower clearance than free Dox. This study exhibited that the unique hybrid of Dox, ANHP, and an MMP-2 cleavable linker produced a benefit over the use of Dox alone. The conjugate effectively targeted HER2-positive cancer with greater efficacy. The group aims to conduct toxicological and pharmacological studies in the future. Meanwhile, the current data suggest a strong therapeutic potential for the conjugate.</div><div class="NLM_p">We employed ester and amide bonds to synthesize PDCs (<b>3</b> and <b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) of Dox that showed promising in vitro results.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In conjugate <b>3</b>, the primary alcohol at position 14 of Dox was reacted with a glutaryl linker to form an ester, and the other end of the linker was attached to the lysine side chain of the peptide (18-4) via an amide bond. For conjugate <b>4</b>, the 3′ amino group of Dox was used to form an amide bond with a glutaryl linker, and the other linkage (amide) was the same as the conjugate <b>3</b>. The peptide 18-4 (WxEAAYQkFL) used here targets a novel receptor keratin 1 (K1) on the surface of breast cancer cells, and the peptide or PDC enter cells via endocytosis after K1 receptor binding.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Conjugate <b>3</b> had a short half-life in human serum (2 h), most likely due to fast hydrolysis of the ester bond. In contrast, conjugate <b>4</b> was relatively stable with a half-life of 48 h when incubated with human serum. The in vitro cell studies showed that conjugate <b>3</b> had higher uptake by the breast cancer cells and higher cytotoxicity (IC<sub>50</sub> 0.9–1.5 μM) compared to conjugate <b>4</b> (18.6–19.1 μM). While Dox was taken up by all cancer and noncancerous cells, the conjugates showed selective uptake by the cancer cells only. Also, the conjugates showed good uptake by the Dox-resistant cell line (MDA-MB-435R), where Dox showed minimal uptake. Both the conjugates showed low cytotoxicity to noncancerous cells (IC50 35–51 μM) and were toxic to Dox resistant cells (IC50 5.4 μM). While conjugate <b>3</b> (ester/amide) fared better than conjugate <b>4</b> (amide/amide) in the cell studies, it is not clear which conjugate will show better efficacy in mice with breast cancer xenografts when used systemically. Upon systemic administration (i.v.), Dox likely will be released quickly from conjugate <b>3</b> and, therefore, may display the same efficacy as free Dox (unconjugated Dox); however, this needs to be evaluated with in vivo experiments.</div><div class="NLM_p">Another study utilized ester/amide bonds to conjugate paclitaxel to a peptide (Angiopep-2) via a succinyl linker.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Here, three molecules of paclitaxel are covalently linked to a single peptide via the side chain of two lysine residues and an N-terminus amine of the peptide to give a peptide–drug conjugate ANG1005 (<b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Angiopep-2, a 19-mer peptide that targets low-density lipoprotein receptor-related protein 1 (LRP-1) and mediates transcytosis across the BBB, facilitates the uptake of the conjugate into the brain for the treatment of patients with solid tumor with brain metastases. The ester bond in the conjugate is cleaved by the esterases present in lysosomes releasing paclitaxel in the brain. ANG1005 was designed to overcome the main challenge of paclitaxel, which is low BBB permeability due to the multidrug resistance efflux pump P-glycoprotein (P-gp) expression in brain tumor cells. Brain uptake of the conjugate in mouse brains using direct perfusion with [<sup>125</sup>I]ANG1005 or [<sup>3</sup>H]paclitaxel showed that total brain uptake of the conjugate was 4.5-fold higher compared to free paclitaxel, and showed that the conjugate could bypass the P-gp system at the BBB when assessed with mdr1a-deficient mice. The in vivo antitumor activity of ANG1005 was investigated in brain tumor (U87 MG glioblastoma) and lung carcinoma tumor (NCI-H460) xenograft models (orthotopic and metastatic) in nude mice, which showed a significant increase in mice survival. In addition, the in vitro cytotoxicity studies with human tumor cell lines carrying glioblastoma, lung, and ovarian carcinoma confirmed that paclitaxel’s activity was maintained in the conjugate ANG1005 where the conjugate was up to 2–3 fold more cytotoxic (2–3 fold lower IC<sub>50</sub>) toward some cell lines compared to paclitaxel.</div><div class="NLM_p">ANG1005 has entered several clinical trials (phase I and phase II) in patients with metastatic brain cancers.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> Kumthekar et al. reported results of a phase 2 open-label study of ANG1005 in patients with brain metastases from breast cancer (BCBM) with or without leptomeningeal carcinomatosis (LC).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> ANG1005 showed significant activity against CNS tumors and improved symptoms with overall increased survival, especially in LC patients with HER2-positive and HER2-negative breast cancers.</div><div class="NLM_p">A conjugate of a radionuclide with peptide octreotide, called lutetium 177 DOTA-TATE (<b>6</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), was FDA approved in 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Conjugate <b>6</b> belongs to peptide receptor radionuclide therapy (PRRT) and is the first PDC to be FDA approved for cancer treatment.<a onclick="showRef(event, 'ref4 ref25'); return false;" href="javascript:void(0);" class="ref ref4 ref25">(4,25)</a> In conjugate <b>6</b>, the radionuclide lutetium 177 (<sup>177</sup>Lu) is chelated to DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and DOTA is covalently linked to tyrosine-3 octreotate (TATE) via an amide bond.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Octreotide, a somatostatin analogue, has a high affinity for somatostatin subtype 2 receptor. The conjugate enters the cells via somatostatin receptors that are expressed on the surface of GEP-NET cells, causing damage specifically to the somatostatin receptor-positive cells.</div><div class="NLM_p last">An ester or an amide linker needs to be manipulated to be cleaved within target cancer cells/tissue that have the specific proteases upregulated. There is currently not enough data that underlines what specific manipulations of ester–amide linkers will maximize the tumor reduction efficacy, stability, and patient outcomes. Nonetheless, several PDCs with ester/amide linkers have shown promising in vitro and in vivo results, along with the clinical approval of <sup>177</sup>Lu-dotatate to aid future clinical studies.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Carbamate</h3><div class="NLM_p">PDCs also utilize carbamate linker that gets cleaved in intracellular endosomes or lysosomes by the enzymatic conditions.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> Sun et al. designed several somatostatin receptor (SSTR) targeting conjugates using carbamate linker.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> They focused on targeting SSTR subtype 2 with a somatostatin analogue peptide. The best conjugate JF-10-81 (<b>7</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) showed potent antitumor and antiangiogenic activity. In vivo studies were performed in rats and mice bearing pancreatic CA20948 tumors, human SCLC NCI-H69 tumors, or human prostate PC-3 tumors. Conjugate <b>7</b> inhibited tumor growth in CA20948 and NCI-H69 tumors but not PC-3 tumors. Lack of inhibitory activity in the PC-3 tumors is attributed to an insignificant expression of SSTR2. This finding suggested that the conjugate requires tumor expression of SSTR2 for the drug to be internalized and efficacious. Conjugate <b>7</b> also resulted in less off-target toxicity than the cytotoxic agent alone. The stability and chemical characteristics of the carbamate linker were essential for the successful and targeted delivery of the cytotoxic agent. The cleavable linker assisted with drug delivery to the target site and appropriately released free camptothecin without jeopardizing receptor affinity or antitumor activity.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. PDCs with a carbamate linker. <span class="smallcaps smallerCapital">d</span>-Amino acids are shown in lower case.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Sayyad et al. explored the use of carbamate linker in the design of new derivatives of PDC <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The new PDCs <b>8</b> and <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) utilized the primary or secondary hydroxyls of the drug to attach to the lysine amino group of the peptide via a carbamate linkage. The authors found that the PDCs with the carbamate linker released the drug slowly compared to the PDCs with an ester linkage.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The direct comparison of the carbamate linker containing conjugates <b>8</b> and <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) with an ester containing conjugate (GSHG, similar to conjugate <b>1</b> in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) showed that <b>8</b> and <b>9</b> were less cytotoxic compared to the GSHG conjugate toward prostate cancer (DU145 and PC3) and breast cancer (MDA-MB-231 and MCF-7) cell lines. This is likely due to the slow release of gemcitabine from <b>8</b> and <b>9</b> conjugates. Whereas GSHG, which showed rapid release of the free drug when incubated with media (RPMI with 10% FBS and 1% P/S) or human serum, was found to be as cytotoxic as gemcitabine. Further, in vivo intraperitoneal injection of the conjugates in mice showed a higher concentration of the intact conjugate in blood for the mice injected with <b>8</b> and <b>9</b> compared to the mice injected with GSHG. Mice injected with GSHG showed higher levels of released drug gemcitabine, whereas those administered <b>8</b> and <b>9</b> had low levels of free drug. The study highlights the in vitro and in vivo stability of a carbamate compared to an ester linker; however, it is unclear which linker chemistry will lead to better efficacy for tumor reduction.</div><div class="NLM_p last">Kumar et al. synthesized peptide–paclitaxel conjugates with carbamate or carbonate linkers and a peptide (MuSSKYQ, Mu = morpholinocarbonyl protecting group) which gets selectively cleaved by prostate-specific antigen (PSA).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Evaluation of these PDCs revealed that the carbamate containing PDC was more stable compared to the PDC with a carbonate.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The PDC with a carbamate linker displayed appropriate stability for the specific release of the drug in the presence of PSA, thereby killing PSA-secreting CWR22Rv1 prostate cancer cells. Based on these and other studies, the order of in vivo linker stability from greatest to least is found to be as follows: amide > carbamate > ester > carbonate.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.3.  Dipeptide or Tripeptide</h3><div class="NLM_p">The bonds discussed above are cleaved by the enriched proteases in the lysosomes of cancer cells. To further facilitate the release of active drug from the PDC, specific dipeptide or tripeptide sequences have been employed. Liang et al. designed PDC <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) with a linker containing dipeptide (Val-Cit or VC) for specific cleavage by a carboxypeptidase, cathepsin B.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The dipeptide is conjugated to Dox via a para-aminobenzyl carbamate (PABC) spacer that undergoes spontaneous 1,6-elimination after the enzymatic cleavage of the C-terminal amide of citrulline. The dipeptide is conjugated to the cancer cell targeting cyclic RGD peptide via a noncleavable maleimide thioether. The linker chemistry used in PDC <b>10</b> with a dipeptide and thioether is similar to what is found in ADC brentuximab vedotin.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The dipeptide (VC) is cleaved by enzyme cathepsin B, which is present in excess in lysosomes of tumor cells. This is followed by further removal of the PABC spacer leading to site-specific drug release. The authors found that conjugate <b>10</b> displayed superior cellular uptake, cytotoxicity toward integrin αvβ3 overexpressing B16 cells, and in vivo efficacy in tumor carrying c57BL/6 mice compared to another PDC (<b>23</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) with a disulfide linker (discussed in <a class="ref internalNav" href="#sec4" aria-label="section 4">section 4</a>) highlighting the potential of a dipeptide linker (VC) containing PDC.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. PDCs with a dipeptide or tripeptide linker.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Another peptide sequence that is used for specific release of the drug at the tumor site is the Ala-Ala-Asn (AAN) tripeptide cleaved by enzyme legumain.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35−37)</a> Legumain is an asparaginyl endopeptidase reported to be overexpressed in tumor cells and microenvironment that specifically cleaves at the C-terminal of asparagine. Inhibition of legumain’s proteolytic activity and its catalytic property for prodrug activation is being utilized for developing cancer therapy. To employ the later approach for cancer therapy, Bajjuri et al. prepared several prodrugs with cytotoxic didesmethylauristatin E (DDAE) or monomethylauristatin E (MMAE) and AAN tripeptide where the drug is linked to the peptide via a carbamate or amide bond.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> There is no targeting peptide in these prodrugs, however, these prodrugs could be conjugated to a targeting peptide to enhance cancer specificity and prepare peptide–drug conjugates. Among different prodrugs that were evaluated, prodrug <b>11</b> (Pro-MMAE-2, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) was found to be most effective and mice treated with <b>11</b> (0.5 mg/kg) inhibited 4T1 breast cancer by 57% in comparison to mice treated with buffer alone.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Further, the prodrug showed no toxicity in contrast to the high mortality rate in MMAE treated mice.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.4.  Amide and a Noncleavable Thioether</h3><div class="NLM_p">Succinimidyl thioether gained a lot of attention in recent years after the approval of several ADCs that contain this functional group as part of the linker.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The succinimidyl thioether bond is rapidly formed by Michael addition of a thiol to the maleimide group, making it a popular choice for conjugating a peptide to a drug. The thioether is quoted as “noncleavable”, even though this bond is reversible and not very stable as the linker breaks over time.<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38−40)</a> Nonetheless, the drug is attached to the linker via a cleavable bond, like amide, to form the PDCs (<b>12</b> and <b>13</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), likely allowing the release of the unmodified drug in the lysosomes by the action of amidases. A similar succinimidyl thioether is also found in PDC <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) discussed above.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PDCs with an amide and a succinimidyl thioether as linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We synthesized a thioether containing PDC <b>12</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) using a bifunctional cross-linker sulfo-SMCC.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Dox was attached to the linker via an amide bond, whereas the thiolated breast cancer targeting peptide (18-4) was conjugated to the maleimide group of the linker to form the succinimidyl thioether bond. The conjugate showed a half-life of ∼18 h when incubated with human serum. It was found that the instability was mainly due to the retro-Michael reaction that gave back the thiolated peptide and the MCC-Dox (maleimide). The release of the thiolated peptide (peptide-SH) was confirmed by the presence of peptide dimer in the human serum aliquots, as observed by mass spectrometry. We also found that conjugate <b>12</b> was not very stable under acidic conditions (half-life 24 h).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> At pH 5, hydrolysis of the acetal group present in doxorubicin led to the loss of intact conjugate. The conjugate was highly cytotoxic toward TNBC cells, namely, MDA-MB-231 (IC<sub>50</sub> = 1.3 μM) and MDA-MB-468 (IC<sub>50</sub> = 4.7 μM), and showed much less toxicity toward noncancerous MCF-10A breast cells (IC<sub>50</sub> = 38.6 μM). The cytotoxicity of the conjugate was in the same range as free Dox (IC<sub>50</sub> range 0.4–1.5 μM), suggesting that the drug was released from the PDC inside the cells and/or the PDC itself was active.</div><div class="NLM_p">Liang et al.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> compared three PDCs containing Dox and cyclic RGD peptide (cRGDfC) linked via three different linkers. The linkers used were (i) dipeptide with thioether (RVCDOX or cRGDfC-VC-DOX or <b>10</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), (ii) a succinimidyl thioether (RSDOX or cRGDfC-S-DOX or <b>13</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), and (iii) a disulfide (RSSDOX or cRGDfC-SS-DOX or <b>23</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). The three conjugates self-assemble into nanoparticles in water with RSDOX forming the largest particles. The average diameters of RSDOX, RVCDOX, and RSSDOX were 384, 207, and 154 nm, respectively. The cellular uptake via receptor-mediated endocytosis was higher for the RVCDOX than the RSDOX and RSSDOX, which showed a similar presence by flow cytometry analysis. The colocalization with the lysosomes (using confocal microscopy) was highest for the RVCDOX followed by RSDOX and the least for RSSDOX. The cytotoxicity of the conjugates on integrin αvβ3 overexpressing B16 cells also followed the same order, RVCDOX > RSDOX > RSSDOX. RVCDOX likely released the free drug faster than the other two conjugates in the lysosomes due to the presence of dipeptide and PABC. RSDOX and RSSDOX could also release free Dox after the amide bond cleavage by amidases in lysosomes. The authors concluded that both RVCDOX and RSDOX delivered a higher concentration of DOX to cytoplasm which led to better efficacy for tumor inhibition in c57BL/6 mice tumor models compared to disulfide containing RSSDOX. The antitumor efficacy of treatment groups RVCDOX and RSDOX was 1.7–2-fold of the treatment group RSSDOX. Based on the reduction in tumor volumes and average tumor weight, the authors found that the order of efficacy was RVCDOX and RSDOX > DOX.HCl > RSSDOX.</div><div class="NLM_p">In 2014, three pharmaceutical companies reported on the instability of the ring-closed succinimidyl thioether linker, and showed that the opening of the thiosuccinimide ring could lead to a stable thioether conjugate (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38−40)</a> Lyon et al. from Seattle Genetics proposed the hydrolysis of the ring with a proximal amino group (primary amine), which acts as an intramolecular base catalyst, to yield ring-opened stable thioether.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Fontaine et al. from ProLynx reported that succinimidyl thioethers with electron-withdrawing N-substituents accelerated the ring-opening reaction leading to the stable ring-opened products with <i>t</i><sub>1/2</sub> of >2 years.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In addition, Tumey et al. from Pfizer reported a simple method for the ring-opening hydrolysis of the succinimidyl thioether using slightly basic conditions like buffer with pH 7.4–9.2 and leaving the reaction at 37–45 °C for 14–48 h.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The conjugates with succinimidyl thioether linker appear to perform well where stability is required for a shorter duration like 1–2 days; however, if prolonged circulation of the PDC is desired, a ring-opened stable thioether linker may be more desirable. While the stability of the thioether bond is an issue, the resulting thioether conjugates (ADCs) have progressed well into the clinics as the conjugates display a favorable pharmacokinetic profile.<a onclick="showRef(event, 'ref3 ref9'); return false;" href="javascript:void(0);" class="ref ref3 ref9">(3,9)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Peptide–drug conjugate with the ring closed succinimidyl thioether and ring-open stable thioether.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.5.  Ester and a Noncleavable Triazole</h3><div class="NLM_p">An azide–alkyne cycloaddition to form a triazole has been applied to link peptide with a drug in PDCs due to its ease and efficiency. Although triazole formation using click chemistry is chemically favorable, after systemic administration, this bond is not subjected to enzyme degradation. Therefore, the release of the drug from the peptide is likely due to the presence of other enzyme cleavable groups such as esters, amides, or other labile groups in the linker region.</div><div class="NLM_p">The group of Pellecchia utilized click chemistry to synthesize a number of erythropoietin-producing hepatocellular receptor A2 (EphA2)-targeting PDCs (<b>14</b>–<b>16</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> EphA2 is a protein from the receptor tyrosine kinase family that serves as a known target for cancer treatment due to its overexpression in tumors and low expression in healthy tissues.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Initially, the team synthesized two peptides, YSA and 123B9, and found that peptide 123B9 is more stable in plasma. The 123B9 peptide was shown to target the EphA2 receptor and simultaneously functioned as an agonist. Agonist activity toward the receptor resulted in the inhibition of several pathways and tumor suppression effect. The dimeric 123B9 was found to activate the receptor at several-fold lower concentration (down to 1 μM) compared to the monomeric 123B9. Next, the authors’ utilized triazole linker via click chemistry for synthesizing PDCs with the dimeric (123B9)<sub>2</sub>. As a result, the PDC (123B9)<sub>2</sub>–L2–paclitaxel (<b>14</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) was developed. Efficacy studies were conducted to determine whether the optimized EphA2-agonistic agent was able to retain binding and selectivity for EphA2 and activate intracellular receptors. Conjugate <b>14</b> was directly compared to Abraxane, which is an injectable albumin-bound formulation of paclitaxel used for the treatment of various cancers. The synthesized PDC (<b>14</b>) was superior to Abraxane in its ability to prevent lung metastases, as indicated by a 75% reduction of the gross lung-metastasis count, compared with that of Abraxane in an intracardiac breast-cancer metastasis model. Abraxane did not show success in the reduction of metastases in organs other than the lungs, whereas the PDC did. Additionally, conjugate <b>14</b> reduced the metastasis number and size through various mechanisms, such as targeting of primary tumor cells, diminishing CTCs, and causing an evident reduction in tumor vasculature, in comparison to Abraxane.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PDCs with an ester and a triazole as linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Conjugates <b>15</b> and <b>16</b> with an EphA2 targeting peptide (123B9 or YNH, respectively) linked to cytotoxic gemcitabine via ester and triazole bonds showed promising results in the treatment of pancreatic cancer.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Athymic mice carrying MIA PaCa-2-luc cells subcutaneous xenografts, when treated with either PBS, gemcitabine, or conjugate <b>15</b>, showed the greatest tumor growth inhibition in the conjugate treated mice. Similarly, an efficacy study with gemcitabine and conjugate <b>16</b> in mice showed that conjugate <b>16</b> led to significant more suppression in tumor growth compared to gemcitabine alone. The conjugates displayed no adverse side effects, the body weight was maintained in mice, and the median survival time of conjugate <b>16</b> treated mice was significantly longer than gemcitabine or untreated mice groups.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">3.  Acid Cleavable Linker Chemistries</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00757" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00757" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acid-sensitive linkers have been employed for the development of several PDCs.<a onclick="showRef(event, 'ref41 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref41 ref46 ref47 ref48">(41,46−48)</a> While linker chemistries like hydrazone have been utilized often, other acid-sensitive groups like acetal, ketal, and carbonate have been less studied.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> The acid-labile bonds get cleaved primarily in the acidic tumor microenvironment (pH 6.5–6.9) or in the acidic cellular compartments, endosomes (pH 5.5–6.2) and lysosomes (pH 4.5–5.0), of cancer cells releasing unmodified drug, while maintaining stability in blood circulation (pH 7.4).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Although the acid-sensitive linkers display good stability in buffer solutions (pH 7.4), the plasma stability has been variable for such linkers making it difficult to predict the clinical outcome of the conjugate. The following PDCs help understand some of the pros and cons of acid-sensitive linkers.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.1.  Hydrazone</h3><div class="NLM_p">Hydrazone is a popular acid-sensitive linker utilized in the design of several drug conjugates.<a onclick="showRef(event, 'ref41 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref41 ref46 ref47 ref48">(41,46−48)</a> The hydrolysis/stability of the hydrazone to give ketone and hydrazide can vary based on the original ketone from which the hydrazone is derived. The examples discussed here contain doxorubicin’s aliphatic C-13 ketone-derived hydrazone linkers. The cytotoxic agent doxorubicin is then released in the tumor microenvironment or after uptake inside the cellular compartments, like endosomes or lysosomes, of the target cancer cells. This allows specific targeting, thereby reducing the damage to healthy cells.</div><div class="NLM_p">To introduce an acid-sensitive hydrazone, most studies utilize the same linker as found in aldoxorubicin. Aldoxorubicin (<b>17</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) is a derivative of Dox where the 13-carbonyl group of Dox is substituted with a hydrazone or more specifically, an EMCH (N-ε-maleimidocaproic acid hydrazide) linker. When administered intravenously, aldoxorubicin reacts with endogenous albumin to form a protein-drug conjugate.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> The conjugate is formed by a covalent (thioether) bond between the maleimide of aldoxorubicin and exposed cysteine-34 (C34) thiol of the protein albumin (mol wt ∼66 kDa). The albumin–drug conjugate formed by aldoxorubicin allows for site-selective delivery of Dox to the tumor.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> This is because albumin, a major circulating protein in the blood (mM concentration), pertains to be a nutrition source for the growth of cancer cells and therefore tends to accumulate in tumors. When aldoxorubicin is administered systemically for cancer treatment, the albumin–aldoxorubicin conjugate formed in the blood allows the release of Dox by hydrolysis of the hydrazone linker, either intracellularly in the acidic environment of lysosomes/endosomes after uptake by tumor cells or extracellularly in the slightly acidic environment of tumor tissues. The clinical results indicated the ability to administer greater doses (3–4 times more) of Dox with minimal cardiotoxicity using aldoxorubicin. A disadvantage of aldoxorubicin is the possible reactions with cysteine and lysine of other proteins that can lead to off-site toxicities. Aldoxorubicin is currently in advanced phase clinical trials for the treatment of soft tissue sarcoma.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> Other investigations with aldoxorubicin include combination treatment with immunotherapy and early stage clinical trials for other cancers, including brain cancer.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Drug conjugates with a hydrazone bond as a linker.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In other examples of drug conjugates with hydrazone linkers (<b>18</b>–<b>20</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), the maleimide of aldoxorubicin is reacted with a targeting agent (e.g., peptide) to form a peptide–drug conjugate before systemic administration.<a onclick="showRef(event, 'ref41 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref41 ref46 ref47 ref48">(41,46−48)</a> These PDCs also contain the succinimidyl thioether linkage, however, the hydrazone bond is more labile than the thioether so it takes priority in releasing the drug from the conjugate for targeted activity. For instance, conjugate <b>18</b> consists of an aldoxorubicin molecule linked to a hybrid 24-mer peptide via both the hydrazone and the thioether linkages.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The N-terminal (HAIYPRH) of the peptide facilitates targeting tumor cells as it specifically binds to transferrin receptor (TfR) overexpressed in tumor cells leading to TfR-mediated endocytosis. While the C-terminal portion is an ERK peptide inhibitor. The N- and C-terminal peptides have a middle GGCG sequence, where the thiol of cysteine allows conjugation to the aldoxorubicin (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). In vitro studies supported the release of Dox from the rest of the conjugate in cells (likely in acidic endosomes or lysosomes) as it was found that the amount of Dox was significantly higher inside the whole cells for the conjugate <b>18</b> compared to the free Dox. In this experiment, MCF-7/ADR cells were incubated with conjugate <b>18</b> or free Dox, and the amount of Dox in whole cells was determined using HPLC. Efficacy studies in MCF-7/ADR tumor bearing mice showed that a group of mice treated with the conjugate <b>18</b> inhibited tumor growth (72.2 ± 4.6% inhibition) more significantly than mice treated with free Dox (45.7 ± 2.8% inhibition). The biodistribution of Dox was higher in the tumor of conjugate treated mice compared to the free Dox treated mice, further indicating the targeting and release of Dox from the conjugate in the tumor environment.</div><div class="NLM_p">We reported a PDC, peptide 18-4–aldoxorubicin conjugate (<b>19</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) for targeting Dox to triple-negative breast cancer (TNBC) cells.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Conjugate <b>19</b>, which consists of a breast cancer cell targeting peptide 18-4 and doxorubicin, was synthesized by reacting aldoxorubicin with an N-terminally thiolated peptide. Due to the presence of an acid-sensitive hydrazone linker, the conjugate was not stable in media and human serum. In DMEM/F12 media with HEPES, <b>19</b> was completely hydrolyzed in <3 h. The half-life in human serum was 6 h, and it was confirmed using mass spectrometry that the hydrazone linker was the susceptible linkage during these conditions. The conjugate, however, showed specific toxicity toward the TNBC cells with an IC<sub>50</sub> of 1.2–2.2 μM, almost the same as the free doxorubicin (IC<sub>50</sub> 0.4–1.5 μM). The PDC was about 9-times less cytotoxic to noncancerous breast tissue-derived MCF-10A cells (IC<sub>50</sub> 15.1 μM), whereas Dox was still highly toxic (IC<sub>50</sub> 0.24 μM). The in vitro cell studies suggest that the hydrazone linker played a major role in the activity of the conjugate, and the thioether linker added to the stability of the conjugate.</div><div class="NLM_p">The albumin binding approach is gaining recognition for the targeted delivery of chemotherapeutics. To develop an ex vivo approach for Dox delivery using albumin, Yousefpour et al. synthesized a PDC (<b>20</b> or <b>ABD-Dox</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) using aldoxorubicin and an albumin-binding peptide.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> An albumin-binding protein domain (ABD) consisting of 47 amino acid residues is designed. ABD strongly interacts with albumin by noncovalent binding in contrast to the aldoxorubicin that binds to albumin by a covalent thioether bond. The noncovalent interaction of the ABD peptide would facilitate easier dissociation of the ABD (or the ABD conjugate) for release into the tumor. ABD was synthesized with additional GGC repeats (four or eight) in the C-terminal. The reaction of ABD-(CGG)<sub>8</sub> with aldoxorubicin gave a mixture of conjugates with 3–4 Dox molecules per peptide, which were highly hydrophobic and insoluble under aqueous conditions. However, ABD-(CGG)<sub>4</sub> reacted with aldoxorubicin to give conjugates with 1–2 Dox molecules that were soluble in PBS at pH 7.4 and used for subsequent in vitro and in vivo experiments. The in vivo PK (via monitoring plasma Dox concentration) in BALB/c mice showed a plasma elimination half-life of 29.4 ± 0.8 h for ABD-Dox, whereas for free Dox it was only in the order of minutes. The biodistribution studies showed that the level of Dox in the tumor at 2, 24, and 72 h was significantly higher for the ABD-Dox treated mice compared to the free Dox treated mice. At 72 h, Dox in the tumor was found to be ≈120-fold greater for the ABD-Dox treated mice compared to the free Dox group. Overall, the results showed that ABD-Dox has better therapeutic efficacy compared to free Dox in both colon and pancreatic mice models, and treatment with ABD-Dox led to the complete disappearance of tumors in both cases. The albumin-binding approach of this study can be used for other anticancer drugs that have limited clinical applications due to poor pharmacokinetic properties such as short circulation half-life, and the use of hydrazone and thioether to attach the drug to the peptide proved to be beneficial.</div><div class="NLM_p last">Mollaev et al. reported a protein–Dox conjugate with an acid-sensitive hydrazone and a disulfide bond in the linker.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The protein used in the conjugate was the receptor-binding domain of human alpha-fetoprotein. The protein was linked to Dox via three functional groups. First, the C-13 ketone of Dox is modified into hydrazone, which is followed by a disulfide bond, and finally, the other end of the linker ends with an amide bond linking the protein (<b>21</b> or PDPH-DOX, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). A similar linker with a hydrazone and a disulfide can be found in approved ADCs gemtuxumab ozogamicin and inotuzumab ozogamicin.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The authors found that the conjugate shared almost equivalent cytotoxicity as unmodified or free Dox and overcame resistance to anthracycline resistant MCF7<sup>Adr</sup> cells. Conjugate was not toxic to the lymphocytes, whereas Dox was highly cytotoxic. The conjugate also fared well in the in vivo efficacy studies showing a substantial decrease in tumor volumes and higher percent survival for the conjugate treated mice versus Dox or PBS treated mice. It was concluded that the hydrolysis of hydrazone along with the thiol reductase activity in lysosomes expedited hydrazone and disulfide bond hydrolysis, and Dox release from the conjugate. The pharmacological profile of the conjugate suggested its potential in cases when the rapid release of anticancer agents is necessary in tumor tissue.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">4.  Reducible Disulfide Linker Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The rationale behind using a disulfide linker is that the excessive reductive environment in tumor cells leads to the release of the free drug at the cancer site. In general, the intracellular glutathione concentration is several-fold (∼1000) higher than the extracellular concentration. The glutathione concentration in cancer cells may be further augmented due to oxidative stress and hypoxia in the tumor microenvironment, facilitating the rapid release of the thiolated drug inside cancer cells.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p">Disulfide linker is utilized by BicycleTx Limited (Cambridge, UK) in the design of PDCs such as <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) for targeting EphA2 receptor that is highly expressed in several solid tumors.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The targeting peptides called Bicycles are developed by phage display screening while the bicycle peptide is attached to the bacteriophage, and the latter allows conjugation of the Bicycle to toxic payloads without affecting EphA2 receptor affinity. A Bicycle consists of a peptide with three thioether bonds between the peptide and a central scaffold, such as 1,3,5-tris(bromomethyl)benzene (TBMB) and 1,3,5-triacryoyl-1,3,5-triazinane (TATA). The thioether bonds provide the targeting peptide a constraint structure leading to high selectivity and nanomolar affinity for the EphA2 receptor. A Bicycle is linked to a cytotoxic mertansine (DM1) via a disulfide bond to obtain PDCs that release the drug inside the cancer cells. The conjugates with the Bicycle peptide showed potent antitumor activity with one undesirable property i.e. high liver uptake. Chemical optimization of the lead Bicycle peptide guided the design of a new Bicycle (BCY6099) with TATA scaffold and polar or charged unnatural amino acids, providing increased hydrophilic character. This led to the design of conjugate <b>22</b> with the new Bicycle peptide BCY6099. Evaluation of conjugate <b>22</b> in an HT-1080 xenograft mouse model displayed comparable efficacy to earlier conjugates. Complete regression of the tumor was observed in 2 weeks at a dose of 3 mg/kg, which was well tolerated. Overall, conjugate <b>22</b> displayed faster renal elimination and low biodistribution to the liver leading to reduced liver toxicity and improved therapeutic efficacy. Clinical evaluation of similar conjugates with BCY6099 Bicycle peptide is currently underway.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. PDCs with a disulfide as a linker.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Liang et al. designed several PDCs to compare different linkers with respect to the antitumor efficacy.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> PDC <b>23</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) was designed with a disulfide linker between Dox and cyclic RGD peptide and was found to release Dox slowly overtime with 39.2% drug released at 48 h. The drug release, however, was dramatically increased in the presence of DTT (50 mM) to almost completion (∼100%) in 48 h. PDC <b>23</b> was compared to PDC <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) containing a thioether linker. The drug release profile (22% in 48 h) of PDC <b>13</b> showed no significant change in the presence of DTT and the conjugate was found to be more stable than <b>23</b>. Furthermore, the cellular uptake, cytotoxicity, and in vivo efficacy were better for the PDC <b>13</b> with the thioether linker compared to the disulfide carrying PDC <b>23</b>.</div><div class="NLM_p">Li et al.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> designed a reduction-responsive peptide–drug conjugate (BP9a-SS-DOX) where a modified analogue of peptide BP9a with a sequence of CAHLHNRS was linked to Dox through disulfide linker to form BP9a-SS-DOX or PDC <b>24</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). The uptake studies showed that BP9a peptide analogue has a high affinity for transferrin receptors (TfR) that are overexpressed in HepG2 liver cancer cells; therefore, it can be used as a promising carrier for selective drug delivery. The disulfide bond between BP9a and Dox is cleaved by reduced glutathione (GSH) present in tumor cells to release Dox-SH. The conjugate showed good selectivity but low potency compared to free Dox. The use of disulfide linker in PDCs may continue, however, with the availability of other linkers that provide higher selectivity and in vivo efficacy the use of disulfide must be carefully implemented. For instance, disulfide in combination with hydrazone has been successfully used in two of the FDA approved ADCs.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Linker Chemistries of the ADCs Approved for Clinical Use</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th class="rowsep0" align="center">ADC</th><th class="rowsep0" align="center">linker chemistry</th><th class="rowsep0" align="center">year approved</th></tr></thead><tbody><tr valign="top" class="rowsep0"><td class="rowsep0" colspan="3" align="center">enzyme cleavable</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="left">brentuximab vedotin (Adcetris)</td><td class="rowsep0" align="left">carbamate, dipeptide, thioether</td><td class="rowsep0" align="left">2011</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="left">polatuzumab vedotin (Polivy)</td><td class="rowsep0" align="left">carbamate, dipeptide, thioether</td><td class="rowsep0" align="left">2019</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="left">enfortumab vedotin (Padcev)</td><td class="rowsep0" align="left">carbamate, dipeptide, thioether</td><td class="rowsep0" align="left">2019</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="left">trastuzumab deruxtecan (Enhertu)</td><td class="rowsep0" align="left">amide, tripeptide, thioether</td><td class="rowsep0" align="left">2019</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="left">trastuzumab emtansine (Kadcyla)</td><td class="rowsep0" align="left">thioether, amide</td><td class="rowsep0" align="left">2013</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" colspan="3" align="center">enzyme or acid cleavable/reducible disulfide</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="left">gemtuzumab ozogamicin (Mylotarg)</td><td class="rowsep0" align="left">disulfide, hydrazone, amide</td><td class="rowsep0" align="left">2000<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="left">inotuzumab ozogamicin (Besponza)</td><td class="rowsep0" align="left">disulfide, hydrazone, amide</td><td class="rowsep0" align="left">2017</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" colspan="3" align="center">acid cleavable</td></tr><tr valign="top"><td align="left">sacituzumab govitecan (Trodelvy)</td><td align="left">carbonate, triazole, thioether</td><td align="left">2020</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">It was taken off market in 2010 and reapproved in 2017.</p></div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">5.  Noncleavable Linker Chemistries</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25513" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25513" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Noncleavable linkers have been used for the synthesis of PDCs. Noncleavable chemistries such as succinimidyl thioether, oxime, and triazole have been employed for conjugating a chemotherapeutic drug to a targeting peptide. However, as mentioned earlier, there can be several functional groups present in the linker, such as group conjugating the drug to the linker, linker to the peptide and sometimes an additional functional group in the middle of the linker which may be cleavable. After systemic administration of a PDC, the most labile group is cleaved first, followed by other groups. This results in a mixture with different concentrations of the unmodified drug, drug with a portion of the linker, or drug with linker and amino acid(s) from the peptide. The advantage of the noncleavable linkers is that these likely do not cleave in the plasma unlike other linker chemistries, and prematurely release some drug in plasma before reaching the target cancer site.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">5.1.  Oxime</h3><div class="NLM_p">In a series of papers, Gabor Mezo and coauthors showed the potential of an oxime as a linker for the design of PDCs.<a onclick="showRef(event, 'ref61 ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref61 ref62 ref63 ref64">(61−64)</a> The group made several PDCs by introducing an oxime bond at the C-13 carbonyl of doxorubicin or daunorubicin (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) and evaluated in vitro and in vivo properties for targeted therapy of breast, colorectal, and pancreatic cancers. The authors found that the oxime bond was more stable compared to ester linkage for conjugating a drug to the targeting peptide, allowing longer circulation half-life. The drug is released after uptake by the cancer cells by the lysosomal enzymes. As oxime is a stable and noncleavable linker, the PDC is likely cleaved at the amide bond or at the peptide portion. Incubation of different conjugates, with a variety of linkers including oxime, with rat liver lysosomal homogenate and comparison of the released fragments showed that the oxime-linked conjugates do not release the free drug, whereas conjugates with the drug linked via ester or dipeptide bond release the free drug in addition to other fragments.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. PDCs with an oxime as a linker.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Fourteen oxime linked daunorubicin (Dau)–GnRH-III conjugates were prepared in which a variety of unnatural and <span class="smallcaps smallerCapital">d</span>-amino acids were used in the peptide sequence.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The peptides used were GnRH peptide derivatives to target the overexpressed GnRH receptors found in many cancers. All 14 Dau–GnRH-III conjugates showed activity against MCF-7 breast cancer cells (IC<sub>50</sub> 0.14–6.64 μM) as well as against HT-29 colon cancer cells (IC<sub>50</sub> 3.31–18.00 μM). The lead conjugates <b>25</b> and <b>26</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) showed stability in 90% human serum for at least 24 h. Ligand competition assay of <b>25</b> and <b>26</b> to GnRH receptors showed that both compounds have a high binding affinity for the GnRH receptors. The degradation of conjugates <b>25</b> and <b>26</b> was analyzed in rat liver lysosome homogenate, in which <b>26</b> showed higher stability compared to <b>25</b>. In general, oxime was found to be highly stable to chemical or enzymatic degradation.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> The conjugates got cleaved at the peptide portion, giving the drug with small peptide fragments attached as the smallest active metabolites. The cellular uptake of <b>26</b> was reported higher than <b>25</b> when treated with MCF-7 and HT-29 for 6 h via flow cytometry. Further, incubation of the MCF-7 breast cancer cells with <b>26</b> and observation of the cellular uptake of the PDC using confocal microscope images taken at different time intervals (5 s to 60 min) showed that in the first minute, Dau signal was present mainly in the cytosol and small vesicles. At 5 min, however, the Dau fluorescence was observed everywhere in the cell, including the nuclei, suggesting the drug reached its site of action within 5 min.</div><div class="NLM_p">Randelovic et al. continued this work and showed in vivo activity of conjugates <b>25</b> and <b>26</b> on breast and colorectal cancer bearing mice using orthotopic models 4T1 and MDA-MB-231 breast cancer and HT-29 colorectal cancer in BALB/s and SCID mice.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The results showed a significant tumor volume reduction as well as metastases inhibition effect with less toxic side effects such as weight and behavior of the animals compared to the free drug. The results of this study prove that GnRH-III–Dau conjugates <b>25</b> and <b>26</b> are promising candidates for targeted tumor therapy in breast and colon cancers.</div><div class="NLM_p">Next, oxime was used to construct PDCs for targeting Wnt/β-catenin pathway found to be hyperactivated in pancreatic cancers. The targeting peptide SKAAKN was conjugated to daunomycin via oxime linkage to prepare several PDCs.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> PDC <b>27</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), with a cathepsin B cleavable peptide (GFLG) inserted at the N-terminal of targeting peptide sequence and two drug molecules conjugated per peptide, was most efficient in uptake by PANC-1 cells and displayed high cytotoxicity. Incubation of <b>27</b> with lysosome homogenate led to the identification of several active Dau-containing metabolites with one or more amino acids while there was no detection of free Dau. In vivo evaluation in PANC-1 tumor bearing SCID male mice showed that tumor volume inhibition was significant for the conjugate <b>27</b> treated mice (17.5% for the dose of 2 mg/kg group and 39.9% for the dose of 10 mg/kg group) compared to the control group (treated with sterile water) on day 70. At the end of the study, on day 74, the tumor weights for the conjugate treated group was significantly lower (27.3% for the dose of 2 mg/kg group and 30.4% for the dose of 10 mg/kg group) than the control group. Mice treated with free Dau were terminated on day 28 due to significant weight loss (21%). Conjugate <b>27</b> was able to inhibit the tumor growth significantly even at the low dose of 2 mg/kg with minimal side effects, further highlighting the potential of conjugate <b>27</b>, with enzyme cleavable linker and higher drug to peptide ratio of 2, for pancreatic cancer treatment. The study indicated the influence of factors like cellular uptake and effective release of the active metabolite (active drug) on improved efficacy of PDCs.</div><div class="NLM_p last">Feni et al. utilized oxime to attach cytotoxic daunorubicin to the linker and additional chemistries like triazole and amide were utilized to put together an integrin targeting PDC (<b>28</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Briefly, an alkyne–azide click reaction was used to develop PDC <b>28</b> with an integrin-targeting cyclic diketopiperazine (DKP)-RGD peptide and a cell-penetrating peptide (CPP) to promote effective and targeted cellular uptake.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Integrins are found to be overexpressed on the surface of some tumor cells and thereby are an appropriate target for cancer drug delivery. Cyclic RGD peptide was conjugated to the CPP using azide PEG<sub>4</sub>-linker via click chemistry. The CPP termed sC18 included an additional four amino acids Gly-Phe-Leu-Gly (GFLG) attached to the side chain of lysine which were then conjugated to the drug daunorubicin via an oxime bond. As both oxime and triazole are noncleavable bonds, the tetrapeptide GFLG was inserted for facilitating cleavage by cathepsin B in the lysosomes for efficient drug release after cellular uptake. In addition, the linker also incorporates several amides which can be cleaved by lysosomal amidases. The affinity of <b>28</b> for tumor-associated integrin receptors, αvβ3 and αvβ5, was determined using an in vitro binding assay. The conjugate expressed good affinity, and further cytotoxicity studies with <b>28</b> revealed that although the conjugate was toxic (EC<sub>50</sub> range 2.7–11.0 μM) to all cell lines (U87, HT-29, and MCF-7), it was much less toxic than the free Dau. The conjugate showed no selectivity toward cells with higher expression of integrin α<sub>v</sub>β<sub>3</sub> (U87).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">5.2.  Triazole</h3><div class="NLM_p">As discussed above, several PDCs utilize the alkyne–azide click reaction for the facile linking of a drug to the peptide. The noncleavable triazole formed by the alkyne–azide reaction provides stability to the PDC structure, and other bonds in the linker region likely facilitate the release of the drug from the PDC after cellular uptake.</div><div class="NLM_p">An interesting example of a conjugate with a triazole linker is a PDC developed for cancer treatment using photodynamic therapy (PDT). PDT incorporates a photosensitizer, molecular oxygen, and appropriate light to produce reactive oxygen to destroy tumor cells. Zheng et al. explored two variables in the conjugate design for targeted PDT, i.e., linker length and number of peptides.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> The click reaction was used to synthesize silicon phthalocyanines axially substituted with cyclic peptide, cRGD (<b>29a</b>–<b>c</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Different ethylene glycol units (<i>n</i> = 2–4; named a–c, respectively) were utilized as a linker between silicon phthalocyanines and the peptides to obtain conjugates with varied lengths and properties. The silicon phthalocyanine that did not contain a peptide was used as a control. Intermediates were reacted to develop the final unsymmetric and symmetric product conjugates with either one or two peptide(s). Human colon carcinoma HT-29 cells and human breast adenocarcinoma MCF-7 cells were used for in vitro studies to evaluate the photodynamic activity of the products.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. PDCs with triazole linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Different cytotoxicities toward the two cell lines occurred with red light (λ > 610 nm). The compounds modified with oligomeric ethylene glycols (no peptide) had the highest potency and enhanced photocytotoxicity correlated with an increase of ethylene glycol chains (<i>n</i> = 3 > 2 > 1). In contrast, conjugates with cRGD moieties had reduced photocytotoxicity, likely due to hindrance and varying cellular uptake mechanisms, and these conjugates were selective. Compounds <b>29a</b>–<b>29c</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) had significantly different potency, which is likely due to the varying distances between the phthalocyanine and the peptide. Conjugate <b>29c</b> was most cytotoxic toward both the cell lines; however, conjugate <b>29b</b> was more selective with higher toxicity toward HT-29 compared to MCF-7. Further studies suggested that the uptake process of <b>29b</b> involved receptor-mediated endocytosis. In vivo studies were conducted to analyze the biodistribution of <b>29b</b> in KM mice with an H22 tumor, which has high integrin expression. Fluorescence images of mice injected with <b>29b</b> showed selective accumulation at the tumor site, and <b>29b</b> was seen to persist at the tumor site up to 24 h. At 24 h, mice were sacrificed, and the fluorescence from isolated organs showed that the tumor region had higher fluorescence (∼2-fold) than the liver and kidney. The two cRGD moieties seemed to attribute to the high specificity of <b>29b</b> toward H22 tumor and led to a reduction of tumor growth by approximately 75%. The study shows the potential of designing a PDC with a cancer cell targeting peptide to improve the outcome of PDT for cancer treatment. For PDT, it is not required that the drug be released free from the conjugate after cellular uptake, so in this case, the use of noncleavable linkers is appropriate.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">6.  Future Outlook and Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">With the current progress in PDC development and an enormous knowledge base from ADCs approved for clinical use,<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3−7)</a> it is just a matter of time until PDCs will prove to be a novel modality for cancer treatment. As addressed above, several factors influence the efficacy of drug conjugates, including the target receptor specificity, cellular uptake, half-life of the conjugate, release of an active drug or drug metabolite, and concentration of the drug at the target site. A higher concentration of drug at the cancer site has been achieved frequently with ADCs due to the inherent conjugation of several drug molecules at different sites on an antibody, and ADCs typically end up with a high drug-to-antibody ratio (DAR) of 3–8. This, however, leads to heterogeneous mixtures with differences in solubility, aggregation, and clearance. The use of high DAR is recommended for better efficacy, and this strategy is also utilized for PDCs as that can easily achieve homogeneity. PDCs such as <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) and <b>27</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) with drug-to-peptide ratios of 3 and 2, respectively, were found to be significantly more efficacious, delivering a higher concentration of the drug at the target site than PDCs with a drug-to-peptide ratio of 1.<a onclick="showRef(event, 'ref21 ref61'); return false;" href="javascript:void(0);" class="ref ref21 ref61">(21,61)</a></div><div class="NLM_p">The release of the active drug or the drug metabolite from the conjugate depends on the linker. All linker chemistries discussed above for the PDCs have been successful in the realm of ADCs.<a onclick="showRef(event, 'ref3 ref9'); return false;" href="javascript:void(0);" class="ref ref3 ref9">(3,9)</a> Based on the recent ADC approvals, however, it appears that enzyme cleavable linkers are more effective (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Noncleavable succinimidyl thioether proved to be useful as it is extensively used to conjugate the antibody to the linker via the thiol group present in the cysteine residues of the antibody, such as ADCs brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, and trastuzumab deruxtecan,<a onclick="showRef(event, 'ref68 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref68 ref69 ref70">(68−70)</a> and in acid/base cleavable ADC sacituzumab govitecan (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">12</a></a>). Trastuzumab emtansine is the only ADC where succinimidyl thioether is the main noncleavable linker; however, this ADC also has additional amide bonds in the linker region for possible cleavage by amidases. It has been postulated that trastuzumab emtansine likely undergoes proteolytic cleavage at the lysine residue from the antibody portion to give lysine–linker–drug as a major active metabolite after lysosomal degradation.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Further, Phillips et al. found that the trastuzumab emtansine displayed superior in vivo efficacy and PK properties compared to similar ADCs with disulfide bond linker when evaluated in HER2-positive breast cancer mice models.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Trastuzumab emtansine displayed favorable pharmacokinetic profile making all the way to the clinics. Several PDCs, such as <b>12</b> or <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), with the same linker chemistry as trastuzumab emtansine have thus been synthesized and are under development.<a onclick="showRef(event, 'ref34 ref41'); return false;" href="javascript:void(0);" class="ref ref34 ref41">(34,41)</a></div><figure id="fig13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0012.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of some approved ADCs with different linker chemistries. The antibody is shown in green, the linker in blue, and the drug in black.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Sacituzumab govitecan (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">12</a></a>) is the most recent ADC that came into clinics.<a onclick="showRef(event, 'ref8 ref72'); return false;" href="javascript:void(0);" class="ref ref8 ref72">(8,72)</a> It consists of a hydrolyzable carbonate linker that breaks under the acidic (low pH) conditions of lysosomes and the tumor microenvironment.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> Lysine is inserted in the linker region to prevent aggregation, and hydrophilic PEG facilitates the solubility of ADC. The less toxic SN-38 drug (e.g., compared to Dxd in trastuzumab deruxtecan) allowed the conjugation of up to eight SN-38 molecules per antibody for this ADC. A carbonate linker is less utilized in the design of PDCs. With the success of sacituzumab govitecan, we hope to see more use of this linker in the development of future PDCs.</div><div class="NLM_p last">In this review, chemical advances made in the linker technology for the development of PDCs are highlighted. Clues from the linker chemistries utilized for ADCs are helpful in the design and successful development of PDCs. Due to the simplicity of peptides compared to antibodies and the ease of possible reactions during PDC synthesis, it is envisioned that PDCs with other chemistries (not seen in ADCs) that give rise to different linkers and structures will be explored. The key role played by the linker chemistry in PDCs for enhancing efficacy, increasing circulation time, and lowering toxicity makes it worth exploring. Strategic implementation of linker functional groups will allow more PDCs to enter clinical trials and, eventually, clinics for cancer treatment and beyond.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01530" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58324" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58324" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kamaljit Kaur</span> - <span class="hlFld-Affiliation affiliation">Chapman
University School of Pharmacy (CUSP), Harry and Diane Rinker Health
Science Campus, Chapman University, Irvine, California 92618-1908, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8190-5658" title="Orcid link">http://orcid.org/0000-0002-8190-5658</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4c27272d393e0c2f242d3c212d2262292839"><span class="__cf_email__" data-cfemail="c0ababa1b5b280a3a8a1b0ada1aeeea5a4b5">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mona Alas</span> - <span class="hlFld-Affiliation affiliation">Chapman
University School of Pharmacy (CUSP), Harry and Diane Rinker Health
Science Campus, Chapman University, Irvine, California 92618-1908, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Azam Saghaeidehkordi</span> - <span class="hlFld-Affiliation affiliation">Chapman
University School of Pharmacy (CUSP), Harry and Diane Rinker Health
Science Campus, Chapman University, Irvine, California 92618-1908, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Mona Alas</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=BIO-d7e1616-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mona Alas</b> is a Pharm.D. student at the Chapman University School of Pharmacy (CUSP) anticipated to graduate in 2021. Before joining CUSP, she was accepted into the prepharmacy Freshman Early Assurance Program (FEAP) at Chapman University. She began her research during her prepharmacy days and continues to show her commitment to research by enrolling in a Capstone project while at CUSP. Her research interests have grown to include medicinal chemistry and the development of novel oncology therapeutics.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Azam Saghaeidehkordi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=BIO-d7e1621-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Azam Saghaeidehkordi</b> is a final year Ph.D. student at Chapman University School of Pharmacy. She also received her Master in pharmaceutical sciences from Chapman University (2018). Both her Master and Ph.D., under the supervision of Professor Kamaljit Kaur, focus on the development of peptide–drug conjugates for breast cancer treatment. Azam received her BS in pharmaceutical sciences from the University of California, Irvine, in 2015 and worked for a pharmaceutical company in diagnostic clinical trials for a year (2015–2016) before joining Chapman. Her interests remain in the areas of biomedical/clinical sciences and cancer treatment.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Kamaljit Kaur</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=BIO-d7e1626-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Kamaljit Kaur</b> is an Associate Professor of Targeted Drug Delivery and Biomedical Diagnostics at the Chapman University School of Pharmacy. She started her academic career in 2004 as an Assistant Professor of Medicinal Chemistry at the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta (Canada). She moved to Chapman University (United States) in 2014 to accept a part-time position as a Distinguished Chancellor Fellow and in 2015 as a full-time founding member of the CUSP faculty. Her education is from India and the United States with her B.Sc. (Chemistry Honors) from University of Delhi, M.Sc. (Organic Chemistry) from Indian Institute of Technology, Kanpur, and Ph.D. (Bioorganic Chemistry) from Case Western Reserve University, Cleveland, Ohio. Her lab combines organic and analytical chemistry methods with biology to engineer peptides for biomedical applications.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55218" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55218" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The National Cancer Institute of the National Institutes of Health (Award Number R15CA208656) supported this research.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–drug conjugate</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">CT</td><td class="NLM_def"><p class="first last">chemotherapeutic</p></td></tr><tr><td class="NLM_term">Dau</td><td class="NLM_def"><p class="first last">daunorubicin</p></td></tr><tr><td class="NLM_term">DDAE</td><td class="NLM_def"><p class="first last">didesmethylauristatin E</p></td></tr><tr><td class="NLM_term">DOTA</td><td class="NLM_def"><p class="first last">1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid</p></td></tr><tr><td class="NLM_term">Dox</td><td class="NLM_def"><p class="first last">doxorubicin</p></td></tr><tr><td class="NLM_term">EMCH</td><td class="NLM_def"><p class="first last">N-ε-maleimidocaproic acid hydrazide</p></td></tr><tr><td class="NLM_term">EphA2</td><td class="NLM_def"><p class="first last">erythropoietin-producing hepatocellular receptor A2</p></td></tr><tr><td class="NLM_term">GEP-NETs</td><td class="NLM_def"><p class="first last">gastroenteropancreatic neuroendocrine tumors</p></td></tr><tr><td class="NLM_term">GnRH-R</td><td class="NLM_def"><p class="first last">gonadotropin releasing hormone-receptor</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">i.v.</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">K1</td><td class="NLM_def"><p class="first last">keratin 1</p></td></tr><tr><td class="NLM_term">LC</td><td class="NLM_def"><p class="first last">leptomeningeal carcinomatosis</p></td></tr><tr><td class="NLM_term"><sup>177</sup>Lu</td><td class="NLM_def"><p class="first last">lutetium 177</p></td></tr><tr><td class="NLM_term">MMAE</td><td class="NLM_def"><p class="first last">monomethylauristatin E</p></td></tr><tr><td class="NLM_term">PABC</td><td class="NLM_def"><p class="first last">para-aminobenzyl carbamate</p></td></tr><tr><td class="NLM_term">PDC</td><td class="NLM_def"><p class="first last">peptide–drug conjugate</p></td></tr><tr><td class="NLM_term">PDT</td><td class="NLM_def"><p class="first last">photodynamic therapy</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">prostate-specific antigen</p></td></tr><tr><td class="NLM_term">TATE</td><td class="NLM_def"><p class="first last">tyrosine-3 octreotate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02275" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02275" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 73 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gotwals, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipolletta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremasco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quaratino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatos-Peyton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzzelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span> <span> </span><span class="NLM_article-title">Prospects for combining targeted and conventional cancer therapy with immunotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1038%2Fnrc.2017.17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=28338065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVWmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=286-301&issue=5&author=P.+Gotwalsauthor=S.+Cameronauthor=D.+Cipollettaauthor=V.+Cremascoauthor=A.+Crystalauthor=B.+Hewesauthor=B.+Muellerauthor=S.+Quaratinoauthor=C.+Sabatos-Peytonauthor=L.+Petruzzelliauthor=J.+A.+Engelmanauthor=G.+Dranoff&title=Prospects+for+combining+targeted+and+conventional+cancer+therapy+with+immunotherapy&doi=10.1038%2Fnrc.2017.17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for combining targeted and conventional cancer therapy with immunotherapy</span></div><div class="casAuthors">Gotwals, Philip; Cameron, Scott; Cipolletta, Daniela; Cremasco, Viviana; Crystal, Adam; Hewes, Becker; Mueller, Britta; Quaratino, Sonia; Sabatos-Peyton, Catherine; Petruzzelli, Lilli; Engelman, Jeffrey A.; Dranoff, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">286-301</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Over the past 25 years, research in cancer therapeutics has largely focused on two distinct lines of enquiry.  In one approach, efforts to understand the underlying cell-autonomous, genetic drivers of tumorigenesis have led to the development of clin. important targeted agents that result in profound, but often not durable, tumor responses in genetically defined patient populations.  In the second parallel approach, exploration of the mechanisms of protective tumor immunity has provided several therapeutic strategies - most notably the 'immune checkpoint' antibodies that reverse the neg. regulators of T cell function - that accomplish durable clin. responses in subsets of patients with various tumor types.  The integration of these potentially complementary research fields provides new opportunities to improve cancer treatments.  Targeted and immune-based therapies have already transformed the std.-of-care for several malignancies.  However, addnl. insights into the effects of targeted therapies, along with conventional chemotherapy and radiation therapy, on the induction of antitumor immunity will help to advance the design of combination strategies that increase the rate of complete and durable clin. response in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTA6tw3u75TrVg90H21EOLACvtfcHk0lhKtnIqdsPpkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVWmtro%253D&md5=19da4f27a87146e290e873de9c7a7739</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.17%26sid%3Dliteratum%253Aachs%26aulast%3DGotwals%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DS.%26aulast%3DCipolletta%26aufirst%3DD.%26aulast%3DCremasco%26aufirst%3DV.%26aulast%3DCrystal%26aufirst%3DA.%26aulast%3DHewes%26aufirst%3DB.%26aulast%3DMueller%26aufirst%3DB.%26aulast%3DQuaratino%26aufirst%3DS.%26aulast%3DSabatos-Peyton%26aufirst%3DC.%26aulast%3DPetruzzelli%26aufirst%3DL.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDranoff%26aufirst%3DG.%26atitle%3DProspects%2520for%2520combining%2520targeted%2520and%2520conventional%2520cancer%2520therapy%2520with%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26issue%3D5%26spage%3D286%26epage%3D301%26doi%3D10.1038%2Fnrc.2017.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrahari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholkar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinh, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khurana, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, D.</span></span> <span> </span><span class="NLM_article-title">Novel delivery approaches for cancer therapeutics</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>219</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2015.09.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.jconrel.2015.09.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=26456750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Kktr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2015&pages=248-268&author=A.+K.+Mitraauthor=V.+Agrahariauthor=A.+Mandalauthor=K.+Cholkarauthor=C.+Natarajanauthor=S.+Shahauthor=M.+Josephauthor=H.+M.+Trinhauthor=R.+Vaishyaauthor=X.+Yangauthor=Y.+Haoauthor=V.+Khuranaauthor=D.+Pal&title=Novel+delivery+approaches+for+cancer+therapeutics&doi=10.1016%2Fj.jconrel.2015.09.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Novel delivery approaches for cancer therapeutics</span></div><div class="casAuthors">Mitra, Ashim K.; Agrahari, Vibhuti; Mandal, Abhirup; Cholkar, Kishore; Natarajan, Chandramouli; Shah, Sujay; Joseph, Mary; Trinh, Hoang M.; Vaishya, Ravi; Yang, Xiaoyan; Hao, Yi; Khurana, Varun; Pal, Dhananjay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">248-268</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Currently, a majority of cancer treatment strategies are based on the removal of tumor mass mainly by surgery.  Chem. and phys. treatments such as chemo- and radiotherapies have also made a major contribution in inhibiting rapid growth of malignant cells.  Furthermore, these approaches are often combined to enhance therapeutic indexes.  It is widely known that surgery, chemo- and radiotherapy also inhibit normal cells growth.  In addn., these treatment modalities are assocd. with severe side effects and high toxicity which in turn lead to low quality of life.  This review encompasses novel strategies for more effective chemotherapeutic delivery aiming to generate better prognosis.  Currently, cancer treatment is a highly dynamic field and significant advances are being made in the development of novel cancer treatment strategies.  In contrast to conventional cancer therapeutics, novel approaches such as ligand or receptor based targeting, triggered release, intracellular drug targeting, gene delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-mediated drug delivery, have added new modalities for cancer treatment.  These approaches have led to selective detection of malignant cells leading to their eradication with minimal side effects.  Lowering, multi-drug resistance and involving influx transportation in targeted drug delivery to cancer cells can also contribute significantly in the therapeutic interventions in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmwohufBvUXbVg90H21EOLACvtfcHk0lgfm0ujymMgrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Kktr3M&md5=340b2ca39f6ac56d2e9ec763b2303163</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2015.09.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2015.09.067%26sid%3Dliteratum%253Aachs%26aulast%3DMitra%26aufirst%3DA.%2BK.%26aulast%3DAgrahari%26aufirst%3DV.%26aulast%3DMandal%26aufirst%3DA.%26aulast%3DCholkar%26aufirst%3DK.%26aulast%3DNatarajan%26aufirst%3DC.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DJoseph%26aufirst%3DM.%26aulast%3DTrinh%26aufirst%3DH.%2BM.%26aulast%3DVaishya%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DKhurana%26aufirst%3DV.%26aulast%3DPal%26aufirst%3DD.%26atitle%3DNovel%2520delivery%2520approaches%2520for%2520cancer%2520therapeutics%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2015%26volume%3D219%26spage%3D248%26epage%3D268%26doi%3D10.1016%2Fj.jconrel.2015.09.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chau, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeg, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates for cancer</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span> (<span class="NLM_issue">10200</span>),  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)31774-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2FS0140-6736%2819%2931774-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31478503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslSit73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=793-804&issue=10200&author=C.+H.+Chauauthor=P.+S.+Steegauthor=W.+D.+Figg&title=Antibody-drug+conjugates+for+cancer&doi=10.1016%2FS0140-6736%2819%2931774-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for cancer</span></div><div class="casAuthors">Chau, Cindy H.; Steeg, Patricia S.; Figg, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10200</span>),
    <span class="NLM_cas:pages">793-804</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chem. linker.  The ADC is designed to selectively deliver the ultratoxic payload directly to the target cancer cells.  To date, five ADCs have received market approval and over 100 are being investigated in various stages of clin. development.  In this Therapeutics paper, we review recent clin. experience with the approved ADCs and other promising late-stage candidates on the horizon, following an overview of the biol. and chem. of ADCs and how the individual components of an ADC (antibody [or target], linker and conjugation chem., and cytotoxic payload) influence its activity.  We briefly discuss opportunities for enhancing ADC efficacy, drug resistance, and future perspectives for this novel antibody-based mol. platform, which has great potential to make a paradigm shift in cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov4-NFqiYwKLVg90H21EOLACvtfcHk0lhRpBfCiWDVmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslSit73I&md5=df4ff41af6d0a667f28575d5c9cee49c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2931774-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252931774-X%26sid%3Dliteratum%253Aachs%26aulast%3DChau%26aufirst%3DC.%2BH.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520cancer%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26issue%3D10200%26spage%3D793%26epage%3D804%26doi%3D10.1016%2FS0140-6736%2819%2931774-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Peptide conjugates with small molecules designed to enhance efficacy and safety</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1855</span>, <span class="refDoi"> DOI: 10.3390/molecules24101855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3390%2Fmolecules24101855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1855&issue=10&author=R.+Heauthor=B.+Finanauthor=J.+P.+Mayerauthor=R.+D.+DiMarchi&title=Peptide+conjugates+with+small+molecules+designed+to+enhance+efficacy+and+safety&doi=10.3390%2Fmolecules24101855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide conjugates with small molecules designed to enhance efficacy and safety</span></div><div class="casAuthors">He, Rongjun; Finan, Brian; Mayer, John P.; DiMarchi, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1855</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Peptides constitute mol. diversity with unique mol. mechanisms of action that are proven indispensable in the management of many human diseases, but of only a mere fraction relative to more traditional small mol.-based medicines.  The integration of these two therapeutic modalities o ers the potential to enhance and broaden pharmacol. while minimizing dose-dependent toxicol.  This review summarizes numerous advances in drug design, synthesis and development that provide direction for next-generation research endeavors in this field.  Medicinal studies in this area have largely focused upon the application of peptides to selectively enhance small mol. cytotoxicity to more effectively treat multiple oncol. diseases.  To a lesser and steadily emerging extent peptides are being therapeutically employed to complement and diversify the pharmacol. of small mol. drugs in diseases other than just cancer.  No matter the disease, the purpose of the mol. integration remains const. and it is to achieve superior therapeutic outcomes with diminished adverse effects.  We review linker technol. and conjugation chemistries that have enabled integrated and targeted pharmacol. with controlled release.  Finally, we offer our perspective on opportunities and obstacles in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_IMrSi0d7urVg90H21EOLACvtfcHk0lhRpBfCiWDVmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb%252FM&md5=da04d398164460a08977abcdcefdc230</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24101855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24101855%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DR.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DPeptide%2520conjugates%2520with%2520small%2520molecules%2520designed%2520to%2520enhance%2520efficacy%2520and%2520safety%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26issue%3D10%26spage%3D1855%26doi%3D10.3390%2Fmolecules24101855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, R.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates for cancer therapy</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>), <span class="NLM_elocation-id">e254-e262</span> <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30030-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2FS1470-2045%2816%2930030-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=27299281" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&issue=6&author=A.+Thomasauthor=B.+A.+Teicherauthor=R.+Hassan&title=Antibody-drug+conjugates+for+cancer+therapy&doi=10.1016%2FS1470-2045%2816%2930030-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930030-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930030-4%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DHassan%26aufirst%3DR.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D6%26doi%3D10.1016%2FS1470-2045%2816%2930030-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vrettos, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span> <span> </span><span class="NLM_article-title">On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.3762/bjoc.14.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3762%2Fbjoc.14.80" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29765474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOnsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=930-954&author=E.+I.+Vrettosauthor=G.+Mezoauthor=A.+G.+Tzakos&title=On+the+design+principles+of+peptide%E2%80%93drug+conjugates+for+targeted+drug+delivery+to+the+malignant+tumor+site&doi=10.3762%2Fbjoc.14.80"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site</span></div><div class="casAuthors">Vrettos, Eirinaios I.; Mezo, Gabor; Tzakos, Andreas G.</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">930-954</span>CODEN:
                <span class="NLM_cas:coden">BJOCBH</span>;
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    
            (<span class="NLM_cas:orgname">Beilstein-Institut zur Foerderung der Chemischen Wissenschaften</span>)
        </div><div class="casAbstract">Cancer is the second leading cause of death affecting nearly one in two people, and the appearance of new cases is projected to rise by >70% by 2030.  To effectively combat the menace of cancer, a variety of strategies have been exploited.  Among them, the development of peptide-drug conjugates (PDCs) is considered as an inextricable part of this armamentarium and is continuously explored as a viable approach to target malignant tumors.  The general architecture of PDCs consists of three building blocks: the tumor-homing peptide, the cytotoxic agent and the biodegradable connecting linker.  The aim of the current review is to provide a spherical perspective on the basic principles governing PDCs, as also the methodol. to construct them.  We aim to offer basic and integral knowledge on the rational design towards the construction of PDCs through analyzing each building block, as also to highlight the overall progress of this rapidly growing field.  Therefore, we focus on several intriguing examples from the recent literature, including important PDCs that have progressed to phase III clin. trials.  Last, we address possible difficulties that may emerge during the synthesis of PDCs, as also report ways to overcome them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRxpOdZLKXfrVg90H21EOLACvtfcHk0liXPcQiv3BDXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOnsLvP&md5=595fce13e61b3e6f58a8ae6969e8b2c8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.14.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.14.80%26sid%3Dliteratum%253Aachs%26aulast%3DVrettos%26aufirst%3DE.%2BI.%26aulast%3DMezo%26aufirst%3DG.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26atitle%3DOn%2520the%2520design%2520principles%2520of%2520peptide%25E2%2580%2593drug%2520conjugates%2520for%2520targeted%2520drug%2520delivery%2520to%2520the%2520malignant%2520tumor%2520site%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2018%26volume%3D14%26spage%3D930%26epage%3D954%26doi%3D10.3762%2Fbjoc.14.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheetham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angacian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span> <span> </span><span class="NLM_article-title">Peptide-drug conjugates as effective prodrug strategies for targeted delivery</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>110–111</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2016.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.addr.2016.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=27370248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSgtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110%E2%80%93111&publication_year=2017&pages=112-126&author=Y.+Wangauthor=A.+G.+Cheethamauthor=G.+Angacianauthor=H.+Suauthor=L.+Xieauthor=H.+Cui&title=Peptide-drug+conjugates+as+effective+prodrug+strategies+for+targeted+delivery&doi=10.1016%2Fj.addr.2016.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-drug conjugates as effective prodrug strategies for targeted delivery</span></div><div class="casAuthors">Wang, Yin; Cheetham, Andrew G.; Angacian, Garren; Su, Hao; Xie, Lisi; Cui, Honggang</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">110-111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112-126</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Peptide-drug conjugates (PDCs) represent an important class of therapeutic agents that combine one or more drug mols. with a short peptide through a biodegradable linker.  This prodrug strategy uniquely and specifically exploits the biol. activities and self-assembling potential of small-mol. peptides to improve the treatment efficacy of medicinal compds.  We review here the recent progress in the design and synthesis of peptide-drug conjugates in the context of targeted drug delivery and cancer chemotherapy.  We analyze carefully the key design features in choosing the peptide sequence and linker chem. for the drug of interest, as well as the strategies to optimize the conjugate design.  We highlight the recent progress in the design and synthesis of self-assembling peptide-drug amphiphiles to construct supramol. nanomedicine and nanofiber hydrogels for both systemic and topical delivery of active pharmaceutical ingredients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxcgDx1p75N7Vg90H21EOLACvtfcHk0liXPcQiv3BDXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSgtbvL&md5=3a23bd362031d78b92bc167a44c62c96</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCheetham%26aufirst%3DA.%2BG.%26aulast%3DAngacian%26aufirst%3DG.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DH.%26atitle%3DPeptide-drug%2520conjugates%2520as%2520effective%2520prodrug%2520strategies%2520for%2520targeted%2520delivery%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D110%25E2%2580%2593111%26spage%3D112%26epage%3D126%26doi%3D10.1016%2Fj.addr.2016.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahdat, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroose, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santin, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweidan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washkowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinsky, K.</span></span> <span> </span><span class="NLM_article-title">Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1814213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1056%2FNEJMoa1814213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=30786188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvVSjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=741-751&issue=8&author=A.+Bardiaauthor=I.+A.+Mayerauthor=L.+T.+Vahdatauthor=S.+M.+Tolaneyauthor=S.+J.+Isakoffauthor=J.+R.+Diamondauthor=J.+O%E2%80%99Shaughnessyauthor=R.+L.+Morooseauthor=A.+D.+Santinauthor=V.+G.+Abramsonauthor=N.+C.+Shahauthor=H.+S.+Rugoauthor=D.+M.+Goldenbergauthor=A.+M.+Sweidanauthor=R.+Iannoneauthor=S.+Washkowitzauthor=R.+M.+Sharkeyauthor=W.+A.+Wegenerauthor=K.+Kalinsky&title=Sacituzumab+govitecan-hziy+in+refractory+metastatic+triple-negative+breast+cancer&doi=10.1056%2FNEJMoa1814213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer</span></div><div class="casAuthors">Bardia, A.; Mayer, I. A.; Vahdat, L. T.; Tolaney, S. M.; Isakoff, S. J.; Diamond, J. R.; O'Shaughnessy, J.; Moroose, R. L.; Santin, A. D.; Abramson, V. G.; Shah, N. C.; Rugo, H. S.; Goldenberg, D. M.; Sweidan, A. M.; Iannone, R.; Washkowitz, S.; Sharkey, R. M.; Wegener, W. A.; Kalinsky, K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">741-751</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Std. chemotherapy is assocd. with low response rates and short progression-free survival among patients with pretreated metastatic triple-neg. breast cancer.  Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker.  Sacituzumab govitecan-hziy enables delivery of high concns. of SN-38 to tumors.  Methods We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy i.v. on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects.  A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kg of body wt. after receiving at least two previous anticancer therapies for metastatic triple-neg. breast cancer.  The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clin. benefit rate (defined as a complete or partial response or stable disease for at least 6 mo); progression-free survival; and overall survival.  Post hoc analyses detd. the response rate and duration, which were assessed by blinded independent central review. results The 108 patients with triple-neg. breast cancer had received a median of 3 previous therapies (range, 2 to 10).  Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events.  Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia.  The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 mo (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 mo, resp.  The clin. benefit rate was 45.4%.  Median progression-free survival was 5.5 mo (95% CI, 4.1 to 6.3), and overall survival was 13.0 mo (95% CI, 11.2 to 13.7).  Conclusions Sacituzumab govitecan-hziy was assocd. with durable objective responses in patients with heavily pretreated metastatic triple-neg. breast cancer.  Myelotoxic effects were the main adverse reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAgQWEPOcqfrVg90H21EOLACvtfcHk0lgFnSwKeXj0MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvVSjs7w%253D&md5=75edc2c274aef0ab90dd2aaf230dabac</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1814213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1814213%26sid%3Dliteratum%253Aachs%26aulast%3DBardia%26aufirst%3DA.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DVahdat%26aufirst%3DL.%2BT.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DMoroose%26aufirst%3DR.%2BL.%26aulast%3DSantin%26aufirst%3DA.%2BD.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DShah%26aufirst%3DN.%2BC.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DSweidan%26aufirst%3DA.%2BM.%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DWashkowitz%26aufirst%3DS.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DWegener%26aufirst%3DW.%2BA.%26aulast%3DKalinsky%26aufirst%3DK.%26atitle%3DSacituzumab%2520govitecan-hziy%2520in%2520refractory%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D8%26spage%3D741%26epage%3D751%26doi%3D10.1056%2FNEJMoa1814213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bargh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isidro-Llobet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Cleavable linkers in antibody–drug conjugates</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4361</span>– <span class="NLM_lpage">4374</span>, <span class="refDoi"> DOI: 10.1039/C8CS00676H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1039%2FC8CS00676H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31294429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=4361-4374&issue=16&author=J.+D.+Barghauthor=A.+Isidro-Llobetauthor=J.+S.+Parkerauthor=D.+R.+Spring&title=Cleavable+linkers+in+antibody%E2%80%93drug+conjugates&doi=10.1039%2FC8CS00676H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cleavable linkers in antibody-drug conjugates</span></div><div class="casAuthors">Bargh, Jonathan D.; Isidro-Llobet, Albert; Parker, Jeremy S.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4361-4374</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Antibody-Drug Conjugates (ADCs) are now established as a major class of therapeutics for the clin. treatment of cancer.  The properties of the linker between the antibody and the payload are proven to be crit. to the success of an ADC.  Although ADC linkers can be 'non-cleavable', the vast majority of ADCs in clin. development have specific release mechanisms to allow controlled linker cleavage at the target site and are thus termed 'cleavable'.  In recent years, the development of new methods of drug release from ADCs has continued in parallel to the deepening understanding of the biol. processes underlying the mechanisms of action of pre-existing technologies.  This review summarises the advances in the field of cleavable linker technologies for ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvG2Xk9IvLpLVg90H21EOLACvtfcHk0lhzAZCaNDIjQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M&md5=bc73619319b21c2b85e3d613ca72f778</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1039%2FC8CS00676H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CS00676H%26sid%3Dliteratum%253Aachs%26aulast%3DBargh%26aufirst%3DJ.%2BD.%26aulast%3DIsidro-Llobet%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DCleavable%2520linkers%2520in%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2019%26volume%3D48%26issue%3D16%26spage%3D4361%26epage%3D4374%26doi%3D10.1039%2FC8CS00676H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowinger, T. B.</span></span> <span> </span><span class="NLM_article-title">Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.pharmthera.2017.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=28757155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yrsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2018&pages=126-142&author=P.+A.+Trailauthor=G.+M.+Dubowchikauthor=T.+B.+Lowinger&title=Antibody+drug+conjugates+for+treatment+of+breast+cancer%3A+Novel+targets+and+diverse+approaches+in+ADC+design&doi=10.1016%2Fj.pharmthera.2017.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design</span></div><div class="casAuthors">Trail, Pamela A.; Dubowchik, Gene M.; Lowinger, Timothy B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">126-142</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Breast cancer is a heterogeneous group of malignancies with a spectrum of mol. subtypes, pathologies and outcomes that together comprise the most common non-cutaneous cancer in women.  Currently, over 80% of breast cancer patients are diagnosed at relatively early stages of disease where there are encouraging data on outcomes and long term survival.  However, there is currently no curative option for those patients with metastatic disease and there is a substantial medical need to identify effective and safe treatment options for these patients.  One approach to improve cancer therapy is by designing therapeutics directed against targets with differential levels of expression on malignant vs. normal cells with the goal of improving tumor selectivity and reducing damage to normal tissues.  Antibody drug conjugates (ADCs) are a rapidly evolving therapeutic class that exploits the target-selectivity of monoclonal antibodies (MAbs) to deliver cytotoxic drugs to antigen-expressing cells (Lambert & Morris, 2017; Senter, 2009; Thomas, Teicher, & Hassan, 2016; Trail, 2013).  The regulatory approval of ADCs for both hematol. malignancies (brentuximab vedotin) (Younes et al., 2010) and solid tumors (ado-trastuzumab emtansine) (Amiri-Kordestani et al., 2014; Verma et al., 2012) clearly demonstrates the clin. potential of ADCs.  This review will focus on targets under consideration for breast cancer directed ADCs and on the technol. modifications being considered to improve ADC efficacy and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ5FTc5Nf4T7Vg90H21EOLACvtfcHk0lhzAZCaNDIjQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yrsL%252FO&md5=ef44cf6eb6cbec0967a24efac33eb7f0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DTrail%26aufirst%3DP.%2BA.%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DLowinger%26aufirst%3DT.%2BB.%26atitle%3DAntibody%2520drug%2520conjugates%2520for%2520treatment%2520of%2520breast%2520cancer%253A%2520Novel%2520targets%2520and%2520diverse%2520approaches%2520in%2520ADC%2520design%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D181%26spage%3D126%26epage%3D142%26doi%3D10.1016%2Fj.pharmthera.2017.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krippendorff, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. K.</span></span> <span> </span><span class="NLM_article-title">Influence of molecular size on the clearance of antibody fragments</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2131</span>– <span class="NLM_lpage">2141</span>, <span class="refDoi"> DOI: 10.1007/s11095-017-2219-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1007%2Fs11095-017-2219-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=28681164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFaqt7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=2131-2141&issue=10&author=Z.+Liauthor=B.+F.+Krippendorffauthor=D.+K.+Shah&title=Influence+of+molecular+size+on+the+clearance+of+antibody+fragments&doi=10.1007%2Fs11095-017-2219-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of Molecular size on the clearance of antibody fragments</span></div><div class="casAuthors">Li, Zhe; Krippendorff, Ben-Fillippo; Shah, Dhaval K.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2131-2141</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The purpose of this paper is to establish a continuous relationship between the size of various antibody fragments and their systemic clearance (CL) in mice.  Two different orthogonal approaches have been used to establish the relationship.  First approach uses CL values estd. by non-compartmental anal. (NCA) to establish a correlation with protein size.  The second approach simultaneously characterizes the PK data for all the proteins using a 2-compartment model to establish a relationship between protein size and pharmacokinetic (PK) parameters.  Simple math. functions (e.g. sigmoidal, power law) were able to characterize the CL vs. protein size relationship generated using the investigated proteins.  The relationship established in mouse was used to predict rat, rabbit, monkey, and human relationships using allometric scaling.  The predicted relationships were found to capture the available spares data from each species reasonably well.  The CL vs. protein size relationship is important for establishing a robust quant. structure-PK relationship (QSPKR) for protein therapeutics.  The relationship presented here can help in a priori predicting plasma exposure of therapeutic proteins, and together with our previously established relationship between plasma and tissue concns. of proteins, it can predict the tissue exposure of non-binding proteins simply based on mol. wt./radius and dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEIFIcpetl87Vg90H21EOLACvtfcHk0lhzAZCaNDIjQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFaqt7%252FO&md5=b03a8d0f6ad83d6471b165110aadd427</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs11095-017-2219-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-017-2219-y%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DKrippendorff%26aufirst%3DB.%2BF.%26aulast%3DShah%26aufirst%3DD.%2BK.%26atitle%3DInfluence%2520of%2520molecular%2520size%2520on%2520the%2520clearance%2520of%2520antibody%2520fragments%26jtitle%3DPharm.%2520Res.%26date%3D2017%26volume%3D34%26issue%3D10%26spage%3D2131%26epage%3D2141%26doi%3D10.1007%2Fs11095-017-2219-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, T. K.</span></span> <span> </span><span class="NLM_article-title">Challenges and new frontiers in analytical characterization of antibody–drug conjugates</span>. <i>MAbs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1080/19420862.2017.1412025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1080%2F19420862.2017.1412025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29293399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=222-243&issue=2&author=A.+Waghauthor=H.+Songauthor=M.+Zengauthor=L.+Taoauthor=T.+K.+Das&title=Challenges+and+new+frontiers+in+analytical+characterization+of+antibody%E2%80%93drug+conjugates&doi=10.1080%2F19420862.2017.1412025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and new frontiers in analytical characterization of antibody-drug conjugates</span></div><div class="casAuthors">Wagh, Anil; Song, Hangtian; Zeng, Ming; Tao, Li; Das, Tapan K.</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-243</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics in which a potent small mol. is linked to an antibody.  ADCs are highly complex and structurally heterogeneous, typically contg. numerous product-related species.  One of the most impactful steps in ADC development is the identification of crit. quality attributes to det. product characteristics that may affect safety and efficacy.  However, due to the addnl. complexity of ADCs relative to the parent antibodies, establishing a solid understanding of the major quality attributes and detg. their criticality are a major undertaking in ADC development.  Here, we review the development challenges, esp. for reliable detection of quality attributes, citing literature and new data from our labs., highlight recent improvements in major anal. techniques for ADC characterization and control, and discuss newer techniques, such as two-dimensional liq. chromatog., that have potential to be included in anal. control strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiXlsU1pCU8rVg90H21EOLACvtfcHk0ljtjVCAieZ5KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wgsb8%253D&md5=22f62bc383d227707994a6142c5bbce0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F19420862.2017.1412025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2017.1412025%26sid%3Dliteratum%253Aachs%26aulast%3DWagh%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DTao%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DT.%2BK.%26atitle%3DChallenges%2520and%2520new%2520frontiers%2520in%2520analytical%2520characterization%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DMAbs%26date%3D2018%26volume%3D10%26issue%3D2%26spage%3D222%26epage%3D243%26doi%3D10.1080%2F19420862.2017.1412025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kopp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurber, G. M.</span></span> <span> </span><span class="NLM_article-title">Severing ties: quantifying the payload release from antibody drug conjugates</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1631</span>– <span class="NLM_lpage">1633</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.chembiol.2019.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31951577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyqsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1631-1633&issue=12&author=A.+Koppauthor=G.+M.+Thurber&title=Severing+ties%3A+quantifying+the+payload+release+from+antibody+drug+conjugates&doi=10.1016%2Fj.chembiol.2019.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Severing Ties: Quantifying the Payload Release from Antibody Drug Conjugates</span></div><div class="casAuthors">Kopp, Anna; Thurber, Greg M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1631-1633</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">As a key mediator of efficacy and toxicity, the linker connecting the payload in antibody drug conjugates dets. cellular distribution and payload release.  Sorkin et al. (2019) have created novel fluorescence-based linkers to quantify the rate of intracellular bond cleavage and track live-cell kinetics for designing more effective agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGralUrkfVS6CbVg90H21EOLACvtfcHk0ljtjVCAieZ5KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyqsrrM&md5=e3807813d7fb21524dd2418d82b7c7c3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DKopp%26aufirst%3DA.%26aulast%3DThurber%26aufirst%3DG.%2BM.%26atitle%3DSevering%2520ties%253A%2520quantifying%2520the%2520payload%2520release%2520from%2520antibody%2520drug%2520conjugates%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D12%26spage%3D1631%26epage%3D1633%26doi%3D10.1016%2Fj.chembiol.2019.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szekacs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uematsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Hydrolysis of carbonates, thiocarbonates, carbamates, and carboxylic esters of alpha-naphthol, beta-naphthol, and p-nitrophenol by human, rat, and mouse liver carboxylesterases</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1023/A:1018987111362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1023%2FA%3A1018987111362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=8321828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADyaK3sXmt1Shsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=639-648&issue=5&author=T.+L.+Huangauthor=A.+Szekacsauthor=T.+Uematsuauthor=E.+Kuwanoauthor=A.+Parkinsonauthor=B.+D.+Hammock&title=Hydrolysis+of+carbonates%2C+thiocarbonates%2C+carbamates%2C+and+carboxylic+esters+of+alpha-naphthol%2C+beta-naphthol%2C+and+p-nitrophenol+by+human%2C+rat%2C+and+mouse+liver+carboxylesterases&doi=10.1023%2FA%3A1018987111362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrolysis of carbonates, thiocarbonates, carbamates, and carboxylic esters of α-naphthol, β-naphthol, and p-nitrophenol by human, rat, and mouse liver carboxylesterases</span></div><div class="casAuthors">Huang, Tien L.; Szekacs, Andras; Uematsu, Tamon; Kuwano, Eiichi; Parkinson, Andrew; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-48</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">Thirty carbonates, thiocarbonates, carbamates, and carboxylic esters of α-naphthol, β-naphthol, and p-nitrophenol were synthesized and tested as substrates for liver carboxylesterases from the crude microsomal fractions of human and mouse, and purified isoenzymes, carboxylesterases A and B, from rat liver microsomes.  The carbonates, thiocarbonates, and carboxylic esters of α-naphthol were cleaved more rapidly than the corresponding β-naphthol isomers by the mammalian liver esterases.  α-Naphthyl esters of acetic, propionic, and butyric acids were among the best substrates tested for these enzymes.  The majority of the substrates was consistently hydrolyzed at higher rates by esterase B compared with esterase A, although the Km values of selected substrates differed widely with these 2 isoenzymes.  Malathion was a 15-fold better substrate for esterase B than for esterase A.  Compared with the corresponding carboxylates, the carbonate moiety of α- and β-naphthol and p-nitrophenol lowered the specific activities of the enzymes by ∼5-fold but improved the stability under basic conditions.  The optimum pH values of mouse liver esterase with the acetate, methylcarbonate, and ethylthiocarbonate of α-naphthol was pH 7.0-7.6.  Human and mouse liver microsomal esterase activities were ∼5 orders of magnitude lower than the activities of purified rat liver esterase B.  A relation between the catalytic activity of the enzymes and the lipophilicity of the naphthyl substrates indicated that (1) in the α- and β-naphthyl carbonate series, an inverse relation between enzyme activity and lipophilicity of the substrates was obsd., whereas (2) in the α-naphthyl carboxylate series, an increase in enzyme activity with increasing lipophilicity of the substrates up to a log P value of ∼4.0 was obsd., after which the enzyme activity decreased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBceyfsg-SDLVg90H21EOLACvtfcHk0ljnY0dz5jT6wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmt1Shsb4%253D&md5=4bfcc197f3947a01deeb8bdd1e758515</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018987111362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018987111362%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.%2BL.%26aulast%3DSzekacs%26aufirst%3DA.%26aulast%3DUematsu%26aufirst%3DT.%26aulast%3DKuwano%26aufirst%3DE.%26aulast%3DParkinson%26aufirst%3DA.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DHydrolysis%2520of%2520carbonates%252C%2520thiocarbonates%252C%2520carbamates%252C%2520and%2520carboxylic%2520esters%2520of%2520alpha-naphthol%252C%2520beta-naphthol%252C%2520and%2520p-nitrophenol%2520by%2520human%252C%2520rat%252C%2520and%2520mouse%2520liver%2520carboxylesterases%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26issue%3D5%26spage%3D639%26epage%3D648%26doi%3D10.1023%2FA%3A1018987111362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laizure, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witbrodt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, R. B.</span></span> <span> </span><span class="NLM_article-title">The role of human carboxylesterases in drug metabolism: have we overlooked their importance?</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1002/phar.1194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1002%2Fphar.1194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=23386599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVOltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=210-222&issue=2&author=S.+C.+Laizureauthor=V.+Herringauthor=Z.+Huauthor=K.+Witbrodtauthor=R.+B.+Parker&title=The+role+of+human+carboxylesterases+in+drug+metabolism%3A+have+we+overlooked+their+importance%3F&doi=10.1002%2Fphar.1194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The role of human carboxylesterases in drug metabolism: have we overlooked their importance?</span></div><div class="casAuthors">Laizure, S. Casey; Herring, Vanessa; Hu, Zheyi; Witbrodt, Kevin; Parker, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-222</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Carboxylesterases are a multigene family of mammalian enzymes widely distributed throughout the body that catalyze the hydrolysis of esters, amides, thioesters, and carbamates.  In humans, two carboxylesterases, hCE1 and hCE2, are important mediators of drug metab.  Both are expressed in the liver, but hCE1 greatly exceeds hCE2.  In the intestine, only hCE2 is present and highly expressed.  The most common drug substrates of these enzymes are ester prodrugs specifically designed to enhance oral bioavailability by hydrolysis to the active carboxylic acid after absorption from the gastrointestinal tract.  Carboxylesterases also play an important role in the hydrolysis of some drugs to inactive metabolites.  It has been widely believed that drugs undergoing hydrolysis by hCE1 and hCE2 are not subject to clin. significant alterations in their disposition, but evidence exists that genetic polymorphisms, drug-drug interactions, drug-disease interactions and other factors are important determinants of the variability in the therapeutic response to carboxylesterase-substrate drugs.  The implications for drug therapy are far-reaching, as substrate drugs include numerous examples from widely prescribed therapeutic classes.  Representative drugs include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, antiplatelet drugs, statins, antivirals, and central nervous system agents.  As research interest increases in the carboxylesterases, evidence is accumulating of their important role in drug metab. and, therefore, the outcomes of pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ8Icv81r0ebVg90H21EOLACvtfcHk0ljnY0dz5jT6wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVOltrs%253D&md5=6a68263c68e92bba8bbcb64e0e30ae92</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fphar.1194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.1194%26sid%3Dliteratum%253Aachs%26aulast%3DLaizure%26aufirst%3DS.%2BC.%26aulast%3DHerring%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWitbrodt%26aufirst%3DK.%26aulast%3DParker%26aufirst%3DR.%2BB.%26atitle%3DThe%2520role%2520of%2520human%2520carboxylesterases%2520in%2520drug%2520metabolism%253A%2520have%2520we%2520overlooked%2520their%2520importance%253F%26jtitle%3DPharmacotherapy%26date%3D2013%26volume%3D33%26issue%3D2%26spage%3D210%26epage%3D222%26doi%3D10.1002%2Fphar.1194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, B.</span></span> <span> </span><span class="NLM_article-title">Qualitative structure-metabolism relationships in the hydrolysis of carbamates</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.3109/03602531003745960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3109%2F03602531003745960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=20441444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=551-589&issue=4&author=F.+Vacondioauthor=C.+Silvaauthor=M.+Morauthor=B.+Testa&title=Qualitative+structure-metabolism+relationships+in+the+hydrolysis+of+carbamates&doi=10.3109%2F03602531003745960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Qualitative structure-metabolism relationships in the hydrolysis of carbamates</span></div><div class="casAuthors">Vacondio, Federica; Silva, Claudia; Mor, Marco; Testa, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">551-589</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The aims of this review were (1) to compile a large no. of reliable literature data on the metabolic hydrolysis of medicinal carbamates and (2) to ext. from such data a qual. relation between mol. structure and lability to metabolic hydrolysis.  The compds. were classified according to the nature of their substituents (R3OCONR1R2), and a metabolic lability score was calcd. for each class.  A trend emerged, such that the metabolic lability of carbamates decreased (i.e., their metabolic stability increased), in the following series: Aryl-OCO-NHAlkyl >> Alkyl-OCO-NHAlkyl ∼ Alkyl-OCO-N(Alkyl)2 ≥ Alkyl-OCO-N(endocyclic) ≥ Aryl-OCO-N(Alkyl)2 ∼ Aryl-OCO-N(endocyclic) ≥ Alkyl-OCO-NHAryl ∼ Alkyl-OCO-NHAcyl >> Alkyl-OCO-NH2 > Cyclic carbamates.  This trend should prove useful in the design of carbamates as drugs or prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgC9J9XyTR0bVg90H21EOLACvtfcHk0lit4iLaUY5sPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtLjF&md5=9dc05a648555f6c07089d3ab6933fa08</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3109%2F03602531003745960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602531003745960%26sid%3Dliteratum%253Aachs%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTesta%26aufirst%3DB.%26atitle%3DQualitative%2520structure-metabolism%2520relationships%2520in%2520the%2520hydrolysis%2520of%2520carbamates%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2010%26volume%3D42%26issue%3D4%26spage%3D551%26epage%3D589%26doi%3D10.3109%2F03602531003745960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karampelas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyros, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayyad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyridaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolios, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millar, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liapakis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamvakopoulos, C.</span></span> <span> </span><span class="NLM_article-title">GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">823</span>, <span class="refDoi"> DOI: 10.1021/bc500081g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc500081g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2cXks1yrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=813-823&issue=4&author=T.+Karampelasauthor=O.+Argyrosauthor=N.+Sayyadauthor=K.+Spyridakiauthor=C.+Pappasauthor=K.+Morganauthor=G.+Koliosauthor=R.+P.+Millarauthor=G.+Liapakisauthor=A.+G.+Tzakosauthor=D.+Fokasauthor=C.+Tamvakopoulos&title=GnRH-Gemcitabine+conjugates+for+the+treatment+of+androgen-independent+prostate+cancer%3A+pharmacokinetic+enhancements+combined+with+targeted+drug+delivery&doi=10.1021%2Fbc500081g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery</span></div><div class="casAuthors">Karampelas, Theodoros; Argyros, Orestis; Sayyad, Nisar; Spyridaki, Katerina; Pappas, Charalampos; Morgan, Kevin; Kolios, George; Millar, Robert P.; Liapakis, George; Tzakos, Andreas G.; Fokas, Demosthenes; Tamvakopoulos, Constantin</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">813-823</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Gemcitabine, a drug with established efficacy against a no. of solid tumors, has therapeutic limitations due to its rapid metabolic inactivation.  The aim of this study was the development of an innovative strategy to produce a metabolically stable analog of gemcitabine that could also be selectively delivered to prostate cancer (CaP) cells based on cell surface expression of the Gonadotropin Releasing Hormone-Receptor (GnRH-R).  The synthesis and evaluation of conjugated mols., consisting of gemcitabine linked to a GnRH agonist, is presented along with results in androgen-independent prostate cancer models.  NMR and ligand binding assays were employed to verify conservation of microenvironments responsible for binding of novel GnRH-gemcitabine conjugates to the GnRH-R.  In vitro cytotoxicity, cellular uptake, and metabolite formation of the conjugates were examd. in CaP cell lines.  Selected conjugates were efficacious in the in vitro assays with one of them, namely, GSG, displaying high antiproliferative activity in CaP cell lines along with significant metabolic and pharmacokinetic advantages in comparison to gemcitabine.  Finally, treatment of GnRH-R pos. xenografted mice with GSG showed a significant advantage in tumor growth inhibition when compared to gemcitabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVm3JbYI0ZDrVg90H21EOLACvtfcHk0lgojZvGTywckw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXks1yrtrk%253D&md5=7bc71e602778674949cfe6b76a27d197</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbc500081g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc500081g%26sid%3Dliteratum%253Aachs%26aulast%3DKarampelas%26aufirst%3DT.%26aulast%3DArgyros%26aufirst%3DO.%26aulast%3DSayyad%26aufirst%3DN.%26aulast%3DSpyridaki%26aufirst%3DK.%26aulast%3DPappas%26aufirst%3DC.%26aulast%3DMorgan%26aufirst%3DK.%26aulast%3DKolios%26aufirst%3DG.%26aulast%3DMillar%26aufirst%3DR.%2BP.%26aulast%3DLiapakis%26aufirst%3DG.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26aulast%3DFokas%26aufirst%3DD.%26aulast%3DTamvakopoulos%26aufirst%3DC.%26atitle%3DGnRH-Gemcitabine%2520conjugates%2520for%2520the%2520treatment%2520of%2520androgen-independent%2520prostate%2520cancer%253A%2520pharmacokinetic%2520enhancements%2520combined%2520with%2520targeted%2520drug%2520delivery%26jtitle%3DBioconjugate%2520Chem.%26date%3D2014%26volume%3D25%26issue%3D4%26spage%3D813%26epage%3D823%26doi%3D10.1021%2Fbc500081g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1080/10717544.2018.1435746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1080%2F10717544.2018.1435746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29405790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=448-460&issue=1&author=Y.+Youauthor=Z.+Xuauthor=Y.+Chen&title=Doxorubicin+conjugated+with+a+trastuzumab+epitope+and+an+MMP-2+sensitive+peptide+linker+for+the+treatment+of+HER2-positive+breast+cancer&doi=10.1080%2F10717544.2018.1435746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer</span></div><div class="casAuthors">You, Yiwen; Xu, Zhiyuan; Chen, Yun</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">448-460</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">HER2-pos. breast cancer correlates with more aggressive tumor growth, a poorer prognosis and reduced overall survival.  Currently, trastuzumab (Herceptin), which is an anti-HER2 antibody, is one of the key drugs.  There is evidence indicating that conjugation of trastuzumab with chemotherapy drugs, such as doxorubicin (DOX), for multiple targets could be more effective.  However, incomplete penetration into tumors has been noted for those conjugates.  Compared to an antibody, peptides may represent an attractive alternative.  For HER2, a similar potency has been obsd. for a 12-amino-acid anti-HER2 peptide mimetic YCDGFYACYMDV-NH2 (AHNP, disulfide-bridged) and full-length trastuzumab.  Thus, a peptide, GPLGLAGDDYCDGFYACYMDV-NH2, which consists of AHNP and an MMP-2 cleavable linker GPLGLAGDD, was first designed, followed by conjugation with DOX via a glycine residue at the N-terminus to form a novel DOX-peptide conjugate MAHNP-DOX.  Using HER2-pos. human breast cancer cells BT474 and SKBR3 as in vitro model systems and nude mice with BT474 xenografts as an in vivo model, this conjugate was comprehensively characterized, and its efficacy was evaluated and compared with that of free DOX.  As a result, MAHNP-DOX demonstrated a much lower in vitro IC50, and its in vivo extent of inhibition in mice was more evident.  During this process, enzymic cleavage of MAHNP-DOX is crit. for its activation and cellular uptake.  In addn., a synergistic response was obsd. after the combination of DOX and AHNP.  This effect was probably due to the involvement of AHNP in the PI3K-AKT signaling pathway, which can be largely activated by DOX and leads to anti-apoptotic signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOqYcIF4w6y7Vg90H21EOLACvtfcHk0lgojZvGTywckw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWhuro%253D&md5=0c03938420411a68adf8b2d7d6973ed8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1080%2F10717544.2018.1435746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10717544.2018.1435746%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DDoxorubicin%2520conjugated%2520with%2520a%2520trastuzumab%2520epitope%2520and%2520an%2520MMP-2%2520sensitive%2520peptide%2520linker%2520for%2520the%2520treatment%2520of%2520HER2-positive%2520breast%2520cancer%26jtitle%3DDrug%2520Delivery%26date%3D2018%26volume%3D25%26issue%3D1%26spage%3D448%26epage%3D460%26doi%3D10.1080%2F10717544.2018.1435746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soudy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, K.</span></span> <span> </span><span class="NLM_article-title">Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7564</span>– <span class="NLM_lpage">7573</span>, <span class="refDoi"> DOI: 10.1021/jm400647r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400647r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVaqsr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7564-7573&issue=19&author=R.+Soudyauthor=C.+Chenauthor=K.+Kaur&title=Novel+peptide-doxorubucin+conjugates+for+targeting+breast+cancer+cells+including+the+multidrug+resistant+cells&doi=10.1021%2Fjm400647r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Peptide-Doxorubucin Conjugates for Targeting Breast Cancer Cells Including the Multidrug Resistant Cells</span></div><div class="casAuthors">Soudy, Rania; Chen, Christopher; Kaur, Kamaljit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7564-7573</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efficacy of chemotherapeutic doxorubucin (Dox) in cancer treatment is limited by two main factors, nonspecific toxicity and the emergence of tumor resistance.  To overcome these hurdles, in this study peptide-Dox conjugates were prepd.  A decapeptide 18-4a (NH2-WxEAAYQkFL-CONH2) with high specificity for breast cancer cells and improved proteolytic stability was conjugated to Dox to give peptide-Dox ester (1) and amide (2) conjugates.  Cell uptake studies showed that the conjugates were 6-10 times selective for breast cancerous cells (MCF-7 and MDA-MB-435) over noncancerous cells (HUVECs and MCF-10A).  One conjugate displayed similar toxicity as free Dox toward the breast cancerous cells and was about 40 times less toxic toward the noncancerous cells and 4-fold more toxic toward the Dox resistant MDA-MB-435-MDR cells than the free Dox.  These data suggest that one conjugate can be used as a potential prodrug for improving the therapeutic index of Dox and potentially many other cytotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-mqk59PdzX7Vg90H21EOLACvtfcHk0lgSsT8PMEoP9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVaqsr7J&md5=ca6f1ecc4388f5506c92f3af73ae4aad</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm400647r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400647r%26sid%3Dliteratum%253Aachs%26aulast%3DSoudy%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKaur%26aufirst%3DK.%26atitle%3DNovel%2520peptide-doxorubucin%2520conjugates%2520for%2520targeting%2520breast%2520cancer%2520cells%2520including%2520the%2520multidrug%2520resistant%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D19%26spage%3D7564%26epage%3D7573%26doi%3D10.1021%2Fjm400647r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soudy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etayash, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahadorani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavasanifar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, K.</span></span> <span> </span><span class="NLM_article-title">Breast cancer targeting peptide binds keratin 1: a new molecular marker for targeted drug delivery to breast cancer</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.6b00652</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00652" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVOmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=593-604&issue=3&author=R.+Soudyauthor=H.+Etayashauthor=K.+Bahadoraniauthor=A.+Lavasanifarauthor=K.+Kaur&title=Breast+cancer+targeting+peptide+binds+keratin+1%3A+a+new+molecular+marker+for+targeted+drug+delivery+to+breast+cancer&doi=10.1021%2Facs.molpharmaceut.6b00652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Breast Cancer Targeting Peptide Binds Keratin 1: A New Molecular Marker for Targeted Drug Delivery to Breast Cancer</span></div><div class="casAuthors">Soudy, Rania; Etayash, Hashem; Bahadorani, Kamran; Lavasanifar, Afsaneh; Kaur, Kamaljit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">593-604</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The biomarkers or receptors expressed on cancer cells and the targeting ligands with high binding affinity for biomarkers play a key role in early detection and treatment of breast cancer.  The breast cancer targeting peptide p160 (12-mer) and its enzymically stable analog 18-4 (10-mer) showed marked potential for breast cancer drug delivery using cell studies and animal models.  Herein, we used affinity purifn., liq. chromatog.-tandem mass spectrometry, and proteomics to identify keratin 1 (KRT1) as the target receptor highly expressed on breast cancer cells for p160 peptide(s).  Western blot and immunocytochem. in MCF-7 breast cancer cells confirmed the identity of KRT1.  We demonstrate that the p160 or 18-4 binding to MCF-7 breast cancer cells is dependent on the expression of KRT1, and we confirm peptide-KRT1 binding specificity using SPR expts. (Kd ∼ 1.1 μM and 0.98 μM for p160 and 18-4, resp.).  Furthermore, we assessed the ability of peptide 18-4 to improve the cellular uptake and anticancer activity of a pro-apoptotic antimicrobial peptide, microcin J25 (MccJ25), in breast cancer cells.  A covalent conjugate of peptide 18-4 with MccJ25 showed preferential cytotoxicity toward breast cancer cells with minimal cytotoxicity against normal HUVEC cells.  The conjugate inhibited the growth of MDA-MB-435 MDR multidrug-resistant cells with an IC50 comparable to that of nonresistant cells.  Conjugation improved selective cellular uptake of MccJ25, and the conjugate triggered cancer cell death by apoptosis.  Our findings establish KRT1 as a new marker for breast cancer targeting.  Addnl., it pinpoints the potential use of antimicrobial lasso peptides as a novel class of anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsUfWpgPm6hrVg90H21EOLACvtfcHk0lgSsT8PMEoP9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVOmsr8%253D&md5=ba3723128b2358a5e0f23b288cb40a83</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00652%26sid%3Dliteratum%253Aachs%26aulast%3DSoudy%26aufirst%3DR.%26aulast%3DEtayash%26aufirst%3DH.%26aulast%3DBahadorani%26aufirst%3DK.%26aulast%3DLavasanifar%26aufirst%3DA.%26aulast%3DKaur%26aufirst%3DK.%26atitle%3DBreast%2520cancer%2520targeting%2520peptide%2520binds%2520keratin%25201%253A%2520a%2520new%2520molecular%2520marker%2520for%2520targeted%2520drug%2520delivery%2520to%2520breast%2520cancer%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2017%26volume%3D14%26issue%3D3%26spage%3D593%26epage%3D604%26doi%3D10.1021%2Facs.molpharmaceut.6b00652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavallee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabathuler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beliveau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaigne, J. P.</span></span> <span> </span><span class="NLM_article-title">Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>155</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1038/bjp.2008.260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1038%2Fbjp.2008.260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=18574456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVygtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2008&pages=185-197&issue=2&author=A.+Reginaauthor=M.+Demeuleauthor=C.+Cheauthor=I.+Lavalleeauthor=J.+Poirierauthor=R.+Gabathulerauthor=R.+Beliveauauthor=J.+P.+Castaigne&title=Antitumour+activity+of+ANG1005%2C+a+conjugate+between+paclitaxel+and+the+new+brain+delivery+vector+Angiopep-2&doi=10.1038%2Fbjp.2008.260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2</span></div><div class="casAuthors">Regina, A.; Demeule, M.; Che, C.; Lavallee, I.; Poirier, J.; Gabathuler, R.; Beliveau, R.; Castaigne, J-P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-197</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background and purpose: Paclitaxel is highly efficacious in the treatment of breast, head and neck, non-small cell lung cancers and ovarian carcinoma.  For malignant gliomas, paclitaxel is prevented from reaching its target by the presence of the efflux pump P-glycoprotein (P-gp) at the blood-brain barrier.  We investigated the utilization of a new drug delivery system to increase brain delivery of paclitaxel.  Exptl. approach: Paclitaxel mols. were conjugated to a brain peptide vector, Angiopep-2, to provide a paclitaxel-Angiopep-2 conjugate named ANG1005.  We detd. the brain uptake capacity, intracellular effects and antitumor properties of ANG1005 in vitro against human tumor cell lines and in vivo in human xenografts.  We then detd. ANG1005 activity on brain tumors with intracerebral human tumor models in nude mice.  Key results: We show by in situ brain perfusion that ANG1005 enters the brain to a greater extent than paclitaxel and bypasses the P-gp.  ANG1005 has an antineoplastic potency similar to that of paclitaxel against human cancer cell lines.  We also demonstrate that ANG1005 caused a more potent inhibition of human tumor xenografts than paclitaxel.  Finally, ANG1005 administration led to a significant increase in the survival of mice with intracerebral implantation of U87 MG glioblastoma cells or NCI-H460 lung carcinoma cells.  Conclusions and implications: These results demonstrate the antitumor potential of a new drug, ANG1005, and establish that conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf7gdI2T8jHbVg90H21EOLACvtfcHk0ljCPqiJG1BFwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVygtL3N&md5=3c86b5d1a64c5754d439dfa787f16637</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.260%26sid%3Dliteratum%253Aachs%26aulast%3DRegina%26aufirst%3DA.%26aulast%3DDemeule%26aufirst%3DM.%26aulast%3DChe%26aufirst%3DC.%26aulast%3DLavallee%26aufirst%3DI.%26aulast%3DPoirier%26aufirst%3DJ.%26aulast%3DGabathuler%26aufirst%3DR.%26aulast%3DBeliveau%26aufirst%3DR.%26aulast%3DCastaigne%26aufirst%3DJ.%2BP.%26atitle%3DAntitumour%2520activity%2520of%2520ANG1005%252C%2520a%2520conjugate%2520between%2520paclitaxel%2520and%2520the%2520new%2520brain%2520delivery%2520vector%2520Angiopep-2%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D155%26issue%3D2%26spage%3D185%26epage%3D197%26doi%3D10.1038%2Fbjp.2008.260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumthekar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccioni, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puhalla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkaczuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahluwalia, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wefel, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span> <span> </span><span class="NLM_article-title">ANG1005, a brain-penetrating peptide–drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2789</span>– <span class="NLM_lpage">2799</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-3258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1158%2F1078-0432.CCR-19-3258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31969331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVyktLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=2789-2799&issue=12&author=P.+Kumthekarauthor=S.+C.+Tangauthor=A.+J.+Brennerauthor=S.+Kesariauthor=D.+E.+Piccioniauthor=C.+Andersauthor=J.+Carrilloauthor=P.+Chalasaniauthor=P.+Kabosauthor=S.+Puhallaauthor=K.+Tkaczukauthor=A.+A.+Garciaauthor=M.+S.+Ahluwaliaauthor=J.+S.+Wefelauthor=N.+Lakhaniauthor=N.+Ibrahim&title=ANG1005%2C+a+brain-penetrating+peptide%E2%80%93drug+conjugate%2C+shows+activity+in+patients+with+breast+cancer+with+leptomeningeal+carcinomatosis+and+recurrent+brain+metastases&doi=10.1158%2F1078-0432.CCR-19-3258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases</span></div><div class="casAuthors">Kumthekar, Priya; Tang, Shou-Ching; Brenner, Andrew J.; Kesari, Santosh; Piccioni, David E.; Anders, Carey; Carrillo, Jose; Chalasani, Pavani; Kabos, Peter; Puhalla, Shannon; Tkaczuk, Katherine; Garcia, Agustin A.; Ahluwalia, Manmeet S.; Wefel, Jeffrey S.; Lakhani, Nehal; Ibrahim, Nuhad</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2789-2799</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: ANG1005, a novel taxane deriv., consists of three paclitaxel mols. covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via LRP1 transport system.  Preclin. and clin. evidence of efficacy with ANG1005 has been previously shown.  Patients and Methods: A multicenter, open-label phase II study in adult patients with measurable recurrent brain metastases from breast cancer (BCBM), with or without leptomeningeal carcinomatosis was conducted (n = 72 BCBM; n = 28 leptomeningeal carcinomatosis subset).  ANG1005 was administered i.v. at 600 mg/m2 every 3 wk.  Tumor assessment was based on central nervous system (CNS) RECIST 1.1 for intracranial, and RECIST 1.1 for extracranial response.  The primary endpoint was detn. of intracranial objective response rate (iORR).  Results: Median age was 47.5 years.  Safety profile was similar to that of paclitaxel with myelosuppression as the predominating toxicity.  Av. no. of prior CNS-directed therapies was 2.8 and 94% of the patients had prior taxane treatment.  Conclusions: Even though the study preset rule for iORR per IRF was not met in this heavily pretreated population, a notable CNS and systemic treatment effect was seen in all patients including symptom improvement and prolonged overall survival compared to historical control for the subset of patients with leptomeningeal carcinomatosis (n = 28).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX579YwjqbP7Vg90H21EOLACvtfcHk0ljCPqiJG1BFwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVyktLjP&md5=1eeddf58a14d5f794b0d626b4755c34b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-3258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-3258%26sid%3Dliteratum%253Aachs%26aulast%3DKumthekar%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DS.%2BC.%26aulast%3DBrenner%26aufirst%3DA.%2BJ.%26aulast%3DKesari%26aufirst%3DS.%26aulast%3DPiccioni%26aufirst%3DD.%2BE.%26aulast%3DAnders%26aufirst%3DC.%26aulast%3DCarrillo%26aufirst%3DJ.%26aulast%3DChalasani%26aufirst%3DP.%26aulast%3DKabos%26aufirst%3DP.%26aulast%3DPuhalla%26aufirst%3DS.%26aulast%3DTkaczuk%26aufirst%3DK.%26aulast%3DGarcia%26aufirst%3DA.%2BA.%26aulast%3DAhluwalia%26aufirst%3DM.%2BS.%26aulast%3DWefel%26aufirst%3DJ.%2BS.%26aulast%3DLakhani%26aufirst%3DN.%26aulast%3DIbrahim%26aufirst%3DN.%26atitle%3DANG1005%252C%2520a%2520brain-penetrating%2520peptide%25E2%2580%2593drug%2520conjugate%252C%2520shows%2520activity%2520in%2520patients%2520with%2520breast%2520cancer%2520with%2520leptomeningeal%2520carcinomatosis%2520and%2520recurrent%2520brain%2520metastases%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26issue%3D12%26spage%3D2789%26epage%3D2799%26doi%3D10.1158%2F1078-0432.CCR-19-3258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrail, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandhasin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankhala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarantopoulos, J.</span></span> <span> </span><span class="NLM_article-title">Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1158%2F1535-7163.MCT-11-0566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=22203732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=308-316&issue=2&author=R.+Kurzrockauthor=N.+Gabrailauthor=C.+Chandhasinauthor=S.+Moulderauthor=C.+Smithauthor=A.+Brennerauthor=K.+Sankhalaauthor=A.+Mitaauthor=K.+Elianauthor=D.+Bouchardauthor=J.+Sarantopoulos&title=Safety%2C+pharmacokinetics%2C+and+activity+of+GRN1005%2C+a+novel+conjugate+of+angiopep-2%2C+a+peptide+facilitating+brain+penetration%2C+and+paclitaxel%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1535-7163.MCT-11-0566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Kurzrock, Razelle; Gabrail, Nash; Chandhasin, Chandtip; Moulder, Stacy; Smith, Carrie; Brenner, Andrew; Sankhala, Kamalesh; Mita, Alain; Elian, Kelly; Bouchard, Danielle; Sarantopoulos, John</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">308-316</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GRN1005 is a novel peptide-drug conjugate composed of paclitaxel covalently linked to a peptide, angiopep-2, that targets the low-d. lipoprotein receptor-related protein 1.  This first-in-human study evaluated the safety, tolerability, pharmacokinetics, and efficacy of GRN1005 in patients with advanced solid tumors.  Patients in sequential cohorts (one patient per cohort until grade 2 toxicity, then 3 + 3 design) received i.v. GRN1005 at escalating doses between 30 and 700 mg/m2 once in every 21 days.  In the max. tolerated dose (MTD) expansion group, patients were required to have brain metastases.  Fifty-six patients received GRN1005, including 41 with brain metastases (median no. of prior therapies = 4).  MTD was 650 mg/m2; the main dose-limiting toxicity was myelosuppression.  Sixteen of 20 patients dosed at the MTD had brain metastases.  Pharmacokinetics was dose linear and the mean terminal-phase elimination half-life was 3.6 h.  No evidence of accumulation was obsd. after repeat dosing.  No anti-GRN1005 antibodies were detected.  Five of the 20 patients (25%) dosed at 650 mg/m2 (MTD), three of whom had previous taxane therapy, achieved an overall partial response (breast, n = 2; non-small cell lung cancer, n = 2; and ovarian cancer, n = 1); responses in all five patients were also accompanied by shrinkage of brain lesions (-17% to -50%).  In addn., six patients (11%; doses 30-700 mg/m2) experienced stable disease that lasted 4 mo or more.  GRN1005 was well tolerated and showed activity in heavily pretreated patients with advanced solid tumors, including those who had brain metastases and/or failed prior taxane therapy.  Mol Cancer Ther; 11(2); 308-16.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKh0X2_uE5TbVg90H21EOLACvtfcHk0lh47xQiQ3hD2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWltLk%253D&md5=c740d108d5f889403d34cfa733de3f8c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0566%26sid%3Dliteratum%253Aachs%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DGabrail%26aufirst%3DN.%26aulast%3DChandhasin%26aufirst%3DC.%26aulast%3DMoulder%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DBrenner%26aufirst%3DA.%26aulast%3DSankhala%26aufirst%3DK.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DElian%26aufirst%3DK.%26aulast%3DBouchard%26aufirst%3DD.%26aulast%3DSarantopoulos%26aufirst%3DJ.%26atitle%3DSafety%252C%2520pharmacokinetics%252C%2520and%2520activity%2520of%2520GRN1005%252C%2520a%2520novel%2520conjugate%2520of%2520angiopep-2%252C%2520a%2520peptide%2520facilitating%2520brain%2520penetration%252C%2520and%2520paclitaxel%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D2%26spage%3D308%26epage%3D316%26doi%3D10.1158%2F1535-7163.MCT-11-0566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patronas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri-Kordestani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davarpanah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burotto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choyke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liewehr, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramaniam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">ANG1005 for breast cancer brain metastases: correlation between (18)F-FLT-PET after first cycle and MRI in response assessment</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>160</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1007/s10549-016-3972-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1007%2Fs10549-016-3972-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=27620882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFarsrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2016&pages=51-59&issue=1&author=C.+C.+O%E2%80%99Sullivanauthor=M.+Lindenbergauthor=C.+Brylaauthor=N.+Patronasauthor=C.+J.+Peerauthor=L.+Amiri-Kordestaniauthor=N.+Davarpanahauthor=E.+M.+Gonzalezauthor=M.+Burottoauthor=P.+Choykeauthor=S.+M.+Steinbergauthor=D.+J.+Liewehrauthor=W.+D.+Figgauthor=T.+Fojoauthor=S.+Balasubramaniamauthor=S.+E.+Bates&title=ANG1005+for+breast+cancer+brain+metastases%3A+correlation+between+%2818%29F-FLT-PET+after+first+cycle+and+MRI+in+response+assessment&doi=10.1007%2Fs10549-016-3972-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment</span></div><div class="casAuthors">O'Sullivan, C. C.; Lindenberg, M.; Bryla, C.; Patronas, N.; Peer, C. J.; Amiri-Kordestani, L.; Davarpanah, N.; Gonzalez, E. M.; Burotto, M.; Choyke, P.; Steinberg, S. M.; Liewehr, D. J.; Figg, W. D.; Fojo, T.; Balasubramaniam, S.; Bates, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-59</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Improved therapies and imaging modalities are needed for the treatment of breast cancer brain metastases (BCBM).  ANG1005 is a drug conjugate consisting of paclitaxel covalently linked to Angiopep-2, designed to cross the blood-brain barrier.  We conducted a biomarker substudy to evaluate 18F-FLT-PET for response assessment.  Ten patients with measurable BCBM received ANG1005 at a dose of 550 mg/m2 IV every 21 days.  Before and after cycle 1, patients underwent PET imaging with 18F-FLT, a thymidine analog, retention of which reflects cellular proliferation, for comparison with gadolinium-contrast magnetic resonance imaging (Gd-MRI) in brain metastases detection and response assessment.  A 20 % change in uptake after one cycle of ANG1005 was deemed significant.  Thirty-two target and twenty non-target metastatic brain lesions were analyzed.  The median tumor redn. by MRI after cycle 1 was -17.5 % (n = 10 patients, lower, upper quartiles: -25.5, -4.8 %) in target lesion size compared with baseline.  Fifteen of twenty-nine target lesions (52 %) and 12/20 nontarget lesions (60 %) showed a ≥20 % decrease post-therapy in FLT-PET SUV change (odds ratio 0.71, 95 % CI: 0.19, 2.61).  The median percentage change in SUVmax was -20.9 % (n = 29 lesions; lower, upper quartiles: -42.4, 2.0 %), and the median percentage change in SUV80 was also -20.9 % (n = 29; lower, upper quartiles: -49.0, 0.0 %).  Two patients had confirmed partial responses by PET and MRI lasting 6 and 18 cycles, resp.  Seven patients had stable disease, receiving a median of six cycles.  ANG1005 warrants further study in BCBM.  Results demonstrated a moderately strong assocn. between MRI and 18F-FLT-PET imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWSt4xacdEFbVg90H21EOLACvtfcHk0lh47xQiQ3hD2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFarsrnI&md5=cd0171317481df301426dac25c1f59dc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs10549-016-3972-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-016-3972-z%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DC.%2BC.%26aulast%3DLindenberg%26aufirst%3DM.%26aulast%3DBryla%26aufirst%3DC.%26aulast%3DPatronas%26aufirst%3DN.%26aulast%3DPeer%26aufirst%3DC.%2BJ.%26aulast%3DAmiri-Kordestani%26aufirst%3DL.%26aulast%3DDavarpanah%26aufirst%3DN.%26aulast%3DGonzalez%26aufirst%3DE.%2BM.%26aulast%3DBurotto%26aufirst%3DM.%26aulast%3DChoyke%26aufirst%3DP.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DLiewehr%26aufirst%3DD.%2BJ.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBalasubramaniam%26aufirst%3DS.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DANG1005%2520for%2520breast%2520cancer%2520brain%2520metastases%253A%2520correlation%2520between%2520%252818%2529F-FLT-PET%2520after%2520first%2520cycle%2520and%2520MRI%2520in%2520response%2520assessment%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2016%26volume%3D160%26issue%3D1%26spage%3D51%26epage%3D59%26doi%3D10.1007%2Fs10549-016-3972-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bushnell, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodeker, K. L.</span></span> <span> </span><span class="NLM_article-title">Overview and current status of peptide receptor radionuclide therapy</span>. <i>Surg Oncol Clin N Am.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.soc.2019.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.soc.2019.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=32151363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BB383htlOhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2020&pages=317-326&issue=2&author=D.+L.+Bushnellauthor=K.+L.+Bodeker&title=Overview+and+current+status+of+peptide+receptor+radionuclide+therapy&doi=10.1016%2Fj.soc.2019.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Overview and Current Status of Peptide Receptor Radionuclide Therapy</span></div><div class="casAuthors">Bushnell David L; Bodeker Kellie L</div><div class="citationInfo"><span class="NLM_cas:title">Surgical oncology clinics of North America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-326</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment of patients with metastatic neuroendocrine tumors, delivering modest objective tumor response rates but notable survival and symptomatic benefits.  The first PRRT approved by the US Food and Drug Administration was lutetium 177-DOTATATE and is for use in adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.  The treatment paradigm typically leads to significant improvement in symptomology coupled with an extended period of progression-free survival.  Side effects are limited, with a small fraction of individuals experiencing clinically significant long-term renal or hematologic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQemTm5bfAXGAwxfk_AGB-EfW6udTcc2ebfXry2rMOai7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383htlOhsg%253D%253D&md5=8d69ffe3ae6a3e9fc2240a102d581ee8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.soc.2019.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.soc.2019.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DBushnell%26aufirst%3DD.%2BL.%26aulast%3DBodeker%26aufirst%3DK.%2BL.%26atitle%3DOverview%2520and%2520current%2520status%2520of%2520peptide%2520receptor%2520radionuclide%2520therapy%26jtitle%3DSurg%2520Oncol%2520Clin%2520N%2520Am.%26date%3D2020%26volume%3D29%26issue%3D2%26spage%3D317%26epage%3D326%26doi%3D10.1016%2Fj.soc.2019.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, F. F.</span></span> <span> </span><span class="NLM_article-title">Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2934</span>– <span class="NLM_lpage">2974</span>, <span class="refDoi"> DOI: 10.1021/cr500171e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr500171e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVSlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=2934-2974&issue=8&author=S.+Banerjeeauthor=M.+R.+Pillaiauthor=F.+F.+Knapp&title=Lutetium-177+therapeutic+radiopharmaceuticals%3A+linking+chemistry%2C+radiochemistry%2C+and+practical+applications&doi=10.1021%2Fcr500171e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications</span></div><div class="casAuthors">Banerjee, Sharmila; Pillai, M. R. A.; Knapp, F. F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2934-2974</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7IvEUDjbcgbVg90H21EOLACvtfcHk0lgfexmgZD9bMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVSlu7w%253D&md5=77855edfd4e4d1afced8a0bf6ddfbd36</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcr500171e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr500171e%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DPillai%26aufirst%3DM.%2BR.%26aulast%3DKnapp%26aufirst%3DF.%2BF.%26atitle%3DLutetium-177%2520therapeutic%2520radiopharmaceuticals%253A%2520linking%2520chemistry%252C%2520radiochemistry%252C%2520and%2520practical%2520applications%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26issue%3D8%26spage%3D2934%26epage%3D2974%26doi%3D10.1021%2Fcr500171e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">3379</span>– <span class="NLM_lpage">3409</span>, <span class="refDoi"> DOI: 10.3390/molecules18033379</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3390%2Fmolecules18033379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=23493103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Git7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=3379-3409&issue=3&author=M.+Jamousauthor=U.+Haberkornauthor=W.+Mier&title=Synthesis+of+peptide+radiopharmaceuticals+for+the+therapy+and+diagnosis+of+tumor+diseases&doi=10.3390%2Fmolecules18033379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases</span></div><div class="casAuthors">Jamous, Mazen; Haberkorn, Uwe; Mier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3379-3409</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Despite the advances in mol. biol. and biochem., the prognosis of patients suffering from tumor diseases remains poor.  The limited therapeutic success can be explained by the insufficient performance of the common chemotherapeutic drugs that lack the ability to specifically target tumor tissues.  Recently peptide radiopharmaceuticals have been developed that enable the concurrent imaging and therapy of tumors expressing a specific target.  Here, with a special emphasis on the synthesis of the building blocks required for the complexation of metallic radioisotopes, the requirements to the design and synthesis of radiolabeled peptides for clin. applications are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0vRMkoMMmibVg90H21EOLACvtfcHk0lgfexmgZD9bMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Git7o%253D&md5=b3d44338aae5b93408ba5ab8a4cc1339</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3390%2Fmolecules18033379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules18033379%26sid%3Dliteratum%253Aachs%26aulast%3DJamous%26aufirst%3DM.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DMier%26aufirst%3DW.%26atitle%3DSynthesis%2520of%2520peptide%2520radiopharmaceuticals%2520for%2520the%2520therapy%2520and%2520diagnosis%2520of%2520tumor%2520diseases%26jtitle%3DMolecules%26date%3D2013%26volume%3D18%26issue%3D3%26spage%3D3379%26epage%3D3409%26doi%3D10.3390%2Fmolecules18033379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuselier, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span> <span> </span><span class="NLM_article-title">Effects of camptothecin conjugated to a somatostatin analogue vector on growth of tumor cell lines in culture and related tumors in rodents</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1080/10717540490446125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1080%2F10717540490446125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=15371104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1WqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=231-238&issue=4&author=L.+Sunauthor=J.+A.+Fuselierauthor=D.+H.+Coy&title=Effects+of+camptothecin+conjugated+to+a+somatostatin+analogue+vector+on+growth+of+tumor+cell+lines+in+culture+and+related+tumors+in+rodents&doi=10.1080%2F10717540490446125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Camptothecin Conjugated to a Somatostatin Analog Vector on Growth of Tumor Cell Lines in Culture and Related Tumors in Rodents</span></div><div class="casAuthors">Sun, Lichun; Fuselier, Joseph; Coy, David</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">231-238</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Two CPT-SSA conjugates, JF-10-71 and JF-10-81, contg. a chem. adjustable release-rate carbamate linker, have been reported previously by us to potently inhibit growth of human neuroblastoma IMR32 cells overexpressing somatostatin receptor type II (SSTR2) but are stable under buffer incubation conditions or in rat plasma.  Further expts. now reveal that the conjugates performed well against many addnl. cell lines, particularly somatostatin receptor contg. rat pancreatic CA20948 cells that were actually more sensitive to the conjugates than free camptothecin itself.  JF-10-71 and JF-10-81 also were examd. for their inhibitory effects on the growth of this and several other tumors transplanted into rats (CA20948) or nude mice.  CA20948 tumors, known to overexpress SSTR2 and grown in Lewis rats, were treated, resp., with nontoxic 400 nmol/kg i.p. doses of JF-10-71 or JF-10-81.  Also, SSTR2-pos. human SCLC NCI-H69 tumors transplanted in nude mice were treated in a similar fashion.  Human prostate PC-3 tumors, which do not contain high concns. of SSTR2, also were grown in nude mice and treated with a 400 nmol/kg i.p. dose of JF-10-71.  Both cytotoxic conjugates significantly inhibited growth of SSTR2-specific pancreatic and SCLC tumors, but JF-10-81 did not significantly affect PC-3 tumor growth.  These exptl. results suggested that CPT-SSA conjugates can effectively target and kill tumor cells growing in vivo and that the effect is mediated by somatostatin receptors resulting in either release of camptothecin at the cell surface or, more likely, after receptor-mediated cellular internalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnDdmX6zjHcLVg90H21EOLACvtfcHk0lhP4_4FB9lOMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1WqtLY%253D&md5=d823ac8c25a86a9ea73604e88be51e78</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1080%2F10717540490446125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10717540490446125%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DFuselier%26aufirst%3DJ.%2BA.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DEffects%2520of%2520camptothecin%2520conjugated%2520to%2520a%2520somatostatin%2520analogue%2520vector%2520on%2520growth%2520of%2520tumor%2520cell%2520lines%2520in%2520culture%2520and%2520related%2520tumors%2520in%2520rodents%26jtitle%3DDrug%2520Delivery%26date%3D2004%26volume%3D11%26issue%3D4%26spage%3D231%26epage%3D238%26doi%3D10.1080%2F10717540490446125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptor-targeted anti-cancer therapy</span>. <i>Curr. Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.2174/156720111793663633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.2174%2F156720111793663633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=21034425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=2-10&issue=1&author=L.+C.+Sunauthor=D.+H.+Coy&title=Somatostatin+receptor-targeted+anti-cancer+therapy&doi=10.2174%2F156720111793663633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin receptor-targeted anti-cancer therapy</span></div><div class="casAuthors">Sun, Li-Chun; Coy, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Delivery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-10</span>CODEN:
                <span class="NLM_cas:coden">CDDUBJ</span>;
        ISSN:<span class="NLM_cas:issn">1567-2018</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Somatostatin receptors (SSTRs), esp. SSTR subtype 2, are found expressed at relatively higher levels in many tumor cells and in tumoral blood vessels relative to normal tissues.  This creates an opportunity for developing various cytotoxic SST conjugates that selectively target SSTR2-specific sites.  Accordingly, some potent chemotherapeutic agents such as camptothecin (CPT), methotrexate (MTX), paclitaxel (PTX) and doxorubicin (DOX) have been coupled to SSTR2-preferential somatostatin (SST) analogs.  These new cytotoxic SST conjugates display significant SSTR-selective anti-tumor abilities in many different types of tumors.  For instance, the CPT-SST conjugate JF-10-81, in which CPT is coupled to the N-terminus of a SSTR2-specific SST analog (JF-07-69), had wide ranging anti-tumor and anti-angiogenic ability.  This conjugate also showed an ability to overcome multi-drug resistance (MDR) in SSTR-over-expressing and CPT-insensitive human pancreatic carcinoid BON cells.  Notably, another DOX-SST conjugate, AN-238, made by coupling pyrrolino-DOX to the SST analog RC-121, displayed indirect anti-tumor activity against SSTR-neg., non-small cell lung cancer H-157 tumor growth by directly targeting SSTR-pos. tumoral vessels of host mice.  These cytotoxic SST conjugates should deliver chemotherapeutic agents to receptor-specific sites, enhance anti-tumor efficacy, reduce toxic side effects to normal tissues, and to some extent, overcome MDR.  These and other peptide conjugates may possibly represent a newer generation of receptor-targeted cancer therapeutics.  This review discusses the progress with ref. to SST-based and SSTR-selective cytotoxic cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo63yfENj4dwrVg90H21EOLACvtfcHk0lhP4_4FB9lOMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSnsb8%253D&md5=113189d5436c92a74ee1017534416301</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F156720111793663633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720111793663633%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%2BC.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DSomatostatin%2520receptor-targeted%2520anti-cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Delivery%26date%3D2011%26volume%3D8%26issue%3D1%26spage%3D2%26epage%3D10%26doi%3D10.2174%2F156720111793663633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuselier, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span> <span> </span><span class="NLM_article-title">Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice</span>. <i>Clin. Med.: Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.4137/CMO.S970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.4137%2FCMO.S970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=21892324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BC3MfhtlaltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=491-499&author=L.+C.+Sunauthor=L.+V.+Mackeyauthor=J.+Luoauthor=J.+A.+Fuselierauthor=D.+H.+Coy&title=Targeted+chemotherapy+using+a+cytotoxic+somatostatin+conjugate+to+inhibit+tumor+growth+and+metastasis+in+nude+mice&doi=10.4137%2FCMO.S970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice</span></div><div class="casAuthors">Sun Li-Chun; Mackey L Vienna; Luo Jing; Fuselier Joseph A; Coy David H</div><div class="citationInfo"><span class="NLM_cas:title">Clinical medicine. Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">491-9</span>
        ISSN:<span class="NLM_cas:issn">1177-9314</span>.
    </div><div class="casAbstract">The major problems of traditional chemotherapy are non-selectivity and non-specificity, resulting in severe toxic side effects.  Peptides are a new-generation of drug-delivery vector to increase efficacy of this therapy and avoid the resulting damage.  The cytotoxic somatostatin (SST) conjugate JF-10-81 was developed by coupling camptothecin (CPT) to the N-terminus of a SST analog (JF-07-69) using an activated carbamate linker.  This conjugate selectively targets somatostatin receptor subtype 2 (SSTR2) and also retains high binding affinity and rapid internalization as well as anti-proliferative activity towards various tumor cells.  JF-10-81 was tested for its inhibitory activity against the growth of human tumors which included neuroblastoma (IMR32), pancreatic cancer (CFPAC-1), leukemia (MOLT-4), pancreatic carcinoid (BON) and prostate cancer (PC-3).  Both SSTR2 mRNAs and proteins were detected in all these tumor cell lines.  The conjugate displayed potent in vivo inhibitory activity, although some of the potency measured in in vitro experiments was lost.  JF-10-81 was found to significantly inhibit growth of these SSTR-positive tumors, resulting in 87% tumor reduction in neuroblastoma IMR32 and 97% in leukemia MOLT-4 bearing animals, even inducing regression of CFPAC-1 tumors.  SSTR-overexpressing BON tumors were unfortunately relatively CPT-insensitive in vitro, however, JF-10-81 again exhibited in vivo potency presumably by specifically increasing CPT concentrations inside the tumor cells so that the inhibition rate for JF-10-81 was 85%.  Also, JF-10-81 was used to treat highly invasive PC-3 tumors where s.c. injections inhibited both tumor growth (almost 60% reduction) and tumor metastasis (over 70%).  This conjugate demonstrated its broad and excellent anti-tumor activity by targeting SSTR2-specific tumor tissues, supporting that short peptides and their analogs may be applied as ideal drug-delivery carriers to improve the traditional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSC5rAW0_emgrrIbt-tGZmxfW6udTcc2eavmw3KPXTnmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfhtlaltA%253D%253D&md5=62147ab10530e0b80becb4b5d02e4247</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4137%2FCMO.S970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FCMO.S970%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%2BC.%26aulast%3DMackey%26aufirst%3DL.%2BV.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DFuselier%26aufirst%3DJ.%2BA.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DTargeted%2520chemotherapy%2520using%2520a%2520cytotoxic%2520somatostatin%2520conjugate%2520to%2520inhibit%2520tumor%2520growth%2520and%2520metastasis%2520in%2520nude%2520mice%26jtitle%3DClin.%2520Med.%253A%2520Oncol.%26date%3D2008%26volume%3D2%26spage%3D491%26epage%3D499%26doi%3D10.4137%2FCMO.S970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sayyad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrettos, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karampelas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatzigiannis, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyridaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liapakis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamvakopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span> <span> </span><span class="NLM_article-title">Development of bioactive gemcitabine-D-Lys(6)-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.ejmech.2019.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=30716713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVWqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2019&pages=256-266&author=N.+Sayyadauthor=E.+I.+Vrettosauthor=T.+Karampelasauthor=C.+M.+Chatzigiannisauthor=K.+Spyridakiauthor=G.+Liapakisauthor=C.+Tamvakopoulosauthor=A.+G.+Tzakos&title=Development+of+bioactive+gemcitabine-D-Lys%286%29-GnRH+prodrugs+with+linker-controllable+drug+release+rate+and+enhanced+biopharmaceutical+profile&doi=10.1016%2Fj.ejmech.2019.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile</span></div><div class="casAuthors">Sayyad, Nisar; Vrettos, Eirinaios I.; Karampelas, Theodoros; Chatzigiannis, Christos M.; Spyridaki, Katerina; Liapakis, George; Tamvakopoulos, Constantin; Tzakos, Andreas G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">256-266</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Peptide-drug conjugates have emerged as a potent approach to enhance the targeting and pharmacokinetic profiles of drugs.  However, the impact of the linker unit has not been explored/exploited in depth.  Gemcitabine (dFdC) is an anticancer agent used against a variety of solid tumors.  Despite its potency, gemcitabine suffers mostly due to its unspecific toxicity, lack of targeting and rapid metabolic inactivation.  To minimize these limitations and enable its targeting to tumors overexpressing the GnRH receptor, we examd. the peptide-drug conjugation approach.  Our design hypothesis was driven by the impact that the linker unit could have on the peptide-drug conjugate efficacy.  Along these lines, in order to exploit the potential to manipulate the potency of gemcitabine through altering the linker unit we constructed three different novel peptide-drug conjugates assembled of gemcitabine, the tumor-homing peptide D-Lys6-GnRH and modified linker building blocks.  Specifically, the linker was sculpted to either allow slow drug release (utilizing carbamate bond) or rapid disassocn. (using amide and ester bonds).  Notably, the new analogs possessed up to 95.5-fold enhanced binding affinity for the GnRH receptor (GnRH-R) compared to the natural peptide ligand D-Lys6-GnRH.  Addnl., their in vitro cytotoxicity was evaluated in four different cancer cell lines.  Their cellular uptake, release of gemcitabine and inactivation of gemcitabine to its inactive metabolite (dFdU) was explored in a representative cell line.  In vitro stability and the consequent drug release were evaluated in cell culture medium and human plasma.  In vivo pharmacokinetic studies were performed in mice, summarizing the relative stability of the three conjugates and the released levels of gemcitabine in comparison with dFdU.  These studies suggest that the fine tuning of the linkage within a peptide-drug conjugate affects the drug release rate and its overall pharmaceutical profile.  This could eventually emerge as an intriguing medicinal chem. approach to optimize bio-profiles of prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKqPVzBEzeibVg90H21EOLACvtfcHk0lgHi5m4qF2pzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVWqs70%253D&md5=b91169fc7d0d97102ea43153d97dfdbe</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DSayyad%26aufirst%3DN.%26aulast%3DVrettos%26aufirst%3DE.%2BI.%26aulast%3DKarampelas%26aufirst%3DT.%26aulast%3DChatzigiannis%26aufirst%3DC.%2BM.%26aulast%3DSpyridaki%26aufirst%3DK.%26aulast%3DLiapakis%26aufirst%3DG.%26aulast%3DTamvakopoulos%26aufirst%3DC.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26atitle%3DDevelopment%2520of%2520bioactive%2520gemcitabine-D-Lys%25286%2529-GnRH%2520prodrugs%2520with%2520linker-controllable%2520drug%2520release%2520rate%2520and%2520enhanced%2520biopharmaceutical%2520profile%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D166%26spage%3D256%26epage%3D266%26doi%3D10.1016%2Fj.ejmech.2019.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denmeade, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. R.</span></span> <span> </span><span class="NLM_article-title">Modulating paclitaxel bioavailability for targeting prostate cancer</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4973</span>– <span class="NLM_lpage">4984</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.04.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.bmc.2007.04.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=17502149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtFOjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=4973-4984&issue=14&author=S.+K.+Kumarauthor=S.+A.+Williamsauthor=J.+T.+Isaacsauthor=S.+R.+Denmeadeauthor=S.+R.+Khan&title=Modulating+paclitaxel+bioavailability+for+targeting+prostate+cancer&doi=10.1016%2Fj.bmc.2007.04.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating paclitaxel bioavailability for targeting prostate cancer</span></div><div class="casAuthors">Kumar, Srinivas K.; Williams, Simon A.; Isaacs, John T.; Denmeade, Samuel R.; Khan, Saeed R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4973-4984</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Four novel water-sol. peptide-paclitaxel conjugates were designed and synthesized as prostate-specific antigen (PSA)-activated prodrugs for prostate cancer therapy.  These prodrugs were composed of a peptide, HSSKLQ or SSKYQ, each of which is selectively cleavable by PSA; a self-immolative linker, either para-aminobenzyl alc. (PABS) or ethylene diamine (EDA); and the parent drug, paclitaxel.  Introduction of a PABA or EDA linker between the peptide and paclitaxel in 4 synthetic prodrugs resulted in products with an increased rate of hydrolysis by PSA.  The stability of prodrugs paclitaxel and HSSKLQ-paclitaxel(I), with the PABA linker, was poor in the serum-contg. medium because of the weak carbonate bond between the PABA and paclitaxel; however, this disadvantage was overcome by introducing a carbamate bond using an EDA linker in prodrug I.  Thus, the incorporation of an EDA linker increased both the stability and PSA-mediated activation of these prodrugs.  The cytotoxicity of each prodrug, as compared to paclitaxel, was detd. against a variety of cell lines, including the PSA-secreting CWR22Rv1 prostate cancer cell line.  The EDA-derived prodrug of SSKYQ-paclitaxel was stable and capable of being efficiently converted to an active drug that killed cells specifically in the presence of PSA, suggesting that this prodrug and similarly designed PSA-cleavable prodrugs may have potential as prostate cancer-specific therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-YHZx18aobrVg90H21EOLACvtfcHk0lgHi5m4qF2pzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtFOjsbY%253D&md5=1e092fe1a5e005b9df5c682655908060</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.04.029%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%2BK.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26aulast%3DIsaacs%26aufirst%3DJ.%2BT.%26aulast%3DDenmeade%26aufirst%3DS.%2BR.%26aulast%3DKhan%26aufirst%3DS.%2BR.%26atitle%3DModulating%2520paclitaxel%2520bioavailability%2520for%2520targeting%2520prostate%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26issue%3D14%26spage%3D4973%26epage%3D4984%26doi%3D10.1016%2Fj.bmc.2007.04.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span> <span> </span><span class="NLM_article-title">Organic carbamates in drug design and medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2895</span>– <span class="NLM_lpage">2940</span>, <span class="refDoi"> DOI: 10.1021/jm501371s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501371s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2895-2940&issue=7&author=A.+K.+Ghoshauthor=M.+Brindisi&title=Organic+carbamates+in+drug+design+and+medicinal+chemistry&doi=10.1021%2Fjm501371s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Organic Carbamates in Drug Design and Medicinal Chemistry</span></div><div class="casAuthors">Ghosh, Arun K.; Brindisi, Margherita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2895-2940</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The carbamate group is a key structural motif in many approved drugs and prodrugs.  There is an increasing use of carbamates in medicinal chem. and many derivs. are specifically designed to make drug-target interactions through their carbamate moiety.  In this Perspective, we present properties and stabilities of carbamates, reagents and chem. methodologies for the synthesis of carbamates, and recent applications of carbamates in drug design and medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGollKFyXYJJHLVg90H21EOLACvtfcHk0liZLwRdP6UrQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVWkuw%253D%253D&md5=e3548247931b74b60e299ada1e27dda5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm501371s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501371s%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DBrindisi%26aufirst%3DM.%26atitle%3DOrganic%2520carbamates%2520in%2520drug%2520design%2520and%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D7%26spage%3D2895%26epage%3D2940%26doi%3D10.1021%2Fjm501371s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2018.01.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.jconrel.2018.01.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29408580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt12qu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2018&pages=129-141&author=Y.+Liangauthor=S.+Liauthor=X.+Wangauthor=Y.+Zhangauthor=Y.+Sunauthor=Y.+Wangauthor=X.+Wangauthor=B.+Heauthor=W.+Daiauthor=H.+Zhangauthor=X.+Wangauthor=Q.+Zhang&title=A+comparative+study+of+the+antitumor+efficacy+of+peptide-doxorubicin+conjugates+with+different+linkers&doi=10.1016%2Fj.jconrel.2018.01.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers</span></div><div class="casAuthors">Liang, Yanqin; Li, Suxin; Wang, Xueling; Zhang, Yuan; Sun, Yanan; Wang, Yaoqi; Wang, Xiaoyou; He, Bing; Dai, Wenbing; Zhang, Hua; Wang, Xueqing; Zhang, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The peptide-drug conjugates caused much attention currently.  The purpose of present study was to elucidate the possible synergistic effect between ligand peptide and stimuli-responsive linkage in amphiphilic peptide-drug conjugates (APDCs) with different linkers.  Esp., the superiority of each strategy as well as the synergistic effect between them was carefully investigated via the parallel comparisons of the three systems throughout of the whole study.  Here, we synthesized three APDCs, namely, cRGD-SS-DOX (RSSDOX), cRGD-S-DOX (RSDOX) and cRGD-VC-DOX (RVCDOX), using doxorubicin (DOX) as a model cytotoxic agent, cRGDfC as a homing peptide, and redn. cleavable disulfide (SS), noncleavable single thioether (S) or cathepsin B cleavable valine-citrulline dipeptide (VC) as linker.  The APDCs showed high drug loading capacity and they were evaluated in vitro in the integrin αvβ3-overexpressing B16 cells and in vivo in tumor-bearing C57BL/6 mice.  Endocytosis mechanism assay demonstrated that three types of APDCs internalized into cells through adynamin and actin depolymg.-mediated pathway following receptor-mediated endocytosis.  Notably, RSDOX or RVCDOX induced stronger antitumor efficacy, which depended on their cellular uptake levels, intracellular trafficking and the colocalization rates with lysosomes.  The in vivo efficacy of RSDOX or RVCDOX was 1.4-1.7 fold of free DOX and 1.7-2.0 fold of RSSDOX, resp.  In addn., RSDOX or RVCDOX demonstrated acceptable system, tissue and blood compatibility.  The compromised efficacy of RSSDOX might be due to the generation of DOX-SH during degrdn. of prodrug, but not DOX.  Taken together, our studies suggest that certain type of APDCs can significantly decrease the toxicity of free DOX and improve therapy outcome, which provides insight for the design of peptide-drug conjugates integrating ligand peptide and stimuli-responsive linkage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaY4DklRVraLVg90H21EOLACvtfcHk0ljn1sDMwxiCdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt12qu7o%253D&md5=0214f7cef5fbe4493f8a6a4ec48be9fd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2018.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2018.01.033%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DDai%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DA%2520comparative%2520study%2520of%2520the%2520antitumor%2520efficacy%2520of%2520peptide-doxorubicin%2520conjugates%2520with%2520different%2520linkers%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2018%26volume%3D275%26spage%3D129%26epage%3D141%26doi%3D10.1016%2Fj.jconrel.2018.01.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bajjuri, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S. C.</span></span> <span> </span><span class="NLM_article-title">The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201000478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1002%2Fcmdc.201000478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=21154805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sru7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=54-59&issue=1&author=K.+M.+Bajjuriauthor=Y.+Liuauthor=C.+Liuauthor=S.+C.+Sinha&title=The+legumain+protease-activated+auristatin+prodrugs+suppress+tumor+growth+and+metastasis+without+toxicity&doi=10.1002%2Fcmdc.201000478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The Legumain Protease-Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity</span></div><div class="casAuthors">Bajjuri, Krishna Mohan; Liu, Yuan; Liu, Cheng; Sinha, Subhash C.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-59</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Naturally occurring antimitotic pentapeptide dolastatin and its synthetic analog auristatin E possess subnanomolar cytotoxicity against many human cancer cell lines and are over a hundred to a thousand times more potent than many pharmaceuticals currently used in clinic. We focused on MMAE and DDAE, and prepd. and evaluated their prodrugs, which undergo tumor assocd. protease catalyzed activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBf4TrZOUgrVg90H21EOLACvtfcHk0ljn1sDMwxiCdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sru7nK&md5=0661ccec322d8470be92bab2a0803da9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000478%26sid%3Dliteratum%253Aachs%26aulast%3DBajjuri%26aufirst%3DK.%2BM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DSinha%26aufirst%3DS.%2BC.%26atitle%3DThe%2520legumain%2520protease-activated%2520auristatin%2520prodrugs%2520suppress%2520tumor%2520growth%2520and%2520metastasis%2520without%2520toxicity%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26issue%3D1%26spage%3D54%26epage%3D59%26doi%3D10.1002%2Fcmdc.201000478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, C. O.</span></span> <span> </span><span class="NLM_article-title">Targeting legumain as a novel therapeutic strategy in cancers</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1268</span>, <span class="refDoi"> DOI: 10.2174/1389450117666161216125344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.2174%2F1389450117666161216125344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=27993111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlelsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1259-1268&issue=11&author=C.+W.+Maiauthor=F.+F.+Chungauthor=C.+O.+Leong&title=Targeting+legumain+as+a+novel+therapeutic+strategy+in+cancers&doi=10.2174%2F1389450117666161216125344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Legumain As a Novel Therapeutic Strategy in Cancers</span></div><div class="casAuthors">Mai, Chun-Wai; Fei-Lei Chung, Felicia; Leong, Chee-Onn</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1259-1268</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Recent reports indicate that the tumor microenvironment plays a pivotal role in cancer development and progression, leading to a paradigm shift in the way cancer is studied and targeted.  In contrast to traditional approaches, where only tumor cells are targeted for the treatment, an emerging approach is to develop therapeutics which target the tumor microenvironment while complementing or enhancing current treatments.  Legumain (LGMN) is a newly identified target which is highly expressed in the tumor microenvironment and in tumor cells, and holds potential both as a biomarker and as a therapeutic target. <P></P> Conclusion: This review will be the first to summarize the expression of LGMN in common cancers, as well as its roles in tumorigenesis and metastasis.  This review also discusses the current developments and future prospects of targeting LGMN through the development of DNA vaccines, azopeptides, small mol. inhibitors and LGMN activated prodrugs, highlighting the potential of LGMN as a target for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNwCisgtgt0LVg90H21EOLACvtfcHk0ljn1sDMwxiCdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlelsbvO&md5=3e3be3ac40b20a2d70f1fa815feaab0b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2174%2F1389450117666161216125344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666161216125344%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DC.%2BW.%26aulast%3DChung%26aufirst%3DF.%2BF.%26aulast%3DLeong%26aufirst%3DC.%2BO.%26atitle%3DTargeting%2520legumain%2520as%2520a%2520novel%2520therapeutic%2520strategy%2520in%2520cancers%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2017%26volume%3D18%26issue%3D11%26spage%3D1259%26epage%3D1268%26doi%3D10.2174%2F1389450117666161216125344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stern, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ofek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Many, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satchi-Fainaro, R.</span></span> <span> </span><span class="NLM_article-title">A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">500</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1021/bc800448u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc800448u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVyktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=500-510&issue=3&author=L.+Sternauthor=R.+Perryauthor=P.+Ofekauthor=A.+Manyauthor=D.+Shabatauthor=R.+Satchi-Fainaro&title=A+novel+antitumor+prodrug+platform+designed+to+be+cleaved+by+the+endoprotease+legumain&doi=10.1021%2Fbc800448u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Antitumor Prodrug Platform Designed to Be Cleaved by the Endoprotease Legumain</span></div><div class="casAuthors">Stern, Liron; Perry, Rotem; Ofek, Paula; Many, Ariel; Shabat, Doron; Satchi-Fainaro, Ronit</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">500-510</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chemotherapeutic treatment of neoplastic diseases is often restricted by adverse systemic toxicity, which limits the dose of drug that can be administered, or by the appearance of drug resistance.  Therefore, novel targeted therapeutic approaches are being developed to improve current conventional therapy in order to increase specificity and biocompatibility, and decrease toxicity.  Legumain represents a recently identified lysosomal protease that has been reported to be overexpressed in the majority of human solid tumors, to promote cell migration and is assocd. with enhanced tissue invasion and metastases.  Therefore, it serves as a promising candidate for prodrug therapy.  We synthesized a novel legumain-cleavable prodrug, carbobenzyloxy-alanine-alanine-asparagine-ethylenediamine-etoposide, which releases the chemotherapeutic agent, etoposide, as the active drug.  The prodrug was characterized and analyzed by 1H NMR and HPLC.  293 Human embryonic kidney (293 HEK) cells were stably transfected with human legumain, to achieve overexpression in vitro (293 HEK-Leg).  293 HEK-Leg cells expressed both active and inactive legumain and secreted it to the medium.  Legumain expression was found to be elevated because of serum starvation in both 293 HEK cells and PC3 human prostate carcinoma cells.  The com. substrate of legumain, carbobenzyloxy-alanine-alanine-asparagine-amino-4-Me coumarin (CBZ-Ala-Ala-Asn-AMC) and the synthesized prodrug were both cleaved by recombinant human legumain (rhlegumain) and legumain expressed in the 293 HEK-Leg cell lysate.  Upon cleavage by rhlegumain, the prodrug showed an inhibitory effect on the proliferation of 293 HEK and 293 HEK-Leg cells.  This study suggests a novel platform for prodrug therapy activated by legumain as a promising approach for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaEr0hM3i9UrVg90H21EOLACvtfcHk0ljLpiEYlUbzHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVyktrc%253D&md5=15a25647a8ffe0b4cd2bbb5d42565e33</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fbc800448u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc800448u%26sid%3Dliteratum%253Aachs%26aulast%3DStern%26aufirst%3DL.%26aulast%3DPerry%26aufirst%3DR.%26aulast%3DOfek%26aufirst%3DP.%26aulast%3DMany%26aufirst%3DA.%26aulast%3DShabat%26aufirst%3DD.%26aulast%3DSatchi-Fainaro%26aufirst%3DR.%26atitle%3DA%2520novel%2520antitumor%2520prodrug%2520platform%2520designed%2520to%2520be%2520cleaved%2520by%2520the%2520endoprotease%2520legumain%26jtitle%3DBioconjugate%2520Chem.%26date%3D2009%26volume%3D20%26issue%3D3%26spage%3D500%26epage%3D510%26doi%3D10.1021%2Fbc800448u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santi, D. V.</span></span> <span> </span><span class="NLM_article-title">Long-term stabilization of maleimide-thiol conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1021/bc5005262</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc5005262" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=145-152&issue=1&author=S.+D.+Fontaineauthor=R.+Reidauthor=L.+Robinsonauthor=G.+W.+Ashleyauthor=D.+V.+Santi&title=Long-term+stabilization+of+maleimide-thiol+conjugates&doi=10.1021%2Fbc5005262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Long-Term Stabilization of Maleimide-Thiol Conjugates</span></div><div class="casAuthors">Fontaine, Shaun D.; Reid, Ralph; Robinson, Louise; Ashley, Gary W.; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-152</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The rates of ring-opening hydrolysis and retro-Michael/Michael addn. (thiol exchange) of N-substituted succinimide thioethers formed by maleimide-thiol conjugation with glutathione and the effects of their maleimide nitrogen substituents on the rates of maleimide hydrolysis and retro-Michael/Michael addn. reactions were detd.  Ring-opening of conjugates prepd. with commonly used maleimides were too slow to serve as prevention against thiol exchange; however, the ring-opening rates of maleimides were greatly accelerated by electron withdrawing N-substituents, and the products had half-lives of over two years.  The PEGylated antibody Cimzia underwent ring-opening and retro-Michael addns. with rates consistent with model compds. except for the difference in acidity of the internal cysteine thiol of Cimizia's antibody vs. the nearly terminal cysteine thiols of the model compds.  Thus, conjugates (particularly antibody-drug conjugates prepd. as drugs) made with maleimides possessing electron-deficient nitrogen substituents can be purposefully hydrolyzed to their ring-opened counterparts in vitro to ensure their in vivo stability to thiol cleavage and exchange reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos9GcsNt5jAbVg90H21EOLACvtfcHk0ljLpiEYlUbzHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfN&md5=ab4fcacf5f9f58159bafa50353eab4d5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbc5005262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc5005262%26sid%3Dliteratum%253Aachs%26aulast%3DFontaine%26aufirst%3DS.%2BD.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DRobinson%26aufirst%3DL.%26aulast%3DAshley%26aufirst%3DG.%2BW.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DLong-term%2520stabilization%2520of%2520maleimide-thiol%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26issue%3D1%26spage%3D145%26epage%3D152%26doi%3D10.1021%2Fbc5005262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doronina, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duniho, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiske, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody–drug conjugates</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1038/nbt.2968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1038%2Fnbt.2968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=25194818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=1059-1062&issue=10&author=R.+P.+Lyonauthor=J.+R.+Setterauthor=T.+D.+Boveeauthor=S.+O.+Doroninaauthor=J.+H.+Hunterauthor=M.+E.+Andersonauthor=C.+L.+Balasubramanianauthor=S.+M.+Dunihoauthor=C.+I.+Leiskeauthor=F.+Liauthor=P.+D.+Senter&title=Self-hydrolyzing+maleimides+improve+the+stability+and+pharmacological+properties+of+antibody%E2%80%93drug+conjugates&doi=10.1038%2Fnbt.2968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates</span></div><div class="casAuthors">Lyon, Robert P.; Setter, Jocelyn R.; Bovee, Tim D.; Doronina, Svetlana O.; Hunter, Joshua H.; Anderson, Martha E.; Balasubramanian, Cindy L.; Duniho, Steven M.; Leiske, Chris I.; Li, Fu; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1059-1062</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many antibody-drug conjugates (ADCs) are unstable in vivo because they are formed from maleimide-contg. components conjugated to reactive thiols.  These thiosuccinimide linkages undergo two competing reactions in plasma: elimination of the maleimide through a retro-Michael reaction, which results in loss of drug-linker from the ADC, and hydrolysis of the thiosuccinimide ring, which results in a deriv. that is resistant to the elimination reaction.  In an effort to create linker technologies with improved stability characteristics, we used diaminopropionic acid (DPR) to prep. a drug-linker incorporating a basic amino group adjacent to the maleimide, positioned to provide intramol. catalysis of thiosuccinimide ring hydrolysis.  This basic group induces the thiosuccinimide to undergo rapid hydrolysis at neutral pH and room temp.  Once hydrolyzed, the drug-linker is no longer subject to maleimide elimination reactions, preventing nonspecific deconjugation.  In vivo studies demonstrate that the increased stability characteristics can lead to improved ADC antitumor activity and reduced neutropenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOKvXMGRGxEbVg90H21EOLACvtfcHk0liU-FG2ZjLUbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7jN&md5=96c3b19b856cc9c685cbdc704a842797</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2968%26sid%3Dliteratum%253Aachs%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DSetter%26aufirst%3DJ.%2BR.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DHunter%26aufirst%3DJ.%2BH.%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26aulast%3DBalasubramanian%26aufirst%3DC.%2BL.%26aulast%3DDuniho%26aufirst%3DS.%2BM.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DSelf-hydrolyzing%2520maleimides%2520improve%2520the%2520stability%2520and%2520pharmacological%2520properties%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26issue%3D10%26spage%3D1059%26epage%3D1062%26doi%3D10.1038%2Fnbt.2968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tumey, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loganzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barletta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, E. I.</span></span> <span> </span><span class="NLM_article-title">Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1871</span>– <span class="NLM_lpage">1880</span>, <span class="refDoi"> DOI: 10.1021/bc500357n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc500357n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFelsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1871-1880&issue=10&author=L.+N.+Tumeyauthor=M.+Charatiauthor=T.+Heauthor=E.+Sousaauthor=D.+Maauthor=X.+Hanauthor=T.+Clarkauthor=J.+Casavantauthor=F.+Loganzoauthor=F.+Barlettaauthor=J.+Lucasauthor=E.+I.+Graziani&title=Mild+method+for+succinimide+hydrolysis+on+ADCs%3A+impact+on+ADC+potency%2C+stability%2C+exposure%2C+and+efficacy&doi=10.1021%2Fbc500357n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy</span></div><div class="casAuthors">Tumey, L. Nathan; Charati, Manoj; He, Tao; Sousa, Eric; Ma, Dangshe; Han, Xiaogang; Clark, Tracey; Casavant, Jeff; Loganzo, Frank; Barletta, Frank; Lucas, Judy; Graziani, Edmund I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1871-1880</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The stability of the connection between the antibody and the toxin can have a profound impact on ADC safety and efficacy.  There has been increasing evidence in recent years that maleimide-based ADCs are prone to payload loss via a retro-Michael type reaction.  Herein, we report a mild method for the hydrolysis of the succinimide-thioether ring which results in a "ring-opened" linker.  ADCs contg. this hydrolyzed succinimide linker show equiv. cytotoxicity, improved in vitro stability, improved PK exposure, and improved efficacy as compared to their nonhydrolyzed counterparts.  This method offers a simple way to improve the stability, exposure, and efficacy of maleimide-based ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTF5ACrG78eLVg90H21EOLACvtfcHk0liU-FG2ZjLUbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFelsb3F&md5=a680174dc91b2ce9a3c72b6519a6c231</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fbc500357n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc500357n%26sid%3Dliteratum%253Aachs%26aulast%3DTumey%26aufirst%3DL.%2BN.%26aulast%3DCharati%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DSousa%26aufirst%3DE.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DClark%26aufirst%3DT.%26aulast%3DCasavant%26aufirst%3DJ.%26aulast%3DLoganzo%26aufirst%3DF.%26aulast%3DBarletta%26aufirst%3DF.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26atitle%3DMild%2520method%2520for%2520succinimide%2520hydrolysis%2520on%2520ADCs%253A%2520impact%2520on%2520ADC%2520potency%252C%2520stability%252C%2520exposure%252C%2520and%2520efficacy%26jtitle%3DBioconjugate%2520Chem.%26date%3D2014%26volume%3D25%26issue%3D10%26spage%3D1871%26epage%3D1880%26doi%3D10.1021%2Fbc500357n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziaei, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saghaeidehkordi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maslennikov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, K.</span></span> <span> </span><span class="NLM_article-title">Targeting triple negative breast cancer cells with novel cytotoxic peptide-doxorubicin conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3098</span>– <span class="NLM_lpage">3106</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.9b00755</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.9b00755" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCns7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=3098-3106&issue=12&author=E.+Ziaeiauthor=A.+Saghaeidehkordiauthor=C.+Dillauthor=I.+Maslennikovauthor=S.+Chenauthor=K.+Kaur&title=Targeting+triple+negative+breast+cancer+cells+with+novel+cytotoxic+peptide-doxorubicin+conjugates&doi=10.1021%2Facs.bioconjchem.9b00755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide-Doxorubicin Conjugates</span></div><div class="casAuthors">Ziaei, Elmira; Saghaeidehkordi, Azam; Dill, Cassandra; Maslennikov, Innokentiy; Chen, Shiuan; Kaur, Kamaljit</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3098-3106</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, we have designed and synthesized two novel peptide-drug conjugates (PDCs) where the drug, doxorubicin (Dox), is linked to the peptide via a succinimidyl thioether bond or a hydrazone linker.  A highly specific and proteolytically stable breast cancer cell targeting peptide (WxEAAYQrFL) is conjugated to Dox to synthesize peptide-Dox thioether (1) or hydrazone (2) conjugate.  The evaluation of the stability in water, media, and human serum showed that the conjugate 1 with the succinimidyl thioether linkage is more stable compared to the acid-sensitive hydrazone contg. conjugate 2.  The cytotoxicity studies showed that the two PDCs were as toxic as free Dox toward the triple neg. breast cancer (TNBC) cells and were 7-30 times less toxic (IC50 1.2-4.7μM for TNBC cells vs. 15-39μM for noncancerous cells) toward the noncancerous breast cells compared to the free doxorubicin (IC50 0.35-1.5μM for TNBC cells vs. 0.24μM for noncancerous cells).  The results from the comparative study of the two PDCs suggest that both may have translational potential for TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplThNVwCoHCrVg90H21EOLACvtfcHk0ljXHtu6C5sRWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCns7fM&md5=1f0933b36e2968aa33307a0d2495c65f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.9b00755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.9b00755%26sid%3Dliteratum%253Aachs%26aulast%3DZiaei%26aufirst%3DE.%26aulast%3DSaghaeidehkordi%26aufirst%3DA.%26aulast%3DDill%26aufirst%3DC.%26aulast%3DMaslennikov%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DK.%26atitle%3DTargeting%2520triple%2520negative%2520breast%2520cancer%2520cells%2520with%2520novel%2520cytotoxic%2520peptide-doxorubicin%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2019%26volume%3D30%26issue%3D12%26spage%3D3098%26epage%3D3106%26doi%3D10.1021%2Facs.bioconjchem.9b00755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morvaridi, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandol, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">17103</span>– <span class="NLM_lpage">17110</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.18632%2Foncotarget.7931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=26959746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=17103-17110&issue=13&author=B.+A.+Quinnauthor=S.+Wangauthor=E.+Barileauthor=S.+K.+Dasauthor=L.+Emdadauthor=D.+Sarkarauthor=S.+K.+Deauthor=S.+K.+Morvaridiauthor=J.+L.+Stebbinsauthor=S.+J.+Pandolauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Therapy+of+pancreatic+cancer+via+an+EphA2+receptor-targeted+delivery+of+gemcitabine&doi=10.18632%2Foncotarget.7931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine</span></div><div class="casAuthors">Quinn Bridget A; Das Swadesh K; Emdad Luni; Sarkar Devanand; Fisher Paul B; Wang Si; Barile Elisa; De Surya K; Stebbins John L; Fisher Paul B; Pellecchia Maurizio; Barile Elisa; De Surya K; Pellecchia Maurizio; Morvaridi Susan Kharagh; Pandol Stephen J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">17103-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.  In some patients, an active transport mechanism allows gemcitabine to enter efficiently into the tumor cells, resulting in a significant clinical benefit.  However, in most patients, low expression of gemcitabine transporters limits the efficacy of the drug to marginal levels, and patients need frequent administration of the drug at high doses, significantly increasing systemic drug toxicity.  In this article we focus on a novel targeted delivery approach for gemcitabine consisting of conjugating the drug with an EphA2 targeting agent.  We show that the EphA2 receptor is highly expressed in pancreatic cancers, and accordingly, the drug-conjugate is more effective than gemcitabine alone in targeting pancreatic tumors.  Our preliminary observations suggest that this approach may provide a general benefit to pancreatic cancer patients and offers a comprehensive strategy for enhancing delivery of diverse therapeutic agents to a wide range of cancers overexpressing EphA2, thereby potentially reducing toxicity while enhancing therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkle74R4yp-ekdrW1FkXG-fW6udTcc2eYGxaGHwmmNTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D&md5=0b5e311729fc3517d90882844ab3d3f2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7931%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DB.%2BA.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DEmdad%26aufirst%3DL.%26aulast%3DSarkar%26aufirst%3DD.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DMorvaridi%26aufirst%3DS.%2BK.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPandol%26aufirst%3DS.%2BJ.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DTherapy%2520of%2520pancreatic%2520cancer%2520via%2520an%2520EphA2%2520receptor-targeted%2520delivery%2520of%2520gemcitabine%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D13%26spage%3D17103%26epage%3D17110%26doi%3D10.18632%2Foncotarget.7931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salem, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udompholkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Reduction of circulating cancer cells and metastases in breast-cancer models by a potent EphA2-agonistic peptide–drug conjugate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2052</span>– <span class="NLM_lpage">2061</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1ylt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2052-2061&issue=5&author=A.+F.+Salemauthor=S.+Wangauthor=S.+Billetauthor=J.+F.+Chenauthor=P.+Udompholkulauthor=L.+Gambiniauthor=C.+Baggioauthor=H.+R.+Tsengauthor=E.+M.+Posadasauthor=N.+A.+Bhowmickauthor=M.+Pellecchia&title=Reduction+of+circulating+cancer+cells+and+metastases+in+breast-cancer+models+by+a+potent+EphA2-agonistic+peptide%E2%80%93drug+conjugate&doi=10.1021%2Facs.jmedchem.7b01837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate</span></div><div class="casAuthors">Salem, Ahmed F.; Wang, Si; Billet, Sandrine; Chen, Jie-Fu; Udompholkul, Parima; Gambini, Luca; Baggio, Carlo; Tseng, Hsian-Rong; Posadas, Edwin M.; Bhowmick, Neil A.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EphA2 overexpression has been assocd. with metastasis in multiple cancer types, including melanomas and ovarian, prostate, lung, and breast cancers.  We have recently proposed the development of peptide-drug conjugates (PDCs) using agonistic EphA2-targeting agents, such as the YSA peptide or its optimized version, 123B9.  Although our studies indicated that YSA- and 123B9-drug conjugates can selectively deliver cytotoxic drugs to cancer cells in vivo, the relatively low cellular agonistic activities (i.e., the high micromolar concns. required) of the agents toward the EphA2 receptor remained a limiting factor to the further development of these PDCs in the clinic.  Here, we report that a dimeric version of 123B9 can induce receptor activation at nanomolar concns.  Furthermore, we demonstrated that the conjugation of dimeric 123B9 with paclitaxel is very effective at targeting circulating tumor cells and inhibiting lung metastasis in breast-cancer models.  These studies represent an important step toward the development of effective EphA2-targeting PDCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBQLb1QD1aSrVg90H21EOLACvtfcHk0lhp_BM_3CRcgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1ylt7o%253D&md5=a03f5dbbc9030174487353d42332b3ab</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01837%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DA.%2BF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBillet%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DUdompholkul%26aufirst%3DP.%26aulast%3DGambini%26aufirst%3DL.%26aulast%3DBaggio%26aufirst%3DC.%26aulast%3DTseng%26aufirst%3DH.%2BR.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DBhowmick%26aufirst%3DN.%2BA.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DReduction%2520of%2520circulating%2520cancer%2520cells%2520and%2520metastases%2520in%2520breast-cancer%2520models%2520by%2520a%2520potent%2520EphA2-agonistic%2520peptide%25E2%2580%2593drug%2520conjugate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D2052%26epage%3D2061%26doi%3D10.1021%2Facs.jmedchem.7b01837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ireton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.2174/1568009053765780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.2174%2F1568009053765780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=15892616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=149-157&issue=3&author=R.+C.+Iretonauthor=J.+Chen&title=EphA2+receptor+tyrosine+kinase+as+a+promising+target+for+cancer+therapeutics&doi=10.2174%2F1568009053765780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span></div><div class="casAuthors">Ireton, Renee C.; Chen, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play crit. roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis.  Eph RTKs and their ligands, the ephrins, are also frequently overexpressed in a variety of cancers and tumor cell lines.  In particular, one family member, EphA2, is overexpressed in breast, prostate, lung, and colon cancers.  Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interactions both in tumor cells and in the tumor microenvironment, namely the tumor stroma and tumor vasculature.  Thus, EphA2 receptors are attractive targets for drug design, as targeting these mols. could simultaneously inhibit several aspects of tumor progression.  This review focuses on the multiple roles of EphA2 in cancer progression, the mechanisms by which EphA2 inhibition may halt this progression, and the pre-clin. results of EphA2 inhibition in various cancer model systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXkP68V5-EhLVg90H21EOLACvtfcHk0lj7KoU8LA6Xdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D&md5=4ec492801946594928f5b87a4727134a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.2174%2F1568009053765780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009053765780%26sid%3Dliteratum%253Aachs%26aulast%3DIreton%26aufirst%3DR.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DEphA2%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520promising%2520target%2520for%2520cancer%2520therapeutics%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2005%26volume%3D5%26issue%3D3%26spage%3D149%26epage%3D157%26doi%3D10.2174%2F1568009053765780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker-Daniels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">Differential regulation of EphA2 in normal and malignant cells</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1042</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)63899-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2FS0002-9440%2810%2963899-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=12651595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVemt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2003&pages=1037-1042&issue=4&author=J.+Walker-Danielsauthor=A.+R.+Hessauthor=M.+J.+Hendrixauthor=M.+S.+Kinch&title=Differential+regulation+of+EphA2+in+normal+and+malignant+cells&doi=10.1016%2FS0002-9440%2810%2963899-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Differential regulation of EphA2 in normal and malignant cells</span></div><div class="casAuthors">Walker-Daniels, Jennifer; Hess, Angela R.; Hendrix, Mary J. C.; Kinch, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1037-1042</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">A review on the biochem. and cellular consequences of EphA2 stimulation, esp. in malignant cells.  The mechanisms that may explain the overexpression and functional alterations of EphA2 in cancer are discussed.  A hypothetical model representing a potential signaling pathway initiated by EphA2 and crit. for vasculogenic mimicry is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOCiDKgpnOxrVg90H21EOLACvtfcHk0lj7KoU8LA6Xdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVemt70%253D&md5=e6298e47af35ad4815d6ba053df0931c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963899-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963899-0%26sid%3Dliteratum%253Aachs%26aulast%3DWalker-Daniels%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DA.%2BR.%26aulast%3DHendrix%26aufirst%3DM.%2BJ.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DDifferential%2520regulation%2520of%2520EphA2%2520in%2520normal%2520and%2520malignant%2520cells%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2003%26volume%3D162%26issue%3D4%26spage%3D1037%26epage%3D1042%26doi%3D10.1016%2FS0002-9440%2810%2963899-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mollaev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorokhovets, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faustova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabolotsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhunina, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamulaeva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabbarov, N.</span></span> <span> </span><span class="NLM_article-title">Type of pH sensitive linker reveals different time-dependent intracellular localization, in vitro and in vivo efficiency in alpha-fetoprotein receptor targeted doxorubicin conjugate</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2018.12.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.ijpharm.2018.12.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=30599230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2lsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2019&pages=138-146&author=M.+Mollaevauthor=N.+Gorokhovetsauthor=E.+Nikolskayaauthor=M.+Faustovaauthor=A.+Zabolotskyauthor=O.+Zhuninaauthor=M.+Sokolauthor=I.+Zamulaevaauthor=E.+Severinauthor=N.+Yabbarov&title=Type+of+pH+sensitive+linker+reveals+different+time-dependent+intracellular+localization%2C+in+vitro+and+in+vivo+efficiency+in+alpha-fetoprotein+receptor+targeted+doxorubicin+conjugate&doi=10.1016%2Fj.ijpharm.2018.12.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Type of pH sensitive linker reveals different time-dependent intracellular localization, in vitro and in vivo efficiency in alpha-fetoprotein receptor targeted doxorubicin conjugate</span></div><div class="casAuthors">Mollaev, M.; Gorokhovets, N.; Nikolskaya, E.; Faustova, M.; Zabolotsky, A.; Zhunina, O.; Sokol, M.; Zamulaeva, I.; Severin, E.; Yabbarov, N.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-146</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Despite the presence of a variety of modern anticancer drugs at the market, doxorubicin (Dox) is still widely used in antineoplastic therapy, although its administration causes severe side effects.  To enhance specific activity of such mols., various approaches have been exploited: targeted moieties like monoclonal antibodies, onco-specific proteins and peptides are utilized as specific vector mols.; environment sensitive linkers are exploited to facilitate transported drug release at the target point etc.  Acid-labile linkers are frequently used in synthesis due to the ability to be cleaved inside specific cellular compartments with acidic environment, avoiding possible recycling mechanisms.  Two types of conjugates contg. different acid-labile linkers have been synthesized.  In vitro efficiency of doxorubicin conjugates with recombinant receptor-binding domain of human alpha-fetoprotein (3dAFPpG) synthesized with use of cis-aconitic anhydride (CAA) and linker based on succinimidyl 3-(2-pyridyldithio)propionate (SPDP) and 3-(2-pyridyldithio)propionic acid hydrazide (PDPH) was compared.  The 3dAFPpG-SPDP-PDPH-Dox revealed a comparable with unmodified doxorubicin cytotoxic effect against the Dox sensitive MCF7 cell line and greater cytotoxicity against the anthracycline resistant MCF7Adr cells.  Meanwhile the 3dAFPpG-CAA-Dox cytotoxic effect was significantly lower, although doxorubicin's pH-dependent release profiles and intracellular accumulation rates were similar.  These differences in cytotoxic activity were arguably explained by the dissimilarities in intracellular doxorubicin localization, which may originate from thiol reductase activity in lysosomes and late endosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWFUYDmUz727Vg90H21EOLACvtfcHk0li9UIPFsr6zUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2lsLg%253D&md5=995e0dd84ee74c2e9349500f1598efa9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2018.12.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2018.12.073%26sid%3Dliteratum%253Aachs%26aulast%3DMollaev%26aufirst%3DM.%26aulast%3DGorokhovets%26aufirst%3DN.%26aulast%3DNikolskaya%26aufirst%3DE.%26aulast%3DFaustova%26aufirst%3DM.%26aulast%3DZabolotsky%26aufirst%3DA.%26aulast%3DZhunina%26aufirst%3DO.%26aulast%3DSokol%26aufirst%3DM.%26aulast%3DZamulaeva%26aufirst%3DI.%26aulast%3DSeverin%26aufirst%3DE.%26aulast%3DYabbarov%26aufirst%3DN.%26atitle%3DType%2520of%2520pH%2520sensitive%2520linker%2520reveals%2520different%2520time-dependent%2520intracellular%2520localization%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520efficiency%2520in%2520alpha-fetoprotein%2520receptor%2520targeted%2520doxorubicin%2520conjugate%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2019%26volume%3D559%26spage%3D138%26epage%3D146%26doi%3D10.1016%2Fj.ijpharm.2018.12.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>512</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2016.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.ijpharm.2016.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=27521706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyktb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2016&pages=1-13&issue=1&author=Y.+Shengauthor=Y.+Youauthor=Y.+Chen&title=Dual-targeting+hybrid+peptide-conjugated+doxorubicin+for+drug+resistance+reversal+in+breast+cancer&doi=10.1016%2Fj.ijpharm.2016.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer</span></div><div class="casAuthors">Sheng, Yuan; You, Yiwen; Chen, Yun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The extended use of doxorubicin (DOX) could be limited due to the emergence of drug resistance assocd. with its treatment.  In addn. to the overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), other mechanisms including apoptosis evasion and tumor cell survival may also be important contributor to drug resistance.  Within this context, targeting extracellular signal-regulated kinases (ERK), one of the principle protein mols. in cell apoptosis has emerged as an attractive therapeutic concept.  In this study, a dual-targeting hybrid peptide HAIYPRHGGCGMPKKKPTPIQLNP (T10-ERK), which is composed of ERK peptide inhibitor MPKKKPTPIQLNP, a thiol spacer (i.e., GGCG) and transferrin receptor (TfR)-binding peptide HAIYPRH, was designed.  Then, this thiol-modified hybrid peptide was conjugated to DOXO-EMCH (6-maleimidocaproyl) hydrazone of DOX, forming a novel peptide-DOX conjugate T10-ERK-DOX.  The structure and properties of this conjugate were characterized using 1H NMR, mass spectrometry and HPLC.  Using MCF-7/ADR cells as an in vitro model system and nude mice bearing MCF-7/ADR xenografts as an in vivo model, the ability of T10-ERK-DOX to reverse drug resistance was accessed as compared with free DOX and T10-DOX.  As a result, T10-ERK-DOX demonstrated a much lower in vitro IC50 (20.8 ± 1.1 μM) and its in vivo extent of inhibition in mice was more evident (72.2 ± 4.6%).  Induction of various apoptosis pathways was also obsd.  Furthermore, the potency of ERK peptide inhibitor to reverse drug resistance was individually assessed, given the pronounced efficacy of T10-DOX indicated by our previous work.  The results provided evidence of its additive effect with T10-DOX, which leads to greater efficacy and less susceptibility to drug resistance.  Finally, the success of multi-targeting strategy in the present study implied that multi-target drugs with rational design could be more promising in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT7-zyXxfctLVg90H21EOLACvtfcHk0li9UIPFsr6zUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyktb%252FJ&md5=b93858a1608988876ba31751957f8c7d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2016.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2016.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DY.%26aulast%3DYou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DDual-targeting%2520hybrid%2520peptide-conjugated%2520doxorubicin%2520for%2520drug%2520resistance%2520reversal%2520in%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2016%26volume%3D512%26issue%3D1%26spage%3D1%26epage%3D13%26doi%3D10.1016%2Fj.ijpharm.2016.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yousefpour, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tewksbury, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellucci, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilkoti, A.</span></span> <span> </span><span class="NLM_article-title">Conjugate of doxorubicin to albumin-binding peptide outperforms aldoxorubicin</span>. <i>Small</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e1804452</span> <span class="refDoi"> DOI: 10.1002/smll.201804452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1002%2Fsmll.201804452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=30756483" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&issue=12&author=P.+Yousefpourauthor=L.+Ahnauthor=J.+Tewksburyauthor=S.+Sahaauthor=S.+A.+Costaauthor=J.+J.+Bellucciauthor=X.+Liauthor=A.+Chilkoti&title=Conjugate+of+doxorubicin+to+albumin-binding+peptide+outperforms+aldoxorubicin&doi=10.1002%2Fsmll.201804452"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fsmll.201804452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsmll.201804452%26sid%3Dliteratum%253Aachs%26aulast%3DYousefpour%26aufirst%3DP.%26aulast%3DAhn%26aufirst%3DL.%26aulast%3DTewksbury%26aufirst%3DJ.%26aulast%3DSaha%26aufirst%3DS.%26aulast%3DCosta%26aufirst%3DS.%2BA.%26aulast%3DBellucci%26aufirst%3DJ.%2BJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChilkoti%26aufirst%3DA.%26atitle%3DConjugate%2520of%2520doxorubicin%2520to%2520albumin-binding%2520peptide%2520outperforms%2520aldoxorubicin%26jtitle%3DSmall%26date%3D2019%26volume%3D15%26issue%3D12%26doi%3D10.1002%2Fsmll.201804452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechet, J. M.</span></span> <span> </span><span class="NLM_article-title">Acetals as pH-sensitive linkages for drug delivery</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1254</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1021/bc049853x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc049853x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotlartbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=1254-1263&issue=6&author=E.+R.+Gilliesauthor=A.+P.+Goodwinauthor=J.+M.+Frechet&title=Acetals+as+pH-sensitive+linkages+for+drug+delivery&doi=10.1021%2Fbc049853x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Acetals as pH-sensitive linkages for drug delivery</span></div><div class="casAuthors">Gillies, Elizabeth R.; Goodwin, Andrew P.; Frechet, Jean M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1254-1263</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PH-sensitive linkages designed to undergo hydrolysis at mildly acidic pH can trigger the release of therapeutics selectively at targets such as tumor and inflammatory tissues and in the endosomes and lysosomes of cells.  Acetals have the potential to be used as linkages for a range of alc. functionalities, and, by altering their chem. structure, it is possible to tune their hydrolysis rate.  The synthesis of four conjugates of model drug mols. with PEO using acetals of varying chem. structure were described herein.  Primary and secondary alcs., as well as syn-1,2-diols, were incorporated in the conjugates.  The hydrolysis kinetics were investigated by HPLC, and the conjugates had half-lives ranging from less than 1 min to several days at pH 5.0, with slower hydrolysis at pH 7.4 in all cases.  These acetal linkages were therefore promising for use in a variety of drug delivery applications ranging from polymer-drug conjugates to pH-sensitive micelles and nanoparticulate systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1xlu6rB_dK7Vg90H21EOLACvtfcHk0lgkVPiITRercg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotlartbY%253D&md5=e9a5cb11f2b4130753c53742b8ed1783</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fbc049853x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049853x%26sid%3Dliteratum%253Aachs%26aulast%3DGillies%26aufirst%3DE.%2BR.%26aulast%3DGoodwin%26aufirst%3DA.%2BP.%26aulast%3DFrechet%26aufirst%3DJ.%2BM.%26atitle%3DAcetals%2520as%2520pH-sensitive%2520linkages%2520for%2520drug%2520delivery%26jtitle%3DBioconjugate%2520Chem.%26date%3D2004%26volume%3D15%26issue%3D6%26spage%3D1254%26epage%3D1263%26doi%3D10.1021%2Fbc049853x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brocchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, R.</span></span> <span> </span><span class="NLM_article-title">Polyacetal-doxorubicin conjugates designed for pH-dependent degradation</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1096</span>– <span class="NLM_lpage">1106</span>, <span class="refDoi"> DOI: 10.1021/bc030028a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc030028a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Wit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2003&pages=1096-1106&issue=6&author=R.+Tomlinsonauthor=J.+Hellerauthor=S.+Brocchiniauthor=R.+Duncan&title=Polyacetal-doxorubicin+conjugates+designed+for+pH-dependent+degradation&doi=10.1021%2Fbc030028a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Polyacetal-doxorubicin conjugates designed for pH-dependent degradation</span></div><div class="casAuthors">Tomlinson, Ryan; Heller, Jorge; Brocchini, Steve; Duncan, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1096-1106</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Terpolymn. of poly(ethylene glycol) (PEG), divinyl ethers, and serinol can be used to synthesize water sol., hydrolytically labile, amino-pendent polyacetals (APEGs) suitable for drug conjugation.  As these polyacetals display pH-dependent degrdn. (with faster rates of hydrolysis at acidic pH) and they are not inherently hepatotropic after i.v. injection, they have potential for development as biodegradable carriers to facilitate improved tumor targeting of anticancer agents.  The aim of this study was to synthesize a polyacetal-doxorubicin (APEG-DOX) conjugate, det. its cytotoxicity in vitro and evaluate its potential for improved tumor targeting in vivo compared to an HPMA copolymer-DOX conjugate in clin. development.  Amino-pendent polyacetals were prepd., and following succinoylation (APEG-succ), the polymeric intermediate conjugated to DOX via one of three methods using carbodiimide mediated coupling (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in aq. soln. was the most successful).  The resultant APEG-DOX conjugates had a DOX content of 3.0-8.5 wt.%, contained <1.2% free DOX (relative to total DOX content) and had a Mw = 60,000-100,000 g/mol and Mw/Mn = 1.7-2.6.  In vitro cytotoxicity studies showed APEG-DOX to be 10-fold less toxic toward B16F10 cells than free DOX (IC50 = 6 μg/mL and 0.6 μg/mL resp.), but confirmed the serinol-succinoyl-DOX liberated during main-chain degrdn. to be biol. active.  When administered iv to C57 black mice bearing s.c. B16F10 melanoma, APEG-DOX of Mw = 86,000 g/mol, and 5.0 wt.% DOX content exhibited significantly (p < 0.05) prolonged blood half-life and enhanced tumor accumulation compared to an HPMA copolymer-GFLG-DOX conjugate of Mw = 30,000 g/mol and 6.2 wt.% DOX content.  Moreover, APEG-DOX exhibited lower uptake by liver and spleen.  These observations suggest that APEG anticancer conjugates warrant further development as novel polymer therapeutics for improved tumor targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWlbuJ08u21bVg90H21EOLACvtfcHk0lgkVPiITRercg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Wit7k%253D&md5=d453bae9571e32211b5bd318f0787d13</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fbc030028a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc030028a%26sid%3Dliteratum%253Aachs%26aulast%3DTomlinson%26aufirst%3DR.%26aulast%3DHeller%26aufirst%3DJ.%26aulast%3DBrocchini%26aufirst%3DS.%26aulast%3DDuncan%26aufirst%3DR.%26atitle%3DPolyacetal-doxorubicin%2520conjugates%2520designed%2520for%2520pH-dependent%2520degradation%26jtitle%3DBioconjugate%2520Chem.%26date%3D2003%26volume%3D14%26issue%3D6%26spage%3D1096%26epage%3D1106%26doi%3D10.1021%2Fbc030028a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Stefano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiume, L.</span></span> <span> </span><span class="NLM_article-title">A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">4–5</span>),  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2004.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.ejps.2004.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=15567293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVamu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=393-397&issue=4%E2%80%935&author=G.+Di%0AStefanoauthor=M.+Lanzaauthor=F.+Kratzauthor=L.+Merinaauthor=L.+Fiume&title=A+novel+method+for+coupling+doxorubicin+to+lactosaminated+human+albumin+by+an+acid+sensitive+hydrazone+bond%3A+synthesis%2C+characterization+and+preliminary+biological+properties+of+the+conjugate&doi=10.1016%2Fj.ejps.2004.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate</span></div><div class="casAuthors">Di Stefano, Giuseppina; Lanza, Marcella; Kratz, Felix; Merina, Luca; Fiume, Luigi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">393-397</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The expression of the asialoglycoprotein receptor on the cells of the large majority of the well differentiated hepatocellular carcinomas can be exploited to improve the chemotherapy of these tumors by coupling anticancer agents to macromols. taken up by the receptor.  In line with this approach, in previous expts. we coupled doxorubicin (DOXO) to lactosaminated human albumin (L-HSA) using the (6-maleimidocaproyl)hydrazone deriv. of the drug as an acid sensitive linker.  Encouraging results were obtained in lab. animals using L-HSA-DOXO.  This conjugate, however, has the disadvantage of a difficult synthesis, which requires protein thiolation with iminothiolane and can hinder its prepn. on a large scale.  Here we describe a very simple method of coupling.  The HS-groups required for the reaction with the maleimide moiety of DOXO-EMCH are made available in L-HSA by a cleavage of the protein disulfides achieved with tris(2-carboxyethyl) phosphine (TCEP).  Contrary to thiolic reducing agents, the use of TCEP eliminates the need of an inert atm. and allows a one-step coupling reaction, without purifn. of the reduced protein before the addn. of DOXO-EMCH.  As the previous L-HSA-DOXO conjugate, the new conjugate accomplishes a very efficient liver targeting of the drug.  This novel method of synthesis should facilitate the prepn. of L-HSA-DOXO in the amts. required for clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXvB-LbVmZXbVg90H21EOLACvtfcHk0lhfNbMg4cHiyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVamu7nK&md5=f2615e5b3e9a11994d87033cbd008133</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2004.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2004.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BStefano%26aufirst%3DG.%26aulast%3DLanza%26aufirst%3DM.%26aulast%3DKratz%26aufirst%3DF.%26aulast%3DMerina%26aufirst%3DL.%26aulast%3DFiume%26aufirst%3DL.%26atitle%3DA%2520novel%2520method%2520for%2520coupling%2520doxorubicin%2520to%2520lactosaminated%2520human%2520albumin%2520by%2520an%2520acid%2520sensitive%2520hydrazone%2520bond%253A%2520synthesis%252C%2520characterization%2520and%2520preliminary%2520biological%2520properties%2520of%2520the%2520conjugate%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D23%26issue%3D4%25E2%2580%25935%26spage%3D393%26epage%3D397%26doi%3D10.1016%2Fj.ejps.2004.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kratz, F.</span></span> <span> </span><span class="NLM_article-title">DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.1517/13543784.16.6.855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1517%2F13543784.16.6.855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=17501697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=855-866&issue=6&author=F.+Kratz&title=DOXO-EMCH+%28INNO-206%29%3A+the+first+albumin-binding+prodrug+of+doxorubicin+to+enter+clinical+trials&doi=10.1517%2F13543784.16.6.855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials</span></div><div class="casAuthors">Kratz, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-866</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The (6-maleimidocaproyl)hydrazone deriv. of doxorubicin (DOXO-EMCH) is an albumin-binding prodrug of doxorubicin with acid-sensitive properties that demonstrates superior antitumor efficacy in murine tumor models and a favorable toxicity profile in mice, rats and dogs, including significantly reduced cardiotoxicity.  After i.v. administration, DOXO-EMCH binds rapidly to the Cys-34 position of circulating albumin and accumulates in solid tumors due to passive targeting.  In a clin. Phase I study, the dose of doxorubicin could be increased by a factor of 4.5-340 mg/m2 when 75 mg/m2 of free doxorubicin is considered to be the dose that can be administered as a single agent concomitant with the typical spectrum of side effects (i.e., myelotoxicity and mucositis).  DOXO-EMCH was able to induce tumor regressions in anthracycline-sensitive tumors (i.e., breast cancer, small cell lung cancer and sarcoma).  Phase II studies will be initiated at the beginning of 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3XBL2mlbCkbVg90H21EOLACvtfcHk0lhfNbMg4cHiyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOju7Y%253D&md5=88fec9cd817a4b10e54506d423eccd35</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.6.855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.6.855%26sid%3Dliteratum%253Aachs%26aulast%3DKratz%26aufirst%3DF.%26atitle%3DDOXO-EMCH%2520%2528INNO-206%2529%253A%2520the%2520first%2520albumin-binding%2520prodrug%2520of%2520doxorubicin%2520to%2520enter%2520clinical%2520trials%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26issue%3D6%26spage%3D855%26epage%3D866%26doi%3D10.1517%2F13543784.16.6.855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kratz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnecke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitzel, M.</span></span> <span> </span><span class="NLM_article-title">Prodrugs of anthracyclines in cancer chemotherapy</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.2174/092986706776055751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.2174%2F092986706776055751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=16515518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Klu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=477-523&issue=5&author=F.+Kratzauthor=A.+Warneckeauthor=B.+Schmidauthor=D.+E.+Chungauthor=M.+Gitzel&title=Prodrugs+of+anthracyclines+in+cancer+chemotherapy&doi=10.2174%2F092986706776055751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs of anthracyclines in cancer chemotherapy</span></div><div class="casAuthors">Kratz, F.; Warnecke, A.; Schmid, B.; Chung, D.-E.; Gitzel, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">477-523</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Designing and developing truly tumor-specific prodrugs remains a challenge in the field of cancer chemotherapy.  Active targeting strategies, on the one hand, aim at exploiting membrane-assocd. receptors or antigens for drug delivery; the enhanced vascular permeability and retention of macromols. in tumor tissue substantiates the concept of passive targeting.  Consequently, research efforts have concd. on conjugating anticancer agents with a wide spectrum of carriers including antibodies, peptides, serum proteins, and synthetic polymers.  Conversely, low-mol. wt. prodrugs of anticancer agents have been developed that do not bear an active or passive targeting moiety, but are activated by tumor-assocd. enzymes at the tumor site.  Anthracyclines probably represent the class of anticancer agents that has been most widely used for the development of prodrugs.  This overview gives an update of the various low- and high-mol. wt. prodrugs of anthracyclines, e.g. with antibodies, peptides, carbohydrates, serum proteins or synthetic polymers, that have been developed over the past 20 years and that exemplify the salient features of a resp. drug delivery system.  A detailed description will be dedicated to anthracycline prodrugs that have reached an advanced stage of preclin. testing or that have entered clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc5fDdtJIfRLVg90H21EOLACvtfcHk0lg_xMo3wnKDIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Klu7s%253D&md5=7c16a1dff064a7b1e8bd6749f2206fe7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2174%2F092986706776055751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986706776055751%26sid%3Dliteratum%253Aachs%26aulast%3DKratz%26aufirst%3DF.%26aulast%3DWarnecke%26aufirst%3DA.%26aulast%3DSchmid%26aufirst%3DB.%26aulast%3DChung%26aufirst%3DD.%2BE.%26aulast%3DGitzel%26aufirst%3DM.%26atitle%3DProdrugs%2520of%2520anthracyclines%2520in%2520cancer%2520chemotherapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2006%26volume%3D13%26issue%3D5%26spage%3D477%26epage%3D523%26doi%3D10.2174%2F092986706776055751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chawla, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhametshina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankhala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasylyev, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganjoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, D. J.</span></span> <span> </span><span class="NLM_article-title">First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial</span>. <i>JAMA Oncol</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1272</span>– <span class="NLM_lpage">1280</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.3101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1001%2Fjamaoncol.2015.3101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=26378637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BC283jtVyrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=1272-1280&issue=9&author=S.+P.+Chawlaauthor=Z.+Papaiauthor=G.+Mukhametshinaauthor=K.+Sankhalaauthor=L.+Vasylyevauthor=A.+Fedenkoauthor=K.+Khamlyauthor=K.+Ganjooauthor=R.+Nagarkarauthor=S.+Wielandauthor=D.+J.+Levitt&title=First-line+aldoxorubicin+vs+doxorubicin+in+metastatic+or+locally+advanced+unresectable+soft-tissue+sarcoma%3A+a+phase+2b+randomized+clinical+trial&doi=10.1001%2Fjamaoncol.2015.3101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial</span></div><div class="casAuthors">Chawla Sant P; Papai Zsuzsanna; Mukhametshina Guzel; Sankhala Kamalesh; Vasylyev Leonid; Fedenko Alexander; Khamly Kenneth; Ganjoo Kristen; Nagarkar Rajnish; Wieland Scott; Levitt Daniel J</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1272-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  Standard therapy for advanced soft-tissue sarcoma has not changed substantially in decades, and patient prognosis remains poor.  Aldoxorubicin, a novel albumin-binding prodrug of doxorubicin, showed clinical activity against advanced soft-tissue sarcoma in phase 1 studies.  OBJECTIVE:  To evaluate efficacy and safety of aldoxorubicin vs doxorubicin in patients with advanced soft-tissue sarcoma.  DESIGN, SETTING, AND PARTICIPANTS:  International, multicenter, phase 2b, open-label, randomized study at general community practices, private practices, or institutional practices.  Between August 2012 and December 2013, 140 patients with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma were screened.  INTERVENTIONS:  Randomization (2:1) to aldoxorubicin 350 mg/m2 (dose equivalent to doxorubicin 260 mg/m2) or doxorubicin 75 mg/m2, administered once every 3 weeks for up to 6 cycles.  MAIN OUTCOMES AND MEASURES:  Primary end point was progression-free survival.  Secondary end points were 6-month progression-free survival, overall survival, tumor response rate, and safety.  All efficacy end points were evaluated by independent and local review.  RESULTS:  A total of 126 patients were randomized, and 123 received aldoxorubicin (n = 83) or doxorubicin (n = 40).  Median (range) patient age was 54.0 (21-77 years); 42 (34%) had leiomyosarcoma.  By independent review, median progression-free survival was significantly improved (5.6 [95% CI, 3.0-8.1] vs 2.7 [95% CI, 1.6-4.3] months; P = .02) with aldoxorubicin compared with doxorubicin, as was the rate of 6-month progression-free survival (46% and 23%; P = .02).  Median overall survival was 15.8 (95% CI, 13.0 to not available) months with aldoxorubicin and 14.3 (95% CI, 8.6-20.6) months with doxorubicin (P = .21).  Overall tumor response rate (by Response Evaluation Criteria in Solid Tumors, version 1.1) by independent review was higher with aldoxorubicin than with doxorubicin (25% [20 patients, all partial response] vs 0%).  Grade 3 or 4 neutropenia was more frequent with aldoxorubicin than with doxorubicin (24 [29%] vs 5 [12%]), but not grade 3 or 4 febrile neutropenia (12 [14%] vs 7 [18%]).  No acute cardiotoxic effects were observed with either treatment, although left ventricular ejection fraction less than 50% occurred in 3 of 40 patients receiving doxorubicin.  CONCLUSIONS AND RELEVANCE:  Single-agent aldoxorubicin therapy showed superior efficacy over doxorubicin by prolonging progression-free survival and improving rates of 6-month progression-free survival and tumor response.  Aldoxorubicin therapy exhibited manageable adverse effects, without unexpected events, and without evidence of acute cardiotoxicity.  Further investigation of aldoxorubicin therapy in advanced soft-tissue sarcoma is warranted.  TRIAL REGISTRATION:  clinicaltrials.gov Identifier: NCT01514188.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8uVdlXrdQf1MGsG_HTXYFfW6udTcc2eY-IOvmLjvTpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283jtVyrtA%253D%253D&md5=e1a9c0c72db1ac52587a5792caeebe2f</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.3101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.3101%26sid%3Dliteratum%253Aachs%26aulast%3DChawla%26aufirst%3DS.%2BP.%26aulast%3DPapai%26aufirst%3DZ.%26aulast%3DMukhametshina%26aufirst%3DG.%26aulast%3DSankhala%26aufirst%3DK.%26aulast%3DVasylyev%26aufirst%3DL.%26aulast%3DFedenko%26aufirst%3DA.%26aulast%3DKhamly%26aufirst%3DK.%26aulast%3DGanjoo%26aufirst%3DK.%26aulast%3DNagarkar%26aufirst%3DR.%26aulast%3DWieland%26aufirst%3DS.%26aulast%3DLevitt%26aufirst%3DD.%2BJ.%26atitle%3DFirst-line%2520aldoxorubicin%2520vs%2520doxorubicin%2520in%2520metastatic%2520or%2520locally%2520advanced%2520unresectable%2520soft-tissue%2520sarcoma%253A%2520a%2520phase%25202b%2520randomized%2520clinical%2520trial%26jtitle%3DJAMA%2520Oncol%26date%3D2015%26volume%3D1%26issue%3D9%26spage%3D1272%26epage%3D1280%26doi%3D10.1001%2Fjamaoncol.2015.3101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forscher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendifar, A.</span></span> <span> </span><span class="NLM_article-title">Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S140638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.2147%2FDDDT.S140638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29670334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOltL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=777-786&author=J.+Gongauthor=J.+Yanauthor=C.+Forscherauthor=A.+Hendifar&title=Aldoxorubicin%3A+a+tumor-targeted+doxorubicin+conjugate+for+relapsed+or+refractory+soft+tissue+sarcomas&doi=10.2147%2FDDDT.S140638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas</span></div><div class="casAuthors">Gong, Jun; Yan, Jessica; Forscher, Charles; Hendifar, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">777-786</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Despite available therapies after initial systemic therapy, prognosis remains poor in relapsed or refractory soft tissue sarcomas (STS).  The rational and clin. development of novel agents to improve outcomes in this area of high unmet need is desperately warranted.  Aldoxorubicin is a prodrug of doxorubicin that binds to serum albumin immediately after administration through an acid-sensitive hydrazone linker and is subsequently transported to tumor tissues where the acidic environment cleaves the linker and facilitates delivery of a tumor-targeted drug payload.  In clin. studies to date, there has been evidence of efficacy and mitigated cardiac toxicity.  In this review, we comprehensively detail the clin. development of aldoxorubicin in STS to date.  Specifically, we highlight available data on the pharmacokinetics and efficacy from Phase I, Phase II, and Phase III trials in advanced or metastatic STS.  We conclude with considerations for future directions of investigation for this promising antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqObWRl-0q_3bVg90H21EOLACvtfcHk0ljxAjuqCMuudw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOltL3J&md5=330bd892680200d98e5c4fc0d3d3cbe5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S140638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S140638%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DForscher%26aufirst%3DC.%26aulast%3DHendifar%26aufirst%3DA.%26atitle%3DAldoxorubicin%253A%2520a%2520tumor-targeted%2520doxorubicin%2520conjugate%2520for%2520relapsed%2520or%2520refractory%2520soft%2520tissue%2520sarcomas%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2018%26volume%3D12%26spage%3D777%26epage%3D786%26doi%3D10.2147%2FDDDT.S140638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, D.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic Agents for the Treatment of Cancer</span>. U.S. Patent US <span class="NLM_patent">20190350952 A1</span> Nov 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Levitt&title=Cytotoxic+Agents+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLevitt%26aufirst%3DD.%26atitle%3DCytotoxic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laabs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A. C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic study of aldoxorubicin in patients with solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0183-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1007%2Fs10637-014-0183-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=25388939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFShu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=341-348&issue=2&author=M.+M.+Mitaauthor=R.+B.+Nataleauthor=E.+M.+Wolinauthor=B.+Laabsauthor=H.+Dinhauthor=S.+Wielandauthor=D.+J.+Levittauthor=A.+C.+Mita&title=Pharmacokinetic+study+of+aldoxorubicin+in+patients+with+solid+tumors&doi=10.1007%2Fs10637-014-0183-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic study of aldoxorubicin in patients with solid tumors</span></div><div class="casAuthors">Mita, Monica M.; Natale, Ronald B.; Wolin, Edward M.; Laabs, Brenda; Dinh, Hillary; Wieland, Scott; Levitt, Daniel J.; Mita, Alain C.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-348</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Introduction: Aldoxorubicin, a prodrug of doxorubicin, binds covalently to serum albumin in the bloodstream and accumulates in tumors.  Aldoxorubicin can be administered at doses several-fold higher than doxorubicin can, without assocd. acute cardiotoxicity.  Purpose: This study fully evaluated the pharmacokinetic profile of aldoxorubicin (serum and urine).  Methods: Eighteen patients with advanced solid tumors received aldoxorubicin 230 or 350 mg/m2 (equiv. in drug load to doxorubicin at doses of 170 or 260 mg/m2, resp.) once every 21 days.  Blood samples were taken in cycle 1 before aldoxorubicin infusion, and at 5, 15, 30, and 60 min, and at 2, 4, 8, 12, 16, 24, 48, and 72 h after infusion.  Urine samples were taken in cycle 1 at 24, 48, and 72 h after infusion.  Limited blood sampling was done in cycle 3, before aldoxorubicin infusion, and at 60 min and at 2, 4, and 8 h after infusion.  Results: The long mean half-life (20.1-21.1 h), narrow mean vol. of distribution (3.96-4.08 L/m2), and slow mean clearance rate (0.136-0.152 L/h/m2) suggest that aldoxorubicin is stable in circulation and does not accumulate readily in body compartments outside of the bloodstream.  Very little doxorubicin and its major metabolite doxorubicinol, which has been implicated in doxorubicin-assocd. cardiotoxicity, are excreted in urine.  This might explain the lack of cardiotoxicity obsd. thus far with aldoxorubicin.  Conclusions: Our findings support dosing and administration schemas used in an ongoing phase 3 clin. study of aldoxorubicin in soft tissue sarcoma, and phase 2 clin. studies in small cell lung cancer, glioblastoma, and Kaposi's sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqynSfZUd-KjLVg90H21EOLACvtfcHk0ljAmR0AnAIZZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFShu73O&md5=3909a7d1fb734b9975797155192f48d4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0183-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0183-5%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DWolin%26aufirst%3DE.%2BM.%26aulast%3DLaabs%26aufirst%3DB.%26aulast%3DDinh%26aufirst%3DH.%26aulast%3DWieland%26aufirst%3DS.%26aulast%3DLevitt%26aufirst%3DD.%2BJ.%26aulast%3DMita%26aufirst%3DA.%2BC.%26atitle%3DPharmacokinetic%2520study%2520of%2520aldoxorubicin%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26issue%3D2%26spage%3D341%26epage%3D348%26doi%3D10.1007%2Fs10637-014-0183-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forman, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinna, A.</span></span> <span> </span><span class="NLM_article-title">Glutathione: overview of its protective roles, measurement, and biosynthesis</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.mam.2008.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.mam.2008.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=18796312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFelurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=1-12&issue=1%E2%80%932&author=H.+J.+Formanauthor=H.+Zhangauthor=A.+Rinna&title=Glutathione%3A+overview+of+its+protective+roles%2C+measurement%2C+and+biosynthesis&doi=10.1016%2Fj.mam.2008.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Glutathione: Overview of its protective roles, measurement, and biosynthesis</span></div><div class="casAuthors">Forman, Henry Jay; Zhang, Hongqiao; Rinna, Alessandra</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This review is the introduction to a special issue concerning, glutathione (GSH), the most abundant low mol. wt. thiol compd. synthesized in cells.  GSH plays crit. roles in protecting cells from oxidative damage and the toxicity of xenobiotic electrophiles, and maintaining redox homeostasis.  Here, the functions and GSH and the sources of oxidants and electrophiles, the elimination of oxidants by redn. and electrophiles by conjugation with GSH are briefly described.  Methods of assessing GSH status in the cells are also described.  GSH synthesis and its regulation are addressed along with therapeutic approaches for manipulating GSH content that have been proposed.  The purpose here is to provide a brief overview of some of the important aspects of glutathione metab. as part of this special issue that will provide a more comprehensive review of the state of knowledge regarding this essential mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlWapNqV0GqLVg90H21EOLACvtfcHk0ljAmR0AnAIZZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFelurY%253D&md5=c1b1aa2b03389bf1434af0762df78fe1</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2008.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2008.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DForman%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DRinna%26aufirst%3DA.%26atitle%3DGlutathione%253A%2520overview%2520of%2520its%2520protective%2520roles%252C%2520measurement%252C%2520and%2520biosynthesis%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2009%26volume%3D30%26issue%3D1%25E2%2580%25932%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.mam.2008.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rietschoten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watcham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G. S.</span></span> <span> </span><span class="NLM_article-title">Identification and optimization of EphA2-selective bicycles for the delivery of cytotoxic payloads</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">4107</span>– <span class="NLM_lpage">4116</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02129</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02129" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltl2nu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4107-4116&issue=8&author=G.+E.+Muddauthor=A.+Brownauthor=L.+Chenauthor=K.+van+Rietschotenauthor=S.+Watchamauthor=D.+P.+Teufelauthor=S.+Pavanauthor=R.+Laniauthor=P.+Huxleyauthor=G.+S.+Bennett&title=Identification+and+optimization+of+EphA2-selective+bicycles+for+the+delivery+of+cytotoxic+payloads&doi=10.1021%2Facs.jmedchem.9b02129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads</span></div><div class="casAuthors">Mudd, Gemma E.; Brown, Amy; Chen, Liuhong; van Rietschoten, Katerine; Watcham, Sophie; Teufel, Daniel P.; Pavan, Silvia; Lani, Rachid; Huxley, Philip; Bennett, Gavin S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4107-4116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bicycles are constrained bicyclic peptides that represent a promising binding modality for use in targeted drug conjugates.  A phage display screen against EphA2, a receptor tyrosine kinase highly expressed in a no. of solid tumors, identified a no. of Bicycle families with low nanomolar affinity.  A Bicycle toxin conjugate (BTC) was generated by derivatization of one of these Bicycles with the potent cytotoxin DM1 via a cleavable linker.  This BTC demonstrated potent antitumor activity in vivo but was poorly tolerated, which was hypothesized to be the result of undesired liver uptake caused by poor physicochem. properties.  Chem. optimization of a second Bicycle, guided by structural biol., provided a high affinity, metabolically stable Bicycle with improved physicochem. properties.  A BTC incorporating this Bicycle also demonstrated potent antitumor activity and was very well tolerated when compared to the initial BTC.  Phage display selection followed by chem. optimization of Bicycles can deliver potent drug conjugates with favorable pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt84NGlw8Gd7Vg90H21EOLACvtfcHk0liJbY5p57nPNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltl2nu78%253D&md5=bf888a942cba4e0ef3d8427395d16a4d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02129%26sid%3Dliteratum%253Aachs%26aulast%3DMudd%26aufirst%3DG.%2BE.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3Dvan%2BRietschoten%26aufirst%3DK.%26aulast%3DWatcham%26aufirst%3DS.%26aulast%3DTeufel%26aufirst%3DD.%2BP.%26aulast%3DPavan%26aufirst%3DS.%26aulast%3DLani%26aufirst%3DR.%26aulast%3DHuxley%26aufirst%3DP.%26aulast%3DBennett%26aufirst%3DG.%2BS.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520EphA2-selective%2520bicycles%2520for%2520the%2520delivery%2520of%2520cytotoxic%2520payloads%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D8%26spage%3D4107%26epage%3D4116%26doi%3D10.1021%2Facs.jmedchem.9b02129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span> <span> </span><span class="NLM_article-title">Transferrin receptor targeted cellular delivery of doxorubicin via a reduction-responsive peptide–drug conjugate</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">168</span>, <span class="refDoi"> DOI: 10.1007/s11095-019-2688-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1007%2Fs11095-019-2688-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31654226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVeqsr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=168&issue=12&author=S.+Liauthor=H.+Zhaoauthor=X.+Maoauthor=Y.+Fanauthor=X.+Liangauthor=R.+Wangauthor=L.+Xiaoauthor=J.+Wangauthor=Q.+Liuauthor=G.+Zhao&title=Transferrin+receptor+targeted+cellular+delivery+of+doxorubicin+via+a+reduction-responsive+peptide%E2%80%93drug+conjugate&doi=10.1007%2Fs11095-019-2688-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Transferrin receptor targeted cellular delivery of doxorubicin via a reduction-responsive peptide-drug conjugate</span></div><div class="casAuthors">Li, Songtao; Zhao, Hongling; Mao, Xiaoxia; Fan, Yanfang; Liang, Xiujun; Wang, Ruxing; Xiao, Lijun; Wang, Jianping; Liu, Qi; Zhao, Guiqin</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">168</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Transferrin receptors (TfRs) are overexpressed in tumor cells but are scarce in normal tissues, which makes TfR an attractive target for drug treatment of cancer.  The objective of this study was to evaluate the potential of BP9a (CAHLHNRS) as a peptide vector for constructing TfR targeted peptide-drug conjugates and selective drug delivery.  Methods: Doxorubicin (DOX) was connected to BP9a via a disulfide-intercalating linker to afford a redn.-responsive BP9a-SS-DOX conjugate.  By using HepG2 human liver cancer cells and L-O2 normal hepatic cells as TfR over-expressing and low-expressing in vitro models, resp., TfR mediated cellular uptake of this conjugate was studied by using flow cytometry and confocal laser scanning microscopy.  The in vitro cytotoxicities of the conjugate against HepG2 and L-O2 cells were examd. by cell counting kit-8 (CCK-8) assay to evaluate its tumorous specificity.  Results: Cellular uptake and TfR blockage test results showed that the BP9a-SS-DOX conjugate gained entry into HepG2 cells via endocytosis mediated by TfR and mainly accumulated in cytoplasm.  The in vitro antiproliferative activity of this conjugate against HepG2 cells (IC50 6.21 ± 1.12 μM) was approx. one-sixth of that of free DOX (IC50 1.03 ± 0.13 μM).  However, its cytotoxic effect on L-O2 cells was obviously reduced compared with that of free DOX.  Conclusions: The BP9a-SS-DOX conjugate showed specific antiproliferative activity against HepG2 liver cancer cells.  Our study suggests that BP9a has the potential to target chemotherapeutic agents to tumor cells over-expressing TfR and facilitate selective drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbeaLo5eV6grVg90H21EOLACvtfcHk0liJbY5p57nPNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVeqsr%252FI&md5=c2d12adaaa2633528c95bde0c6f2963d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1007%2Fs11095-019-2688-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-019-2688-2%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DX.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DG.%26atitle%3DTransferrin%2520receptor%2520targeted%2520cellular%2520delivery%2520of%2520doxorubicin%2520via%2520a%2520reduction-responsive%2520peptide%25E2%2580%2593drug%2520conjugate%26jtitle%3DPharm.%2520Res.%26date%3D2019%26volume%3D36%26issue%3D12%26spage%3D168%26doi%3D10.1007%2Fs11095-019-2688-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dokus, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lajko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randelovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohidai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span> <span> </span><span class="NLM_article-title">Phage display-based homing peptide-daunomycin conjugates for selective drug targeting to PANC-1 pancreatic cancer</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">576</span>, <span class="refDoi"> DOI: 10.3390/pharmaceutics12060576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3390%2Fpharmaceutics12060576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFGnsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=576&issue=6&author=L.+E.+Dokusauthor=E.+Lajkoauthor=I.+Randelovicauthor=D.+Mezoauthor=G.+Schlosserauthor=L.+Kohidaiauthor=J.+Tovariauthor=G.+Mezo&title=Phage+display-based+homing+peptide-daunomycin+conjugates+for+selective+drug+targeting+to+PANC-1+pancreatic+cancer&doi=10.3390%2Fpharmaceutics12060576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Phage display-based homing peptide-daunomycin conjugates for selective drug targeting to PANC-1 pancreatic cancer</span></div><div class="casAuthors">Dokus, Levente E.; Lajko, Eszter; Randelovic, Ivan; Mezo, Diana; Schlosser, Gitta; Kohidai, Laszlo; Tovari, Jozsef; Mezo, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">576</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and dangerous cancerous diseases, leading to a high rate of mortality.  Therefore, the development of new, more efficient treatment approaches is necessary to cure this illness.  Peptide-based drug targeting provides a new tool for this purpose.  Previously, a hexapeptide Cys-Lys-Ala-Ala-Lys-Asn (CKAAKN) was applied efficiently as the homing device for drug-loaded nanostructures in PDAC cells.  In this research, Cys was replaced by Ser in the sequence and this new SKAAKN targeting moiety was used in conjugates contg. daunomycin (Dau).  Five different structures were developed and tested.  The results indicated that linear versions with one Dau were not effective on PANC-1 cells in vitro; however, branched conjugates with two Dau mols. showed significant antitumor activity.  Differences in the antitumor effect of the conjugates could be explained with the different cellular uptake and lysosomal degrdn.  The most efficient conjugate was Dau=Aoa-GFLG-K(Dau=Aoa)SKAAKN-OH (conjugate 4) that also showed significant tumor growth inhibition on s.c. implanted PANC-1 tumor-bearing mice with negligible side effects.  Our novel results suggest that peptide-based drug delivery systems could be a promising tool for the treatment of pancreatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHefZ-MzGahLVg90H21EOLACvtfcHk0lhMOutrGVLqog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFGnsbzP&md5=bb8a2a924ee2244cc4e62d8e3d5b6e55</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics12060576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics12060576%26sid%3Dliteratum%253Aachs%26aulast%3DDokus%26aufirst%3DL.%2BE.%26aulast%3DLajko%26aufirst%3DE.%26aulast%3DRandelovic%26aufirst%3DI.%26aulast%3DMezo%26aufirst%3DD.%26aulast%3DSchlosser%26aufirst%3DG.%26aulast%3DKohidai%26aufirst%3DL.%26aulast%3DTovari%26aufirst%3DJ.%26aulast%3DMezo%26aufirst%3DG.%26atitle%3DPhage%2520display-based%2520homing%2520peptide-daunomycin%2520conjugates%2520for%2520selective%2520drug%2520targeting%2520to%2520PANC-1%2520pancreatic%2520cancer%26jtitle%3DPharmaceutics%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D576%26doi%3D10.3390%2Fpharmaceutics12060576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Randelovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapuvari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkuhler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovari, J.</span></span> <span> </span><span class="NLM_article-title">Improved in vivo anti-tumor and anti-metastatic effect of GnRH-III-daunorubicin analogs on colorectal and breast carcinoma bearing mice</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4763</span>, <span class="refDoi"> DOI: 10.3390/ijms20194763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3390%2Fijms20194763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovVWgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=4763&issue=19&author=I.+Randelovicauthor=S.+Schusterauthor=B.+Kapuvariauthor=G.+Fossatiauthor=C.+Steinkuhlerauthor=G.+Mezoauthor=J.+Tovari&title=Improved+in+vivo+anti-tumor+and+anti-metastatic+effect+of+GnRH-III-daunorubicin+analogs+on+colorectal+and+breast+carcinoma+bearing+mice&doi=10.3390%2Fijms20194763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Improved in vivo anti-tumor and anti-metastatic effect of GnRH-III-daunorubicin analogs on colorectal and breast carcinoma bearing mice</span></div><div class="casAuthors">Randelovic, Ivan; Schuster, Sabine; Kapuvari, Bence; Fossati, Gianluca; Steinkuhler, Christian; Mezo, Gabor; Tovari, Jozsef</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4763</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Among various homing devices, gonadotropin-releasing hormone-III (GnRH-III) peptide represents a suitable targeting moiety for drug delivery systems.  The anti-tumor activity of the previously developed GnRH-III-[4Lys(Bu),8Lys(Dau = Aoa)] conjugate and the novel synthesized GnRH-III-[2ΔHis,3d-Tic,4Lys(Bu),8Lys(Dau = Aoa)] conjugate, contg. the anti-cancer drug daunorubicin, were evaluated.  Here, we demonstrate that both GnRH-III-Dau conjugates possess an efficient growth inhibitory effect on more than 20 cancer cell lines, whereby the biol. activity is strongly connected to the expression of gonadotropin-releasing hormone receptors (GnRH-R).  The novel conjugate showed a higher in vitro anti-proliferative activity and a higher uptake capacity.  Moreover, the treatment with GnRH-III-Dau conjugates cause a significant in vivo tumor growth and metastases inhibitory effect in three different orthotopic models, including 4T1 mice and MDA-MB-231 human breast carcinoma, as well as HT-29 human colorectal cancer bearing BALB/s and SCID mice, while toxic side-effects were substantially reduced in comparison to the treatment with the free drug.  These findings illustrate that our novel lead compd. is a highly promising candidate for targeted tumor therapy in both colon cancer and metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2QyO2YJrgdbVg90H21EOLACvtfcHk0lhMOutrGVLqog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovVWgs74%253D&md5=068322b233f70d77d0ac12ded68b4e63</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3390%2Fijms20194763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20194763%26sid%3Dliteratum%253Aachs%26aulast%3DRandelovic%26aufirst%3DI.%26aulast%3DSchuster%26aufirst%3DS.%26aulast%3DKapuvari%26aufirst%3DB.%26aulast%3DFossati%26aufirst%3DG.%26aulast%3DSteinkuhler%26aufirst%3DC.%26aulast%3DMezo%26aufirst%3DG.%26aulast%3DTovari%26aufirst%3DJ.%26atitle%3DImproved%2520in%2520vivo%2520anti-tumor%2520and%2520anti-metastatic%2520effect%2520of%2520GnRH-III-daunorubicin%2520analogs%2520on%2520colorectal%2520and%2520breast%2520carcinoma%2520bearing%2520mice%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26issue%3D19%26spage%3D4763%26doi%3D10.3390%2Fijms20194763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biri-Kovacs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buday, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span> <span> </span><span class="NLM_article-title">Enhanced in vitro antitumor activity of GnRH-III-daunorubicin bioconjugates influenced by sequence modification</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">223</span>, <span class="refDoi"> DOI: 10.3390/pharmaceutics10040223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3390%2Fpharmaceutics10040223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWktbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=223&issue=4&author=S.+Schusterauthor=B.+Biri-Kovacsauthor=B.+Szederauthor=L.+Budayauthor=J.+Gardiauthor=Z.+Szaboauthor=G.+Halmosauthor=G.+Mezo&title=Enhanced+in+vitro+antitumor+activity+of+GnRH-III-daunorubicin+bioconjugates+influenced+by+sequence+modification&doi=10.3390%2Fpharmaceutics10040223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced in vitro antitumor activity of GnRH-III-daunorubicin bioconjugates influenced by sequence modification</span></div><div class="casAuthors">Schuster, Sabine; Biri-Kovacs, Beata; Szeder, Balint; Buday, Laszlo; Gardi, Janos; Szabo, Zsuzsanna; Halmos, Gabor; Mezo, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">223</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Receptors for gonadotropin releasing hormone (GnRH) are highly expressed in various human cancers including breast, ovarian, endometrial, prostate and colorectal cancer.  Ligands like human GnRH-I or the sea lamprey analog GnRH-III represent a promising approach for the development of efficient drug delivery systems for targeted tumor therapy.  Here, we report on the synthesis and cytostatic effect of 14 oxime bond-linked daunorubicin GnRH-III conjugates contg. a variety of unnatural amino acids within the peptide sequence.  All compds. demonstrated a reduced cell viability in vitro on estrogen receptor α (ERα) pos. and ERα neg. cancer cells.  The best candidate revealed an increased cancer cell growth inhibitory effect compared to our lead-compd. GnRH-III-[4Lys(Bu),8Lys(Dau=Aoa)].  Flow cytometry and fluorescence microscopy studies showed that the cellular uptake of the novel conjugate is substantially improved leading to an accelerated delivery of the drug to its site of action.  However, the release of the active drug-metabolite by lysosomal enzymes was not neg. affected by amino acid substitution, while the compd. provided a high stability in human blood plasma.  Receptor binding studies were carried out to ensure a high binding affinity of the new compd. for the GnRH-receptor.  It was demonstrated that GnRH-III-[2ΔHis,3D-Tic,4Lys(Bu),8Lys(Dau=Aoa)] is a highly potent and promising anticancer drug delivery system for targeted tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6ABL1UU0E1bVg90H21EOLACvtfcHk0ljz57ZtEuwS6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWktbfJ&md5=9504f9d50ffc5f0886ce86036aa49901</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics10040223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics10040223%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DS.%26aulast%3DBiri-Kovacs%26aufirst%3DB.%26aulast%3DSzeder%26aufirst%3DB.%26aulast%3DBuday%26aufirst%3DL.%26aulast%3DGardi%26aufirst%3DJ.%26aulast%3DSzabo%26aufirst%3DZ.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DMezo%26aufirst%3DG.%26atitle%3DEnhanced%2520in%2520vitro%2520antitumor%2520activity%2520of%2520GnRH-III-daunorubicin%2520bioconjugates%2520influenced%2520by%2520sequence%2520modification%26jtitle%3DPharmaceutics%26date%3D2018%26volume%3D10%26issue%3D4%26spage%3D223%26doi%3D10.3390%2Fpharmaceutics10040223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biri-Kovacs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farkas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buday, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">756</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.3762/bjoc.14.64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3762%2Fbjoc.14.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29719573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOhtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=756-771&author=S.+Schusterauthor=B.+Biri-Kovacsauthor=B.+Szederauthor=V.+Farkasauthor=L.+Budayauthor=Z.+Szaboauthor=G.+Halmosauthor=G.+Mezo&title=Synthesis+and+in+vitro+biochemical+evaluation+of+oxime+bond-linked+daunorubicin-GnRH-III+conjugates+developed+for+targeted+drug+delivery&doi=10.3762%2Fbjoc.14.64"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery</span></div><div class="casAuthors">Schuster, Sabine; Biri-Kovacs, Beata; Szeder, Balint; Farkas, Viktor; Buday, Laszlo; Szabo, Zsuzsanna; Halmos, Gabor; Mezo, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">756-771</span>CODEN:
                <span class="NLM_cas:coden">BJOCBH</span>;
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    
            (<span class="NLM_cas:orgname">Beilstein-Institut zur Foerderung der Chemischen Wissenschaften</span>)
        </div><div class="casAbstract">Gonadotropin releasing hormone-III (GnRH-III), a native isoform of the human GnRH isolated from sea lamprey, specifically binds to GnRH receptors on cancer cells enabling its application as targeting moieties for anticancer drugs.  Recently, we reported on the identification of a novel daunorubicin-GnRH-III conjugate GnRH-III-[4Lys(Bu), 8Lys(Dau = Aoa)] with efficient in vitro and in vivo antitumor activity.  To get a deeper insight into the mechanism of action of our lead compd., the cellular uptake was followed by confocal laser scanning microscopy.  Hereby, the drug daunorubicin could be visualized in different subcellular compartments by following the localization of the drug in a time-dependent manner.  Colocalization studies were carried out to prove the presence of the drug in lysosomes (early stage) and on its site of action (nuclei after 10 min).  Addnl. flow cytometry studies demonstrated that the cellular uptake of the bioconjugate was inhibited in the presence of the competitive ligand triptorelin indicating a receptor-mediated pathway.  For comparative purpose, six novel daunorubicin-GnRH-III bioconjugates have been synthesized and biochem. characterized in which 6Asp was replaced by D-Asp, D-Glu and D-Trp.  In addn. to the anal. of the in vitro cytostatic effect and cellular uptake, receptor binding studies with 125I-triptorelin as radiotracer and degrdn. of the GnRH-III conjugates in the presence of rat liver lysosomal homogenate have been performed.  All derivs. showed high binding affinities to GnRH receptors and displayed in vitro cytostatic effects on HT-29 and MCF-7 cancer cells with IC50 values in a low micromolar range.  Moreover, we found that the release of the active drug metabolite and the cellular uptake of the bioconjugates were strongly affected by the amino acid exchange which in turn had an impact on the antitumor activity of the bioconjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMWaEckn1wM7Vg90H21EOLACvtfcHk0ljz57ZtEuwS6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOhtLvN&md5=71e5a06718a97f23b1afdf0da12a830e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.14.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.14.64%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DS.%26aulast%3DBiri-Kovacs%26aufirst%3DB.%26aulast%3DSzeder%26aufirst%3DB.%26aulast%3DFarkas%26aufirst%3DV.%26aulast%3DBuday%26aufirst%3DL.%26aulast%3DSzabo%26aufirst%3DZ.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DMezo%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520biochemical%2520evaluation%2520of%2520oxime%2520bond-linked%2520daunorubicin-GnRH-III%2520conjugates%2520developed%2520for%2520targeted%2520drug%2520delivery%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2018%26volume%3D14%26spage%3D756%26epage%3D771%26doi%3D10.3762%2Fbjoc.14.64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orban, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosze, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manea, M.</span></span> <span> </span><span class="NLM_article-title">Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>156</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2011.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.jconrel.2011.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=21864594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyltLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2011&pages=170-178&issue=2&author=P.+Schlageauthor=G.+Mezoauthor=E.+Orbanauthor=S.+Boszeauthor=M.+Manea&title=Anthracycline-GnRH+derivative+bioconjugates+with+different+linkages%3A+synthesis%2C+in+vitro+drug+release+and+cytostatic+effect&doi=10.1016%2Fj.jconrel.2011.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Anthracycline-GnRH derivative bioconjugates with different linkages: Synthesis, in vitro drug release and cytostatic effect</span></div><div class="casAuthors">Schlage, Pascal; Mezo, Gabor; Orban, Erika; Bosze, Szilvia; Manea, Marilena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">170-178</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To increase the selectivity and consequently to minimize the side effects of chemotherapeutic agents, receptor mediated tumor targeting approaches have been developed.  In the present work, various anthracycline-GnRH deriv. bioconjugates were synthesized with the aim of investigating the influence of (i) different anthracycline anticancer drugs, (ii) different linkages between the targeting moiety and the anticancer drug, and (iii) different targeting moieties (e.g., GnRH-III and [D-Lys6]-GnRH-I) on their in vitro drug release and cytostatic effect.  The anthracyclines, daunorubicin or doxorubicin, were attached to the ε-amino group of Lys of GnRH-III or [D-Lys6]-GnRH-I through oxime, hydrazone or ester bonds.  In another bioconjugate, a self-immolative p-aminobenzyloxycarbonyl spacer was used to link daunorubicin to GnRH-III.  The in vitro degrdn. of the bioconjugates was investigated in the presence of rat liver lysosomal homogenate and cathepsin B. The cellular uptake of the compds. was evaluated by flow cytometry and their in vitro cytostatic effect was detd. by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide assay.  The results indicate that on the tested cancer cell lines there is no significant difference in the cellular uptake and in vitro cytostatic effect of bioconjugates contg. GnRH-III or [D-Lys6]-GnRH-I as a targeting moiety.  The bioconjugates contg. ester bond, hydrazone bond and the self-immolative spacer exert the highest cytostatic effect, followed by oxime bond-linked compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzZMbP_ij8mrVg90H21EOLACvtfcHk0ljSOB2JBG1XhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyltLfN&md5=01381af92574573bc83152fc433edcd1</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2011.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2011.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DSchlage%26aufirst%3DP.%26aulast%3DMezo%26aufirst%3DG.%26aulast%3DOrban%26aufirst%3DE.%26aulast%3DBosze%26aufirst%3DS.%26aulast%3DManea%26aufirst%3DM.%26atitle%3DAnthracycline-GnRH%2520derivative%2520bioconjugates%2520with%2520different%2520linkages%253A%2520synthesis%252C%2520in%2520vitro%2520drug%2520release%2520and%2520cytostatic%2520effect%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2011%26volume%3D156%26issue%3D2%26spage%3D170%26epage%3D178%26doi%3D10.1016%2Fj.jconrel.2011.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arosio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piarulli, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neundorf, I.</span></span> <span> </span><span class="NLM_article-title">Kiss and run: promoting effective and targeted cellular uptake of a drug delivery vehicle composed of an integrin-targeting diketopiperazine peptidomimetic and a cell-penetrating peptide</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2011</span>– <span class="NLM_lpage">2022</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.9b00292</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.9b00292" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2lsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=2011-2022&issue=7&author=L.+Feniauthor=S.+Parenteauthor=C.+Robertauthor=S.+Gazzolaauthor=D.+Arosioauthor=U.+Piarulliauthor=I.+Neundorf&title=Kiss+and+run%3A+promoting+effective+and+targeted+cellular+uptake+of+a+drug+delivery+vehicle+composed+of+an+integrin-targeting+diketopiperazine+peptidomimetic+and+a+cell-penetrating+peptide&doi=10.1021%2Facs.bioconjchem.9b00292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide</span></div><div class="casAuthors">Feni, Lucia; Parente, Sara; Robert, Clemence; Gazzola, Silvia; Arosio, Daniela; Piarulli, Umberto; Neundorf, Ines</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2011-2022</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cell-penetrating peptides (CPPs) have emerged as powerful tools in terms of drug delivery.  Those short, often cationic peptides are characterized by their usually low toxicity and their ability to transport diverse cargos inside almost any kinds of cells.  Still, one major drawback is their nonselective uptake making their application in targeted cancer therapies questionable.  In this work, we aimed to combine the power of a CPP (sC18) with an integrin-targeting unit (c[DKP-f3-RGD]).  The latter is composed of the Arg-Gly-Asp peptide sequence cyclized via a diketopiperazine scaffold and is characterized by its high selectivity toward integrin αvβ3.  The two parts were linked via copper-catalyzed alkyne-azide click reaction (CuAAC), while the CPP was addnl. functionalized with either a fluorescent dye or the anticancer drug daunorubicin.  Both functionalities allowed a careful biol. evaluation of these novel peptide-conjugates regarding their cellular uptake mechanism, as well as cytotoxicity in αvβ3 integrin receptor expressing cells vs. cells that do not express αvβ3.  Our results show that the uptake follows a "kiss-and-run"-like model, in which the conjugates first target and recognize the receptor, but translocate mainly by CPP mediation.  Thereby, we obsd. significantly more pronounced toxic effects in αvβ3 expressing U87 cells compared to HT-29 and MCF-7 cells, when the cells were exposed to the substances with only very short contact times (15 min).  All in all, we present new concepts for the design of cancer selective peptide-drug conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo52geONXxf1rVg90H21EOLACvtfcHk0ljSOB2JBG1XhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2lsLnL&md5=7fd7487362f162c12a84139697c35575</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.9b00292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.9b00292%26sid%3Dliteratum%253Aachs%26aulast%3DFeni%26aufirst%3DL.%26aulast%3DParente%26aufirst%3DS.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DGazzola%26aufirst%3DS.%26aulast%3DArosio%26aufirst%3DD.%26aulast%3DPiarulli%26aufirst%3DU.%26aulast%3DNeundorf%26aufirst%3DI.%26atitle%3DKiss%2520and%2520run%253A%2520promoting%2520effective%2520and%2520targeted%2520cellular%2520uptake%2520of%2520a%2520drug%2520delivery%2520vehicle%2520composed%2520of%2520an%2520integrin-targeting%2520diketopiperazine%2520peptidomimetic%2520and%2520a%2520cell-penetrating%2520peptide%26jtitle%3DBioconjugate%2520Chem.%26date%3D2019%26volume%3D30%26issue%3D7%26spage%3D2011%26epage%3D2022%26doi%3D10.1021%2Facs.bioconjchem.9b00292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, K. K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and photodynamic activities of integrin-targeting silicon(IV) phthalocyanine-cRGD conjugates</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.05.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.ejmech.2018.05.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29852329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCrsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=24-33&author=B.+Y.+Zhengauthor=X.+Q.+Yangauthor=Y.+Zhaoauthor=Q.+F.+Zhengauthor=M.+R.+Keauthor=T.+Linauthor=R.+X.+Chenauthor=K.+K.+K.+Hoauthor=N.+Kumarauthor=J.+D.+Huang&title=Synthesis+and+photodynamic+activities+of+integrin-targeting+silicon%28IV%29+phthalocyanine-cRGD+conjugates&doi=10.1016%2Fj.ejmech.2018.05.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and photodynamic activities of integrin-targeting silicon(IV) phthalocyanine-cRGD conjugates</span></div><div class="casAuthors">Zheng, Bi-Yuan; Yang, Xiao-Qing; Zhao, Yang; Zheng, Qiao-Feng; Ke, Mei-Rong; Lin, Tao; Chen, Ren-Xun; Ho, Kitty K. K.; Kumar, Naresh; Huang, Jian-Dong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24-33</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel sym. or unsym. silicon (IV) phthalocyanines axially substituted with cyclic Arg-Gly-Asp (cRGD) ligands through different ethylene glycol chains have been synthesized by a facile and mild "click" reaction.  All the compds. show efficient photosensitizing activities in N,N-dimethylformamide, and are essentially non-aggregated in RPMI 1640 medium with 0.05% Cremophor EL.  Owing to the presence of two cRGD ligands, the conjugate 6b exhibits highest selectivity toward αvβ+3 HT-29 cells in photocytotoxicities.  It shows higher cellular uptake and ROS generation efficiency toward the αvβ+3 HT-29 cells compared with that of αvβ-3 MCF-7 cells.  The competitive cellular uptake and subcellular localization indicate that 6b is internalized mainly through integrin-mediated endocytosis.  In addn., the in vivo studies showed that 6b can mainly accumulate in tumor sites and show a significant PDT effect resulting in 75% tumor growth inhibition.  The results indicate that 6b is a highly promising photosensitizer for targeted photodynamic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_K805KgeYbVg90H21EOLACvtfcHk0liyfPhu6D9IPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCrsr7I&md5=864d71078705663a9f420b0b426ce86e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.05.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.05.039%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DB.%2BY.%26aulast%3DYang%26aufirst%3DX.%2BQ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DQ.%2BF.%26aulast%3DKe%26aufirst%3DM.%2BR.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DR.%2BX.%26aulast%3DHo%26aufirst%3DK.%2BK.%2BK.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DJ.%2BD.%26atitle%3DSynthesis%2520and%2520photodynamic%2520activities%2520of%2520integrin-targeting%2520silicon%2528IV%2529%2520phthalocyanine-cRGD%2520conjugates%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D24%26epage%3D33%26doi%3D10.1016%2Fj.ejmech.2018.05.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Polatuzumab vedotin: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1467</span>– <span class="NLM_lpage">1475</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01175-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1007%2Fs40265-019-01175-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31352604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BB3MvitVSmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1467-1475&issue=13&author=E.+D.+Deeks&title=Polatuzumab+vedotin%3A+first+global+approval&doi=10.1007%2Fs40265-019-01175-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Polatuzumab Vedotin: First Global Approval</span></div><div class="casAuthors">Deeks Emma D</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1467-1475</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polatuzumab vedotin (polatuzumab vedotin-piiq; Polivy®) is an antibody-drug conjugate comprising a monoclonal antibody against CD79b (a B cell receptor component) covalently conjugated to the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE) via a cleavable linker.  After binding to CD79b on the B-cell surface, polatuzumab vedotin is internalized and the linker is cleaved, releasing MMAE into the cell, where it inhibits division and induces apoptosis.  Polatuzumab vedotin is being developed by Genentech (a subsidiary of Roche) for the treatment of haematological malignancies.  In June 2019, the US FDA granted accelerated approval to polatuzumab vedotin, in combination with bendamustine plus rituximab, for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies.  Use of the compound in combination with bendamustine plus rituximab is also under regulatory review for relapsed/refractory DLBCL in the EU and is in ongoing phase 1b/2 development in this setting or relapsed/refractory follicular lymphoma (FL) in several countries.  Various other polatuzumab vedotin combination therapy regimens are also in phase 1b/2 development for relapsed/refractory non-Hodgkin lymphoma (NHL) [including DLBCL and FL] or in phase 2 or 3 development for previously untreated DLBCL, while polatuzumab vedotin monotherapy has been in phase 1 development for relapsed/refractory B-cell NHL in Japan.  This article summarizes the milestones in the development of polatuzumab vedotin leading to this first approval for its use in combination with bendamustine plus rituximab for relapsed/refractory DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWjRJKq7mXFhjv2lLSLOxFfW6udTcc2eZR30Kehi2J1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvitVSmsA%253D%253D&md5=2aed4fe7658078144e9a1169ecf60e37</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01175-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01175-0%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DPolatuzumab%2520vedotin%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D13%26spage%3D1467%26epage%3D1475%26doi%3D10.1007%2Fs40265-019-01175-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balar, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galsky, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinelli, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melhem-Bertrandt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrylak, D. P.</span></span> <span> </span><span class="NLM_article-title">Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">2592</span>– <span class="NLM_lpage">2600</span>, <span class="refDoi"> DOI: 10.1200/JCO.19.01140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1200%2FJCO.19.01140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31356140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovVSitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=2592-2600&issue=29&author=J.+E.+Rosenbergauthor=P.+H.+O%E2%80%99Donnellauthor=A.+V.+Balarauthor=B.+A.+McGregorauthor=E.+I.+Heathauthor=E.+Y.+Yuauthor=M.+D.+Galskyauthor=N.+M.+Hahnauthor=E.+M.+Gartnerauthor=J.+M.+Pinelliauthor=S.+Y.+Liangauthor=A.+Melhem-Bertrandtauthor=D.+P.+Petrylak&title=Pivotal+trial+of+enfortumab+vedotin+in+urothelial+carcinoma+after+platinum+and+anti-programmed+death+1%2Fprogrammed+death+ligand+1+therapy&doi=10.1200%2FJCO.19.01140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy</span></div><div class="casAuthors">Rosenberg, Jonathan E.; O'Donnell, Peter H.; Balar, Arjun V.; McGregor, Bradley A.; Heath, Elisabeth I.; Yu, Evan Y.; Galsky, Matthew D.; Hahn, Noah M.; Gartner, Elaina M.; Pinelli, Juan M.; Liang, Shang-Ying; Melhem-Bertrandt, Amal; Petrylak, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">2592-2613</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">PURPOSE Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, esp. for patients who were previously treated with platinum and anti-programmed death 1 or anti-programmed death ligand 1 (PD-1/L1) therapy.  Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4, which is highly expressed in urothelial carcinoma.  METHODS EV-201 is a global, phase II, single-arm study of enfortumab vedotin 1.25mg/kg (i.v. on days 1, 8, and 15 of every 28-day cycle) in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum chemotherapy and anti-PD-1/L1 therapy.  The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review.  Key secondary end points were duration of response, progression-free survival, overall survival, safety, and tolerability.  RESULTS Enfortumab vedotin was administered to 125 patients with metastatic urothelial carcinoma.  Median follow-up was 10.2 mo (range, 0.5 to 16.5 mo).  Confirmed objective response rate was 44% (95% CI, 35.1% to 53.2%), including 12% complete responses.  Similar responses were obsd. in prespecified subgroups, such as those patients with liver metastases and those with no response to prior anti-PD-1/L1 therapy.  Median duration of response was 7.6 mo (range, 0.95 to 11.301 mo).  The most common treatment-related adverse events were fatigue (50%), any peripheral neuropathy (50%), alopecia (49%), any rash (48%), decreased appetite (44%), and dysgeusia (40%).  No single treatment-related adverse events grade 3 or greater occurred in 10% or more of patients.  CONCLUSION Enfortumab vedotin demonstrated a clin. meaningful response rate with a manageable and tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum and anti-PD-1/L1 therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSAj5iZGBZybVg90H21EOLACvtfcHk0ljyUpbqUseGUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovVSitrc%253D&md5=01f8e50e459d254f0a687abc479da014</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1200%2FJCO.19.01140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.19.01140%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%2BH.%26aulast%3DBalar%26aufirst%3DA.%2BV.%26aulast%3DMcGregor%26aufirst%3DB.%2BA.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DYu%26aufirst%3DE.%2BY.%26aulast%3DGalsky%26aufirst%3DM.%2BD.%26aulast%3DHahn%26aufirst%3DN.%2BM.%26aulast%3DGartner%26aufirst%3DE.%2BM.%26aulast%3DPinelli%26aufirst%3DJ.%2BM.%26aulast%3DLiang%26aufirst%3DS.%2BY.%26aulast%3DMelhem-Bertrandt%26aufirst%3DA.%26aulast%3DPetrylak%26aufirst%3DD.%2BP.%26atitle%3DPivotal%2520trial%2520of%2520enfortumab%2520vedotin%2520in%2520urothelial%2520carcinoma%2520after%2520platinum%2520and%2520anti-programmed%2520death%25201%252Fprogrammed%2520death%2520ligand%25201%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26issue%3D29%26spage%3D2592%26epage%3D2600%26doi%3D10.1200%2FJCO.19.01140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redfern, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jikoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">816</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30097-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2FS1470-2045%2819%2930097-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31047803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXoslWru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=816-826&issue=6&author=K.+Tamuraauthor=J.+Tsurutaniauthor=S.+Takahashiauthor=H.+Iwataauthor=I.+E.+Kropauthor=C.+Redfernauthor=Y.+Sagaraauthor=T.+Doiauthor=H.+Parkauthor=R.+K.+Murthyauthor=R.+A.+Redmanauthor=T.+Jikohauthor=C.+Leeauthor=M.+Sugiharaauthor=J.+Shahidiauthor=A.+Yverauthor=S.+Modi&title=Trastuzumab+deruxtecan+%28DS-8201a%29+in+patients+with+advanced+HER2-positive+breast+cancer+previously+treated+with+trastuzumab+emtansine%3A+a+dose-expansion%2C+phase+1+study&doi=10.1016%2FS1470-2045%2819%2930097-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study</span></div><div class="casAuthors">Tamura, Kenji; Tsurutani, Junji; Takahashi, Shunji; Iwata, Hiroji; Krop, Ian E.; Redfern, Charles; Sagara, Yasuaki; Doi, Toshihiko; Park, Haeseong; Murthy, Rashmi K.; Redman, Rebecca A.; Jikoh, Takahiro; Lee, Caleb; Sugihara, Masahiro; Shahidi, Javad; Yver, Antoine; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">816-826</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent topoisomerase I inhibitor payload.  A phase 1, non-randomised, open-label, multiple-dose study was done to assess the safety, tolerability, and activity of trastuzumab deruxtecan in HER2-expressing, advanced solid tumors.  The dose escalation (part 1) has previously been reported and the recommended doses for expansion of 5·4 mg/kg or 6·4 mg/kg were established.  In this Article, we report the safety and preliminary activity results from this phase 1 trial in all patients with HER2-pos. advanced-stage breast cancer with previous trastuzumab emtansine treatment who received trastuzumab deruxtecan at the recommended doses for expansion.  We did an open-label, dose-escalation and dose-expansion phase 1 trial at eight hospitals and clinics in the USA and six in Japan.  Eligible patients were at least 18 years old in the USA and at least 20 years of age in Japan and had advanced solid tumors (regardless of HER2 expression in dose escalation or HER2 expression or mutation in dose expansion).  The recommended doses for expansion of 5·4 mg/kg or 6·4 mg/kg trastuzumab deruxtecan were administered i.v. to patients once every 3 wk until withdrawal of consent, unacceptable toxicity, or progressive disease.  In this Article, all patients with HER2-pos. advanced-stage breast cancer with previous trastuzumab emtansine treatment who received trastuzumab deruxtecan at the recommended doses for expansion were analyzed together.  The primary endpoints of the study were safety and preliminary activity (proportion of patients who achieved an objective response as assessed by the investigators).  The activity evaluable set included all patients who received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion, and for whom both baseline and post-treatment activity data were available.  The safety anal. set included all patients who received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion.  Enrolment for patients with HER2-pos. breast cancer has been completed.  This trial is registered at ClinicalTrials.gov, no. NCT02564900, and ClinicalTrials.jp, no. JapicCTI-152978.  Between Aug 28, 2015, and Aug 10, 2018, 115 of 118 patients with HER2-pos. breast cancer were treated with at least one dose of trastuzumab deruxtecan at the recommended doses for expansion.  All patients had at least one treatment-emergent adverse event.  Frequent grade 3 or worse treatment-emergent adverse events included anemia (19 [17%] of 115) and decreased neutrophil (16 [14%]), white blood cell (ten [9%]), and platelet (nine [8%]) counts.  At least one serious treatment-emergent adverse event occurred for 22 (19%) patients.  Investigators reported 20 cases of interstitial lung disease, pneumonitis, or organizing pneumonia, including one grade 3 event and two treatment-related deaths due to pneumonitis.  One death unrelated to study treatment was due to progressive disease. 66 (59·5%; 95% CI 49·7-68·7) of 111 patients had a confirmed objective response.  Trastuzumab deruxtecan had a manageable safety profile and showed preliminary activity in trastuzumab emtansine-pretreated patients with HER2-pos. breast cancer.  These results suggest that further development in phase 2 and 3 clin. trials for HER2-pos. breast cancer is warranted.Daiichi Sankyo Co, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHxbpFWZOJ27Vg90H21EOLACvtfcHk0ljyUpbqUseGUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXoslWru7w%253D&md5=6d0a54273d4c6cdf206c09be73722590</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930097-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930097-X%26sid%3Dliteratum%253Aachs%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DRedfern%26aufirst%3DC.%26aulast%3DSagara%26aufirst%3DY.%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DMurthy%26aufirst%3DR.%2BK.%26aulast%3DRedman%26aufirst%3DR.%2BA.%26aulast%3DJikoh%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DSugihara%26aufirst%3DM.%26aulast%3DShahidi%26aufirst%3DJ.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DTrastuzumab%2520deruxtecan%2520%2528DS-8201a%2529%2520in%2520patients%2520with%2520advanced%2520HER2-positive%2520breast%2520cancer%2520previously%2520treated%2520with%2520trastuzumab%2520emtansine%253A%2520a%2520dose-expansion%252C%2520phase%25201%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26issue%3D6%26spage%3D816%26epage%3D826%26doi%3D10.1016%2FS1470-2045%2819%2930097-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis
Phillips, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blattler, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwall, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenkare-Mitra, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9280</span>– <span class="NLM_lpage">9290</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=19010901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&issue=22&author=G.+D.+Lewis%0APhillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+Chariauthor=R.+J.+Lutzauthor=W.+L.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody-cytotoxic+drug+conjugate&doi=10.1158%2F0008-5472.CAN-08-1776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span></div><div class="casAuthors">Lewis Phillips, Gail D.; Li, Guangmin; Dugger, Debra L.; Crocker, Lisa M.; Parsons, Kathryn L.; Mai, Elaine; Blaettler, Walter A.; Lambert, John M.; Chari, Ravi V. J.; Lutz, Robert J.; Wong, Wai Lee T.; Jacobson, Frederic S.; Koeppen, Hartmut; Schwall, Ralph H.; Kenkare-Mitra, Sara R.; Spencer, Susan D.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9280-9290</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER2 is a validated target in breast cancer therapy.  Two drugs are currently approved for HER2-pos. breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007.  Despite these advances, some patients progress through therapy and succumb to their disease.  A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors.  We detd. in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymg. agents) conjugates using disulfide and thioether linkers.  Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells.  In vivo activity was detd. in mouse breast cancer models, and toxicity was assessed in rats as measured by body wt. loss.  Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.  Serum concns. of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker.  Potent activity was obsd. on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected.  In addn., trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors.  In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells.  Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpP5fkJnRorrVg90H21EOLACvtfcHk0lj0a-k7NtqU7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK&md5=e86e8687d5f8884f8e28514299dcbbf1</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody-cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D22%26spage%3D9280%26epage%3D9290%26doi%3D10.1158%2F0008-5472.CAN-08-1776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahdat, L. T.</span></span> <span> </span><span class="NLM_article-title">Sacituzumab govitecan: an antibody–drug conjugate</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1080/14712598.2017.1331214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1080%2F14712598.2017.1331214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=28503956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVags7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=1027-1031&issue=8&author=S.+Sahotaauthor=L.+T.+Vahdat&title=Sacituzumab+govitecan%3A+an+antibody%E2%80%93drug+conjugate&doi=10.1080%2F14712598.2017.1331214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Sacituzumab govitecan: an antibody-drug conjugate</span></div><div class="casAuthors">Sahota, Sheena; Vahdat, Linda T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1027-1031</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Despite advances in the diagnosis and treatment of patients with cancer, patients with metastatic cancer have limited therapeutic options after initial lines of therapy.  Understanding tumor biol. has translated into the identification of actionable targets that resulted in therapeutics.  Antibody-drug conjugates (ADC) are capitalizing on this explosion of scientific information.  ADCs allow an antibody to a unique target to be conjugated via an innovative linker, to a highly toxic drug which is delivered to its target.  Sacituzumab govitecan is an ADC that combines the active mol. in irinotecan, SN-38, to an antibody targeting trop2.: In this review, the authors introduce the reader to the ADC sacituzumab govitecan providing the reader with details about its pharmacokinetics, pharmacodynamics, efficacy and safety.  The authors also give their expert anal. about its potential future use.: Sacituzumab govitecan is a novel and well-tolerated therapeutic showing promising results in difficult to treat cancers.  Further studies are underway to optimize the group of patients that would benefit from it.  Given its excellent performance, we are cautiously optimistic it will be approved by the FDA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4PTnZwxC9rVg90H21EOLACvtfcHk0lizJyrseFFrig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVags7s%253D&md5=e2a9aeb979d52eca095bd455aa73667b</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1080%2F14712598.2017.1331214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14712598.2017.1331214%26sid%3Dliteratum%253Aachs%26aulast%3DSahota%26aufirst%3DS.%26aulast%3DVahdat%26aufirst%3DL.%2BT.%26atitle%3DSacituzumab%2520govitecan%253A%2520an%2520antibody%25E2%2580%2593drug%2520conjugate%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2017%26volume%3D17%26issue%3D8%26spage%3D1027%26epage%3D1031%26doi%3D10.1080%2F14712598.2017.1331214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span> <span> </span><span class="NLM_article-title">Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody–drug conjugate (ADC)</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">22496</span>– <span class="NLM_lpage">22512</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.18632%2Foncotarget.4318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=26101915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BC2MbmtVarsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=22496-22512&issue=26&author=D.+M.+Goldenbergauthor=T.+M.+Cardilloauthor=S.+V.+Govindanauthor=E.+A.+Rossiauthor=R.+M.+Sharkey&title=Trop-2+is+a+novel+target+for+solid+cancer+therapy+with+sacituzumab+govitecan+%28IMMU-132%29%2C+an+antibody%E2%80%93drug+conjugate+%28ADC%29&doi=10.18632%2Foncotarget.4318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)</span></div><div class="casAuthors">Goldenberg David M; Cardillo Thomas M; Govindan Serengulam V; Rossi Edmund A; Sharkey Robert M</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">22496-512</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers.  The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody.  In vitro and in vivo studies show enhanced efficacy, while there is a gradual release of SN-38 that contributes to the overall effect.  IMMU-132 is most efficacious at a high drug:antibody ratio (DAR) of 7.6:1, which does not affect binding and pharmacokinetics.  It targets up to 136-fold more SN-38 to a human cancer xenograft than irinotecan, SN-38's prodrug.  IMMU-132 delivers SN-38 in its most active, non-glucuronidated form, which may explain the lower frequency of severe diarrhea than with irinotecan.  Thus, this ADC, carrying a moderately-toxic drug targeting Trop-2 represents a novel cancer therapeutic that is showing promising activity in patients with several metastatic cancer types, including triple-negative breast cancer, non-small-cell and small-cell lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_AS8-S1EVm3RxY89Cm6SyfW6udTcc2ebCbMamJlk4arntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbmtVarsA%253D%253D&md5=df2f5d058386096fad912f53659cb15c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4318%26sid%3Dliteratum%253Aachs%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DCardillo%26aufirst%3DT.%2BM.%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DRossi%26aufirst%3DE.%2BA.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26atitle%3DTrop-2%2520is%2520a%2520novel%2520target%2520for%2520solid%2520cancer%2520therapy%2520with%2520sacituzumab%2520govitecan%2520%2528IMMU-132%2529%252C%2520an%2520antibody%25E2%2580%2593drug%2520conjugate%2520%2528ADC%2529%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D26%26spage%3D22496%26epage%3D22512%26doi%3D10.18632%2Foncotarget.4318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Shang Eun Park, Naglaa Salem El-Sayed, Kiumars Shamloo, Sandeep Lohan, Sumit Kumar, Muhammad Imran Sajid, <span class="NLM_string-name hlFld-ContribAuthor">Rakesh Kumar Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Delivery of Cabazitaxel Using Cyclic Cell-Penetrating Peptide and Biomarkers of Extracellular Matrix for Prostate and Breast Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.1c00319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.1c00319%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DTargeted%252BDelivery%252Bof%252BCabazitaxel%252BUsing%252BCyclic%252BCell-Penetrating%252BPeptide%252Band%252BBiomarkers%252Bof%252BExtracellular%252BMatrix%252Bfor%252BProstate%252Band%252BBreast%252BCancer%252BTherapy%26aulast%3DPark%26aufirst%3DShang%2BEun%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D22062021%26date%3D02072021%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Laurent Knerr, Thazha P. Prakash, Richard Lee, William J. Drury III, Mehran Nikan, Wuxia Fu, Elaine Pirie, Leonardo De Maria, Eric Valeur, Ahlke Hayen, Maria Ölwegård-Halvarsson, Johan Broddefalk, Carina Ämmälä, Michael E. Østergaard, Johan Meuller, Linda Sundström, Patrik Andersson, David Janzén, Rasmus Jansson-Löfmark, Punit P. Seth, <span class="NLM_string-name hlFld-ContribAuthor">Shalini Andersson</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (9)
                                     , 3416-3429. <a href="https://doi.org/10.1021/jacs.0c12043" title="DOI URL">https://doi.org/10.1021/jacs.0c12043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c12043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c12043%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DGlucagon%252BLike%252BPeptide%252B1%252BReceptor%252BAgonists%252Bfor%252BTargeted%252BDelivery%252Bof%252BAntisense%252BOligonucleotides%252Bto%252BPancreatic%252BBeta%252BCell%26aulast%3DKnerr%26aufirst%3DLaurent%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D22112020%26date%3D24022021%26volume%3D143%26issue%3D9%26spage%3D3416%26epage%3D3429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaqi  Zhou</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Li</span>, <span class="hlFld-ContribAuthor ">Wenlong  Huang</span>, <span class="hlFld-ContribAuthor ">Wei  Shi</span>, <span class="hlFld-ContribAuthor ">Hai  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Source and exploration of the peptides used to construct peptide-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113712. <a href="https://doi.org/10.1016/j.ejmech.2021.113712" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113712</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113712%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSource%252Band%252Bexploration%252Bof%252Bthe%252Bpeptides%252Bused%252Bto%252Bconstruct%252Bpeptide-drug%252Bconjugates%26aulast%3DZhou%26aufirst%3DJiaqi%26date%3D2021%26volume%3D224%26spage%3D113712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">He  Lian</span>, <span class="hlFld-ContribAuthor ">Ping  Guan</span>, <span class="hlFld-ContribAuthor ">Hongyan  Tan</span>, <span class="hlFld-ContribAuthor ">Xiaoshu  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhaoxu  Meng</span>. </span><span class="cited-content_cbyCitation_article-title">Near-infrared light triggered multi-hit therapeutic nanosystem for tumor specific photothermal effect amplified signal pathway regulation and ferroptosis. </span><span class="cited-content_cbyCitation_journal-name">Bioactive Materials</span><span> <strong>2021,</strong> <em>575 </em><a href="https://doi.org/10.1016/j.bioactmat.2021.07.014" title="DOI URL">https://doi.org/10.1016/j.bioactmat.2021.07.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioactmat.2021.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioactmat.2021.07.014%26sid%3Dliteratum%253Aachs%26jtitle%3DBioactive%2520Materials%26atitle%3DNear-infrared%252Blight%252Btriggered%252Bmulti-hit%252Btherapeutic%252Bnanosystem%252Bfor%252Btumor%252Bspecific%252Bphotothermal%252Beffect%252Bamplified%252Bsignal%252Bpathway%252Bregulation%252Band%252Bferroptosis%26aulast%3DLian%26aufirst%3DHe%26date%3D2021%26volume%3D575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Shen  Zhu</span>, <span class="hlFld-ContribAuthor ">Kexing  Tang</span>, <span class="hlFld-ContribAuthor ">Jiayi  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide–drug conjugate-based novel molecular drug delivery system in cancer. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2021,</strong> <em>70 </em><a href="https://doi.org/10.1016/j.tips.2021.07.001" title="DOI URL">https://doi.org/10.1016/j.tips.2021.07.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2021.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2021.07.001%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DPeptide%2525E2%252580%252593drug%252Bconjugate-based%252Bnovel%252Bmolecular%252Bdrug%252Bdelivery%252Bsystem%252Bin%252Bcancer%26aulast%3DZhu%26aufirst%3DYi-Shen%26date%3D2021%26volume%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Battistini</span>, <span class="hlFld-ContribAuthor ">Kelly  Bugatti</span>, <span class="hlFld-ContribAuthor ">Andrea  Sartori</span>, <span class="hlFld-ContribAuthor ">Claudio  Curti</span>, <span class="hlFld-ContribAuthor ">Franca  Zanardi</span>. </span><span class="cited-content_cbyCitation_article-title">RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (17)
                                     , 2506-2528. <a href="https://doi.org/10.1002/ejoc.202100240" title="DOI URL">https://doi.org/10.1002/ejoc.202100240</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100240%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRGD%252BPeptide%2525E2%252580%252590Drug%252BConjugates%252Bas%252BEffective%252BDual%252BTargeting%252BPlatforms%25253A%252BRecent%252BAdvances%26aulast%3DBattistini%26aufirst%3DLucia%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D17%26spage%3D2506%26epage%3D2528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Azam  Saghaeidehkordi</span>, <span class="hlFld-ContribAuthor ">Shiuan  Chen</span>, <span class="hlFld-ContribAuthor ">Sun  Yang</span>, <span class="hlFld-ContribAuthor ">Kamaljit  Kaur</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 661. <a href="https://doi.org/10.3390/pharmaceutics13050661" title="DOI URL">https://doi.org/10.3390/pharmaceutics13050661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics13050661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics13050661%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DEvaluation%252Bof%252Ba%252BKeratin%252B1%252BTargeting%252BPeptide-Doxorubicin%252BConjugate%252Bin%252Ba%252BMouse%252BModel%252Bof%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DSaghaeidehkordi%26aufirst%3DAzam%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic of a PDC. The chemical structures of different linker chemistries are shown with the plausible method of release of the drug from PDC after cellular uptake or under in vivo conditions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PDCs with an ester and/or an amide as linkers. The peptide is shown in red, the linker in blue, and the drug in black. <span class="smallcaps smallerCapital">d</span>-Amino acids are shown in lower case.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. PDCs with a carbamate linker. <span class="smallcaps smallerCapital">d</span>-Amino acids are shown in lower case.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. PDCs with a dipeptide or tripeptide linker.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PDCs with an amide and a succinimidyl thioether as linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Peptide–drug conjugate with the ring closed succinimidyl thioether and ring-open stable thioether.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PDCs with an ester and a triazole as linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Drug conjugates with a hydrazone bond as a linker.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. PDCs with a disulfide as a linker.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. PDCs with an oxime as a linker.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. PDCs with triazole linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/medium/jm0c01530_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0012.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of some approved ADCs with different linker chemistries. The antibody is shown in green, the linker in blue, and the drug in black.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01530/20210107/images/large/jm0c01530_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01530&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 73 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gotwals, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipolletta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremasco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quaratino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatos-Peyton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzzelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span> <span> </span><span class="NLM_article-title">Prospects for combining targeted and conventional cancer therapy with immunotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1038%2Fnrc.2017.17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=28338065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVWmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=286-301&issue=5&author=P.+Gotwalsauthor=S.+Cameronauthor=D.+Cipollettaauthor=V.+Cremascoauthor=A.+Crystalauthor=B.+Hewesauthor=B.+Muellerauthor=S.+Quaratinoauthor=C.+Sabatos-Peytonauthor=L.+Petruzzelliauthor=J.+A.+Engelmanauthor=G.+Dranoff&title=Prospects+for+combining+targeted+and+conventional+cancer+therapy+with+immunotherapy&doi=10.1038%2Fnrc.2017.17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for combining targeted and conventional cancer therapy with immunotherapy</span></div><div class="casAuthors">Gotwals, Philip; Cameron, Scott; Cipolletta, Daniela; Cremasco, Viviana; Crystal, Adam; Hewes, Becker; Mueller, Britta; Quaratino, Sonia; Sabatos-Peyton, Catherine; Petruzzelli, Lilli; Engelman, Jeffrey A.; Dranoff, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">286-301</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Over the past 25 years, research in cancer therapeutics has largely focused on two distinct lines of enquiry.  In one approach, efforts to understand the underlying cell-autonomous, genetic drivers of tumorigenesis have led to the development of clin. important targeted agents that result in profound, but often not durable, tumor responses in genetically defined patient populations.  In the second parallel approach, exploration of the mechanisms of protective tumor immunity has provided several therapeutic strategies - most notably the 'immune checkpoint' antibodies that reverse the neg. regulators of T cell function - that accomplish durable clin. responses in subsets of patients with various tumor types.  The integration of these potentially complementary research fields provides new opportunities to improve cancer treatments.  Targeted and immune-based therapies have already transformed the std.-of-care for several malignancies.  However, addnl. insights into the effects of targeted therapies, along with conventional chemotherapy and radiation therapy, on the induction of antitumor immunity will help to advance the design of combination strategies that increase the rate of complete and durable clin. response in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTA6tw3u75TrVg90H21EOLACvtfcHk0lgTuueJB1WOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVWmtro%253D&md5=19da4f27a87146e290e873de9c7a7739</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.17%26sid%3Dliteratum%253Aachs%26aulast%3DGotwals%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DS.%26aulast%3DCipolletta%26aufirst%3DD.%26aulast%3DCremasco%26aufirst%3DV.%26aulast%3DCrystal%26aufirst%3DA.%26aulast%3DHewes%26aufirst%3DB.%26aulast%3DMueller%26aufirst%3DB.%26aulast%3DQuaratino%26aufirst%3DS.%26aulast%3DSabatos-Peyton%26aufirst%3DC.%26aulast%3DPetruzzelli%26aufirst%3DL.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDranoff%26aufirst%3DG.%26atitle%3DProspects%2520for%2520combining%2520targeted%2520and%2520conventional%2520cancer%2520therapy%2520with%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26issue%3D5%26spage%3D286%26epage%3D301%26doi%3D10.1038%2Fnrc.2017.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrahari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholkar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinh, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khurana, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, D.</span></span> <span> </span><span class="NLM_article-title">Novel delivery approaches for cancer therapeutics</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>219</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2015.09.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.jconrel.2015.09.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=26456750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Kktr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2015&pages=248-268&author=A.+K.+Mitraauthor=V.+Agrahariauthor=A.+Mandalauthor=K.+Cholkarauthor=C.+Natarajanauthor=S.+Shahauthor=M.+Josephauthor=H.+M.+Trinhauthor=R.+Vaishyaauthor=X.+Yangauthor=Y.+Haoauthor=V.+Khuranaauthor=D.+Pal&title=Novel+delivery+approaches+for+cancer+therapeutics&doi=10.1016%2Fj.jconrel.2015.09.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Novel delivery approaches for cancer therapeutics</span></div><div class="casAuthors">Mitra, Ashim K.; Agrahari, Vibhuti; Mandal, Abhirup; Cholkar, Kishore; Natarajan, Chandramouli; Shah, Sujay; Joseph, Mary; Trinh, Hoang M.; Vaishya, Ravi; Yang, Xiaoyan; Hao, Yi; Khurana, Varun; Pal, Dhananjay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">248-268</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Currently, a majority of cancer treatment strategies are based on the removal of tumor mass mainly by surgery.  Chem. and phys. treatments such as chemo- and radiotherapies have also made a major contribution in inhibiting rapid growth of malignant cells.  Furthermore, these approaches are often combined to enhance therapeutic indexes.  It is widely known that surgery, chemo- and radiotherapy also inhibit normal cells growth.  In addn., these treatment modalities are assocd. with severe side effects and high toxicity which in turn lead to low quality of life.  This review encompasses novel strategies for more effective chemotherapeutic delivery aiming to generate better prognosis.  Currently, cancer treatment is a highly dynamic field and significant advances are being made in the development of novel cancer treatment strategies.  In contrast to conventional cancer therapeutics, novel approaches such as ligand or receptor based targeting, triggered release, intracellular drug targeting, gene delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-mediated drug delivery, have added new modalities for cancer treatment.  These approaches have led to selective detection of malignant cells leading to their eradication with minimal side effects.  Lowering, multi-drug resistance and involving influx transportation in targeted drug delivery to cancer cells can also contribute significantly in the therapeutic interventions in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmwohufBvUXbVg90H21EOLACvtfcHk0lgTuueJB1WOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Kktr3M&md5=340b2ca39f6ac56d2e9ec763b2303163</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2015.09.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2015.09.067%26sid%3Dliteratum%253Aachs%26aulast%3DMitra%26aufirst%3DA.%2BK.%26aulast%3DAgrahari%26aufirst%3DV.%26aulast%3DMandal%26aufirst%3DA.%26aulast%3DCholkar%26aufirst%3DK.%26aulast%3DNatarajan%26aufirst%3DC.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DJoseph%26aufirst%3DM.%26aulast%3DTrinh%26aufirst%3DH.%2BM.%26aulast%3DVaishya%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DKhurana%26aufirst%3DV.%26aulast%3DPal%26aufirst%3DD.%26atitle%3DNovel%2520delivery%2520approaches%2520for%2520cancer%2520therapeutics%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2015%26volume%3D219%26spage%3D248%26epage%3D268%26doi%3D10.1016%2Fj.jconrel.2015.09.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chau, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeg, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates for cancer</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span> (<span class="NLM_issue">10200</span>),  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)31774-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2FS0140-6736%2819%2931774-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31478503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslSit73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=793-804&issue=10200&author=C.+H.+Chauauthor=P.+S.+Steegauthor=W.+D.+Figg&title=Antibody-drug+conjugates+for+cancer&doi=10.1016%2FS0140-6736%2819%2931774-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for cancer</span></div><div class="casAuthors">Chau, Cindy H.; Steeg, Patricia S.; Figg, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10200</span>),
    <span class="NLM_cas:pages">793-804</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chem. linker.  The ADC is designed to selectively deliver the ultratoxic payload directly to the target cancer cells.  To date, five ADCs have received market approval and over 100 are being investigated in various stages of clin. development.  In this Therapeutics paper, we review recent clin. experience with the approved ADCs and other promising late-stage candidates on the horizon, following an overview of the biol. and chem. of ADCs and how the individual components of an ADC (antibody [or target], linker and conjugation chem., and cytotoxic payload) influence its activity.  We briefly discuss opportunities for enhancing ADC efficacy, drug resistance, and future perspectives for this novel antibody-based mol. platform, which has great potential to make a paradigm shift in cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov4-NFqiYwKLVg90H21EOLACvtfcHk0li-ArxxEqL-YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslSit73I&md5=df4ff41af6d0a667f28575d5c9cee49c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2931774-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252931774-X%26sid%3Dliteratum%253Aachs%26aulast%3DChau%26aufirst%3DC.%2BH.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520cancer%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26issue%3D10200%26spage%3D793%26epage%3D804%26doi%3D10.1016%2FS0140-6736%2819%2931774-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Peptide conjugates with small molecules designed to enhance efficacy and safety</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1855</span>, <span class="refDoi"> DOI: 10.3390/molecules24101855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3390%2Fmolecules24101855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1855&issue=10&author=R.+Heauthor=B.+Finanauthor=J.+P.+Mayerauthor=R.+D.+DiMarchi&title=Peptide+conjugates+with+small+molecules+designed+to+enhance+efficacy+and+safety&doi=10.3390%2Fmolecules24101855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide conjugates with small molecules designed to enhance efficacy and safety</span></div><div class="casAuthors">He, Rongjun; Finan, Brian; Mayer, John P.; DiMarchi, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1855</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Peptides constitute mol. diversity with unique mol. mechanisms of action that are proven indispensable in the management of many human diseases, but of only a mere fraction relative to more traditional small mol.-based medicines.  The integration of these two therapeutic modalities o ers the potential to enhance and broaden pharmacol. while minimizing dose-dependent toxicol.  This review summarizes numerous advances in drug design, synthesis and development that provide direction for next-generation research endeavors in this field.  Medicinal studies in this area have largely focused upon the application of peptides to selectively enhance small mol. cytotoxicity to more effectively treat multiple oncol. diseases.  To a lesser and steadily emerging extent peptides are being therapeutically employed to complement and diversify the pharmacol. of small mol. drugs in diseases other than just cancer.  No matter the disease, the purpose of the mol. integration remains const. and it is to achieve superior therapeutic outcomes with diminished adverse effects.  We review linker technol. and conjugation chemistries that have enabled integrated and targeted pharmacol. with controlled release.  Finally, we offer our perspective on opportunities and obstacles in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_IMrSi0d7urVg90H21EOLACvtfcHk0li-ArxxEqL-YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb%252FM&md5=da04d398164460a08977abcdcefdc230</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24101855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24101855%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DR.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DPeptide%2520conjugates%2520with%2520small%2520molecules%2520designed%2520to%2520enhance%2520efficacy%2520and%2520safety%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26issue%3D10%26spage%3D1855%26doi%3D10.3390%2Fmolecules24101855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, R.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates for cancer therapy</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>), <span class="NLM_elocation-id">e254-e262</span> <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30030-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2FS1470-2045%2816%2930030-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=27299281" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&issue=6&author=A.+Thomasauthor=B.+A.+Teicherauthor=R.+Hassan&title=Antibody-drug+conjugates+for+cancer+therapy&doi=10.1016%2FS1470-2045%2816%2930030-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930030-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930030-4%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DHassan%26aufirst%3DR.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D6%26doi%3D10.1016%2FS1470-2045%2816%2930030-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vrettos, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span> <span> </span><span class="NLM_article-title">On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.3762/bjoc.14.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3762%2Fbjoc.14.80" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29765474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOnsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=930-954&author=E.+I.+Vrettosauthor=G.+Mezoauthor=A.+G.+Tzakos&title=On+the+design+principles+of+peptide%E2%80%93drug+conjugates+for+targeted+drug+delivery+to+the+malignant+tumor+site&doi=10.3762%2Fbjoc.14.80"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site</span></div><div class="casAuthors">Vrettos, Eirinaios I.; Mezo, Gabor; Tzakos, Andreas G.</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">930-954</span>CODEN:
                <span class="NLM_cas:coden">BJOCBH</span>;
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    
            (<span class="NLM_cas:orgname">Beilstein-Institut zur Foerderung der Chemischen Wissenschaften</span>)
        </div><div class="casAbstract">Cancer is the second leading cause of death affecting nearly one in two people, and the appearance of new cases is projected to rise by >70% by 2030.  To effectively combat the menace of cancer, a variety of strategies have been exploited.  Among them, the development of peptide-drug conjugates (PDCs) is considered as an inextricable part of this armamentarium and is continuously explored as a viable approach to target malignant tumors.  The general architecture of PDCs consists of three building blocks: the tumor-homing peptide, the cytotoxic agent and the biodegradable connecting linker.  The aim of the current review is to provide a spherical perspective on the basic principles governing PDCs, as also the methodol. to construct them.  We aim to offer basic and integral knowledge on the rational design towards the construction of PDCs through analyzing each building block, as also to highlight the overall progress of this rapidly growing field.  Therefore, we focus on several intriguing examples from the recent literature, including important PDCs that have progressed to phase III clin. trials.  Last, we address possible difficulties that may emerge during the synthesis of PDCs, as also report ways to overcome them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRxpOdZLKXfrVg90H21EOLACvtfcHk0lh9-CbqghQT0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOnsLvP&md5=595fce13e61b3e6f58a8ae6969e8b2c8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.14.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.14.80%26sid%3Dliteratum%253Aachs%26aulast%3DVrettos%26aufirst%3DE.%2BI.%26aulast%3DMezo%26aufirst%3DG.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26atitle%3DOn%2520the%2520design%2520principles%2520of%2520peptide%25E2%2580%2593drug%2520conjugates%2520for%2520targeted%2520drug%2520delivery%2520to%2520the%2520malignant%2520tumor%2520site%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2018%26volume%3D14%26spage%3D930%26epage%3D954%26doi%3D10.3762%2Fbjoc.14.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheetham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angacian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span> <span> </span><span class="NLM_article-title">Peptide-drug conjugates as effective prodrug strategies for targeted delivery</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>110–111</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2016.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.addr.2016.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=27370248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSgtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110%E2%80%93111&publication_year=2017&pages=112-126&author=Y.+Wangauthor=A.+G.+Cheethamauthor=G.+Angacianauthor=H.+Suauthor=L.+Xieauthor=H.+Cui&title=Peptide-drug+conjugates+as+effective+prodrug+strategies+for+targeted+delivery&doi=10.1016%2Fj.addr.2016.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-drug conjugates as effective prodrug strategies for targeted delivery</span></div><div class="casAuthors">Wang, Yin; Cheetham, Andrew G.; Angacian, Garren; Su, Hao; Xie, Lisi; Cui, Honggang</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">110-111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112-126</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Peptide-drug conjugates (PDCs) represent an important class of therapeutic agents that combine one or more drug mols. with a short peptide through a biodegradable linker.  This prodrug strategy uniquely and specifically exploits the biol. activities and self-assembling potential of small-mol. peptides to improve the treatment efficacy of medicinal compds.  We review here the recent progress in the design and synthesis of peptide-drug conjugates in the context of targeted drug delivery and cancer chemotherapy.  We analyze carefully the key design features in choosing the peptide sequence and linker chem. for the drug of interest, as well as the strategies to optimize the conjugate design.  We highlight the recent progress in the design and synthesis of self-assembling peptide-drug amphiphiles to construct supramol. nanomedicine and nanofiber hydrogels for both systemic and topical delivery of active pharmaceutical ingredients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxcgDx1p75N7Vg90H21EOLACvtfcHk0ljYjCgEQpCMDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSgtbvL&md5=3a23bd362031d78b92bc167a44c62c96</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCheetham%26aufirst%3DA.%2BG.%26aulast%3DAngacian%26aufirst%3DG.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DH.%26atitle%3DPeptide-drug%2520conjugates%2520as%2520effective%2520prodrug%2520strategies%2520for%2520targeted%2520delivery%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D110%25E2%2580%2593111%26spage%3D112%26epage%3D126%26doi%3D10.1016%2Fj.addr.2016.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahdat, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroose, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santin, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweidan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washkowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinsky, K.</span></span> <span> </span><span class="NLM_article-title">Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1814213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1056%2FNEJMoa1814213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=30786188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvVSjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=741-751&issue=8&author=A.+Bardiaauthor=I.+A.+Mayerauthor=L.+T.+Vahdatauthor=S.+M.+Tolaneyauthor=S.+J.+Isakoffauthor=J.+R.+Diamondauthor=J.+O%E2%80%99Shaughnessyauthor=R.+L.+Morooseauthor=A.+D.+Santinauthor=V.+G.+Abramsonauthor=N.+C.+Shahauthor=H.+S.+Rugoauthor=D.+M.+Goldenbergauthor=A.+M.+Sweidanauthor=R.+Iannoneauthor=S.+Washkowitzauthor=R.+M.+Sharkeyauthor=W.+A.+Wegenerauthor=K.+Kalinsky&title=Sacituzumab+govitecan-hziy+in+refractory+metastatic+triple-negative+breast+cancer&doi=10.1056%2FNEJMoa1814213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer</span></div><div class="casAuthors">Bardia, A.; Mayer, I. A.; Vahdat, L. T.; Tolaney, S. M.; Isakoff, S. J.; Diamond, J. R.; O'Shaughnessy, J.; Moroose, R. L.; Santin, A. D.; Abramson, V. G.; Shah, N. C.; Rugo, H. S.; Goldenberg, D. M.; Sweidan, A. M.; Iannone, R.; Washkowitz, S.; Sharkey, R. M.; Wegener, W. A.; Kalinsky, K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">741-751</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Std. chemotherapy is assocd. with low response rates and short progression-free survival among patients with pretreated metastatic triple-neg. breast cancer.  Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker.  Sacituzumab govitecan-hziy enables delivery of high concns. of SN-38 to tumors.  Methods We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy i.v. on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects.  A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kg of body wt. after receiving at least two previous anticancer therapies for metastatic triple-neg. breast cancer.  The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clin. benefit rate (defined as a complete or partial response or stable disease for at least 6 mo); progression-free survival; and overall survival.  Post hoc analyses detd. the response rate and duration, which were assessed by blinded independent central review. results The 108 patients with triple-neg. breast cancer had received a median of 3 previous therapies (range, 2 to 10).  Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events.  Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia.  The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 mo (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 mo, resp.  The clin. benefit rate was 45.4%.  Median progression-free survival was 5.5 mo (95% CI, 4.1 to 6.3), and overall survival was 13.0 mo (95% CI, 11.2 to 13.7).  Conclusions Sacituzumab govitecan-hziy was assocd. with durable objective responses in patients with heavily pretreated metastatic triple-neg. breast cancer.  Myelotoxic effects were the main adverse reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAgQWEPOcqfrVg90H21EOLACvtfcHk0ljYjCgEQpCMDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvVSjs7w%253D&md5=75edc2c274aef0ab90dd2aaf230dabac</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1814213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1814213%26sid%3Dliteratum%253Aachs%26aulast%3DBardia%26aufirst%3DA.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DVahdat%26aufirst%3DL.%2BT.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DMoroose%26aufirst%3DR.%2BL.%26aulast%3DSantin%26aufirst%3DA.%2BD.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DShah%26aufirst%3DN.%2BC.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DSweidan%26aufirst%3DA.%2BM.%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DWashkowitz%26aufirst%3DS.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DWegener%26aufirst%3DW.%2BA.%26aulast%3DKalinsky%26aufirst%3DK.%26atitle%3DSacituzumab%2520govitecan-hziy%2520in%2520refractory%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D8%26spage%3D741%26epage%3D751%26doi%3D10.1056%2FNEJMoa1814213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bargh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isidro-Llobet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Cleavable linkers in antibody–drug conjugates</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4361</span>– <span class="NLM_lpage">4374</span>, <span class="refDoi"> DOI: 10.1039/C8CS00676H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1039%2FC8CS00676H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31294429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=4361-4374&issue=16&author=J.+D.+Barghauthor=A.+Isidro-Llobetauthor=J.+S.+Parkerauthor=D.+R.+Spring&title=Cleavable+linkers+in+antibody%E2%80%93drug+conjugates&doi=10.1039%2FC8CS00676H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cleavable linkers in antibody-drug conjugates</span></div><div class="casAuthors">Bargh, Jonathan D.; Isidro-Llobet, Albert; Parker, Jeremy S.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4361-4374</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Antibody-Drug Conjugates (ADCs) are now established as a major class of therapeutics for the clin. treatment of cancer.  The properties of the linker between the antibody and the payload are proven to be crit. to the success of an ADC.  Although ADC linkers can be 'non-cleavable', the vast majority of ADCs in clin. development have specific release mechanisms to allow controlled linker cleavage at the target site and are thus termed 'cleavable'.  In recent years, the development of new methods of drug release from ADCs has continued in parallel to the deepening understanding of the biol. processes underlying the mechanisms of action of pre-existing technologies.  This review summarises the advances in the field of cleavable linker technologies for ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvG2Xk9IvLpLVg90H21EOLACvtfcHk0ljv6c8USYKR8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M&md5=bc73619319b21c2b85e3d613ca72f778</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1039%2FC8CS00676H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CS00676H%26sid%3Dliteratum%253Aachs%26aulast%3DBargh%26aufirst%3DJ.%2BD.%26aulast%3DIsidro-Llobet%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DCleavable%2520linkers%2520in%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2019%26volume%3D48%26issue%3D16%26spage%3D4361%26epage%3D4374%26doi%3D10.1039%2FC8CS00676H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowinger, T. B.</span></span> <span> </span><span class="NLM_article-title">Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.pharmthera.2017.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=28757155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yrsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2018&pages=126-142&author=P.+A.+Trailauthor=G.+M.+Dubowchikauthor=T.+B.+Lowinger&title=Antibody+drug+conjugates+for+treatment+of+breast+cancer%3A+Novel+targets+and+diverse+approaches+in+ADC+design&doi=10.1016%2Fj.pharmthera.2017.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design</span></div><div class="casAuthors">Trail, Pamela A.; Dubowchik, Gene M.; Lowinger, Timothy B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">126-142</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Breast cancer is a heterogeneous group of malignancies with a spectrum of mol. subtypes, pathologies and outcomes that together comprise the most common non-cutaneous cancer in women.  Currently, over 80% of breast cancer patients are diagnosed at relatively early stages of disease where there are encouraging data on outcomes and long term survival.  However, there is currently no curative option for those patients with metastatic disease and there is a substantial medical need to identify effective and safe treatment options for these patients.  One approach to improve cancer therapy is by designing therapeutics directed against targets with differential levels of expression on malignant vs. normal cells with the goal of improving tumor selectivity and reducing damage to normal tissues.  Antibody drug conjugates (ADCs) are a rapidly evolving therapeutic class that exploits the target-selectivity of monoclonal antibodies (MAbs) to deliver cytotoxic drugs to antigen-expressing cells (Lambert & Morris, 2017; Senter, 2009; Thomas, Teicher, & Hassan, 2016; Trail, 2013).  The regulatory approval of ADCs for both hematol. malignancies (brentuximab vedotin) (Younes et al., 2010) and solid tumors (ado-trastuzumab emtansine) (Amiri-Kordestani et al., 2014; Verma et al., 2012) clearly demonstrates the clin. potential of ADCs.  This review will focus on targets under consideration for breast cancer directed ADCs and on the technol. modifications being considered to improve ADC efficacy and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ5FTc5Nf4T7Vg90H21EOLACvtfcHk0lhOOGK0N9Eh9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yrsL%252FO&md5=ef44cf6eb6cbec0967a24efac33eb7f0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DTrail%26aufirst%3DP.%2BA.%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DLowinger%26aufirst%3DT.%2BB.%26atitle%3DAntibody%2520drug%2520conjugates%2520for%2520treatment%2520of%2520breast%2520cancer%253A%2520Novel%2520targets%2520and%2520diverse%2520approaches%2520in%2520ADC%2520design%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D181%26spage%3D126%26epage%3D142%26doi%3D10.1016%2Fj.pharmthera.2017.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krippendorff, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. K.</span></span> <span> </span><span class="NLM_article-title">Influence of molecular size on the clearance of antibody fragments</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2131</span>– <span class="NLM_lpage">2141</span>, <span class="refDoi"> DOI: 10.1007/s11095-017-2219-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1007%2Fs11095-017-2219-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=28681164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFaqt7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=2131-2141&issue=10&author=Z.+Liauthor=B.+F.+Krippendorffauthor=D.+K.+Shah&title=Influence+of+molecular+size+on+the+clearance+of+antibody+fragments&doi=10.1007%2Fs11095-017-2219-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of Molecular size on the clearance of antibody fragments</span></div><div class="casAuthors">Li, Zhe; Krippendorff, Ben-Fillippo; Shah, Dhaval K.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2131-2141</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The purpose of this paper is to establish a continuous relationship between the size of various antibody fragments and their systemic clearance (CL) in mice.  Two different orthogonal approaches have been used to establish the relationship.  First approach uses CL values estd. by non-compartmental anal. (NCA) to establish a correlation with protein size.  The second approach simultaneously characterizes the PK data for all the proteins using a 2-compartment model to establish a relationship between protein size and pharmacokinetic (PK) parameters.  Simple math. functions (e.g. sigmoidal, power law) were able to characterize the CL vs. protein size relationship generated using the investigated proteins.  The relationship established in mouse was used to predict rat, rabbit, monkey, and human relationships using allometric scaling.  The predicted relationships were found to capture the available spares data from each species reasonably well.  The CL vs. protein size relationship is important for establishing a robust quant. structure-PK relationship (QSPKR) for protein therapeutics.  The relationship presented here can help in a priori predicting plasma exposure of therapeutic proteins, and together with our previously established relationship between plasma and tissue concns. of proteins, it can predict the tissue exposure of non-binding proteins simply based on mol. wt./radius and dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEIFIcpetl87Vg90H21EOLACvtfcHk0lhOOGK0N9Eh9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFaqt7%252FO&md5=b03a8d0f6ad83d6471b165110aadd427</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs11095-017-2219-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-017-2219-y%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DKrippendorff%26aufirst%3DB.%2BF.%26aulast%3DShah%26aufirst%3DD.%2BK.%26atitle%3DInfluence%2520of%2520molecular%2520size%2520on%2520the%2520clearance%2520of%2520antibody%2520fragments%26jtitle%3DPharm.%2520Res.%26date%3D2017%26volume%3D34%26issue%3D10%26spage%3D2131%26epage%3D2141%26doi%3D10.1007%2Fs11095-017-2219-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, T. K.</span></span> <span> </span><span class="NLM_article-title">Challenges and new frontiers in analytical characterization of antibody–drug conjugates</span>. <i>MAbs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1080/19420862.2017.1412025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1080%2F19420862.2017.1412025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29293399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=222-243&issue=2&author=A.+Waghauthor=H.+Songauthor=M.+Zengauthor=L.+Taoauthor=T.+K.+Das&title=Challenges+and+new+frontiers+in+analytical+characterization+of+antibody%E2%80%93drug+conjugates&doi=10.1080%2F19420862.2017.1412025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and new frontiers in analytical characterization of antibody-drug conjugates</span></div><div class="casAuthors">Wagh, Anil; Song, Hangtian; Zeng, Ming; Tao, Li; Das, Tapan K.</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-243</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics in which a potent small mol. is linked to an antibody.  ADCs are highly complex and structurally heterogeneous, typically contg. numerous product-related species.  One of the most impactful steps in ADC development is the identification of crit. quality attributes to det. product characteristics that may affect safety and efficacy.  However, due to the addnl. complexity of ADCs relative to the parent antibodies, establishing a solid understanding of the major quality attributes and detg. their criticality are a major undertaking in ADC development.  Here, we review the development challenges, esp. for reliable detection of quality attributes, citing literature and new data from our labs., highlight recent improvements in major anal. techniques for ADC characterization and control, and discuss newer techniques, such as two-dimensional liq. chromatog., that have potential to be included in anal. control strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiXlsU1pCU8rVg90H21EOLACvtfcHk0ljHhEmlyKEUww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wgsb8%253D&md5=22f62bc383d227707994a6142c5bbce0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F19420862.2017.1412025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2017.1412025%26sid%3Dliteratum%253Aachs%26aulast%3DWagh%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DTao%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DT.%2BK.%26atitle%3DChallenges%2520and%2520new%2520frontiers%2520in%2520analytical%2520characterization%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DMAbs%26date%3D2018%26volume%3D10%26issue%3D2%26spage%3D222%26epage%3D243%26doi%3D10.1080%2F19420862.2017.1412025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kopp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurber, G. M.</span></span> <span> </span><span class="NLM_article-title">Severing ties: quantifying the payload release from antibody drug conjugates</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1631</span>– <span class="NLM_lpage">1633</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.chembiol.2019.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31951577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyqsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1631-1633&issue=12&author=A.+Koppauthor=G.+M.+Thurber&title=Severing+ties%3A+quantifying+the+payload+release+from+antibody+drug+conjugates&doi=10.1016%2Fj.chembiol.2019.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Severing Ties: Quantifying the Payload Release from Antibody Drug Conjugates</span></div><div class="casAuthors">Kopp, Anna; Thurber, Greg M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1631-1633</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">As a key mediator of efficacy and toxicity, the linker connecting the payload in antibody drug conjugates dets. cellular distribution and payload release.  Sorkin et al. (2019) have created novel fluorescence-based linkers to quantify the rate of intracellular bond cleavage and track live-cell kinetics for designing more effective agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGralUrkfVS6CbVg90H21EOLACvtfcHk0ljHhEmlyKEUww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyqsrrM&md5=e3807813d7fb21524dd2418d82b7c7c3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DKopp%26aufirst%3DA.%26aulast%3DThurber%26aufirst%3DG.%2BM.%26atitle%3DSevering%2520ties%253A%2520quantifying%2520the%2520payload%2520release%2520from%2520antibody%2520drug%2520conjugates%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D12%26spage%3D1631%26epage%3D1633%26doi%3D10.1016%2Fj.chembiol.2019.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szekacs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uematsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Hydrolysis of carbonates, thiocarbonates, carbamates, and carboxylic esters of alpha-naphthol, beta-naphthol, and p-nitrophenol by human, rat, and mouse liver carboxylesterases</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1023/A:1018987111362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1023%2FA%3A1018987111362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=8321828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADyaK3sXmt1Shsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=639-648&issue=5&author=T.+L.+Huangauthor=A.+Szekacsauthor=T.+Uematsuauthor=E.+Kuwanoauthor=A.+Parkinsonauthor=B.+D.+Hammock&title=Hydrolysis+of+carbonates%2C+thiocarbonates%2C+carbamates%2C+and+carboxylic+esters+of+alpha-naphthol%2C+beta-naphthol%2C+and+p-nitrophenol+by+human%2C+rat%2C+and+mouse+liver+carboxylesterases&doi=10.1023%2FA%3A1018987111362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrolysis of carbonates, thiocarbonates, carbamates, and carboxylic esters of α-naphthol, β-naphthol, and p-nitrophenol by human, rat, and mouse liver carboxylesterases</span></div><div class="casAuthors">Huang, Tien L.; Szekacs, Andras; Uematsu, Tamon; Kuwano, Eiichi; Parkinson, Andrew; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-48</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">Thirty carbonates, thiocarbonates, carbamates, and carboxylic esters of α-naphthol, β-naphthol, and p-nitrophenol were synthesized and tested as substrates for liver carboxylesterases from the crude microsomal fractions of human and mouse, and purified isoenzymes, carboxylesterases A and B, from rat liver microsomes.  The carbonates, thiocarbonates, and carboxylic esters of α-naphthol were cleaved more rapidly than the corresponding β-naphthol isomers by the mammalian liver esterases.  α-Naphthyl esters of acetic, propionic, and butyric acids were among the best substrates tested for these enzymes.  The majority of the substrates was consistently hydrolyzed at higher rates by esterase B compared with esterase A, although the Km values of selected substrates differed widely with these 2 isoenzymes.  Malathion was a 15-fold better substrate for esterase B than for esterase A.  Compared with the corresponding carboxylates, the carbonate moiety of α- and β-naphthol and p-nitrophenol lowered the specific activities of the enzymes by ∼5-fold but improved the stability under basic conditions.  The optimum pH values of mouse liver esterase with the acetate, methylcarbonate, and ethylthiocarbonate of α-naphthol was pH 7.0-7.6.  Human and mouse liver microsomal esterase activities were ∼5 orders of magnitude lower than the activities of purified rat liver esterase B.  A relation between the catalytic activity of the enzymes and the lipophilicity of the naphthyl substrates indicated that (1) in the α- and β-naphthyl carbonate series, an inverse relation between enzyme activity and lipophilicity of the substrates was obsd., whereas (2) in the α-naphthyl carboxylate series, an increase in enzyme activity with increasing lipophilicity of the substrates up to a log P value of ∼4.0 was obsd., after which the enzyme activity decreased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBceyfsg-SDLVg90H21EOLACvtfcHk0lihWoiHdMFTxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmt1Shsb4%253D&md5=4bfcc197f3947a01deeb8bdd1e758515</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018987111362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018987111362%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.%2BL.%26aulast%3DSzekacs%26aufirst%3DA.%26aulast%3DUematsu%26aufirst%3DT.%26aulast%3DKuwano%26aufirst%3DE.%26aulast%3DParkinson%26aufirst%3DA.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DHydrolysis%2520of%2520carbonates%252C%2520thiocarbonates%252C%2520carbamates%252C%2520and%2520carboxylic%2520esters%2520of%2520alpha-naphthol%252C%2520beta-naphthol%252C%2520and%2520p-nitrophenol%2520by%2520human%252C%2520rat%252C%2520and%2520mouse%2520liver%2520carboxylesterases%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26issue%3D5%26spage%3D639%26epage%3D648%26doi%3D10.1023%2FA%3A1018987111362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laizure, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witbrodt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, R. B.</span></span> <span> </span><span class="NLM_article-title">The role of human carboxylesterases in drug metabolism: have we overlooked their importance?</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1002/phar.1194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1002%2Fphar.1194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=23386599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVOltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=210-222&issue=2&author=S.+C.+Laizureauthor=V.+Herringauthor=Z.+Huauthor=K.+Witbrodtauthor=R.+B.+Parker&title=The+role+of+human+carboxylesterases+in+drug+metabolism%3A+have+we+overlooked+their+importance%3F&doi=10.1002%2Fphar.1194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The role of human carboxylesterases in drug metabolism: have we overlooked their importance?</span></div><div class="casAuthors">Laizure, S. Casey; Herring, Vanessa; Hu, Zheyi; Witbrodt, Kevin; Parker, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-222</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Carboxylesterases are a multigene family of mammalian enzymes widely distributed throughout the body that catalyze the hydrolysis of esters, amides, thioesters, and carbamates.  In humans, two carboxylesterases, hCE1 and hCE2, are important mediators of drug metab.  Both are expressed in the liver, but hCE1 greatly exceeds hCE2.  In the intestine, only hCE2 is present and highly expressed.  The most common drug substrates of these enzymes are ester prodrugs specifically designed to enhance oral bioavailability by hydrolysis to the active carboxylic acid after absorption from the gastrointestinal tract.  Carboxylesterases also play an important role in the hydrolysis of some drugs to inactive metabolites.  It has been widely believed that drugs undergoing hydrolysis by hCE1 and hCE2 are not subject to clin. significant alterations in their disposition, but evidence exists that genetic polymorphisms, drug-drug interactions, drug-disease interactions and other factors are important determinants of the variability in the therapeutic response to carboxylesterase-substrate drugs.  The implications for drug therapy are far-reaching, as substrate drugs include numerous examples from widely prescribed therapeutic classes.  Representative drugs include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, antiplatelet drugs, statins, antivirals, and central nervous system agents.  As research interest increases in the carboxylesterases, evidence is accumulating of their important role in drug metab. and, therefore, the outcomes of pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ8Icv81r0ebVg90H21EOLACvtfcHk0lihWoiHdMFTxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVOltrs%253D&md5=6a68263c68e92bba8bbcb64e0e30ae92</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fphar.1194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.1194%26sid%3Dliteratum%253Aachs%26aulast%3DLaizure%26aufirst%3DS.%2BC.%26aulast%3DHerring%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWitbrodt%26aufirst%3DK.%26aulast%3DParker%26aufirst%3DR.%2BB.%26atitle%3DThe%2520role%2520of%2520human%2520carboxylesterases%2520in%2520drug%2520metabolism%253A%2520have%2520we%2520overlooked%2520their%2520importance%253F%26jtitle%3DPharmacotherapy%26date%3D2013%26volume%3D33%26issue%3D2%26spage%3D210%26epage%3D222%26doi%3D10.1002%2Fphar.1194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, B.</span></span> <span> </span><span class="NLM_article-title">Qualitative structure-metabolism relationships in the hydrolysis of carbamates</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.3109/03602531003745960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3109%2F03602531003745960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=20441444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=551-589&issue=4&author=F.+Vacondioauthor=C.+Silvaauthor=M.+Morauthor=B.+Testa&title=Qualitative+structure-metabolism+relationships+in+the+hydrolysis+of+carbamates&doi=10.3109%2F03602531003745960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Qualitative structure-metabolism relationships in the hydrolysis of carbamates</span></div><div class="casAuthors">Vacondio, Federica; Silva, Claudia; Mor, Marco; Testa, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">551-589</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The aims of this review were (1) to compile a large no. of reliable literature data on the metabolic hydrolysis of medicinal carbamates and (2) to ext. from such data a qual. relation between mol. structure and lability to metabolic hydrolysis.  The compds. were classified according to the nature of their substituents (R3OCONR1R2), and a metabolic lability score was calcd. for each class.  A trend emerged, such that the metabolic lability of carbamates decreased (i.e., their metabolic stability increased), in the following series: Aryl-OCO-NHAlkyl >> Alkyl-OCO-NHAlkyl ∼ Alkyl-OCO-N(Alkyl)2 ≥ Alkyl-OCO-N(endocyclic) ≥ Aryl-OCO-N(Alkyl)2 ∼ Aryl-OCO-N(endocyclic) ≥ Alkyl-OCO-NHAryl ∼ Alkyl-OCO-NHAcyl >> Alkyl-OCO-NH2 > Cyclic carbamates.  This trend should prove useful in the design of carbamates as drugs or prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgC9J9XyTR0bVg90H21EOLACvtfcHk0ljpqznERE5nQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtLjF&md5=9dc05a648555f6c07089d3ab6933fa08</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3109%2F03602531003745960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602531003745960%26sid%3Dliteratum%253Aachs%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTesta%26aufirst%3DB.%26atitle%3DQualitative%2520structure-metabolism%2520relationships%2520in%2520the%2520hydrolysis%2520of%2520carbamates%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2010%26volume%3D42%26issue%3D4%26spage%3D551%26epage%3D589%26doi%3D10.3109%2F03602531003745960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karampelas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyros, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayyad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyridaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolios, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millar, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liapakis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamvakopoulos, C.</span></span> <span> </span><span class="NLM_article-title">GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">823</span>, <span class="refDoi"> DOI: 10.1021/bc500081g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc500081g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2cXks1yrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=813-823&issue=4&author=T.+Karampelasauthor=O.+Argyrosauthor=N.+Sayyadauthor=K.+Spyridakiauthor=C.+Pappasauthor=K.+Morganauthor=G.+Koliosauthor=R.+P.+Millarauthor=G.+Liapakisauthor=A.+G.+Tzakosauthor=D.+Fokasauthor=C.+Tamvakopoulos&title=GnRH-Gemcitabine+conjugates+for+the+treatment+of+androgen-independent+prostate+cancer%3A+pharmacokinetic+enhancements+combined+with+targeted+drug+delivery&doi=10.1021%2Fbc500081g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery</span></div><div class="casAuthors">Karampelas, Theodoros; Argyros, Orestis; Sayyad, Nisar; Spyridaki, Katerina; Pappas, Charalampos; Morgan, Kevin; Kolios, George; Millar, Robert P.; Liapakis, George; Tzakos, Andreas G.; Fokas, Demosthenes; Tamvakopoulos, Constantin</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">813-823</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Gemcitabine, a drug with established efficacy against a no. of solid tumors, has therapeutic limitations due to its rapid metabolic inactivation.  The aim of this study was the development of an innovative strategy to produce a metabolically stable analog of gemcitabine that could also be selectively delivered to prostate cancer (CaP) cells based on cell surface expression of the Gonadotropin Releasing Hormone-Receptor (GnRH-R).  The synthesis and evaluation of conjugated mols., consisting of gemcitabine linked to a GnRH agonist, is presented along with results in androgen-independent prostate cancer models.  NMR and ligand binding assays were employed to verify conservation of microenvironments responsible for binding of novel GnRH-gemcitabine conjugates to the GnRH-R.  In vitro cytotoxicity, cellular uptake, and metabolite formation of the conjugates were examd. in CaP cell lines.  Selected conjugates were efficacious in the in vitro assays with one of them, namely, GSG, displaying high antiproliferative activity in CaP cell lines along with significant metabolic and pharmacokinetic advantages in comparison to gemcitabine.  Finally, treatment of GnRH-R pos. xenografted mice with GSG showed a significant advantage in tumor growth inhibition when compared to gemcitabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVm3JbYI0ZDrVg90H21EOLACvtfcHk0ljpqznERE5nQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXks1yrtrk%253D&md5=7bc71e602778674949cfe6b76a27d197</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbc500081g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc500081g%26sid%3Dliteratum%253Aachs%26aulast%3DKarampelas%26aufirst%3DT.%26aulast%3DArgyros%26aufirst%3DO.%26aulast%3DSayyad%26aufirst%3DN.%26aulast%3DSpyridaki%26aufirst%3DK.%26aulast%3DPappas%26aufirst%3DC.%26aulast%3DMorgan%26aufirst%3DK.%26aulast%3DKolios%26aufirst%3DG.%26aulast%3DMillar%26aufirst%3DR.%2BP.%26aulast%3DLiapakis%26aufirst%3DG.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26aulast%3DFokas%26aufirst%3DD.%26aulast%3DTamvakopoulos%26aufirst%3DC.%26atitle%3DGnRH-Gemcitabine%2520conjugates%2520for%2520the%2520treatment%2520of%2520androgen-independent%2520prostate%2520cancer%253A%2520pharmacokinetic%2520enhancements%2520combined%2520with%2520targeted%2520drug%2520delivery%26jtitle%3DBioconjugate%2520Chem.%26date%3D2014%26volume%3D25%26issue%3D4%26spage%3D813%26epage%3D823%26doi%3D10.1021%2Fbc500081g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1080/10717544.2018.1435746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1080%2F10717544.2018.1435746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29405790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=448-460&issue=1&author=Y.+Youauthor=Z.+Xuauthor=Y.+Chen&title=Doxorubicin+conjugated+with+a+trastuzumab+epitope+and+an+MMP-2+sensitive+peptide+linker+for+the+treatment+of+HER2-positive+breast+cancer&doi=10.1080%2F10717544.2018.1435746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer</span></div><div class="casAuthors">You, Yiwen; Xu, Zhiyuan; Chen, Yun</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">448-460</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">HER2-pos. breast cancer correlates with more aggressive tumor growth, a poorer prognosis and reduced overall survival.  Currently, trastuzumab (Herceptin), which is an anti-HER2 antibody, is one of the key drugs.  There is evidence indicating that conjugation of trastuzumab with chemotherapy drugs, such as doxorubicin (DOX), for multiple targets could be more effective.  However, incomplete penetration into tumors has been noted for those conjugates.  Compared to an antibody, peptides may represent an attractive alternative.  For HER2, a similar potency has been obsd. for a 12-amino-acid anti-HER2 peptide mimetic YCDGFYACYMDV-NH2 (AHNP, disulfide-bridged) and full-length trastuzumab.  Thus, a peptide, GPLGLAGDDYCDGFYACYMDV-NH2, which consists of AHNP and an MMP-2 cleavable linker GPLGLAGDD, was first designed, followed by conjugation with DOX via a glycine residue at the N-terminus to form a novel DOX-peptide conjugate MAHNP-DOX.  Using HER2-pos. human breast cancer cells BT474 and SKBR3 as in vitro model systems and nude mice with BT474 xenografts as an in vivo model, this conjugate was comprehensively characterized, and its efficacy was evaluated and compared with that of free DOX.  As a result, MAHNP-DOX demonstrated a much lower in vitro IC50, and its in vivo extent of inhibition in mice was more evident.  During this process, enzymic cleavage of MAHNP-DOX is crit. for its activation and cellular uptake.  In addn., a synergistic response was obsd. after the combination of DOX and AHNP.  This effect was probably due to the involvement of AHNP in the PI3K-AKT signaling pathway, which can be largely activated by DOX and leads to anti-apoptotic signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOqYcIF4w6y7Vg90H21EOLACvtfcHk0lgwAXGXZdCC4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWhuro%253D&md5=0c03938420411a68adf8b2d7d6973ed8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1080%2F10717544.2018.1435746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10717544.2018.1435746%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DDoxorubicin%2520conjugated%2520with%2520a%2520trastuzumab%2520epitope%2520and%2520an%2520MMP-2%2520sensitive%2520peptide%2520linker%2520for%2520the%2520treatment%2520of%2520HER2-positive%2520breast%2520cancer%26jtitle%3DDrug%2520Delivery%26date%3D2018%26volume%3D25%26issue%3D1%26spage%3D448%26epage%3D460%26doi%3D10.1080%2F10717544.2018.1435746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soudy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, K.</span></span> <span> </span><span class="NLM_article-title">Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7564</span>– <span class="NLM_lpage">7573</span>, <span class="refDoi"> DOI: 10.1021/jm400647r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400647r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVaqsr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7564-7573&issue=19&author=R.+Soudyauthor=C.+Chenauthor=K.+Kaur&title=Novel+peptide-doxorubucin+conjugates+for+targeting+breast+cancer+cells+including+the+multidrug+resistant+cells&doi=10.1021%2Fjm400647r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Peptide-Doxorubucin Conjugates for Targeting Breast Cancer Cells Including the Multidrug Resistant Cells</span></div><div class="casAuthors">Soudy, Rania; Chen, Christopher; Kaur, Kamaljit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7564-7573</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efficacy of chemotherapeutic doxorubucin (Dox) in cancer treatment is limited by two main factors, nonspecific toxicity and the emergence of tumor resistance.  To overcome these hurdles, in this study peptide-Dox conjugates were prepd.  A decapeptide 18-4a (NH2-WxEAAYQkFL-CONH2) with high specificity for breast cancer cells and improved proteolytic stability was conjugated to Dox to give peptide-Dox ester (1) and amide (2) conjugates.  Cell uptake studies showed that the conjugates were 6-10 times selective for breast cancerous cells (MCF-7 and MDA-MB-435) over noncancerous cells (HUVECs and MCF-10A).  One conjugate displayed similar toxicity as free Dox toward the breast cancerous cells and was about 40 times less toxic toward the noncancerous cells and 4-fold more toxic toward the Dox resistant MDA-MB-435-MDR cells than the free Dox.  These data suggest that one conjugate can be used as a potential prodrug for improving the therapeutic index of Dox and potentially many other cytotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-mqk59PdzX7Vg90H21EOLACvtfcHk0lgwAXGXZdCC4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVaqsr7J&md5=ca6f1ecc4388f5506c92f3af73ae4aad</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm400647r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400647r%26sid%3Dliteratum%253Aachs%26aulast%3DSoudy%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKaur%26aufirst%3DK.%26atitle%3DNovel%2520peptide-doxorubucin%2520conjugates%2520for%2520targeting%2520breast%2520cancer%2520cells%2520including%2520the%2520multidrug%2520resistant%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D19%26spage%3D7564%26epage%3D7573%26doi%3D10.1021%2Fjm400647r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soudy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etayash, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahadorani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavasanifar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, K.</span></span> <span> </span><span class="NLM_article-title">Breast cancer targeting peptide binds keratin 1: a new molecular marker for targeted drug delivery to breast cancer</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.6b00652</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00652" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVOmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=593-604&issue=3&author=R.+Soudyauthor=H.+Etayashauthor=K.+Bahadoraniauthor=A.+Lavasanifarauthor=K.+Kaur&title=Breast+cancer+targeting+peptide+binds+keratin+1%3A+a+new+molecular+marker+for+targeted+drug+delivery+to+breast+cancer&doi=10.1021%2Facs.molpharmaceut.6b00652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Breast Cancer Targeting Peptide Binds Keratin 1: A New Molecular Marker for Targeted Drug Delivery to Breast Cancer</span></div><div class="casAuthors">Soudy, Rania; Etayash, Hashem; Bahadorani, Kamran; Lavasanifar, Afsaneh; Kaur, Kamaljit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">593-604</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The biomarkers or receptors expressed on cancer cells and the targeting ligands with high binding affinity for biomarkers play a key role in early detection and treatment of breast cancer.  The breast cancer targeting peptide p160 (12-mer) and its enzymically stable analog 18-4 (10-mer) showed marked potential for breast cancer drug delivery using cell studies and animal models.  Herein, we used affinity purifn., liq. chromatog.-tandem mass spectrometry, and proteomics to identify keratin 1 (KRT1) as the target receptor highly expressed on breast cancer cells for p160 peptide(s).  Western blot and immunocytochem. in MCF-7 breast cancer cells confirmed the identity of KRT1.  We demonstrate that the p160 or 18-4 binding to MCF-7 breast cancer cells is dependent on the expression of KRT1, and we confirm peptide-KRT1 binding specificity using SPR expts. (Kd ∼ 1.1 μM and 0.98 μM for p160 and 18-4, resp.).  Furthermore, we assessed the ability of peptide 18-4 to improve the cellular uptake and anticancer activity of a pro-apoptotic antimicrobial peptide, microcin J25 (MccJ25), in breast cancer cells.  A covalent conjugate of peptide 18-4 with MccJ25 showed preferential cytotoxicity toward breast cancer cells with minimal cytotoxicity against normal HUVEC cells.  The conjugate inhibited the growth of MDA-MB-435 MDR multidrug-resistant cells with an IC50 comparable to that of nonresistant cells.  Conjugation improved selective cellular uptake of MccJ25, and the conjugate triggered cancer cell death by apoptosis.  Our findings establish KRT1 as a new marker for breast cancer targeting.  Addnl., it pinpoints the potential use of antimicrobial lasso peptides as a novel class of anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsUfWpgPm6hrVg90H21EOLACvtfcHk0lgwAXGXZdCC4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVOmsr8%253D&md5=ba3723128b2358a5e0f23b288cb40a83</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00652%26sid%3Dliteratum%253Aachs%26aulast%3DSoudy%26aufirst%3DR.%26aulast%3DEtayash%26aufirst%3DH.%26aulast%3DBahadorani%26aufirst%3DK.%26aulast%3DLavasanifar%26aufirst%3DA.%26aulast%3DKaur%26aufirst%3DK.%26atitle%3DBreast%2520cancer%2520targeting%2520peptide%2520binds%2520keratin%25201%253A%2520a%2520new%2520molecular%2520marker%2520for%2520targeted%2520drug%2520delivery%2520to%2520breast%2520cancer%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2017%26volume%3D14%26issue%3D3%26spage%3D593%26epage%3D604%26doi%3D10.1021%2Facs.molpharmaceut.6b00652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavallee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabathuler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beliveau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaigne, J. P.</span></span> <span> </span><span class="NLM_article-title">Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>155</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1038/bjp.2008.260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1038%2Fbjp.2008.260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=18574456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVygtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2008&pages=185-197&issue=2&author=A.+Reginaauthor=M.+Demeuleauthor=C.+Cheauthor=I.+Lavalleeauthor=J.+Poirierauthor=R.+Gabathulerauthor=R.+Beliveauauthor=J.+P.+Castaigne&title=Antitumour+activity+of+ANG1005%2C+a+conjugate+between+paclitaxel+and+the+new+brain+delivery+vector+Angiopep-2&doi=10.1038%2Fbjp.2008.260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2</span></div><div class="casAuthors">Regina, A.; Demeule, M.; Che, C.; Lavallee, I.; Poirier, J.; Gabathuler, R.; Beliveau, R.; Castaigne, J-P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-197</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background and purpose: Paclitaxel is highly efficacious in the treatment of breast, head and neck, non-small cell lung cancers and ovarian carcinoma.  For malignant gliomas, paclitaxel is prevented from reaching its target by the presence of the efflux pump P-glycoprotein (P-gp) at the blood-brain barrier.  We investigated the utilization of a new drug delivery system to increase brain delivery of paclitaxel.  Exptl. approach: Paclitaxel mols. were conjugated to a brain peptide vector, Angiopep-2, to provide a paclitaxel-Angiopep-2 conjugate named ANG1005.  We detd. the brain uptake capacity, intracellular effects and antitumor properties of ANG1005 in vitro against human tumor cell lines and in vivo in human xenografts.  We then detd. ANG1005 activity on brain tumors with intracerebral human tumor models in nude mice.  Key results: We show by in situ brain perfusion that ANG1005 enters the brain to a greater extent than paclitaxel and bypasses the P-gp.  ANG1005 has an antineoplastic potency similar to that of paclitaxel against human cancer cell lines.  We also demonstrate that ANG1005 caused a more potent inhibition of human tumor xenografts than paclitaxel.  Finally, ANG1005 administration led to a significant increase in the survival of mice with intracerebral implantation of U87 MG glioblastoma cells or NCI-H460 lung carcinoma cells.  Conclusions and implications: These results demonstrate the antitumor potential of a new drug, ANG1005, and establish that conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf7gdI2T8jHbVg90H21EOLACvtfcHk0ljPea8WBHJWAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVygtL3N&md5=3c86b5d1a64c5754d439dfa787f16637</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.260%26sid%3Dliteratum%253Aachs%26aulast%3DRegina%26aufirst%3DA.%26aulast%3DDemeule%26aufirst%3DM.%26aulast%3DChe%26aufirst%3DC.%26aulast%3DLavallee%26aufirst%3DI.%26aulast%3DPoirier%26aufirst%3DJ.%26aulast%3DGabathuler%26aufirst%3DR.%26aulast%3DBeliveau%26aufirst%3DR.%26aulast%3DCastaigne%26aufirst%3DJ.%2BP.%26atitle%3DAntitumour%2520activity%2520of%2520ANG1005%252C%2520a%2520conjugate%2520between%2520paclitaxel%2520and%2520the%2520new%2520brain%2520delivery%2520vector%2520Angiopep-2%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D155%26issue%3D2%26spage%3D185%26epage%3D197%26doi%3D10.1038%2Fbjp.2008.260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumthekar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccioni, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puhalla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkaczuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahluwalia, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wefel, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span> <span> </span><span class="NLM_article-title">ANG1005, a brain-penetrating peptide–drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2789</span>– <span class="NLM_lpage">2799</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-3258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1158%2F1078-0432.CCR-19-3258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31969331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVyktLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=2789-2799&issue=12&author=P.+Kumthekarauthor=S.+C.+Tangauthor=A.+J.+Brennerauthor=S.+Kesariauthor=D.+E.+Piccioniauthor=C.+Andersauthor=J.+Carrilloauthor=P.+Chalasaniauthor=P.+Kabosauthor=S.+Puhallaauthor=K.+Tkaczukauthor=A.+A.+Garciaauthor=M.+S.+Ahluwaliaauthor=J.+S.+Wefelauthor=N.+Lakhaniauthor=N.+Ibrahim&title=ANG1005%2C+a+brain-penetrating+peptide%E2%80%93drug+conjugate%2C+shows+activity+in+patients+with+breast+cancer+with+leptomeningeal+carcinomatosis+and+recurrent+brain+metastases&doi=10.1158%2F1078-0432.CCR-19-3258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases</span></div><div class="casAuthors">Kumthekar, Priya; Tang, Shou-Ching; Brenner, Andrew J.; Kesari, Santosh; Piccioni, David E.; Anders, Carey; Carrillo, Jose; Chalasani, Pavani; Kabos, Peter; Puhalla, Shannon; Tkaczuk, Katherine; Garcia, Agustin A.; Ahluwalia, Manmeet S.; Wefel, Jeffrey S.; Lakhani, Nehal; Ibrahim, Nuhad</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2789-2799</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: ANG1005, a novel taxane deriv., consists of three paclitaxel mols. covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via LRP1 transport system.  Preclin. and clin. evidence of efficacy with ANG1005 has been previously shown.  Patients and Methods: A multicenter, open-label phase II study in adult patients with measurable recurrent brain metastases from breast cancer (BCBM), with or without leptomeningeal carcinomatosis was conducted (n = 72 BCBM; n = 28 leptomeningeal carcinomatosis subset).  ANG1005 was administered i.v. at 600 mg/m2 every 3 wk.  Tumor assessment was based on central nervous system (CNS) RECIST 1.1 for intracranial, and RECIST 1.1 for extracranial response.  The primary endpoint was detn. of intracranial objective response rate (iORR).  Results: Median age was 47.5 years.  Safety profile was similar to that of paclitaxel with myelosuppression as the predominating toxicity.  Av. no. of prior CNS-directed therapies was 2.8 and 94% of the patients had prior taxane treatment.  Conclusions: Even though the study preset rule for iORR per IRF was not met in this heavily pretreated population, a notable CNS and systemic treatment effect was seen in all patients including symptom improvement and prolonged overall survival compared to historical control for the subset of patients with leptomeningeal carcinomatosis (n = 28).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX579YwjqbP7Vg90H21EOLACvtfcHk0ljYZZb5AWQ_HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVyktLjP&md5=1eeddf58a14d5f794b0d626b4755c34b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-3258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-3258%26sid%3Dliteratum%253Aachs%26aulast%3DKumthekar%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DS.%2BC.%26aulast%3DBrenner%26aufirst%3DA.%2BJ.%26aulast%3DKesari%26aufirst%3DS.%26aulast%3DPiccioni%26aufirst%3DD.%2BE.%26aulast%3DAnders%26aufirst%3DC.%26aulast%3DCarrillo%26aufirst%3DJ.%26aulast%3DChalasani%26aufirst%3DP.%26aulast%3DKabos%26aufirst%3DP.%26aulast%3DPuhalla%26aufirst%3DS.%26aulast%3DTkaczuk%26aufirst%3DK.%26aulast%3DGarcia%26aufirst%3DA.%2BA.%26aulast%3DAhluwalia%26aufirst%3DM.%2BS.%26aulast%3DWefel%26aufirst%3DJ.%2BS.%26aulast%3DLakhani%26aufirst%3DN.%26aulast%3DIbrahim%26aufirst%3DN.%26atitle%3DANG1005%252C%2520a%2520brain-penetrating%2520peptide%25E2%2580%2593drug%2520conjugate%252C%2520shows%2520activity%2520in%2520patients%2520with%2520breast%2520cancer%2520with%2520leptomeningeal%2520carcinomatosis%2520and%2520recurrent%2520brain%2520metastases%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26issue%3D12%26spage%3D2789%26epage%3D2799%26doi%3D10.1158%2F1078-0432.CCR-19-3258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrail, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandhasin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankhala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarantopoulos, J.</span></span> <span> </span><span class="NLM_article-title">Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1158%2F1535-7163.MCT-11-0566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=22203732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=308-316&issue=2&author=R.+Kurzrockauthor=N.+Gabrailauthor=C.+Chandhasinauthor=S.+Moulderauthor=C.+Smithauthor=A.+Brennerauthor=K.+Sankhalaauthor=A.+Mitaauthor=K.+Elianauthor=D.+Bouchardauthor=J.+Sarantopoulos&title=Safety%2C+pharmacokinetics%2C+and+activity+of+GRN1005%2C+a+novel+conjugate+of+angiopep-2%2C+a+peptide+facilitating+brain+penetration%2C+and+paclitaxel%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1535-7163.MCT-11-0566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Kurzrock, Razelle; Gabrail, Nash; Chandhasin, Chandtip; Moulder, Stacy; Smith, Carrie; Brenner, Andrew; Sankhala, Kamalesh; Mita, Alain; Elian, Kelly; Bouchard, Danielle; Sarantopoulos, John</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">308-316</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GRN1005 is a novel peptide-drug conjugate composed of paclitaxel covalently linked to a peptide, angiopep-2, that targets the low-d. lipoprotein receptor-related protein 1.  This first-in-human study evaluated the safety, tolerability, pharmacokinetics, and efficacy of GRN1005 in patients with advanced solid tumors.  Patients in sequential cohorts (one patient per cohort until grade 2 toxicity, then 3 + 3 design) received i.v. GRN1005 at escalating doses between 30 and 700 mg/m2 once in every 21 days.  In the max. tolerated dose (MTD) expansion group, patients were required to have brain metastases.  Fifty-six patients received GRN1005, including 41 with brain metastases (median no. of prior therapies = 4).  MTD was 650 mg/m2; the main dose-limiting toxicity was myelosuppression.  Sixteen of 20 patients dosed at the MTD had brain metastases.  Pharmacokinetics was dose linear and the mean terminal-phase elimination half-life was 3.6 h.  No evidence of accumulation was obsd. after repeat dosing.  No anti-GRN1005 antibodies were detected.  Five of the 20 patients (25%) dosed at 650 mg/m2 (MTD), three of whom had previous taxane therapy, achieved an overall partial response (breast, n = 2; non-small cell lung cancer, n = 2; and ovarian cancer, n = 1); responses in all five patients were also accompanied by shrinkage of brain lesions (-17% to -50%).  In addn., six patients (11%; doses 30-700 mg/m2) experienced stable disease that lasted 4 mo or more.  GRN1005 was well tolerated and showed activity in heavily pretreated patients with advanced solid tumors, including those who had brain metastases and/or failed prior taxane therapy.  Mol Cancer Ther; 11(2); 308-16.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKh0X2_uE5TbVg90H21EOLACvtfcHk0ljYZZb5AWQ_HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWltLk%253D&md5=c740d108d5f889403d34cfa733de3f8c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0566%26sid%3Dliteratum%253Aachs%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DGabrail%26aufirst%3DN.%26aulast%3DChandhasin%26aufirst%3DC.%26aulast%3DMoulder%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DBrenner%26aufirst%3DA.%26aulast%3DSankhala%26aufirst%3DK.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DElian%26aufirst%3DK.%26aulast%3DBouchard%26aufirst%3DD.%26aulast%3DSarantopoulos%26aufirst%3DJ.%26atitle%3DSafety%252C%2520pharmacokinetics%252C%2520and%2520activity%2520of%2520GRN1005%252C%2520a%2520novel%2520conjugate%2520of%2520angiopep-2%252C%2520a%2520peptide%2520facilitating%2520brain%2520penetration%252C%2520and%2520paclitaxel%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D2%26spage%3D308%26epage%3D316%26doi%3D10.1158%2F1535-7163.MCT-11-0566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patronas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri-Kordestani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davarpanah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burotto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choyke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liewehr, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramaniam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">ANG1005 for breast cancer brain metastases: correlation between (18)F-FLT-PET after first cycle and MRI in response assessment</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>160</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1007/s10549-016-3972-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1007%2Fs10549-016-3972-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=27620882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFarsrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2016&pages=51-59&issue=1&author=C.+C.+O%E2%80%99Sullivanauthor=M.+Lindenbergauthor=C.+Brylaauthor=N.+Patronasauthor=C.+J.+Peerauthor=L.+Amiri-Kordestaniauthor=N.+Davarpanahauthor=E.+M.+Gonzalezauthor=M.+Burottoauthor=P.+Choykeauthor=S.+M.+Steinbergauthor=D.+J.+Liewehrauthor=W.+D.+Figgauthor=T.+Fojoauthor=S.+Balasubramaniamauthor=S.+E.+Bates&title=ANG1005+for+breast+cancer+brain+metastases%3A+correlation+between+%2818%29F-FLT-PET+after+first+cycle+and+MRI+in+response+assessment&doi=10.1007%2Fs10549-016-3972-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment</span></div><div class="casAuthors">O'Sullivan, C. C.; Lindenberg, M.; Bryla, C.; Patronas, N.; Peer, C. J.; Amiri-Kordestani, L.; Davarpanah, N.; Gonzalez, E. M.; Burotto, M.; Choyke, P.; Steinberg, S. M.; Liewehr, D. J.; Figg, W. D.; Fojo, T.; Balasubramaniam, S.; Bates, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-59</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Improved therapies and imaging modalities are needed for the treatment of breast cancer brain metastases (BCBM).  ANG1005 is a drug conjugate consisting of paclitaxel covalently linked to Angiopep-2, designed to cross the blood-brain barrier.  We conducted a biomarker substudy to evaluate 18F-FLT-PET for response assessment.  Ten patients with measurable BCBM received ANG1005 at a dose of 550 mg/m2 IV every 21 days.  Before and after cycle 1, patients underwent PET imaging with 18F-FLT, a thymidine analog, retention of which reflects cellular proliferation, for comparison with gadolinium-contrast magnetic resonance imaging (Gd-MRI) in brain metastases detection and response assessment.  A 20 % change in uptake after one cycle of ANG1005 was deemed significant.  Thirty-two target and twenty non-target metastatic brain lesions were analyzed.  The median tumor redn. by MRI after cycle 1 was -17.5 % (n = 10 patients, lower, upper quartiles: -25.5, -4.8 %) in target lesion size compared with baseline.  Fifteen of twenty-nine target lesions (52 %) and 12/20 nontarget lesions (60 %) showed a ≥20 % decrease post-therapy in FLT-PET SUV change (odds ratio 0.71, 95 % CI: 0.19, 2.61).  The median percentage change in SUVmax was -20.9 % (n = 29 lesions; lower, upper quartiles: -42.4, 2.0 %), and the median percentage change in SUV80 was also -20.9 % (n = 29; lower, upper quartiles: -49.0, 0.0 %).  Two patients had confirmed partial responses by PET and MRI lasting 6 and 18 cycles, resp.  Seven patients had stable disease, receiving a median of six cycles.  ANG1005 warrants further study in BCBM.  Results demonstrated a moderately strong assocn. between MRI and 18F-FLT-PET imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWSt4xacdEFbVg90H21EOLACvtfcHk0lgY-qLFKFwB3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFarsrnI&md5=cd0171317481df301426dac25c1f59dc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs10549-016-3972-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-016-3972-z%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DC.%2BC.%26aulast%3DLindenberg%26aufirst%3DM.%26aulast%3DBryla%26aufirst%3DC.%26aulast%3DPatronas%26aufirst%3DN.%26aulast%3DPeer%26aufirst%3DC.%2BJ.%26aulast%3DAmiri-Kordestani%26aufirst%3DL.%26aulast%3DDavarpanah%26aufirst%3DN.%26aulast%3DGonzalez%26aufirst%3DE.%2BM.%26aulast%3DBurotto%26aufirst%3DM.%26aulast%3DChoyke%26aufirst%3DP.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DLiewehr%26aufirst%3DD.%2BJ.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBalasubramaniam%26aufirst%3DS.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DANG1005%2520for%2520breast%2520cancer%2520brain%2520metastases%253A%2520correlation%2520between%2520%252818%2529F-FLT-PET%2520after%2520first%2520cycle%2520and%2520MRI%2520in%2520response%2520assessment%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2016%26volume%3D160%26issue%3D1%26spage%3D51%26epage%3D59%26doi%3D10.1007%2Fs10549-016-3972-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bushnell, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodeker, K. L.</span></span> <span> </span><span class="NLM_article-title">Overview and current status of peptide receptor radionuclide therapy</span>. <i>Surg Oncol Clin N Am.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.soc.2019.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.soc.2019.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=32151363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BB383htlOhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2020&pages=317-326&issue=2&author=D.+L.+Bushnellauthor=K.+L.+Bodeker&title=Overview+and+current+status+of+peptide+receptor+radionuclide+therapy&doi=10.1016%2Fj.soc.2019.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Overview and Current Status of Peptide Receptor Radionuclide Therapy</span></div><div class="casAuthors">Bushnell David L; Bodeker Kellie L</div><div class="citationInfo"><span class="NLM_cas:title">Surgical oncology clinics of North America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-326</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment of patients with metastatic neuroendocrine tumors, delivering modest objective tumor response rates but notable survival and symptomatic benefits.  The first PRRT approved by the US Food and Drug Administration was lutetium 177-DOTATATE and is for use in adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.  The treatment paradigm typically leads to significant improvement in symptomology coupled with an extended period of progression-free survival.  Side effects are limited, with a small fraction of individuals experiencing clinically significant long-term renal or hematologic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQemTm5bfAXGAwxfk_AGB-EfW6udTcc2eYDThiuQ0fvorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383htlOhsg%253D%253D&md5=8d69ffe3ae6a3e9fc2240a102d581ee8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.soc.2019.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.soc.2019.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DBushnell%26aufirst%3DD.%2BL.%26aulast%3DBodeker%26aufirst%3DK.%2BL.%26atitle%3DOverview%2520and%2520current%2520status%2520of%2520peptide%2520receptor%2520radionuclide%2520therapy%26jtitle%3DSurg%2520Oncol%2520Clin%2520N%2520Am.%26date%3D2020%26volume%3D29%26issue%3D2%26spage%3D317%26epage%3D326%26doi%3D10.1016%2Fj.soc.2019.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, F. F.</span></span> <span> </span><span class="NLM_article-title">Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2934</span>– <span class="NLM_lpage">2974</span>, <span class="refDoi"> DOI: 10.1021/cr500171e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr500171e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVSlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=2934-2974&issue=8&author=S.+Banerjeeauthor=M.+R.+Pillaiauthor=F.+F.+Knapp&title=Lutetium-177+therapeutic+radiopharmaceuticals%3A+linking+chemistry%2C+radiochemistry%2C+and+practical+applications&doi=10.1021%2Fcr500171e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications</span></div><div class="casAuthors">Banerjee, Sharmila; Pillai, M. R. A.; Knapp, F. F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2934-2974</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7IvEUDjbcgbVg90H21EOLACvtfcHk0lgY-qLFKFwB3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVSlu7w%253D&md5=77855edfd4e4d1afced8a0bf6ddfbd36</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcr500171e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr500171e%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DPillai%26aufirst%3DM.%2BR.%26aulast%3DKnapp%26aufirst%3DF.%2BF.%26atitle%3DLutetium-177%2520therapeutic%2520radiopharmaceuticals%253A%2520linking%2520chemistry%252C%2520radiochemistry%252C%2520and%2520practical%2520applications%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26issue%3D8%26spage%3D2934%26epage%3D2974%26doi%3D10.1021%2Fcr500171e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">3379</span>– <span class="NLM_lpage">3409</span>, <span class="refDoi"> DOI: 10.3390/molecules18033379</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3390%2Fmolecules18033379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=23493103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Git7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=3379-3409&issue=3&author=M.+Jamousauthor=U.+Haberkornauthor=W.+Mier&title=Synthesis+of+peptide+radiopharmaceuticals+for+the+therapy+and+diagnosis+of+tumor+diseases&doi=10.3390%2Fmolecules18033379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases</span></div><div class="casAuthors">Jamous, Mazen; Haberkorn, Uwe; Mier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3379-3409</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Despite the advances in mol. biol. and biochem., the prognosis of patients suffering from tumor diseases remains poor.  The limited therapeutic success can be explained by the insufficient performance of the common chemotherapeutic drugs that lack the ability to specifically target tumor tissues.  Recently peptide radiopharmaceuticals have been developed that enable the concurrent imaging and therapy of tumors expressing a specific target.  Here, with a special emphasis on the synthesis of the building blocks required for the complexation of metallic radioisotopes, the requirements to the design and synthesis of radiolabeled peptides for clin. applications are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0vRMkoMMmibVg90H21EOLACvtfcHk0ljanzTKSWR6lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Git7o%253D&md5=b3d44338aae5b93408ba5ab8a4cc1339</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3390%2Fmolecules18033379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules18033379%26sid%3Dliteratum%253Aachs%26aulast%3DJamous%26aufirst%3DM.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DMier%26aufirst%3DW.%26atitle%3DSynthesis%2520of%2520peptide%2520radiopharmaceuticals%2520for%2520the%2520therapy%2520and%2520diagnosis%2520of%2520tumor%2520diseases%26jtitle%3DMolecules%26date%3D2013%26volume%3D18%26issue%3D3%26spage%3D3379%26epage%3D3409%26doi%3D10.3390%2Fmolecules18033379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuselier, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span> <span> </span><span class="NLM_article-title">Effects of camptothecin conjugated to a somatostatin analogue vector on growth of tumor cell lines in culture and related tumors in rodents</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1080/10717540490446125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1080%2F10717540490446125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=15371104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1WqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=231-238&issue=4&author=L.+Sunauthor=J.+A.+Fuselierauthor=D.+H.+Coy&title=Effects+of+camptothecin+conjugated+to+a+somatostatin+analogue+vector+on+growth+of+tumor+cell+lines+in+culture+and+related+tumors+in+rodents&doi=10.1080%2F10717540490446125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Camptothecin Conjugated to a Somatostatin Analog Vector on Growth of Tumor Cell Lines in Culture and Related Tumors in Rodents</span></div><div class="casAuthors">Sun, Lichun; Fuselier, Joseph; Coy, David</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">231-238</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Two CPT-SSA conjugates, JF-10-71 and JF-10-81, contg. a chem. adjustable release-rate carbamate linker, have been reported previously by us to potently inhibit growth of human neuroblastoma IMR32 cells overexpressing somatostatin receptor type II (SSTR2) but are stable under buffer incubation conditions or in rat plasma.  Further expts. now reveal that the conjugates performed well against many addnl. cell lines, particularly somatostatin receptor contg. rat pancreatic CA20948 cells that were actually more sensitive to the conjugates than free camptothecin itself.  JF-10-71 and JF-10-81 also were examd. for their inhibitory effects on the growth of this and several other tumors transplanted into rats (CA20948) or nude mice.  CA20948 tumors, known to overexpress SSTR2 and grown in Lewis rats, were treated, resp., with nontoxic 400 nmol/kg i.p. doses of JF-10-71 or JF-10-81.  Also, SSTR2-pos. human SCLC NCI-H69 tumors transplanted in nude mice were treated in a similar fashion.  Human prostate PC-3 tumors, which do not contain high concns. of SSTR2, also were grown in nude mice and treated with a 400 nmol/kg i.p. dose of JF-10-71.  Both cytotoxic conjugates significantly inhibited growth of SSTR2-specific pancreatic and SCLC tumors, but JF-10-81 did not significantly affect PC-3 tumor growth.  These exptl. results suggested that CPT-SSA conjugates can effectively target and kill tumor cells growing in vivo and that the effect is mediated by somatostatin receptors resulting in either release of camptothecin at the cell surface or, more likely, after receptor-mediated cellular internalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnDdmX6zjHcLVg90H21EOLACvtfcHk0ljanzTKSWR6lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1WqtLY%253D&md5=d823ac8c25a86a9ea73604e88be51e78</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1080%2F10717540490446125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10717540490446125%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DFuselier%26aufirst%3DJ.%2BA.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DEffects%2520of%2520camptothecin%2520conjugated%2520to%2520a%2520somatostatin%2520analogue%2520vector%2520on%2520growth%2520of%2520tumor%2520cell%2520lines%2520in%2520culture%2520and%2520related%2520tumors%2520in%2520rodents%26jtitle%3DDrug%2520Delivery%26date%3D2004%26volume%3D11%26issue%3D4%26spage%3D231%26epage%3D238%26doi%3D10.1080%2F10717540490446125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptor-targeted anti-cancer therapy</span>. <i>Curr. Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.2174/156720111793663633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.2174%2F156720111793663633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=21034425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=2-10&issue=1&author=L.+C.+Sunauthor=D.+H.+Coy&title=Somatostatin+receptor-targeted+anti-cancer+therapy&doi=10.2174%2F156720111793663633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin receptor-targeted anti-cancer therapy</span></div><div class="casAuthors">Sun, Li-Chun; Coy, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Delivery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-10</span>CODEN:
                <span class="NLM_cas:coden">CDDUBJ</span>;
        ISSN:<span class="NLM_cas:issn">1567-2018</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Somatostatin receptors (SSTRs), esp. SSTR subtype 2, are found expressed at relatively higher levels in many tumor cells and in tumoral blood vessels relative to normal tissues.  This creates an opportunity for developing various cytotoxic SST conjugates that selectively target SSTR2-specific sites.  Accordingly, some potent chemotherapeutic agents such as camptothecin (CPT), methotrexate (MTX), paclitaxel (PTX) and doxorubicin (DOX) have been coupled to SSTR2-preferential somatostatin (SST) analogs.  These new cytotoxic SST conjugates display significant SSTR-selective anti-tumor abilities in many different types of tumors.  For instance, the CPT-SST conjugate JF-10-81, in which CPT is coupled to the N-terminus of a SSTR2-specific SST analog (JF-07-69), had wide ranging anti-tumor and anti-angiogenic ability.  This conjugate also showed an ability to overcome multi-drug resistance (MDR) in SSTR-over-expressing and CPT-insensitive human pancreatic carcinoid BON cells.  Notably, another DOX-SST conjugate, AN-238, made by coupling pyrrolino-DOX to the SST analog RC-121, displayed indirect anti-tumor activity against SSTR-neg., non-small cell lung cancer H-157 tumor growth by directly targeting SSTR-pos. tumoral vessels of host mice.  These cytotoxic SST conjugates should deliver chemotherapeutic agents to receptor-specific sites, enhance anti-tumor efficacy, reduce toxic side effects to normal tissues, and to some extent, overcome MDR.  These and other peptide conjugates may possibly represent a newer generation of receptor-targeted cancer therapeutics.  This review discusses the progress with ref. to SST-based and SSTR-selective cytotoxic cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo63yfENj4dwrVg90H21EOLACvtfcHk0liKn5Fo3tz-jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSnsb8%253D&md5=113189d5436c92a74ee1017534416301</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F156720111793663633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720111793663633%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%2BC.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DSomatostatin%2520receptor-targeted%2520anti-cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Delivery%26date%3D2011%26volume%3D8%26issue%3D1%26spage%3D2%26epage%3D10%26doi%3D10.2174%2F156720111793663633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuselier, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span> <span> </span><span class="NLM_article-title">Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice</span>. <i>Clin. Med.: Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.4137/CMO.S970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.4137%2FCMO.S970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=21892324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BC3MfhtlaltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=491-499&author=L.+C.+Sunauthor=L.+V.+Mackeyauthor=J.+Luoauthor=J.+A.+Fuselierauthor=D.+H.+Coy&title=Targeted+chemotherapy+using+a+cytotoxic+somatostatin+conjugate+to+inhibit+tumor+growth+and+metastasis+in+nude+mice&doi=10.4137%2FCMO.S970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice</span></div><div class="casAuthors">Sun Li-Chun; Mackey L Vienna; Luo Jing; Fuselier Joseph A; Coy David H</div><div class="citationInfo"><span class="NLM_cas:title">Clinical medicine. Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">491-9</span>
        ISSN:<span class="NLM_cas:issn">1177-9314</span>.
    </div><div class="casAbstract">The major problems of traditional chemotherapy are non-selectivity and non-specificity, resulting in severe toxic side effects.  Peptides are a new-generation of drug-delivery vector to increase efficacy of this therapy and avoid the resulting damage.  The cytotoxic somatostatin (SST) conjugate JF-10-81 was developed by coupling camptothecin (CPT) to the N-terminus of a SST analog (JF-07-69) using an activated carbamate linker.  This conjugate selectively targets somatostatin receptor subtype 2 (SSTR2) and also retains high binding affinity and rapid internalization as well as anti-proliferative activity towards various tumor cells.  JF-10-81 was tested for its inhibitory activity against the growth of human tumors which included neuroblastoma (IMR32), pancreatic cancer (CFPAC-1), leukemia (MOLT-4), pancreatic carcinoid (BON) and prostate cancer (PC-3).  Both SSTR2 mRNAs and proteins were detected in all these tumor cell lines.  The conjugate displayed potent in vivo inhibitory activity, although some of the potency measured in in vitro experiments was lost.  JF-10-81 was found to significantly inhibit growth of these SSTR-positive tumors, resulting in 87% tumor reduction in neuroblastoma IMR32 and 97% in leukemia MOLT-4 bearing animals, even inducing regression of CFPAC-1 tumors.  SSTR-overexpressing BON tumors were unfortunately relatively CPT-insensitive in vitro, however, JF-10-81 again exhibited in vivo potency presumably by specifically increasing CPT concentrations inside the tumor cells so that the inhibition rate for JF-10-81 was 85%.  Also, JF-10-81 was used to treat highly invasive PC-3 tumors where s.c. injections inhibited both tumor growth (almost 60% reduction) and tumor metastasis (over 70%).  This conjugate demonstrated its broad and excellent anti-tumor activity by targeting SSTR2-specific tumor tissues, supporting that short peptides and their analogs may be applied as ideal drug-delivery carriers to improve the traditional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSC5rAW0_emgrrIbt-tGZmxfW6udTcc2eaG2s4ZHCHi2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfhtlaltA%253D%253D&md5=62147ab10530e0b80becb4b5d02e4247</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4137%2FCMO.S970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FCMO.S970%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%2BC.%26aulast%3DMackey%26aufirst%3DL.%2BV.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DFuselier%26aufirst%3DJ.%2BA.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DTargeted%2520chemotherapy%2520using%2520a%2520cytotoxic%2520somatostatin%2520conjugate%2520to%2520inhibit%2520tumor%2520growth%2520and%2520metastasis%2520in%2520nude%2520mice%26jtitle%3DClin.%2520Med.%253A%2520Oncol.%26date%3D2008%26volume%3D2%26spage%3D491%26epage%3D499%26doi%3D10.4137%2FCMO.S970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sayyad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrettos, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karampelas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatzigiannis, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyridaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liapakis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamvakopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span> <span> </span><span class="NLM_article-title">Development of bioactive gemcitabine-D-Lys(6)-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.ejmech.2019.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=30716713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVWqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2019&pages=256-266&author=N.+Sayyadauthor=E.+I.+Vrettosauthor=T.+Karampelasauthor=C.+M.+Chatzigiannisauthor=K.+Spyridakiauthor=G.+Liapakisauthor=C.+Tamvakopoulosauthor=A.+G.+Tzakos&title=Development+of+bioactive+gemcitabine-D-Lys%286%29-GnRH+prodrugs+with+linker-controllable+drug+release+rate+and+enhanced+biopharmaceutical+profile&doi=10.1016%2Fj.ejmech.2019.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile</span></div><div class="casAuthors">Sayyad, Nisar; Vrettos, Eirinaios I.; Karampelas, Theodoros; Chatzigiannis, Christos M.; Spyridaki, Katerina; Liapakis, George; Tamvakopoulos, Constantin; Tzakos, Andreas G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">256-266</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Peptide-drug conjugates have emerged as a potent approach to enhance the targeting and pharmacokinetic profiles of drugs.  However, the impact of the linker unit has not been explored/exploited in depth.  Gemcitabine (dFdC) is an anticancer agent used against a variety of solid tumors.  Despite its potency, gemcitabine suffers mostly due to its unspecific toxicity, lack of targeting and rapid metabolic inactivation.  To minimize these limitations and enable its targeting to tumors overexpressing the GnRH receptor, we examd. the peptide-drug conjugation approach.  Our design hypothesis was driven by the impact that the linker unit could have on the peptide-drug conjugate efficacy.  Along these lines, in order to exploit the potential to manipulate the potency of gemcitabine through altering the linker unit we constructed three different novel peptide-drug conjugates assembled of gemcitabine, the tumor-homing peptide D-Lys6-GnRH and modified linker building blocks.  Specifically, the linker was sculpted to either allow slow drug release (utilizing carbamate bond) or rapid disassocn. (using amide and ester bonds).  Notably, the new analogs possessed up to 95.5-fold enhanced binding affinity for the GnRH receptor (GnRH-R) compared to the natural peptide ligand D-Lys6-GnRH.  Addnl., their in vitro cytotoxicity was evaluated in four different cancer cell lines.  Their cellular uptake, release of gemcitabine and inactivation of gemcitabine to its inactive metabolite (dFdU) was explored in a representative cell line.  In vitro stability and the consequent drug release were evaluated in cell culture medium and human plasma.  In vivo pharmacokinetic studies were performed in mice, summarizing the relative stability of the three conjugates and the released levels of gemcitabine in comparison with dFdU.  These studies suggest that the fine tuning of the linkage within a peptide-drug conjugate affects the drug release rate and its overall pharmaceutical profile.  This could eventually emerge as an intriguing medicinal chem. approach to optimize bio-profiles of prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKqPVzBEzeibVg90H21EOLACvtfcHk0liKn5Fo3tz-jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVWqs70%253D&md5=b91169fc7d0d97102ea43153d97dfdbe</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DSayyad%26aufirst%3DN.%26aulast%3DVrettos%26aufirst%3DE.%2BI.%26aulast%3DKarampelas%26aufirst%3DT.%26aulast%3DChatzigiannis%26aufirst%3DC.%2BM.%26aulast%3DSpyridaki%26aufirst%3DK.%26aulast%3DLiapakis%26aufirst%3DG.%26aulast%3DTamvakopoulos%26aufirst%3DC.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26atitle%3DDevelopment%2520of%2520bioactive%2520gemcitabine-D-Lys%25286%2529-GnRH%2520prodrugs%2520with%2520linker-controllable%2520drug%2520release%2520rate%2520and%2520enhanced%2520biopharmaceutical%2520profile%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D166%26spage%3D256%26epage%3D266%26doi%3D10.1016%2Fj.ejmech.2019.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denmeade, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. R.</span></span> <span> </span><span class="NLM_article-title">Modulating paclitaxel bioavailability for targeting prostate cancer</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4973</span>– <span class="NLM_lpage">4984</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.04.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.bmc.2007.04.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=17502149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtFOjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=4973-4984&issue=14&author=S.+K.+Kumarauthor=S.+A.+Williamsauthor=J.+T.+Isaacsauthor=S.+R.+Denmeadeauthor=S.+R.+Khan&title=Modulating+paclitaxel+bioavailability+for+targeting+prostate+cancer&doi=10.1016%2Fj.bmc.2007.04.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating paclitaxel bioavailability for targeting prostate cancer</span></div><div class="casAuthors">Kumar, Srinivas K.; Williams, Simon A.; Isaacs, John T.; Denmeade, Samuel R.; Khan, Saeed R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4973-4984</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Four novel water-sol. peptide-paclitaxel conjugates were designed and synthesized as prostate-specific antigen (PSA)-activated prodrugs for prostate cancer therapy.  These prodrugs were composed of a peptide, HSSKLQ or SSKYQ, each of which is selectively cleavable by PSA; a self-immolative linker, either para-aminobenzyl alc. (PABS) or ethylene diamine (EDA); and the parent drug, paclitaxel.  Introduction of a PABA or EDA linker between the peptide and paclitaxel in 4 synthetic prodrugs resulted in products with an increased rate of hydrolysis by PSA.  The stability of prodrugs paclitaxel and HSSKLQ-paclitaxel(I), with the PABA linker, was poor in the serum-contg. medium because of the weak carbonate bond between the PABA and paclitaxel; however, this disadvantage was overcome by introducing a carbamate bond using an EDA linker in prodrug I.  Thus, the incorporation of an EDA linker increased both the stability and PSA-mediated activation of these prodrugs.  The cytotoxicity of each prodrug, as compared to paclitaxel, was detd. against a variety of cell lines, including the PSA-secreting CWR22Rv1 prostate cancer cell line.  The EDA-derived prodrug of SSKYQ-paclitaxel was stable and capable of being efficiently converted to an active drug that killed cells specifically in the presence of PSA, suggesting that this prodrug and similarly designed PSA-cleavable prodrugs may have potential as prostate cancer-specific therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-YHZx18aobrVg90H21EOLACvtfcHk0lh_1GjB2i654Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtFOjsbY%253D&md5=1e092fe1a5e005b9df5c682655908060</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.04.029%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%2BK.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26aulast%3DIsaacs%26aufirst%3DJ.%2BT.%26aulast%3DDenmeade%26aufirst%3DS.%2BR.%26aulast%3DKhan%26aufirst%3DS.%2BR.%26atitle%3DModulating%2520paclitaxel%2520bioavailability%2520for%2520targeting%2520prostate%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26issue%3D14%26spage%3D4973%26epage%3D4984%26doi%3D10.1016%2Fj.bmc.2007.04.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span> <span> </span><span class="NLM_article-title">Organic carbamates in drug design and medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2895</span>– <span class="NLM_lpage">2940</span>, <span class="refDoi"> DOI: 10.1021/jm501371s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501371s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2895-2940&issue=7&author=A.+K.+Ghoshauthor=M.+Brindisi&title=Organic+carbamates+in+drug+design+and+medicinal+chemistry&doi=10.1021%2Fjm501371s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Organic Carbamates in Drug Design and Medicinal Chemistry</span></div><div class="casAuthors">Ghosh, Arun K.; Brindisi, Margherita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2895-2940</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The carbamate group is a key structural motif in many approved drugs and prodrugs.  There is an increasing use of carbamates in medicinal chem. and many derivs. are specifically designed to make drug-target interactions through their carbamate moiety.  In this Perspective, we present properties and stabilities of carbamates, reagents and chem. methodologies for the synthesis of carbamates, and recent applications of carbamates in drug design and medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGollKFyXYJJHLVg90H21EOLACvtfcHk0lh_1GjB2i654Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVWkuw%253D%253D&md5=e3548247931b74b60e299ada1e27dda5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm501371s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501371s%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DBrindisi%26aufirst%3DM.%26atitle%3DOrganic%2520carbamates%2520in%2520drug%2520design%2520and%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D7%26spage%3D2895%26epage%3D2940%26doi%3D10.1021%2Fjm501371s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2018.01.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.jconrel.2018.01.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29408580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt12qu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2018&pages=129-141&author=Y.+Liangauthor=S.+Liauthor=X.+Wangauthor=Y.+Zhangauthor=Y.+Sunauthor=Y.+Wangauthor=X.+Wangauthor=B.+Heauthor=W.+Daiauthor=H.+Zhangauthor=X.+Wangauthor=Q.+Zhang&title=A+comparative+study+of+the+antitumor+efficacy+of+peptide-doxorubicin+conjugates+with+different+linkers&doi=10.1016%2Fj.jconrel.2018.01.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers</span></div><div class="casAuthors">Liang, Yanqin; Li, Suxin; Wang, Xueling; Zhang, Yuan; Sun, Yanan; Wang, Yaoqi; Wang, Xiaoyou; He, Bing; Dai, Wenbing; Zhang, Hua; Wang, Xueqing; Zhang, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The peptide-drug conjugates caused much attention currently.  The purpose of present study was to elucidate the possible synergistic effect between ligand peptide and stimuli-responsive linkage in amphiphilic peptide-drug conjugates (APDCs) with different linkers.  Esp., the superiority of each strategy as well as the synergistic effect between them was carefully investigated via the parallel comparisons of the three systems throughout of the whole study.  Here, we synthesized three APDCs, namely, cRGD-SS-DOX (RSSDOX), cRGD-S-DOX (RSDOX) and cRGD-VC-DOX (RVCDOX), using doxorubicin (DOX) as a model cytotoxic agent, cRGDfC as a homing peptide, and redn. cleavable disulfide (SS), noncleavable single thioether (S) or cathepsin B cleavable valine-citrulline dipeptide (VC) as linker.  The APDCs showed high drug loading capacity and they were evaluated in vitro in the integrin αvβ3-overexpressing B16 cells and in vivo in tumor-bearing C57BL/6 mice.  Endocytosis mechanism assay demonstrated that three types of APDCs internalized into cells through adynamin and actin depolymg.-mediated pathway following receptor-mediated endocytosis.  Notably, RSDOX or RVCDOX induced stronger antitumor efficacy, which depended on their cellular uptake levels, intracellular trafficking and the colocalization rates with lysosomes.  The in vivo efficacy of RSDOX or RVCDOX was 1.4-1.7 fold of free DOX and 1.7-2.0 fold of RSSDOX, resp.  In addn., RSDOX or RVCDOX demonstrated acceptable system, tissue and blood compatibility.  The compromised efficacy of RSSDOX might be due to the generation of DOX-SH during degrdn. of prodrug, but not DOX.  Taken together, our studies suggest that certain type of APDCs can significantly decrease the toxicity of free DOX and improve therapy outcome, which provides insight for the design of peptide-drug conjugates integrating ligand peptide and stimuli-responsive linkage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaY4DklRVraLVg90H21EOLACvtfcHk0lj4ZMuVDJO6Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt12qu7o%253D&md5=0214f7cef5fbe4493f8a6a4ec48be9fd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2018.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2018.01.033%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DDai%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DA%2520comparative%2520study%2520of%2520the%2520antitumor%2520efficacy%2520of%2520peptide-doxorubicin%2520conjugates%2520with%2520different%2520linkers%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2018%26volume%3D275%26spage%3D129%26epage%3D141%26doi%3D10.1016%2Fj.jconrel.2018.01.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bajjuri, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S. C.</span></span> <span> </span><span class="NLM_article-title">The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201000478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1002%2Fcmdc.201000478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=21154805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sru7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=54-59&issue=1&author=K.+M.+Bajjuriauthor=Y.+Liuauthor=C.+Liuauthor=S.+C.+Sinha&title=The+legumain+protease-activated+auristatin+prodrugs+suppress+tumor+growth+and+metastasis+without+toxicity&doi=10.1002%2Fcmdc.201000478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The Legumain Protease-Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity</span></div><div class="casAuthors">Bajjuri, Krishna Mohan; Liu, Yuan; Liu, Cheng; Sinha, Subhash C.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-59</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Naturally occurring antimitotic pentapeptide dolastatin and its synthetic analog auristatin E possess subnanomolar cytotoxicity against many human cancer cell lines and are over a hundred to a thousand times more potent than many pharmaceuticals currently used in clinic. We focused on MMAE and DDAE, and prepd. and evaluated their prodrugs, which undergo tumor assocd. protease catalyzed activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBf4TrZOUgrVg90H21EOLACvtfcHk0lj4ZMuVDJO6Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sru7nK&md5=0661ccec322d8470be92bab2a0803da9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000478%26sid%3Dliteratum%253Aachs%26aulast%3DBajjuri%26aufirst%3DK.%2BM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DSinha%26aufirst%3DS.%2BC.%26atitle%3DThe%2520legumain%2520protease-activated%2520auristatin%2520prodrugs%2520suppress%2520tumor%2520growth%2520and%2520metastasis%2520without%2520toxicity%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26issue%3D1%26spage%3D54%26epage%3D59%26doi%3D10.1002%2Fcmdc.201000478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, C. O.</span></span> <span> </span><span class="NLM_article-title">Targeting legumain as a novel therapeutic strategy in cancers</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1268</span>, <span class="refDoi"> DOI: 10.2174/1389450117666161216125344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.2174%2F1389450117666161216125344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=27993111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlelsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1259-1268&issue=11&author=C.+W.+Maiauthor=F.+F.+Chungauthor=C.+O.+Leong&title=Targeting+legumain+as+a+novel+therapeutic+strategy+in+cancers&doi=10.2174%2F1389450117666161216125344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Legumain As a Novel Therapeutic Strategy in Cancers</span></div><div class="casAuthors">Mai, Chun-Wai; Fei-Lei Chung, Felicia; Leong, Chee-Onn</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1259-1268</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Recent reports indicate that the tumor microenvironment plays a pivotal role in cancer development and progression, leading to a paradigm shift in the way cancer is studied and targeted.  In contrast to traditional approaches, where only tumor cells are targeted for the treatment, an emerging approach is to develop therapeutics which target the tumor microenvironment while complementing or enhancing current treatments.  Legumain (LGMN) is a newly identified target which is highly expressed in the tumor microenvironment and in tumor cells, and holds potential both as a biomarker and as a therapeutic target. <P></P> Conclusion: This review will be the first to summarize the expression of LGMN in common cancers, as well as its roles in tumorigenesis and metastasis.  This review also discusses the current developments and future prospects of targeting LGMN through the development of DNA vaccines, azopeptides, small mol. inhibitors and LGMN activated prodrugs, highlighting the potential of LGMN as a target for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNwCisgtgt0LVg90H21EOLACvtfcHk0lg_DZzO2UOeWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlelsbvO&md5=3e3be3ac40b20a2d70f1fa815feaab0b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2174%2F1389450117666161216125344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666161216125344%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DC.%2BW.%26aulast%3DChung%26aufirst%3DF.%2BF.%26aulast%3DLeong%26aufirst%3DC.%2BO.%26atitle%3DTargeting%2520legumain%2520as%2520a%2520novel%2520therapeutic%2520strategy%2520in%2520cancers%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2017%26volume%3D18%26issue%3D11%26spage%3D1259%26epage%3D1268%26doi%3D10.2174%2F1389450117666161216125344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stern, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ofek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Many, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satchi-Fainaro, R.</span></span> <span> </span><span class="NLM_article-title">A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">500</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1021/bc800448u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc800448u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVyktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=500-510&issue=3&author=L.+Sternauthor=R.+Perryauthor=P.+Ofekauthor=A.+Manyauthor=D.+Shabatauthor=R.+Satchi-Fainaro&title=A+novel+antitumor+prodrug+platform+designed+to+be+cleaved+by+the+endoprotease+legumain&doi=10.1021%2Fbc800448u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Antitumor Prodrug Platform Designed to Be Cleaved by the Endoprotease Legumain</span></div><div class="casAuthors">Stern, Liron; Perry, Rotem; Ofek, Paula; Many, Ariel; Shabat, Doron; Satchi-Fainaro, Ronit</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">500-510</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chemotherapeutic treatment of neoplastic diseases is often restricted by adverse systemic toxicity, which limits the dose of drug that can be administered, or by the appearance of drug resistance.  Therefore, novel targeted therapeutic approaches are being developed to improve current conventional therapy in order to increase specificity and biocompatibility, and decrease toxicity.  Legumain represents a recently identified lysosomal protease that has been reported to be overexpressed in the majority of human solid tumors, to promote cell migration and is assocd. with enhanced tissue invasion and metastases.  Therefore, it serves as a promising candidate for prodrug therapy.  We synthesized a novel legumain-cleavable prodrug, carbobenzyloxy-alanine-alanine-asparagine-ethylenediamine-etoposide, which releases the chemotherapeutic agent, etoposide, as the active drug.  The prodrug was characterized and analyzed by 1H NMR and HPLC.  293 Human embryonic kidney (293 HEK) cells were stably transfected with human legumain, to achieve overexpression in vitro (293 HEK-Leg).  293 HEK-Leg cells expressed both active and inactive legumain and secreted it to the medium.  Legumain expression was found to be elevated because of serum starvation in both 293 HEK cells and PC3 human prostate carcinoma cells.  The com. substrate of legumain, carbobenzyloxy-alanine-alanine-asparagine-amino-4-Me coumarin (CBZ-Ala-Ala-Asn-AMC) and the synthesized prodrug were both cleaved by recombinant human legumain (rhlegumain) and legumain expressed in the 293 HEK-Leg cell lysate.  Upon cleavage by rhlegumain, the prodrug showed an inhibitory effect on the proliferation of 293 HEK and 293 HEK-Leg cells.  This study suggests a novel platform for prodrug therapy activated by legumain as a promising approach for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaEr0hM3i9UrVg90H21EOLACvtfcHk0lg_DZzO2UOeWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVyktrc%253D&md5=15a25647a8ffe0b4cd2bbb5d42565e33</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fbc800448u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc800448u%26sid%3Dliteratum%253Aachs%26aulast%3DStern%26aufirst%3DL.%26aulast%3DPerry%26aufirst%3DR.%26aulast%3DOfek%26aufirst%3DP.%26aulast%3DMany%26aufirst%3DA.%26aulast%3DShabat%26aufirst%3DD.%26aulast%3DSatchi-Fainaro%26aufirst%3DR.%26atitle%3DA%2520novel%2520antitumor%2520prodrug%2520platform%2520designed%2520to%2520be%2520cleaved%2520by%2520the%2520endoprotease%2520legumain%26jtitle%3DBioconjugate%2520Chem.%26date%3D2009%26volume%3D20%26issue%3D3%26spage%3D500%26epage%3D510%26doi%3D10.1021%2Fbc800448u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santi, D. V.</span></span> <span> </span><span class="NLM_article-title">Long-term stabilization of maleimide-thiol conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1021/bc5005262</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc5005262" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=145-152&issue=1&author=S.+D.+Fontaineauthor=R.+Reidauthor=L.+Robinsonauthor=G.+W.+Ashleyauthor=D.+V.+Santi&title=Long-term+stabilization+of+maleimide-thiol+conjugates&doi=10.1021%2Fbc5005262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Long-Term Stabilization of Maleimide-Thiol Conjugates</span></div><div class="casAuthors">Fontaine, Shaun D.; Reid, Ralph; Robinson, Louise; Ashley, Gary W.; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-152</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The rates of ring-opening hydrolysis and retro-Michael/Michael addn. (thiol exchange) of N-substituted succinimide thioethers formed by maleimide-thiol conjugation with glutathione and the effects of their maleimide nitrogen substituents on the rates of maleimide hydrolysis and retro-Michael/Michael addn. reactions were detd.  Ring-opening of conjugates prepd. with commonly used maleimides were too slow to serve as prevention against thiol exchange; however, the ring-opening rates of maleimides were greatly accelerated by electron withdrawing N-substituents, and the products had half-lives of over two years.  The PEGylated antibody Cimzia underwent ring-opening and retro-Michael addns. with rates consistent with model compds. except for the difference in acidity of the internal cysteine thiol of Cimizia's antibody vs. the nearly terminal cysteine thiols of the model compds.  Thus, conjugates (particularly antibody-drug conjugates prepd. as drugs) made with maleimides possessing electron-deficient nitrogen substituents can be purposefully hydrolyzed to their ring-opened counterparts in vitro to ensure their in vivo stability to thiol cleavage and exchange reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos9GcsNt5jAbVg90H21EOLACvtfcHk0lg_DZzO2UOeWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfN&md5=ab4fcacf5f9f58159bafa50353eab4d5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbc5005262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc5005262%26sid%3Dliteratum%253Aachs%26aulast%3DFontaine%26aufirst%3DS.%2BD.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DRobinson%26aufirst%3DL.%26aulast%3DAshley%26aufirst%3DG.%2BW.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DLong-term%2520stabilization%2520of%2520maleimide-thiol%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26issue%3D1%26spage%3D145%26epage%3D152%26doi%3D10.1021%2Fbc5005262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doronina, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duniho, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiske, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody–drug conjugates</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1038/nbt.2968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1038%2Fnbt.2968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=25194818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=1059-1062&issue=10&author=R.+P.+Lyonauthor=J.+R.+Setterauthor=T.+D.+Boveeauthor=S.+O.+Doroninaauthor=J.+H.+Hunterauthor=M.+E.+Andersonauthor=C.+L.+Balasubramanianauthor=S.+M.+Dunihoauthor=C.+I.+Leiskeauthor=F.+Liauthor=P.+D.+Senter&title=Self-hydrolyzing+maleimides+improve+the+stability+and+pharmacological+properties+of+antibody%E2%80%93drug+conjugates&doi=10.1038%2Fnbt.2968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates</span></div><div class="casAuthors">Lyon, Robert P.; Setter, Jocelyn R.; Bovee, Tim D.; Doronina, Svetlana O.; Hunter, Joshua H.; Anderson, Martha E.; Balasubramanian, Cindy L.; Duniho, Steven M.; Leiske, Chris I.; Li, Fu; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1059-1062</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many antibody-drug conjugates (ADCs) are unstable in vivo because they are formed from maleimide-contg. components conjugated to reactive thiols.  These thiosuccinimide linkages undergo two competing reactions in plasma: elimination of the maleimide through a retro-Michael reaction, which results in loss of drug-linker from the ADC, and hydrolysis of the thiosuccinimide ring, which results in a deriv. that is resistant to the elimination reaction.  In an effort to create linker technologies with improved stability characteristics, we used diaminopropionic acid (DPR) to prep. a drug-linker incorporating a basic amino group adjacent to the maleimide, positioned to provide intramol. catalysis of thiosuccinimide ring hydrolysis.  This basic group induces the thiosuccinimide to undergo rapid hydrolysis at neutral pH and room temp.  Once hydrolyzed, the drug-linker is no longer subject to maleimide elimination reactions, preventing nonspecific deconjugation.  In vivo studies demonstrate that the increased stability characteristics can lead to improved ADC antitumor activity and reduced neutropenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOKvXMGRGxEbVg90H21EOLACvtfcHk0lgDpdITURABhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7jN&md5=96c3b19b856cc9c685cbdc704a842797</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2968%26sid%3Dliteratum%253Aachs%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DSetter%26aufirst%3DJ.%2BR.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DHunter%26aufirst%3DJ.%2BH.%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26aulast%3DBalasubramanian%26aufirst%3DC.%2BL.%26aulast%3DDuniho%26aufirst%3DS.%2BM.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DSelf-hydrolyzing%2520maleimides%2520improve%2520the%2520stability%2520and%2520pharmacological%2520properties%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26issue%3D10%26spage%3D1059%26epage%3D1062%26doi%3D10.1038%2Fnbt.2968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tumey, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loganzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barletta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, E. I.</span></span> <span> </span><span class="NLM_article-title">Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1871</span>– <span class="NLM_lpage">1880</span>, <span class="refDoi"> DOI: 10.1021/bc500357n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc500357n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFelsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1871-1880&issue=10&author=L.+N.+Tumeyauthor=M.+Charatiauthor=T.+Heauthor=E.+Sousaauthor=D.+Maauthor=X.+Hanauthor=T.+Clarkauthor=J.+Casavantauthor=F.+Loganzoauthor=F.+Barlettaauthor=J.+Lucasauthor=E.+I.+Graziani&title=Mild+method+for+succinimide+hydrolysis+on+ADCs%3A+impact+on+ADC+potency%2C+stability%2C+exposure%2C+and+efficacy&doi=10.1021%2Fbc500357n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy</span></div><div class="casAuthors">Tumey, L. Nathan; Charati, Manoj; He, Tao; Sousa, Eric; Ma, Dangshe; Han, Xiaogang; Clark, Tracey; Casavant, Jeff; Loganzo, Frank; Barletta, Frank; Lucas, Judy; Graziani, Edmund I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1871-1880</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The stability of the connection between the antibody and the toxin can have a profound impact on ADC safety and efficacy.  There has been increasing evidence in recent years that maleimide-based ADCs are prone to payload loss via a retro-Michael type reaction.  Herein, we report a mild method for the hydrolysis of the succinimide-thioether ring which results in a "ring-opened" linker.  ADCs contg. this hydrolyzed succinimide linker show equiv. cytotoxicity, improved in vitro stability, improved PK exposure, and improved efficacy as compared to their nonhydrolyzed counterparts.  This method offers a simple way to improve the stability, exposure, and efficacy of maleimide-based ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTF5ACrG78eLVg90H21EOLACvtfcHk0lgDpdITURABhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFelsb3F&md5=a680174dc91b2ce9a3c72b6519a6c231</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fbc500357n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc500357n%26sid%3Dliteratum%253Aachs%26aulast%3DTumey%26aufirst%3DL.%2BN.%26aulast%3DCharati%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DSousa%26aufirst%3DE.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DClark%26aufirst%3DT.%26aulast%3DCasavant%26aufirst%3DJ.%26aulast%3DLoganzo%26aufirst%3DF.%26aulast%3DBarletta%26aufirst%3DF.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26atitle%3DMild%2520method%2520for%2520succinimide%2520hydrolysis%2520on%2520ADCs%253A%2520impact%2520on%2520ADC%2520potency%252C%2520stability%252C%2520exposure%252C%2520and%2520efficacy%26jtitle%3DBioconjugate%2520Chem.%26date%3D2014%26volume%3D25%26issue%3D10%26spage%3D1871%26epage%3D1880%26doi%3D10.1021%2Fbc500357n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziaei, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saghaeidehkordi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maslennikov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, K.</span></span> <span> </span><span class="NLM_article-title">Targeting triple negative breast cancer cells with novel cytotoxic peptide-doxorubicin conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3098</span>– <span class="NLM_lpage">3106</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.9b00755</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.9b00755" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCns7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=3098-3106&issue=12&author=E.+Ziaeiauthor=A.+Saghaeidehkordiauthor=C.+Dillauthor=I.+Maslennikovauthor=S.+Chenauthor=K.+Kaur&title=Targeting+triple+negative+breast+cancer+cells+with+novel+cytotoxic+peptide-doxorubicin+conjugates&doi=10.1021%2Facs.bioconjchem.9b00755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide-Doxorubicin Conjugates</span></div><div class="casAuthors">Ziaei, Elmira; Saghaeidehkordi, Azam; Dill, Cassandra; Maslennikov, Innokentiy; Chen, Shiuan; Kaur, Kamaljit</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3098-3106</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, we have designed and synthesized two novel peptide-drug conjugates (PDCs) where the drug, doxorubicin (Dox), is linked to the peptide via a succinimidyl thioether bond or a hydrazone linker.  A highly specific and proteolytically stable breast cancer cell targeting peptide (WxEAAYQrFL) is conjugated to Dox to synthesize peptide-Dox thioether (1) or hydrazone (2) conjugate.  The evaluation of the stability in water, media, and human serum showed that the conjugate 1 with the succinimidyl thioether linkage is more stable compared to the acid-sensitive hydrazone contg. conjugate 2.  The cytotoxicity studies showed that the two PDCs were as toxic as free Dox toward the triple neg. breast cancer (TNBC) cells and were 7-30 times less toxic (IC50 1.2-4.7μM for TNBC cells vs. 15-39μM for noncancerous cells) toward the noncancerous breast cells compared to the free doxorubicin (IC50 0.35-1.5μM for TNBC cells vs. 0.24μM for noncancerous cells).  The results from the comparative study of the two PDCs suggest that both may have translational potential for TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplThNVwCoHCrVg90H21EOLACvtfcHk0lhf1fqQ8o-IQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCns7fM&md5=1f0933b36e2968aa33307a0d2495c65f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.9b00755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.9b00755%26sid%3Dliteratum%253Aachs%26aulast%3DZiaei%26aufirst%3DE.%26aulast%3DSaghaeidehkordi%26aufirst%3DA.%26aulast%3DDill%26aufirst%3DC.%26aulast%3DMaslennikov%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DK.%26atitle%3DTargeting%2520triple%2520negative%2520breast%2520cancer%2520cells%2520with%2520novel%2520cytotoxic%2520peptide-doxorubicin%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2019%26volume%3D30%26issue%3D12%26spage%3D3098%26epage%3D3106%26doi%3D10.1021%2Facs.bioconjchem.9b00755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morvaridi, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandol, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">17103</span>– <span class="NLM_lpage">17110</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.18632%2Foncotarget.7931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=26959746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=17103-17110&issue=13&author=B.+A.+Quinnauthor=S.+Wangauthor=E.+Barileauthor=S.+K.+Dasauthor=L.+Emdadauthor=D.+Sarkarauthor=S.+K.+Deauthor=S.+K.+Morvaridiauthor=J.+L.+Stebbinsauthor=S.+J.+Pandolauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Therapy+of+pancreatic+cancer+via+an+EphA2+receptor-targeted+delivery+of+gemcitabine&doi=10.18632%2Foncotarget.7931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine</span></div><div class="casAuthors">Quinn Bridget A; Das Swadesh K; Emdad Luni; Sarkar Devanand; Fisher Paul B; Wang Si; Barile Elisa; De Surya K; Stebbins John L; Fisher Paul B; Pellecchia Maurizio; Barile Elisa; De Surya K; Pellecchia Maurizio; Morvaridi Susan Kharagh; Pandol Stephen J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">17103-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.  In some patients, an active transport mechanism allows gemcitabine to enter efficiently into the tumor cells, resulting in a significant clinical benefit.  However, in most patients, low expression of gemcitabine transporters limits the efficacy of the drug to marginal levels, and patients need frequent administration of the drug at high doses, significantly increasing systemic drug toxicity.  In this article we focus on a novel targeted delivery approach for gemcitabine consisting of conjugating the drug with an EphA2 targeting agent.  We show that the EphA2 receptor is highly expressed in pancreatic cancers, and accordingly, the drug-conjugate is more effective than gemcitabine alone in targeting pancreatic tumors.  Our preliminary observations suggest that this approach may provide a general benefit to pancreatic cancer patients and offers a comprehensive strategy for enhancing delivery of diverse therapeutic agents to a wide range of cancers overexpressing EphA2, thereby potentially reducing toxicity while enhancing therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkle74R4yp-ekdrW1FkXG-fW6udTcc2ebIoffKOcIhU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D&md5=0b5e311729fc3517d90882844ab3d3f2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7931%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DB.%2BA.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DEmdad%26aufirst%3DL.%26aulast%3DSarkar%26aufirst%3DD.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DMorvaridi%26aufirst%3DS.%2BK.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPandol%26aufirst%3DS.%2BJ.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DTherapy%2520of%2520pancreatic%2520cancer%2520via%2520an%2520EphA2%2520receptor-targeted%2520delivery%2520of%2520gemcitabine%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D13%26spage%3D17103%26epage%3D17110%26doi%3D10.18632%2Foncotarget.7931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salem, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udompholkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Reduction of circulating cancer cells and metastases in breast-cancer models by a potent EphA2-agonistic peptide–drug conjugate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2052</span>– <span class="NLM_lpage">2061</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1ylt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2052-2061&issue=5&author=A.+F.+Salemauthor=S.+Wangauthor=S.+Billetauthor=J.+F.+Chenauthor=P.+Udompholkulauthor=L.+Gambiniauthor=C.+Baggioauthor=H.+R.+Tsengauthor=E.+M.+Posadasauthor=N.+A.+Bhowmickauthor=M.+Pellecchia&title=Reduction+of+circulating+cancer+cells+and+metastases+in+breast-cancer+models+by+a+potent+EphA2-agonistic+peptide%E2%80%93drug+conjugate&doi=10.1021%2Facs.jmedchem.7b01837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate</span></div><div class="casAuthors">Salem, Ahmed F.; Wang, Si; Billet, Sandrine; Chen, Jie-Fu; Udompholkul, Parima; Gambini, Luca; Baggio, Carlo; Tseng, Hsian-Rong; Posadas, Edwin M.; Bhowmick, Neil A.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EphA2 overexpression has been assocd. with metastasis in multiple cancer types, including melanomas and ovarian, prostate, lung, and breast cancers.  We have recently proposed the development of peptide-drug conjugates (PDCs) using agonistic EphA2-targeting agents, such as the YSA peptide or its optimized version, 123B9.  Although our studies indicated that YSA- and 123B9-drug conjugates can selectively deliver cytotoxic drugs to cancer cells in vivo, the relatively low cellular agonistic activities (i.e., the high micromolar concns. required) of the agents toward the EphA2 receptor remained a limiting factor to the further development of these PDCs in the clinic.  Here, we report that a dimeric version of 123B9 can induce receptor activation at nanomolar concns.  Furthermore, we demonstrated that the conjugation of dimeric 123B9 with paclitaxel is very effective at targeting circulating tumor cells and inhibiting lung metastasis in breast-cancer models.  These studies represent an important step toward the development of effective EphA2-targeting PDCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBQLb1QD1aSrVg90H21EOLACvtfcHk0liDPCJ42RyR1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1ylt7o%253D&md5=a03f5dbbc9030174487353d42332b3ab</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01837%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DA.%2BF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBillet%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DUdompholkul%26aufirst%3DP.%26aulast%3DGambini%26aufirst%3DL.%26aulast%3DBaggio%26aufirst%3DC.%26aulast%3DTseng%26aufirst%3DH.%2BR.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DBhowmick%26aufirst%3DN.%2BA.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DReduction%2520of%2520circulating%2520cancer%2520cells%2520and%2520metastases%2520in%2520breast-cancer%2520models%2520by%2520a%2520potent%2520EphA2-agonistic%2520peptide%25E2%2580%2593drug%2520conjugate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D2052%26epage%3D2061%26doi%3D10.1021%2Facs.jmedchem.7b01837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ireton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.2174/1568009053765780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.2174%2F1568009053765780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=15892616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=149-157&issue=3&author=R.+C.+Iretonauthor=J.+Chen&title=EphA2+receptor+tyrosine+kinase+as+a+promising+target+for+cancer+therapeutics&doi=10.2174%2F1568009053765780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span></div><div class="casAuthors">Ireton, Renee C.; Chen, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play crit. roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis.  Eph RTKs and their ligands, the ephrins, are also frequently overexpressed in a variety of cancers and tumor cell lines.  In particular, one family member, EphA2, is overexpressed in breast, prostate, lung, and colon cancers.  Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interactions both in tumor cells and in the tumor microenvironment, namely the tumor stroma and tumor vasculature.  Thus, EphA2 receptors are attractive targets for drug design, as targeting these mols. could simultaneously inhibit several aspects of tumor progression.  This review focuses on the multiple roles of EphA2 in cancer progression, the mechanisms by which EphA2 inhibition may halt this progression, and the pre-clin. results of EphA2 inhibition in various cancer model systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXkP68V5-EhLVg90H21EOLACvtfcHk0liDPCJ42RyR1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D&md5=4ec492801946594928f5b87a4727134a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.2174%2F1568009053765780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009053765780%26sid%3Dliteratum%253Aachs%26aulast%3DIreton%26aufirst%3DR.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DEphA2%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520promising%2520target%2520for%2520cancer%2520therapeutics%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2005%26volume%3D5%26issue%3D3%26spage%3D149%26epage%3D157%26doi%3D10.2174%2F1568009053765780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker-Daniels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">Differential regulation of EphA2 in normal and malignant cells</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1042</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)63899-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2FS0002-9440%2810%2963899-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=12651595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVemt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2003&pages=1037-1042&issue=4&author=J.+Walker-Danielsauthor=A.+R.+Hessauthor=M.+J.+Hendrixauthor=M.+S.+Kinch&title=Differential+regulation+of+EphA2+in+normal+and+malignant+cells&doi=10.1016%2FS0002-9440%2810%2963899-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Differential regulation of EphA2 in normal and malignant cells</span></div><div class="casAuthors">Walker-Daniels, Jennifer; Hess, Angela R.; Hendrix, Mary J. C.; Kinch, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1037-1042</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">A review on the biochem. and cellular consequences of EphA2 stimulation, esp. in malignant cells.  The mechanisms that may explain the overexpression and functional alterations of EphA2 in cancer are discussed.  A hypothetical model representing a potential signaling pathway initiated by EphA2 and crit. for vasculogenic mimicry is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOCiDKgpnOxrVg90H21EOLACvtfcHk0ljL70UC_9Y_5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVemt70%253D&md5=e6298e47af35ad4815d6ba053df0931c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963899-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963899-0%26sid%3Dliteratum%253Aachs%26aulast%3DWalker-Daniels%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DA.%2BR.%26aulast%3DHendrix%26aufirst%3DM.%2BJ.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DDifferential%2520regulation%2520of%2520EphA2%2520in%2520normal%2520and%2520malignant%2520cells%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2003%26volume%3D162%26issue%3D4%26spage%3D1037%26epage%3D1042%26doi%3D10.1016%2FS0002-9440%2810%2963899-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mollaev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorokhovets, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faustova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabolotsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhunina, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamulaeva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabbarov, N.</span></span> <span> </span><span class="NLM_article-title">Type of pH sensitive linker reveals different time-dependent intracellular localization, in vitro and in vivo efficiency in alpha-fetoprotein receptor targeted doxorubicin conjugate</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2018.12.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.ijpharm.2018.12.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=30599230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2lsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2019&pages=138-146&author=M.+Mollaevauthor=N.+Gorokhovetsauthor=E.+Nikolskayaauthor=M.+Faustovaauthor=A.+Zabolotskyauthor=O.+Zhuninaauthor=M.+Sokolauthor=I.+Zamulaevaauthor=E.+Severinauthor=N.+Yabbarov&title=Type+of+pH+sensitive+linker+reveals+different+time-dependent+intracellular+localization%2C+in+vitro+and+in+vivo+efficiency+in+alpha-fetoprotein+receptor+targeted+doxorubicin+conjugate&doi=10.1016%2Fj.ijpharm.2018.12.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Type of pH sensitive linker reveals different time-dependent intracellular localization, in vitro and in vivo efficiency in alpha-fetoprotein receptor targeted doxorubicin conjugate</span></div><div class="casAuthors">Mollaev, M.; Gorokhovets, N.; Nikolskaya, E.; Faustova, M.; Zabolotsky, A.; Zhunina, O.; Sokol, M.; Zamulaeva, I.; Severin, E.; Yabbarov, N.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-146</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Despite the presence of a variety of modern anticancer drugs at the market, doxorubicin (Dox) is still widely used in antineoplastic therapy, although its administration causes severe side effects.  To enhance specific activity of such mols., various approaches have been exploited: targeted moieties like monoclonal antibodies, onco-specific proteins and peptides are utilized as specific vector mols.; environment sensitive linkers are exploited to facilitate transported drug release at the target point etc.  Acid-labile linkers are frequently used in synthesis due to the ability to be cleaved inside specific cellular compartments with acidic environment, avoiding possible recycling mechanisms.  Two types of conjugates contg. different acid-labile linkers have been synthesized.  In vitro efficiency of doxorubicin conjugates with recombinant receptor-binding domain of human alpha-fetoprotein (3dAFPpG) synthesized with use of cis-aconitic anhydride (CAA) and linker based on succinimidyl 3-(2-pyridyldithio)propionate (SPDP) and 3-(2-pyridyldithio)propionic acid hydrazide (PDPH) was compared.  The 3dAFPpG-SPDP-PDPH-Dox revealed a comparable with unmodified doxorubicin cytotoxic effect against the Dox sensitive MCF7 cell line and greater cytotoxicity against the anthracycline resistant MCF7Adr cells.  Meanwhile the 3dAFPpG-CAA-Dox cytotoxic effect was significantly lower, although doxorubicin's pH-dependent release profiles and intracellular accumulation rates were similar.  These differences in cytotoxic activity were arguably explained by the dissimilarities in intracellular doxorubicin localization, which may originate from thiol reductase activity in lysosomes and late endosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWFUYDmUz727Vg90H21EOLACvtfcHk0ljL70UC_9Y_5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2lsLg%253D&md5=995e0dd84ee74c2e9349500f1598efa9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2018.12.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2018.12.073%26sid%3Dliteratum%253Aachs%26aulast%3DMollaev%26aufirst%3DM.%26aulast%3DGorokhovets%26aufirst%3DN.%26aulast%3DNikolskaya%26aufirst%3DE.%26aulast%3DFaustova%26aufirst%3DM.%26aulast%3DZabolotsky%26aufirst%3DA.%26aulast%3DZhunina%26aufirst%3DO.%26aulast%3DSokol%26aufirst%3DM.%26aulast%3DZamulaeva%26aufirst%3DI.%26aulast%3DSeverin%26aufirst%3DE.%26aulast%3DYabbarov%26aufirst%3DN.%26atitle%3DType%2520of%2520pH%2520sensitive%2520linker%2520reveals%2520different%2520time-dependent%2520intracellular%2520localization%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520efficiency%2520in%2520alpha-fetoprotein%2520receptor%2520targeted%2520doxorubicin%2520conjugate%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2019%26volume%3D559%26spage%3D138%26epage%3D146%26doi%3D10.1016%2Fj.ijpharm.2018.12.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>512</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2016.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.ijpharm.2016.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=27521706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyktb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2016&pages=1-13&issue=1&author=Y.+Shengauthor=Y.+Youauthor=Y.+Chen&title=Dual-targeting+hybrid+peptide-conjugated+doxorubicin+for+drug+resistance+reversal+in+breast+cancer&doi=10.1016%2Fj.ijpharm.2016.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer</span></div><div class="casAuthors">Sheng, Yuan; You, Yiwen; Chen, Yun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The extended use of doxorubicin (DOX) could be limited due to the emergence of drug resistance assocd. with its treatment.  In addn. to the overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), other mechanisms including apoptosis evasion and tumor cell survival may also be important contributor to drug resistance.  Within this context, targeting extracellular signal-regulated kinases (ERK), one of the principle protein mols. in cell apoptosis has emerged as an attractive therapeutic concept.  In this study, a dual-targeting hybrid peptide HAIYPRHGGCGMPKKKPTPIQLNP (T10-ERK), which is composed of ERK peptide inhibitor MPKKKPTPIQLNP, a thiol spacer (i.e., GGCG) and transferrin receptor (TfR)-binding peptide HAIYPRH, was designed.  Then, this thiol-modified hybrid peptide was conjugated to DOXO-EMCH (6-maleimidocaproyl) hydrazone of DOX, forming a novel peptide-DOX conjugate T10-ERK-DOX.  The structure and properties of this conjugate were characterized using 1H NMR, mass spectrometry and HPLC.  Using MCF-7/ADR cells as an in vitro model system and nude mice bearing MCF-7/ADR xenografts as an in vivo model, the ability of T10-ERK-DOX to reverse drug resistance was accessed as compared with free DOX and T10-DOX.  As a result, T10-ERK-DOX demonstrated a much lower in vitro IC50 (20.8 ± 1.1 μM) and its in vivo extent of inhibition in mice was more evident (72.2 ± 4.6%).  Induction of various apoptosis pathways was also obsd.  Furthermore, the potency of ERK peptide inhibitor to reverse drug resistance was individually assessed, given the pronounced efficacy of T10-DOX indicated by our previous work.  The results provided evidence of its additive effect with T10-DOX, which leads to greater efficacy and less susceptibility to drug resistance.  Finally, the success of multi-targeting strategy in the present study implied that multi-target drugs with rational design could be more promising in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT7-zyXxfctLVg90H21EOLACvtfcHk0ljDOFiekdeZdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyktb%252FJ&md5=b93858a1608988876ba31751957f8c7d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2016.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2016.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DY.%26aulast%3DYou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DDual-targeting%2520hybrid%2520peptide-conjugated%2520doxorubicin%2520for%2520drug%2520resistance%2520reversal%2520in%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2016%26volume%3D512%26issue%3D1%26spage%3D1%26epage%3D13%26doi%3D10.1016%2Fj.ijpharm.2016.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yousefpour, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tewksbury, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellucci, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilkoti, A.</span></span> <span> </span><span class="NLM_article-title">Conjugate of doxorubicin to albumin-binding peptide outperforms aldoxorubicin</span>. <i>Small</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e1804452</span> <span class="refDoi"> DOI: 10.1002/smll.201804452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1002%2Fsmll.201804452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=30756483" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&issue=12&author=P.+Yousefpourauthor=L.+Ahnauthor=J.+Tewksburyauthor=S.+Sahaauthor=S.+A.+Costaauthor=J.+J.+Bellucciauthor=X.+Liauthor=A.+Chilkoti&title=Conjugate+of+doxorubicin+to+albumin-binding+peptide+outperforms+aldoxorubicin&doi=10.1002%2Fsmll.201804452"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fsmll.201804452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsmll.201804452%26sid%3Dliteratum%253Aachs%26aulast%3DYousefpour%26aufirst%3DP.%26aulast%3DAhn%26aufirst%3DL.%26aulast%3DTewksbury%26aufirst%3DJ.%26aulast%3DSaha%26aufirst%3DS.%26aulast%3DCosta%26aufirst%3DS.%2BA.%26aulast%3DBellucci%26aufirst%3DJ.%2BJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChilkoti%26aufirst%3DA.%26atitle%3DConjugate%2520of%2520doxorubicin%2520to%2520albumin-binding%2520peptide%2520outperforms%2520aldoxorubicin%26jtitle%3DSmall%26date%3D2019%26volume%3D15%26issue%3D12%26doi%3D10.1002%2Fsmll.201804452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechet, J. M.</span></span> <span> </span><span class="NLM_article-title">Acetals as pH-sensitive linkages for drug delivery</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1254</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1021/bc049853x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc049853x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotlartbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=1254-1263&issue=6&author=E.+R.+Gilliesauthor=A.+P.+Goodwinauthor=J.+M.+Frechet&title=Acetals+as+pH-sensitive+linkages+for+drug+delivery&doi=10.1021%2Fbc049853x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Acetals as pH-sensitive linkages for drug delivery</span></div><div class="casAuthors">Gillies, Elizabeth R.; Goodwin, Andrew P.; Frechet, Jean M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1254-1263</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PH-sensitive linkages designed to undergo hydrolysis at mildly acidic pH can trigger the release of therapeutics selectively at targets such as tumor and inflammatory tissues and in the endosomes and lysosomes of cells.  Acetals have the potential to be used as linkages for a range of alc. functionalities, and, by altering their chem. structure, it is possible to tune their hydrolysis rate.  The synthesis of four conjugates of model drug mols. with PEO using acetals of varying chem. structure were described herein.  Primary and secondary alcs., as well as syn-1,2-diols, were incorporated in the conjugates.  The hydrolysis kinetics were investigated by HPLC, and the conjugates had half-lives ranging from less than 1 min to several days at pH 5.0, with slower hydrolysis at pH 7.4 in all cases.  These acetal linkages were therefore promising for use in a variety of drug delivery applications ranging from polymer-drug conjugates to pH-sensitive micelles and nanoparticulate systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1xlu6rB_dK7Vg90H21EOLACvtfcHk0ljDOFiekdeZdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotlartbY%253D&md5=e9a5cb11f2b4130753c53742b8ed1783</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fbc049853x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049853x%26sid%3Dliteratum%253Aachs%26aulast%3DGillies%26aufirst%3DE.%2BR.%26aulast%3DGoodwin%26aufirst%3DA.%2BP.%26aulast%3DFrechet%26aufirst%3DJ.%2BM.%26atitle%3DAcetals%2520as%2520pH-sensitive%2520linkages%2520for%2520drug%2520delivery%26jtitle%3DBioconjugate%2520Chem.%26date%3D2004%26volume%3D15%26issue%3D6%26spage%3D1254%26epage%3D1263%26doi%3D10.1021%2Fbc049853x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brocchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, R.</span></span> <span> </span><span class="NLM_article-title">Polyacetal-doxorubicin conjugates designed for pH-dependent degradation</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1096</span>– <span class="NLM_lpage">1106</span>, <span class="refDoi"> DOI: 10.1021/bc030028a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc030028a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Wit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2003&pages=1096-1106&issue=6&author=R.+Tomlinsonauthor=J.+Hellerauthor=S.+Brocchiniauthor=R.+Duncan&title=Polyacetal-doxorubicin+conjugates+designed+for+pH-dependent+degradation&doi=10.1021%2Fbc030028a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Polyacetal-doxorubicin conjugates designed for pH-dependent degradation</span></div><div class="casAuthors">Tomlinson, Ryan; Heller, Jorge; Brocchini, Steve; Duncan, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1096-1106</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Terpolymn. of poly(ethylene glycol) (PEG), divinyl ethers, and serinol can be used to synthesize water sol., hydrolytically labile, amino-pendent polyacetals (APEGs) suitable for drug conjugation.  As these polyacetals display pH-dependent degrdn. (with faster rates of hydrolysis at acidic pH) and they are not inherently hepatotropic after i.v. injection, they have potential for development as biodegradable carriers to facilitate improved tumor targeting of anticancer agents.  The aim of this study was to synthesize a polyacetal-doxorubicin (APEG-DOX) conjugate, det. its cytotoxicity in vitro and evaluate its potential for improved tumor targeting in vivo compared to an HPMA copolymer-DOX conjugate in clin. development.  Amino-pendent polyacetals were prepd., and following succinoylation (APEG-succ), the polymeric intermediate conjugated to DOX via one of three methods using carbodiimide mediated coupling (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in aq. soln. was the most successful).  The resultant APEG-DOX conjugates had a DOX content of 3.0-8.5 wt.%, contained <1.2% free DOX (relative to total DOX content) and had a Mw = 60,000-100,000 g/mol and Mw/Mn = 1.7-2.6.  In vitro cytotoxicity studies showed APEG-DOX to be 10-fold less toxic toward B16F10 cells than free DOX (IC50 = 6 μg/mL and 0.6 μg/mL resp.), but confirmed the serinol-succinoyl-DOX liberated during main-chain degrdn. to be biol. active.  When administered iv to C57 black mice bearing s.c. B16F10 melanoma, APEG-DOX of Mw = 86,000 g/mol, and 5.0 wt.% DOX content exhibited significantly (p < 0.05) prolonged blood half-life and enhanced tumor accumulation compared to an HPMA copolymer-GFLG-DOX conjugate of Mw = 30,000 g/mol and 6.2 wt.% DOX content.  Moreover, APEG-DOX exhibited lower uptake by liver and spleen.  These observations suggest that APEG anticancer conjugates warrant further development as novel polymer therapeutics for improved tumor targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWlbuJ08u21bVg90H21EOLACvtfcHk0liqnGGvr_9q4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Wit7k%253D&md5=d453bae9571e32211b5bd318f0787d13</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fbc030028a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc030028a%26sid%3Dliteratum%253Aachs%26aulast%3DTomlinson%26aufirst%3DR.%26aulast%3DHeller%26aufirst%3DJ.%26aulast%3DBrocchini%26aufirst%3DS.%26aulast%3DDuncan%26aufirst%3DR.%26atitle%3DPolyacetal-doxorubicin%2520conjugates%2520designed%2520for%2520pH-dependent%2520degradation%26jtitle%3DBioconjugate%2520Chem.%26date%3D2003%26volume%3D14%26issue%3D6%26spage%3D1096%26epage%3D1106%26doi%3D10.1021%2Fbc030028a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Stefano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiume, L.</span></span> <span> </span><span class="NLM_article-title">A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">4–5</span>),  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2004.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.ejps.2004.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=15567293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVamu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=393-397&issue=4%E2%80%935&author=G.+Di%0AStefanoauthor=M.+Lanzaauthor=F.+Kratzauthor=L.+Merinaauthor=L.+Fiume&title=A+novel+method+for+coupling+doxorubicin+to+lactosaminated+human+albumin+by+an+acid+sensitive+hydrazone+bond%3A+synthesis%2C+characterization+and+preliminary+biological+properties+of+the+conjugate&doi=10.1016%2Fj.ejps.2004.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate</span></div><div class="casAuthors">Di Stefano, Giuseppina; Lanza, Marcella; Kratz, Felix; Merina, Luca; Fiume, Luigi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">393-397</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The expression of the asialoglycoprotein receptor on the cells of the large majority of the well differentiated hepatocellular carcinomas can be exploited to improve the chemotherapy of these tumors by coupling anticancer agents to macromols. taken up by the receptor.  In line with this approach, in previous expts. we coupled doxorubicin (DOXO) to lactosaminated human albumin (L-HSA) using the (6-maleimidocaproyl)hydrazone deriv. of the drug as an acid sensitive linker.  Encouraging results were obtained in lab. animals using L-HSA-DOXO.  This conjugate, however, has the disadvantage of a difficult synthesis, which requires protein thiolation with iminothiolane and can hinder its prepn. on a large scale.  Here we describe a very simple method of coupling.  The HS-groups required for the reaction with the maleimide moiety of DOXO-EMCH are made available in L-HSA by a cleavage of the protein disulfides achieved with tris(2-carboxyethyl) phosphine (TCEP).  Contrary to thiolic reducing agents, the use of TCEP eliminates the need of an inert atm. and allows a one-step coupling reaction, without purifn. of the reduced protein before the addn. of DOXO-EMCH.  As the previous L-HSA-DOXO conjugate, the new conjugate accomplishes a very efficient liver targeting of the drug.  This novel method of synthesis should facilitate the prepn. of L-HSA-DOXO in the amts. required for clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXvB-LbVmZXbVg90H21EOLACvtfcHk0liqnGGvr_9q4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVamu7nK&md5=f2615e5b3e9a11994d87033cbd008133</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2004.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2004.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BStefano%26aufirst%3DG.%26aulast%3DLanza%26aufirst%3DM.%26aulast%3DKratz%26aufirst%3DF.%26aulast%3DMerina%26aufirst%3DL.%26aulast%3DFiume%26aufirst%3DL.%26atitle%3DA%2520novel%2520method%2520for%2520coupling%2520doxorubicin%2520to%2520lactosaminated%2520human%2520albumin%2520by%2520an%2520acid%2520sensitive%2520hydrazone%2520bond%253A%2520synthesis%252C%2520characterization%2520and%2520preliminary%2520biological%2520properties%2520of%2520the%2520conjugate%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D23%26issue%3D4%25E2%2580%25935%26spage%3D393%26epage%3D397%26doi%3D10.1016%2Fj.ejps.2004.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kratz, F.</span></span> <span> </span><span class="NLM_article-title">DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.1517/13543784.16.6.855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1517%2F13543784.16.6.855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=17501697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=855-866&issue=6&author=F.+Kratz&title=DOXO-EMCH+%28INNO-206%29%3A+the+first+albumin-binding+prodrug+of+doxorubicin+to+enter+clinical+trials&doi=10.1517%2F13543784.16.6.855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials</span></div><div class="casAuthors">Kratz, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-866</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The (6-maleimidocaproyl)hydrazone deriv. of doxorubicin (DOXO-EMCH) is an albumin-binding prodrug of doxorubicin with acid-sensitive properties that demonstrates superior antitumor efficacy in murine tumor models and a favorable toxicity profile in mice, rats and dogs, including significantly reduced cardiotoxicity.  After i.v. administration, DOXO-EMCH binds rapidly to the Cys-34 position of circulating albumin and accumulates in solid tumors due to passive targeting.  In a clin. Phase I study, the dose of doxorubicin could be increased by a factor of 4.5-340 mg/m2 when 75 mg/m2 of free doxorubicin is considered to be the dose that can be administered as a single agent concomitant with the typical spectrum of side effects (i.e., myelotoxicity and mucositis).  DOXO-EMCH was able to induce tumor regressions in anthracycline-sensitive tumors (i.e., breast cancer, small cell lung cancer and sarcoma).  Phase II studies will be initiated at the beginning of 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3XBL2mlbCkbVg90H21EOLACvtfcHk0lhzyUTGaiTBRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOju7Y%253D&md5=88fec9cd817a4b10e54506d423eccd35</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.6.855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.6.855%26sid%3Dliteratum%253Aachs%26aulast%3DKratz%26aufirst%3DF.%26atitle%3DDOXO-EMCH%2520%2528INNO-206%2529%253A%2520the%2520first%2520albumin-binding%2520prodrug%2520of%2520doxorubicin%2520to%2520enter%2520clinical%2520trials%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26issue%3D6%26spage%3D855%26epage%3D866%26doi%3D10.1517%2F13543784.16.6.855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kratz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnecke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitzel, M.</span></span> <span> </span><span class="NLM_article-title">Prodrugs of anthracyclines in cancer chemotherapy</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.2174/092986706776055751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.2174%2F092986706776055751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=16515518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Klu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=477-523&issue=5&author=F.+Kratzauthor=A.+Warneckeauthor=B.+Schmidauthor=D.+E.+Chungauthor=M.+Gitzel&title=Prodrugs+of+anthracyclines+in+cancer+chemotherapy&doi=10.2174%2F092986706776055751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs of anthracyclines in cancer chemotherapy</span></div><div class="casAuthors">Kratz, F.; Warnecke, A.; Schmid, B.; Chung, D.-E.; Gitzel, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">477-523</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Designing and developing truly tumor-specific prodrugs remains a challenge in the field of cancer chemotherapy.  Active targeting strategies, on the one hand, aim at exploiting membrane-assocd. receptors or antigens for drug delivery; the enhanced vascular permeability and retention of macromols. in tumor tissue substantiates the concept of passive targeting.  Consequently, research efforts have concd. on conjugating anticancer agents with a wide spectrum of carriers including antibodies, peptides, serum proteins, and synthetic polymers.  Conversely, low-mol. wt. prodrugs of anticancer agents have been developed that do not bear an active or passive targeting moiety, but are activated by tumor-assocd. enzymes at the tumor site.  Anthracyclines probably represent the class of anticancer agents that has been most widely used for the development of prodrugs.  This overview gives an update of the various low- and high-mol. wt. prodrugs of anthracyclines, e.g. with antibodies, peptides, carbohydrates, serum proteins or synthetic polymers, that have been developed over the past 20 years and that exemplify the salient features of a resp. drug delivery system.  A detailed description will be dedicated to anthracycline prodrugs that have reached an advanced stage of preclin. testing or that have entered clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc5fDdtJIfRLVg90H21EOLACvtfcHk0lhzyUTGaiTBRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Klu7s%253D&md5=7c16a1dff064a7b1e8bd6749f2206fe7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2174%2F092986706776055751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986706776055751%26sid%3Dliteratum%253Aachs%26aulast%3DKratz%26aufirst%3DF.%26aulast%3DWarnecke%26aufirst%3DA.%26aulast%3DSchmid%26aufirst%3DB.%26aulast%3DChung%26aufirst%3DD.%2BE.%26aulast%3DGitzel%26aufirst%3DM.%26atitle%3DProdrugs%2520of%2520anthracyclines%2520in%2520cancer%2520chemotherapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2006%26volume%3D13%26issue%3D5%26spage%3D477%26epage%3D523%26doi%3D10.2174%2F092986706776055751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chawla, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhametshina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankhala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasylyev, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganjoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, D. J.</span></span> <span> </span><span class="NLM_article-title">First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial</span>. <i>JAMA Oncol</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1272</span>– <span class="NLM_lpage">1280</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.3101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1001%2Fjamaoncol.2015.3101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=26378637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BC283jtVyrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=1272-1280&issue=9&author=S.+P.+Chawlaauthor=Z.+Papaiauthor=G.+Mukhametshinaauthor=K.+Sankhalaauthor=L.+Vasylyevauthor=A.+Fedenkoauthor=K.+Khamlyauthor=K.+Ganjooauthor=R.+Nagarkarauthor=S.+Wielandauthor=D.+J.+Levitt&title=First-line+aldoxorubicin+vs+doxorubicin+in+metastatic+or+locally+advanced+unresectable+soft-tissue+sarcoma%3A+a+phase+2b+randomized+clinical+trial&doi=10.1001%2Fjamaoncol.2015.3101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial</span></div><div class="casAuthors">Chawla Sant P; Papai Zsuzsanna; Mukhametshina Guzel; Sankhala Kamalesh; Vasylyev Leonid; Fedenko Alexander; Khamly Kenneth; Ganjoo Kristen; Nagarkar Rajnish; Wieland Scott; Levitt Daniel J</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1272-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  Standard therapy for advanced soft-tissue sarcoma has not changed substantially in decades, and patient prognosis remains poor.  Aldoxorubicin, a novel albumin-binding prodrug of doxorubicin, showed clinical activity against advanced soft-tissue sarcoma in phase 1 studies.  OBJECTIVE:  To evaluate efficacy and safety of aldoxorubicin vs doxorubicin in patients with advanced soft-tissue sarcoma.  DESIGN, SETTING, AND PARTICIPANTS:  International, multicenter, phase 2b, open-label, randomized study at general community practices, private practices, or institutional practices.  Between August 2012 and December 2013, 140 patients with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma were screened.  INTERVENTIONS:  Randomization (2:1) to aldoxorubicin 350 mg/m2 (dose equivalent to doxorubicin 260 mg/m2) or doxorubicin 75 mg/m2, administered once every 3 weeks for up to 6 cycles.  MAIN OUTCOMES AND MEASURES:  Primary end point was progression-free survival.  Secondary end points were 6-month progression-free survival, overall survival, tumor response rate, and safety.  All efficacy end points were evaluated by independent and local review.  RESULTS:  A total of 126 patients were randomized, and 123 received aldoxorubicin (n = 83) or doxorubicin (n = 40).  Median (range) patient age was 54.0 (21-77 years); 42 (34%) had leiomyosarcoma.  By independent review, median progression-free survival was significantly improved (5.6 [95% CI, 3.0-8.1] vs 2.7 [95% CI, 1.6-4.3] months; P = .02) with aldoxorubicin compared with doxorubicin, as was the rate of 6-month progression-free survival (46% and 23%; P = .02).  Median overall survival was 15.8 (95% CI, 13.0 to not available) months with aldoxorubicin and 14.3 (95% CI, 8.6-20.6) months with doxorubicin (P = .21).  Overall tumor response rate (by Response Evaluation Criteria in Solid Tumors, version 1.1) by independent review was higher with aldoxorubicin than with doxorubicin (25% [20 patients, all partial response] vs 0%).  Grade 3 or 4 neutropenia was more frequent with aldoxorubicin than with doxorubicin (24 [29%] vs 5 [12%]), but not grade 3 or 4 febrile neutropenia (12 [14%] vs 7 [18%]).  No acute cardiotoxic effects were observed with either treatment, although left ventricular ejection fraction less than 50% occurred in 3 of 40 patients receiving doxorubicin.  CONCLUSIONS AND RELEVANCE:  Single-agent aldoxorubicin therapy showed superior efficacy over doxorubicin by prolonging progression-free survival and improving rates of 6-month progression-free survival and tumor response.  Aldoxorubicin therapy exhibited manageable adverse effects, without unexpected events, and without evidence of acute cardiotoxicity.  Further investigation of aldoxorubicin therapy in advanced soft-tissue sarcoma is warranted.  TRIAL REGISTRATION:  clinicaltrials.gov Identifier: NCT01514188.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8uVdlXrdQf1MGsG_HTXYFfW6udTcc2eZCPIkDtYRLDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283jtVyrtA%253D%253D&md5=e1a9c0c72db1ac52587a5792caeebe2f</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.3101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.3101%26sid%3Dliteratum%253Aachs%26aulast%3DChawla%26aufirst%3DS.%2BP.%26aulast%3DPapai%26aufirst%3DZ.%26aulast%3DMukhametshina%26aufirst%3DG.%26aulast%3DSankhala%26aufirst%3DK.%26aulast%3DVasylyev%26aufirst%3DL.%26aulast%3DFedenko%26aufirst%3DA.%26aulast%3DKhamly%26aufirst%3DK.%26aulast%3DGanjoo%26aufirst%3DK.%26aulast%3DNagarkar%26aufirst%3DR.%26aulast%3DWieland%26aufirst%3DS.%26aulast%3DLevitt%26aufirst%3DD.%2BJ.%26atitle%3DFirst-line%2520aldoxorubicin%2520vs%2520doxorubicin%2520in%2520metastatic%2520or%2520locally%2520advanced%2520unresectable%2520soft-tissue%2520sarcoma%253A%2520a%2520phase%25202b%2520randomized%2520clinical%2520trial%26jtitle%3DJAMA%2520Oncol%26date%3D2015%26volume%3D1%26issue%3D9%26spage%3D1272%26epage%3D1280%26doi%3D10.1001%2Fjamaoncol.2015.3101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forscher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendifar, A.</span></span> <span> </span><span class="NLM_article-title">Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S140638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.2147%2FDDDT.S140638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29670334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOltL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=777-786&author=J.+Gongauthor=J.+Yanauthor=C.+Forscherauthor=A.+Hendifar&title=Aldoxorubicin%3A+a+tumor-targeted+doxorubicin+conjugate+for+relapsed+or+refractory+soft+tissue+sarcomas&doi=10.2147%2FDDDT.S140638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas</span></div><div class="casAuthors">Gong, Jun; Yan, Jessica; Forscher, Charles; Hendifar, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">777-786</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Despite available therapies after initial systemic therapy, prognosis remains poor in relapsed or refractory soft tissue sarcomas (STS).  The rational and clin. development of novel agents to improve outcomes in this area of high unmet need is desperately warranted.  Aldoxorubicin is a prodrug of doxorubicin that binds to serum albumin immediately after administration through an acid-sensitive hydrazone linker and is subsequently transported to tumor tissues where the acidic environment cleaves the linker and facilitates delivery of a tumor-targeted drug payload.  In clin. studies to date, there has been evidence of efficacy and mitigated cardiac toxicity.  In this review, we comprehensively detail the clin. development of aldoxorubicin in STS to date.  Specifically, we highlight available data on the pharmacokinetics and efficacy from Phase I, Phase II, and Phase III trials in advanced or metastatic STS.  We conclude with considerations for future directions of investigation for this promising antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqObWRl-0q_3bVg90H21EOLACvtfcHk0lge2i-2yKkpBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOltL3J&md5=330bd892680200d98e5c4fc0d3d3cbe5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S140638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S140638%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DForscher%26aufirst%3DC.%26aulast%3DHendifar%26aufirst%3DA.%26atitle%3DAldoxorubicin%253A%2520a%2520tumor-targeted%2520doxorubicin%2520conjugate%2520for%2520relapsed%2520or%2520refractory%2520soft%2520tissue%2520sarcomas%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2018%26volume%3D12%26spage%3D777%26epage%3D786%26doi%3D10.2147%2FDDDT.S140638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, D.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic Agents for the Treatment of Cancer</span>. U.S. Patent US <span class="NLM_patent">20190350952 A1</span> Nov 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Levitt&title=Cytotoxic+Agents+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLevitt%26aufirst%3DD.%26atitle%3DCytotoxic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laabs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A. C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic study of aldoxorubicin in patients with solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0183-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1007%2Fs10637-014-0183-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=25388939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFShu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=341-348&issue=2&author=M.+M.+Mitaauthor=R.+B.+Nataleauthor=E.+M.+Wolinauthor=B.+Laabsauthor=H.+Dinhauthor=S.+Wielandauthor=D.+J.+Levittauthor=A.+C.+Mita&title=Pharmacokinetic+study+of+aldoxorubicin+in+patients+with+solid+tumors&doi=10.1007%2Fs10637-014-0183-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic study of aldoxorubicin in patients with solid tumors</span></div><div class="casAuthors">Mita, Monica M.; Natale, Ronald B.; Wolin, Edward M.; Laabs, Brenda; Dinh, Hillary; Wieland, Scott; Levitt, Daniel J.; Mita, Alain C.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-348</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Introduction: Aldoxorubicin, a prodrug of doxorubicin, binds covalently to serum albumin in the bloodstream and accumulates in tumors.  Aldoxorubicin can be administered at doses several-fold higher than doxorubicin can, without assocd. acute cardiotoxicity.  Purpose: This study fully evaluated the pharmacokinetic profile of aldoxorubicin (serum and urine).  Methods: Eighteen patients with advanced solid tumors received aldoxorubicin 230 or 350 mg/m2 (equiv. in drug load to doxorubicin at doses of 170 or 260 mg/m2, resp.) once every 21 days.  Blood samples were taken in cycle 1 before aldoxorubicin infusion, and at 5, 15, 30, and 60 min, and at 2, 4, 8, 12, 16, 24, 48, and 72 h after infusion.  Urine samples were taken in cycle 1 at 24, 48, and 72 h after infusion.  Limited blood sampling was done in cycle 3, before aldoxorubicin infusion, and at 60 min and at 2, 4, and 8 h after infusion.  Results: The long mean half-life (20.1-21.1 h), narrow mean vol. of distribution (3.96-4.08 L/m2), and slow mean clearance rate (0.136-0.152 L/h/m2) suggest that aldoxorubicin is stable in circulation and does not accumulate readily in body compartments outside of the bloodstream.  Very little doxorubicin and its major metabolite doxorubicinol, which has been implicated in doxorubicin-assocd. cardiotoxicity, are excreted in urine.  This might explain the lack of cardiotoxicity obsd. thus far with aldoxorubicin.  Conclusions: Our findings support dosing and administration schemas used in an ongoing phase 3 clin. study of aldoxorubicin in soft tissue sarcoma, and phase 2 clin. studies in small cell lung cancer, glioblastoma, and Kaposi's sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqynSfZUd-KjLVg90H21EOLACvtfcHk0lgUzIkUigkSwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFShu73O&md5=3909a7d1fb734b9975797155192f48d4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0183-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0183-5%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DWolin%26aufirst%3DE.%2BM.%26aulast%3DLaabs%26aufirst%3DB.%26aulast%3DDinh%26aufirst%3DH.%26aulast%3DWieland%26aufirst%3DS.%26aulast%3DLevitt%26aufirst%3DD.%2BJ.%26aulast%3DMita%26aufirst%3DA.%2BC.%26atitle%3DPharmacokinetic%2520study%2520of%2520aldoxorubicin%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26issue%3D2%26spage%3D341%26epage%3D348%26doi%3D10.1007%2Fs10637-014-0183-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forman, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinna, A.</span></span> <span> </span><span class="NLM_article-title">Glutathione: overview of its protective roles, measurement, and biosynthesis</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.mam.2008.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.mam.2008.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=18796312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFelurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=1-12&issue=1%E2%80%932&author=H.+J.+Formanauthor=H.+Zhangauthor=A.+Rinna&title=Glutathione%3A+overview+of+its+protective+roles%2C+measurement%2C+and+biosynthesis&doi=10.1016%2Fj.mam.2008.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Glutathione: Overview of its protective roles, measurement, and biosynthesis</span></div><div class="casAuthors">Forman, Henry Jay; Zhang, Hongqiao; Rinna, Alessandra</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This review is the introduction to a special issue concerning, glutathione (GSH), the most abundant low mol. wt. thiol compd. synthesized in cells.  GSH plays crit. roles in protecting cells from oxidative damage and the toxicity of xenobiotic electrophiles, and maintaining redox homeostasis.  Here, the functions and GSH and the sources of oxidants and electrophiles, the elimination of oxidants by redn. and electrophiles by conjugation with GSH are briefly described.  Methods of assessing GSH status in the cells are also described.  GSH synthesis and its regulation are addressed along with therapeutic approaches for manipulating GSH content that have been proposed.  The purpose here is to provide a brief overview of some of the important aspects of glutathione metab. as part of this special issue that will provide a more comprehensive review of the state of knowledge regarding this essential mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlWapNqV0GqLVg90H21EOLACvtfcHk0lgUzIkUigkSwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFelurY%253D&md5=c1b1aa2b03389bf1434af0762df78fe1</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2008.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2008.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DForman%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DRinna%26aufirst%3DA.%26atitle%3DGlutathione%253A%2520overview%2520of%2520its%2520protective%2520roles%252C%2520measurement%252C%2520and%2520biosynthesis%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2009%26volume%3D30%26issue%3D1%25E2%2580%25932%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.mam.2008.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rietschoten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watcham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G. S.</span></span> <span> </span><span class="NLM_article-title">Identification and optimization of EphA2-selective bicycles for the delivery of cytotoxic payloads</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">4107</span>– <span class="NLM_lpage">4116</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02129</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02129" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltl2nu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4107-4116&issue=8&author=G.+E.+Muddauthor=A.+Brownauthor=L.+Chenauthor=K.+van+Rietschotenauthor=S.+Watchamauthor=D.+P.+Teufelauthor=S.+Pavanauthor=R.+Laniauthor=P.+Huxleyauthor=G.+S.+Bennett&title=Identification+and+optimization+of+EphA2-selective+bicycles+for+the+delivery+of+cytotoxic+payloads&doi=10.1021%2Facs.jmedchem.9b02129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads</span></div><div class="casAuthors">Mudd, Gemma E.; Brown, Amy; Chen, Liuhong; van Rietschoten, Katerine; Watcham, Sophie; Teufel, Daniel P.; Pavan, Silvia; Lani, Rachid; Huxley, Philip; Bennett, Gavin S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4107-4116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bicycles are constrained bicyclic peptides that represent a promising binding modality for use in targeted drug conjugates.  A phage display screen against EphA2, a receptor tyrosine kinase highly expressed in a no. of solid tumors, identified a no. of Bicycle families with low nanomolar affinity.  A Bicycle toxin conjugate (BTC) was generated by derivatization of one of these Bicycles with the potent cytotoxin DM1 via a cleavable linker.  This BTC demonstrated potent antitumor activity in vivo but was poorly tolerated, which was hypothesized to be the result of undesired liver uptake caused by poor physicochem. properties.  Chem. optimization of a second Bicycle, guided by structural biol., provided a high affinity, metabolically stable Bicycle with improved physicochem. properties.  A BTC incorporating this Bicycle also demonstrated potent antitumor activity and was very well tolerated when compared to the initial BTC.  Phage display selection followed by chem. optimization of Bicycles can deliver potent drug conjugates with favorable pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt84NGlw8Gd7Vg90H21EOLACvtfcHk0ljXvmuP7vgKeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltl2nu78%253D&md5=bf888a942cba4e0ef3d8427395d16a4d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02129%26sid%3Dliteratum%253Aachs%26aulast%3DMudd%26aufirst%3DG.%2BE.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3Dvan%2BRietschoten%26aufirst%3DK.%26aulast%3DWatcham%26aufirst%3DS.%26aulast%3DTeufel%26aufirst%3DD.%2BP.%26aulast%3DPavan%26aufirst%3DS.%26aulast%3DLani%26aufirst%3DR.%26aulast%3DHuxley%26aufirst%3DP.%26aulast%3DBennett%26aufirst%3DG.%2BS.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520EphA2-selective%2520bicycles%2520for%2520the%2520delivery%2520of%2520cytotoxic%2520payloads%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D8%26spage%3D4107%26epage%3D4116%26doi%3D10.1021%2Facs.jmedchem.9b02129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span> <span> </span><span class="NLM_article-title">Transferrin receptor targeted cellular delivery of doxorubicin via a reduction-responsive peptide–drug conjugate</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">168</span>, <span class="refDoi"> DOI: 10.1007/s11095-019-2688-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1007%2Fs11095-019-2688-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31654226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVeqsr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=168&issue=12&author=S.+Liauthor=H.+Zhaoauthor=X.+Maoauthor=Y.+Fanauthor=X.+Liangauthor=R.+Wangauthor=L.+Xiaoauthor=J.+Wangauthor=Q.+Liuauthor=G.+Zhao&title=Transferrin+receptor+targeted+cellular+delivery+of+doxorubicin+via+a+reduction-responsive+peptide%E2%80%93drug+conjugate&doi=10.1007%2Fs11095-019-2688-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Transferrin receptor targeted cellular delivery of doxorubicin via a reduction-responsive peptide-drug conjugate</span></div><div class="casAuthors">Li, Songtao; Zhao, Hongling; Mao, Xiaoxia; Fan, Yanfang; Liang, Xiujun; Wang, Ruxing; Xiao, Lijun; Wang, Jianping; Liu, Qi; Zhao, Guiqin</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">168</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Transferrin receptors (TfRs) are overexpressed in tumor cells but are scarce in normal tissues, which makes TfR an attractive target for drug treatment of cancer.  The objective of this study was to evaluate the potential of BP9a (CAHLHNRS) as a peptide vector for constructing TfR targeted peptide-drug conjugates and selective drug delivery.  Methods: Doxorubicin (DOX) was connected to BP9a via a disulfide-intercalating linker to afford a redn.-responsive BP9a-SS-DOX conjugate.  By using HepG2 human liver cancer cells and L-O2 normal hepatic cells as TfR over-expressing and low-expressing in vitro models, resp., TfR mediated cellular uptake of this conjugate was studied by using flow cytometry and confocal laser scanning microscopy.  The in vitro cytotoxicities of the conjugate against HepG2 and L-O2 cells were examd. by cell counting kit-8 (CCK-8) assay to evaluate its tumorous specificity.  Results: Cellular uptake and TfR blockage test results showed that the BP9a-SS-DOX conjugate gained entry into HepG2 cells via endocytosis mediated by TfR and mainly accumulated in cytoplasm.  The in vitro antiproliferative activity of this conjugate against HepG2 cells (IC50 6.21 ± 1.12 μM) was approx. one-sixth of that of free DOX (IC50 1.03 ± 0.13 μM).  However, its cytotoxic effect on L-O2 cells was obviously reduced compared with that of free DOX.  Conclusions: The BP9a-SS-DOX conjugate showed specific antiproliferative activity against HepG2 liver cancer cells.  Our study suggests that BP9a has the potential to target chemotherapeutic agents to tumor cells over-expressing TfR and facilitate selective drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbeaLo5eV6grVg90H21EOLACvtfcHk0ljXvmuP7vgKeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVeqsr%252FI&md5=c2d12adaaa2633528c95bde0c6f2963d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1007%2Fs11095-019-2688-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-019-2688-2%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DX.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DG.%26atitle%3DTransferrin%2520receptor%2520targeted%2520cellular%2520delivery%2520of%2520doxorubicin%2520via%2520a%2520reduction-responsive%2520peptide%25E2%2580%2593drug%2520conjugate%26jtitle%3DPharm.%2520Res.%26date%3D2019%26volume%3D36%26issue%3D12%26spage%3D168%26doi%3D10.1007%2Fs11095-019-2688-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dokus, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lajko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randelovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohidai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span> <span> </span><span class="NLM_article-title">Phage display-based homing peptide-daunomycin conjugates for selective drug targeting to PANC-1 pancreatic cancer</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">576</span>, <span class="refDoi"> DOI: 10.3390/pharmaceutics12060576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3390%2Fpharmaceutics12060576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFGnsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=576&issue=6&author=L.+E.+Dokusauthor=E.+Lajkoauthor=I.+Randelovicauthor=D.+Mezoauthor=G.+Schlosserauthor=L.+Kohidaiauthor=J.+Tovariauthor=G.+Mezo&title=Phage+display-based+homing+peptide-daunomycin+conjugates+for+selective+drug+targeting+to+PANC-1+pancreatic+cancer&doi=10.3390%2Fpharmaceutics12060576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Phage display-based homing peptide-daunomycin conjugates for selective drug targeting to PANC-1 pancreatic cancer</span></div><div class="casAuthors">Dokus, Levente E.; Lajko, Eszter; Randelovic, Ivan; Mezo, Diana; Schlosser, Gitta; Kohidai, Laszlo; Tovari, Jozsef; Mezo, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">576</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and dangerous cancerous diseases, leading to a high rate of mortality.  Therefore, the development of new, more efficient treatment approaches is necessary to cure this illness.  Peptide-based drug targeting provides a new tool for this purpose.  Previously, a hexapeptide Cys-Lys-Ala-Ala-Lys-Asn (CKAAKN) was applied efficiently as the homing device for drug-loaded nanostructures in PDAC cells.  In this research, Cys was replaced by Ser in the sequence and this new SKAAKN targeting moiety was used in conjugates contg. daunomycin (Dau).  Five different structures were developed and tested.  The results indicated that linear versions with one Dau were not effective on PANC-1 cells in vitro; however, branched conjugates with two Dau mols. showed significant antitumor activity.  Differences in the antitumor effect of the conjugates could be explained with the different cellular uptake and lysosomal degrdn.  The most efficient conjugate was Dau=Aoa-GFLG-K(Dau=Aoa)SKAAKN-OH (conjugate 4) that also showed significant tumor growth inhibition on s.c. implanted PANC-1 tumor-bearing mice with negligible side effects.  Our novel results suggest that peptide-based drug delivery systems could be a promising tool for the treatment of pancreatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHefZ-MzGahLVg90H21EOLACvtfcHk0ljgK40fO1hUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFGnsbzP&md5=bb8a2a924ee2244cc4e62d8e3d5b6e55</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics12060576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics12060576%26sid%3Dliteratum%253Aachs%26aulast%3DDokus%26aufirst%3DL.%2BE.%26aulast%3DLajko%26aufirst%3DE.%26aulast%3DRandelovic%26aufirst%3DI.%26aulast%3DMezo%26aufirst%3DD.%26aulast%3DSchlosser%26aufirst%3DG.%26aulast%3DKohidai%26aufirst%3DL.%26aulast%3DTovari%26aufirst%3DJ.%26aulast%3DMezo%26aufirst%3DG.%26atitle%3DPhage%2520display-based%2520homing%2520peptide-daunomycin%2520conjugates%2520for%2520selective%2520drug%2520targeting%2520to%2520PANC-1%2520pancreatic%2520cancer%26jtitle%3DPharmaceutics%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D576%26doi%3D10.3390%2Fpharmaceutics12060576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Randelovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapuvari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkuhler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovari, J.</span></span> <span> </span><span class="NLM_article-title">Improved in vivo anti-tumor and anti-metastatic effect of GnRH-III-daunorubicin analogs on colorectal and breast carcinoma bearing mice</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4763</span>, <span class="refDoi"> DOI: 10.3390/ijms20194763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3390%2Fijms20194763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovVWgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=4763&issue=19&author=I.+Randelovicauthor=S.+Schusterauthor=B.+Kapuvariauthor=G.+Fossatiauthor=C.+Steinkuhlerauthor=G.+Mezoauthor=J.+Tovari&title=Improved+in+vivo+anti-tumor+and+anti-metastatic+effect+of+GnRH-III-daunorubicin+analogs+on+colorectal+and+breast+carcinoma+bearing+mice&doi=10.3390%2Fijms20194763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Improved in vivo anti-tumor and anti-metastatic effect of GnRH-III-daunorubicin analogs on colorectal and breast carcinoma bearing mice</span></div><div class="casAuthors">Randelovic, Ivan; Schuster, Sabine; Kapuvari, Bence; Fossati, Gianluca; Steinkuhler, Christian; Mezo, Gabor; Tovari, Jozsef</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4763</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Among various homing devices, gonadotropin-releasing hormone-III (GnRH-III) peptide represents a suitable targeting moiety for drug delivery systems.  The anti-tumor activity of the previously developed GnRH-III-[4Lys(Bu),8Lys(Dau = Aoa)] conjugate and the novel synthesized GnRH-III-[2ΔHis,3d-Tic,4Lys(Bu),8Lys(Dau = Aoa)] conjugate, contg. the anti-cancer drug daunorubicin, were evaluated.  Here, we demonstrate that both GnRH-III-Dau conjugates possess an efficient growth inhibitory effect on more than 20 cancer cell lines, whereby the biol. activity is strongly connected to the expression of gonadotropin-releasing hormone receptors (GnRH-R).  The novel conjugate showed a higher in vitro anti-proliferative activity and a higher uptake capacity.  Moreover, the treatment with GnRH-III-Dau conjugates cause a significant in vivo tumor growth and metastases inhibitory effect in three different orthotopic models, including 4T1 mice and MDA-MB-231 human breast carcinoma, as well as HT-29 human colorectal cancer bearing BALB/s and SCID mice, while toxic side-effects were substantially reduced in comparison to the treatment with the free drug.  These findings illustrate that our novel lead compd. is a highly promising candidate for targeted tumor therapy in both colon cancer and metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2QyO2YJrgdbVg90H21EOLACvtfcHk0ljgK40fO1hUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovVWgs74%253D&md5=068322b233f70d77d0ac12ded68b4e63</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3390%2Fijms20194763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20194763%26sid%3Dliteratum%253Aachs%26aulast%3DRandelovic%26aufirst%3DI.%26aulast%3DSchuster%26aufirst%3DS.%26aulast%3DKapuvari%26aufirst%3DB.%26aulast%3DFossati%26aufirst%3DG.%26aulast%3DSteinkuhler%26aufirst%3DC.%26aulast%3DMezo%26aufirst%3DG.%26aulast%3DTovari%26aufirst%3DJ.%26atitle%3DImproved%2520in%2520vivo%2520anti-tumor%2520and%2520anti-metastatic%2520effect%2520of%2520GnRH-III-daunorubicin%2520analogs%2520on%2520colorectal%2520and%2520breast%2520carcinoma%2520bearing%2520mice%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26issue%3D19%26spage%3D4763%26doi%3D10.3390%2Fijms20194763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biri-Kovacs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buday, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span> <span> </span><span class="NLM_article-title">Enhanced in vitro antitumor activity of GnRH-III-daunorubicin bioconjugates influenced by sequence modification</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">223</span>, <span class="refDoi"> DOI: 10.3390/pharmaceutics10040223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3390%2Fpharmaceutics10040223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWktbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=223&issue=4&author=S.+Schusterauthor=B.+Biri-Kovacsauthor=B.+Szederauthor=L.+Budayauthor=J.+Gardiauthor=Z.+Szaboauthor=G.+Halmosauthor=G.+Mezo&title=Enhanced+in+vitro+antitumor+activity+of+GnRH-III-daunorubicin+bioconjugates+influenced+by+sequence+modification&doi=10.3390%2Fpharmaceutics10040223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced in vitro antitumor activity of GnRH-III-daunorubicin bioconjugates influenced by sequence modification</span></div><div class="casAuthors">Schuster, Sabine; Biri-Kovacs, Beata; Szeder, Balint; Buday, Laszlo; Gardi, Janos; Szabo, Zsuzsanna; Halmos, Gabor; Mezo, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">223</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Receptors for gonadotropin releasing hormone (GnRH) are highly expressed in various human cancers including breast, ovarian, endometrial, prostate and colorectal cancer.  Ligands like human GnRH-I or the sea lamprey analog GnRH-III represent a promising approach for the development of efficient drug delivery systems for targeted tumor therapy.  Here, we report on the synthesis and cytostatic effect of 14 oxime bond-linked daunorubicin GnRH-III conjugates contg. a variety of unnatural amino acids within the peptide sequence.  All compds. demonstrated a reduced cell viability in vitro on estrogen receptor α (ERα) pos. and ERα neg. cancer cells.  The best candidate revealed an increased cancer cell growth inhibitory effect compared to our lead-compd. GnRH-III-[4Lys(Bu),8Lys(Dau=Aoa)].  Flow cytometry and fluorescence microscopy studies showed that the cellular uptake of the novel conjugate is substantially improved leading to an accelerated delivery of the drug to its site of action.  However, the release of the active drug-metabolite by lysosomal enzymes was not neg. affected by amino acid substitution, while the compd. provided a high stability in human blood plasma.  Receptor binding studies were carried out to ensure a high binding affinity of the new compd. for the GnRH-receptor.  It was demonstrated that GnRH-III-[2ΔHis,3D-Tic,4Lys(Bu),8Lys(Dau=Aoa)] is a highly potent and promising anticancer drug delivery system for targeted tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6ABL1UU0E1bVg90H21EOLACvtfcHk0ljgK40fO1hUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWktbfJ&md5=9504f9d50ffc5f0886ce86036aa49901</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics10040223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics10040223%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DS.%26aulast%3DBiri-Kovacs%26aufirst%3DB.%26aulast%3DSzeder%26aufirst%3DB.%26aulast%3DBuday%26aufirst%3DL.%26aulast%3DGardi%26aufirst%3DJ.%26aulast%3DSzabo%26aufirst%3DZ.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DMezo%26aufirst%3DG.%26atitle%3DEnhanced%2520in%2520vitro%2520antitumor%2520activity%2520of%2520GnRH-III-daunorubicin%2520bioconjugates%2520influenced%2520by%2520sequence%2520modification%26jtitle%3DPharmaceutics%26date%3D2018%26volume%3D10%26issue%3D4%26spage%3D223%26doi%3D10.3390%2Fpharmaceutics10040223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biri-Kovacs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farkas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buday, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">756</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.3762/bjoc.14.64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.3762%2Fbjoc.14.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29719573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOhtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=756-771&author=S.+Schusterauthor=B.+Biri-Kovacsauthor=B.+Szederauthor=V.+Farkasauthor=L.+Budayauthor=Z.+Szaboauthor=G.+Halmosauthor=G.+Mezo&title=Synthesis+and+in+vitro+biochemical+evaluation+of+oxime+bond-linked+daunorubicin-GnRH-III+conjugates+developed+for+targeted+drug+delivery&doi=10.3762%2Fbjoc.14.64"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery</span></div><div class="casAuthors">Schuster, Sabine; Biri-Kovacs, Beata; Szeder, Balint; Farkas, Viktor; Buday, Laszlo; Szabo, Zsuzsanna; Halmos, Gabor; Mezo, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">756-771</span>CODEN:
                <span class="NLM_cas:coden">BJOCBH</span>;
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    
            (<span class="NLM_cas:orgname">Beilstein-Institut zur Foerderung der Chemischen Wissenschaften</span>)
        </div><div class="casAbstract">Gonadotropin releasing hormone-III (GnRH-III), a native isoform of the human GnRH isolated from sea lamprey, specifically binds to GnRH receptors on cancer cells enabling its application as targeting moieties for anticancer drugs.  Recently, we reported on the identification of a novel daunorubicin-GnRH-III conjugate GnRH-III-[4Lys(Bu), 8Lys(Dau = Aoa)] with efficient in vitro and in vivo antitumor activity.  To get a deeper insight into the mechanism of action of our lead compd., the cellular uptake was followed by confocal laser scanning microscopy.  Hereby, the drug daunorubicin could be visualized in different subcellular compartments by following the localization of the drug in a time-dependent manner.  Colocalization studies were carried out to prove the presence of the drug in lysosomes (early stage) and on its site of action (nuclei after 10 min).  Addnl. flow cytometry studies demonstrated that the cellular uptake of the bioconjugate was inhibited in the presence of the competitive ligand triptorelin indicating a receptor-mediated pathway.  For comparative purpose, six novel daunorubicin-GnRH-III bioconjugates have been synthesized and biochem. characterized in which 6Asp was replaced by D-Asp, D-Glu and D-Trp.  In addn. to the anal. of the in vitro cytostatic effect and cellular uptake, receptor binding studies with 125I-triptorelin as radiotracer and degrdn. of the GnRH-III conjugates in the presence of rat liver lysosomal homogenate have been performed.  All derivs. showed high binding affinities to GnRH receptors and displayed in vitro cytostatic effects on HT-29 and MCF-7 cancer cells with IC50 values in a low micromolar range.  Moreover, we found that the release of the active drug metabolite and the cellular uptake of the bioconjugates were strongly affected by the amino acid exchange which in turn had an impact on the antitumor activity of the bioconjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMWaEckn1wM7Vg90H21EOLACvtfcHk0ljjfORlDu_RVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOhtLvN&md5=71e5a06718a97f23b1afdf0da12a830e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.14.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.14.64%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DS.%26aulast%3DBiri-Kovacs%26aufirst%3DB.%26aulast%3DSzeder%26aufirst%3DB.%26aulast%3DFarkas%26aufirst%3DV.%26aulast%3DBuday%26aufirst%3DL.%26aulast%3DSzabo%26aufirst%3DZ.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DMezo%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520biochemical%2520evaluation%2520of%2520oxime%2520bond-linked%2520daunorubicin-GnRH-III%2520conjugates%2520developed%2520for%2520targeted%2520drug%2520delivery%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2018%26volume%3D14%26spage%3D756%26epage%3D771%26doi%3D10.3762%2Fbjoc.14.64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orban, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosze, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manea, M.</span></span> <span> </span><span class="NLM_article-title">Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>156</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2011.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.jconrel.2011.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=21864594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyltLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2011&pages=170-178&issue=2&author=P.+Schlageauthor=G.+Mezoauthor=E.+Orbanauthor=S.+Boszeauthor=M.+Manea&title=Anthracycline-GnRH+derivative+bioconjugates+with+different+linkages%3A+synthesis%2C+in+vitro+drug+release+and+cytostatic+effect&doi=10.1016%2Fj.jconrel.2011.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Anthracycline-GnRH derivative bioconjugates with different linkages: Synthesis, in vitro drug release and cytostatic effect</span></div><div class="casAuthors">Schlage, Pascal; Mezo, Gabor; Orban, Erika; Bosze, Szilvia; Manea, Marilena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">170-178</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To increase the selectivity and consequently to minimize the side effects of chemotherapeutic agents, receptor mediated tumor targeting approaches have been developed.  In the present work, various anthracycline-GnRH deriv. bioconjugates were synthesized with the aim of investigating the influence of (i) different anthracycline anticancer drugs, (ii) different linkages between the targeting moiety and the anticancer drug, and (iii) different targeting moieties (e.g., GnRH-III and [D-Lys6]-GnRH-I) on their in vitro drug release and cytostatic effect.  The anthracyclines, daunorubicin or doxorubicin, were attached to the ε-amino group of Lys of GnRH-III or [D-Lys6]-GnRH-I through oxime, hydrazone or ester bonds.  In another bioconjugate, a self-immolative p-aminobenzyloxycarbonyl spacer was used to link daunorubicin to GnRH-III.  The in vitro degrdn. of the bioconjugates was investigated in the presence of rat liver lysosomal homogenate and cathepsin B. The cellular uptake of the compds. was evaluated by flow cytometry and their in vitro cytostatic effect was detd. by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide assay.  The results indicate that on the tested cancer cell lines there is no significant difference in the cellular uptake and in vitro cytostatic effect of bioconjugates contg. GnRH-III or [D-Lys6]-GnRH-I as a targeting moiety.  The bioconjugates contg. ester bond, hydrazone bond and the self-immolative spacer exert the highest cytostatic effect, followed by oxime bond-linked compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzZMbP_ij8mrVg90H21EOLACvtfcHk0ljjfORlDu_RVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyltLfN&md5=01381af92574573bc83152fc433edcd1</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2011.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2011.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DSchlage%26aufirst%3DP.%26aulast%3DMezo%26aufirst%3DG.%26aulast%3DOrban%26aufirst%3DE.%26aulast%3DBosze%26aufirst%3DS.%26aulast%3DManea%26aufirst%3DM.%26atitle%3DAnthracycline-GnRH%2520derivative%2520bioconjugates%2520with%2520different%2520linkages%253A%2520synthesis%252C%2520in%2520vitro%2520drug%2520release%2520and%2520cytostatic%2520effect%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2011%26volume%3D156%26issue%3D2%26spage%3D170%26epage%3D178%26doi%3D10.1016%2Fj.jconrel.2011.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arosio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piarulli, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neundorf, I.</span></span> <span> </span><span class="NLM_article-title">Kiss and run: promoting effective and targeted cellular uptake of a drug delivery vehicle composed of an integrin-targeting diketopiperazine peptidomimetic and a cell-penetrating peptide</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2011</span>– <span class="NLM_lpage">2022</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.9b00292</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.9b00292" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2lsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=2011-2022&issue=7&author=L.+Feniauthor=S.+Parenteauthor=C.+Robertauthor=S.+Gazzolaauthor=D.+Arosioauthor=U.+Piarulliauthor=I.+Neundorf&title=Kiss+and+run%3A+promoting+effective+and+targeted+cellular+uptake+of+a+drug+delivery+vehicle+composed+of+an+integrin-targeting+diketopiperazine+peptidomimetic+and+a+cell-penetrating+peptide&doi=10.1021%2Facs.bioconjchem.9b00292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide</span></div><div class="casAuthors">Feni, Lucia; Parente, Sara; Robert, Clemence; Gazzola, Silvia; Arosio, Daniela; Piarulli, Umberto; Neundorf, Ines</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2011-2022</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cell-penetrating peptides (CPPs) have emerged as powerful tools in terms of drug delivery.  Those short, often cationic peptides are characterized by their usually low toxicity and their ability to transport diverse cargos inside almost any kinds of cells.  Still, one major drawback is their nonselective uptake making their application in targeted cancer therapies questionable.  In this work, we aimed to combine the power of a CPP (sC18) with an integrin-targeting unit (c[DKP-f3-RGD]).  The latter is composed of the Arg-Gly-Asp peptide sequence cyclized via a diketopiperazine scaffold and is characterized by its high selectivity toward integrin αvβ3.  The two parts were linked via copper-catalyzed alkyne-azide click reaction (CuAAC), while the CPP was addnl. functionalized with either a fluorescent dye or the anticancer drug daunorubicin.  Both functionalities allowed a careful biol. evaluation of these novel peptide-conjugates regarding their cellular uptake mechanism, as well as cytotoxicity in αvβ3 integrin receptor expressing cells vs. cells that do not express αvβ3.  Our results show that the uptake follows a "kiss-and-run"-like model, in which the conjugates first target and recognize the receptor, but translocate mainly by CPP mediation.  Thereby, we obsd. significantly more pronounced toxic effects in αvβ3 expressing U87 cells compared to HT-29 and MCF-7 cells, when the cells were exposed to the substances with only very short contact times (15 min).  All in all, we present new concepts for the design of cancer selective peptide-drug conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo52geONXxf1rVg90H21EOLACvtfcHk0lg-nijDH3ATqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2lsLnL&md5=7fd7487362f162c12a84139697c35575</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.9b00292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.9b00292%26sid%3Dliteratum%253Aachs%26aulast%3DFeni%26aufirst%3DL.%26aulast%3DParente%26aufirst%3DS.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DGazzola%26aufirst%3DS.%26aulast%3DArosio%26aufirst%3DD.%26aulast%3DPiarulli%26aufirst%3DU.%26aulast%3DNeundorf%26aufirst%3DI.%26atitle%3DKiss%2520and%2520run%253A%2520promoting%2520effective%2520and%2520targeted%2520cellular%2520uptake%2520of%2520a%2520drug%2520delivery%2520vehicle%2520composed%2520of%2520an%2520integrin-targeting%2520diketopiperazine%2520peptidomimetic%2520and%2520a%2520cell-penetrating%2520peptide%26jtitle%3DBioconjugate%2520Chem.%26date%3D2019%26volume%3D30%26issue%3D7%26spage%3D2011%26epage%3D2022%26doi%3D10.1021%2Facs.bioconjchem.9b00292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, K. K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and photodynamic activities of integrin-targeting silicon(IV) phthalocyanine-cRGD conjugates</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.05.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2Fj.ejmech.2018.05.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=29852329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCrsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=24-33&author=B.+Y.+Zhengauthor=X.+Q.+Yangauthor=Y.+Zhaoauthor=Q.+F.+Zhengauthor=M.+R.+Keauthor=T.+Linauthor=R.+X.+Chenauthor=K.+K.+K.+Hoauthor=N.+Kumarauthor=J.+D.+Huang&title=Synthesis+and+photodynamic+activities+of+integrin-targeting+silicon%28IV%29+phthalocyanine-cRGD+conjugates&doi=10.1016%2Fj.ejmech.2018.05.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and photodynamic activities of integrin-targeting silicon(IV) phthalocyanine-cRGD conjugates</span></div><div class="casAuthors">Zheng, Bi-Yuan; Yang, Xiao-Qing; Zhao, Yang; Zheng, Qiao-Feng; Ke, Mei-Rong; Lin, Tao; Chen, Ren-Xun; Ho, Kitty K. K.; Kumar, Naresh; Huang, Jian-Dong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24-33</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel sym. or unsym. silicon (IV) phthalocyanines axially substituted with cyclic Arg-Gly-Asp (cRGD) ligands through different ethylene glycol chains have been synthesized by a facile and mild "click" reaction.  All the compds. show efficient photosensitizing activities in N,N-dimethylformamide, and are essentially non-aggregated in RPMI 1640 medium with 0.05% Cremophor EL.  Owing to the presence of two cRGD ligands, the conjugate 6b exhibits highest selectivity toward αvβ+3 HT-29 cells in photocytotoxicities.  It shows higher cellular uptake and ROS generation efficiency toward the αvβ+3 HT-29 cells compared with that of αvβ-3 MCF-7 cells.  The competitive cellular uptake and subcellular localization indicate that 6b is internalized mainly through integrin-mediated endocytosis.  In addn., the in vivo studies showed that 6b can mainly accumulate in tumor sites and show a significant PDT effect resulting in 75% tumor growth inhibition.  The results indicate that 6b is a highly promising photosensitizer for targeted photodynamic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_K805KgeYbVg90H21EOLACvtfcHk0lg-nijDH3ATqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCrsr7I&md5=864d71078705663a9f420b0b426ce86e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.05.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.05.039%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DB.%2BY.%26aulast%3DYang%26aufirst%3DX.%2BQ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DQ.%2BF.%26aulast%3DKe%26aufirst%3DM.%2BR.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DR.%2BX.%26aulast%3DHo%26aufirst%3DK.%2BK.%2BK.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DJ.%2BD.%26atitle%3DSynthesis%2520and%2520photodynamic%2520activities%2520of%2520integrin-targeting%2520silicon%2528IV%2529%2520phthalocyanine-cRGD%2520conjugates%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D24%26epage%3D33%26doi%3D10.1016%2Fj.ejmech.2018.05.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Polatuzumab vedotin: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1467</span>– <span class="NLM_lpage">1475</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01175-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1007%2Fs40265-019-01175-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31352604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BB3MvitVSmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1467-1475&issue=13&author=E.+D.+Deeks&title=Polatuzumab+vedotin%3A+first+global+approval&doi=10.1007%2Fs40265-019-01175-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Polatuzumab Vedotin: First Global Approval</span></div><div class="casAuthors">Deeks Emma D</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1467-1475</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polatuzumab vedotin (polatuzumab vedotin-piiq; Polivy®) is an antibody-drug conjugate comprising a monoclonal antibody against CD79b (a B cell receptor component) covalently conjugated to the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE) via a cleavable linker.  After binding to CD79b on the B-cell surface, polatuzumab vedotin is internalized and the linker is cleaved, releasing MMAE into the cell, where it inhibits division and induces apoptosis.  Polatuzumab vedotin is being developed by Genentech (a subsidiary of Roche) for the treatment of haematological malignancies.  In June 2019, the US FDA granted accelerated approval to polatuzumab vedotin, in combination with bendamustine plus rituximab, for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies.  Use of the compound in combination with bendamustine plus rituximab is also under regulatory review for relapsed/refractory DLBCL in the EU and is in ongoing phase 1b/2 development in this setting or relapsed/refractory follicular lymphoma (FL) in several countries.  Various other polatuzumab vedotin combination therapy regimens are also in phase 1b/2 development for relapsed/refractory non-Hodgkin lymphoma (NHL) [including DLBCL and FL] or in phase 2 or 3 development for previously untreated DLBCL, while polatuzumab vedotin monotherapy has been in phase 1 development for relapsed/refractory B-cell NHL in Japan.  This article summarizes the milestones in the development of polatuzumab vedotin leading to this first approval for its use in combination with bendamustine plus rituximab for relapsed/refractory DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWjRJKq7mXFhjv2lLSLOxFfW6udTcc2eYxcHpB-CVWUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvitVSmsA%253D%253D&md5=2aed4fe7658078144e9a1169ecf60e37</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01175-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01175-0%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DPolatuzumab%2520vedotin%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D13%26spage%3D1467%26epage%3D1475%26doi%3D10.1007%2Fs40265-019-01175-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balar, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galsky, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinelli, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melhem-Bertrandt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrylak, D. P.</span></span> <span> </span><span class="NLM_article-title">Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">2592</span>– <span class="NLM_lpage">2600</span>, <span class="refDoi"> DOI: 10.1200/JCO.19.01140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1200%2FJCO.19.01140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31356140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovVSitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=2592-2600&issue=29&author=J.+E.+Rosenbergauthor=P.+H.+O%E2%80%99Donnellauthor=A.+V.+Balarauthor=B.+A.+McGregorauthor=E.+I.+Heathauthor=E.+Y.+Yuauthor=M.+D.+Galskyauthor=N.+M.+Hahnauthor=E.+M.+Gartnerauthor=J.+M.+Pinelliauthor=S.+Y.+Liangauthor=A.+Melhem-Bertrandtauthor=D.+P.+Petrylak&title=Pivotal+trial+of+enfortumab+vedotin+in+urothelial+carcinoma+after+platinum+and+anti-programmed+death+1%2Fprogrammed+death+ligand+1+therapy&doi=10.1200%2FJCO.19.01140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy</span></div><div class="casAuthors">Rosenberg, Jonathan E.; O'Donnell, Peter H.; Balar, Arjun V.; McGregor, Bradley A.; Heath, Elisabeth I.; Yu, Evan Y.; Galsky, Matthew D.; Hahn, Noah M.; Gartner, Elaina M.; Pinelli, Juan M.; Liang, Shang-Ying; Melhem-Bertrandt, Amal; Petrylak, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">2592-2613</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">PURPOSE Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, esp. for patients who were previously treated with platinum and anti-programmed death 1 or anti-programmed death ligand 1 (PD-1/L1) therapy.  Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4, which is highly expressed in urothelial carcinoma.  METHODS EV-201 is a global, phase II, single-arm study of enfortumab vedotin 1.25mg/kg (i.v. on days 1, 8, and 15 of every 28-day cycle) in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum chemotherapy and anti-PD-1/L1 therapy.  The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review.  Key secondary end points were duration of response, progression-free survival, overall survival, safety, and tolerability.  RESULTS Enfortumab vedotin was administered to 125 patients with metastatic urothelial carcinoma.  Median follow-up was 10.2 mo (range, 0.5 to 16.5 mo).  Confirmed objective response rate was 44% (95% CI, 35.1% to 53.2%), including 12% complete responses.  Similar responses were obsd. in prespecified subgroups, such as those patients with liver metastases and those with no response to prior anti-PD-1/L1 therapy.  Median duration of response was 7.6 mo (range, 0.95 to 11.301 mo).  The most common treatment-related adverse events were fatigue (50%), any peripheral neuropathy (50%), alopecia (49%), any rash (48%), decreased appetite (44%), and dysgeusia (40%).  No single treatment-related adverse events grade 3 or greater occurred in 10% or more of patients.  CONCLUSION Enfortumab vedotin demonstrated a clin. meaningful response rate with a manageable and tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum and anti-PD-1/L1 therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSAj5iZGBZybVg90H21EOLACvtfcHk0lh4cpAPWjLRQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovVSitrc%253D&md5=01f8e50e459d254f0a687abc479da014</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1200%2FJCO.19.01140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.19.01140%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%2BH.%26aulast%3DBalar%26aufirst%3DA.%2BV.%26aulast%3DMcGregor%26aufirst%3DB.%2BA.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DYu%26aufirst%3DE.%2BY.%26aulast%3DGalsky%26aufirst%3DM.%2BD.%26aulast%3DHahn%26aufirst%3DN.%2BM.%26aulast%3DGartner%26aufirst%3DE.%2BM.%26aulast%3DPinelli%26aufirst%3DJ.%2BM.%26aulast%3DLiang%26aufirst%3DS.%2BY.%26aulast%3DMelhem-Bertrandt%26aufirst%3DA.%26aulast%3DPetrylak%26aufirst%3DD.%2BP.%26atitle%3DPivotal%2520trial%2520of%2520enfortumab%2520vedotin%2520in%2520urothelial%2520carcinoma%2520after%2520platinum%2520and%2520anti-programmed%2520death%25201%252Fprogrammed%2520death%2520ligand%25201%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26issue%3D29%26spage%3D2592%26epage%3D2600%26doi%3D10.1200%2FJCO.19.01140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redfern, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jikoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">816</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30097-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1016%2FS1470-2045%2819%2930097-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=31047803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC1MXoslWru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=816-826&issue=6&author=K.+Tamuraauthor=J.+Tsurutaniauthor=S.+Takahashiauthor=H.+Iwataauthor=I.+E.+Kropauthor=C.+Redfernauthor=Y.+Sagaraauthor=T.+Doiauthor=H.+Parkauthor=R.+K.+Murthyauthor=R.+A.+Redmanauthor=T.+Jikohauthor=C.+Leeauthor=M.+Sugiharaauthor=J.+Shahidiauthor=A.+Yverauthor=S.+Modi&title=Trastuzumab+deruxtecan+%28DS-8201a%29+in+patients+with+advanced+HER2-positive+breast+cancer+previously+treated+with+trastuzumab+emtansine%3A+a+dose-expansion%2C+phase+1+study&doi=10.1016%2FS1470-2045%2819%2930097-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study</span></div><div class="casAuthors">Tamura, Kenji; Tsurutani, Junji; Takahashi, Shunji; Iwata, Hiroji; Krop, Ian E.; Redfern, Charles; Sagara, Yasuaki; Doi, Toshihiko; Park, Haeseong; Murthy, Rashmi K.; Redman, Rebecca A.; Jikoh, Takahiro; Lee, Caleb; Sugihara, Masahiro; Shahidi, Javad; Yver, Antoine; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">816-826</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent topoisomerase I inhibitor payload.  A phase 1, non-randomised, open-label, multiple-dose study was done to assess the safety, tolerability, and activity of trastuzumab deruxtecan in HER2-expressing, advanced solid tumors.  The dose escalation (part 1) has previously been reported and the recommended doses for expansion of 5·4 mg/kg or 6·4 mg/kg were established.  In this Article, we report the safety and preliminary activity results from this phase 1 trial in all patients with HER2-pos. advanced-stage breast cancer with previous trastuzumab emtansine treatment who received trastuzumab deruxtecan at the recommended doses for expansion.  We did an open-label, dose-escalation and dose-expansion phase 1 trial at eight hospitals and clinics in the USA and six in Japan.  Eligible patients were at least 18 years old in the USA and at least 20 years of age in Japan and had advanced solid tumors (regardless of HER2 expression in dose escalation or HER2 expression or mutation in dose expansion).  The recommended doses for expansion of 5·4 mg/kg or 6·4 mg/kg trastuzumab deruxtecan were administered i.v. to patients once every 3 wk until withdrawal of consent, unacceptable toxicity, or progressive disease.  In this Article, all patients with HER2-pos. advanced-stage breast cancer with previous trastuzumab emtansine treatment who received trastuzumab deruxtecan at the recommended doses for expansion were analyzed together.  The primary endpoints of the study were safety and preliminary activity (proportion of patients who achieved an objective response as assessed by the investigators).  The activity evaluable set included all patients who received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion, and for whom both baseline and post-treatment activity data were available.  The safety anal. set included all patients who received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion.  Enrolment for patients with HER2-pos. breast cancer has been completed.  This trial is registered at ClinicalTrials.gov, no. NCT02564900, and ClinicalTrials.jp, no. JapicCTI-152978.  Between Aug 28, 2015, and Aug 10, 2018, 115 of 118 patients with HER2-pos. breast cancer were treated with at least one dose of trastuzumab deruxtecan at the recommended doses for expansion.  All patients had at least one treatment-emergent adverse event.  Frequent grade 3 or worse treatment-emergent adverse events included anemia (19 [17%] of 115) and decreased neutrophil (16 [14%]), white blood cell (ten [9%]), and platelet (nine [8%]) counts.  At least one serious treatment-emergent adverse event occurred for 22 (19%) patients.  Investigators reported 20 cases of interstitial lung disease, pneumonitis, or organizing pneumonia, including one grade 3 event and two treatment-related deaths due to pneumonitis.  One death unrelated to study treatment was due to progressive disease. 66 (59·5%; 95% CI 49·7-68·7) of 111 patients had a confirmed objective response.  Trastuzumab deruxtecan had a manageable safety profile and showed preliminary activity in trastuzumab emtansine-pretreated patients with HER2-pos. breast cancer.  These results suggest that further development in phase 2 and 3 clin. trials for HER2-pos. breast cancer is warranted.Daiichi Sankyo Co, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHxbpFWZOJ27Vg90H21EOLACvtfcHk0lhn0D_NKgzt-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXoslWru7w%253D&md5=6d0a54273d4c6cdf206c09be73722590</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930097-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930097-X%26sid%3Dliteratum%253Aachs%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DRedfern%26aufirst%3DC.%26aulast%3DSagara%26aufirst%3DY.%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DMurthy%26aufirst%3DR.%2BK.%26aulast%3DRedman%26aufirst%3DR.%2BA.%26aulast%3DJikoh%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DSugihara%26aufirst%3DM.%26aulast%3DShahidi%26aufirst%3DJ.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DTrastuzumab%2520deruxtecan%2520%2528DS-8201a%2529%2520in%2520patients%2520with%2520advanced%2520HER2-positive%2520breast%2520cancer%2520previously%2520treated%2520with%2520trastuzumab%2520emtansine%253A%2520a%2520dose-expansion%252C%2520phase%25201%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26issue%3D6%26spage%3D816%26epage%3D826%26doi%3D10.1016%2FS1470-2045%2819%2930097-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis
Phillips, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blattler, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwall, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenkare-Mitra, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9280</span>– <span class="NLM_lpage">9290</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=19010901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&issue=22&author=G.+D.+Lewis%0APhillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+Chariauthor=R.+J.+Lutzauthor=W.+L.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody-cytotoxic+drug+conjugate&doi=10.1158%2F0008-5472.CAN-08-1776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span></div><div class="casAuthors">Lewis Phillips, Gail D.; Li, Guangmin; Dugger, Debra L.; Crocker, Lisa M.; Parsons, Kathryn L.; Mai, Elaine; Blaettler, Walter A.; Lambert, John M.; Chari, Ravi V. J.; Lutz, Robert J.; Wong, Wai Lee T.; Jacobson, Frederic S.; Koeppen, Hartmut; Schwall, Ralph H.; Kenkare-Mitra, Sara R.; Spencer, Susan D.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9280-9290</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER2 is a validated target in breast cancer therapy.  Two drugs are currently approved for HER2-pos. breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007.  Despite these advances, some patients progress through therapy and succumb to their disease.  A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors.  We detd. in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymg. agents) conjugates using disulfide and thioether linkers.  Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells.  In vivo activity was detd. in mouse breast cancer models, and toxicity was assessed in rats as measured by body wt. loss.  Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.  Serum concns. of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker.  Potent activity was obsd. on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected.  In addn., trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors.  In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells.  Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpP5fkJnRorrVg90H21EOLACvtfcHk0ljVPgvGTOYUTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK&md5=e86e8687d5f8884f8e28514299dcbbf1</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody-cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D22%26spage%3D9280%26epage%3D9290%26doi%3D10.1158%2F0008-5472.CAN-08-1776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahdat, L. T.</span></span> <span> </span><span class="NLM_article-title">Sacituzumab govitecan: an antibody–drug conjugate</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1080/14712598.2017.1331214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.1080%2F14712598.2017.1331214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=28503956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVags7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=1027-1031&issue=8&author=S.+Sahotaauthor=L.+T.+Vahdat&title=Sacituzumab+govitecan%3A+an+antibody%E2%80%93drug+conjugate&doi=10.1080%2F14712598.2017.1331214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Sacituzumab govitecan: an antibody-drug conjugate</span></div><div class="casAuthors">Sahota, Sheena; Vahdat, Linda T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1027-1031</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Despite advances in the diagnosis and treatment of patients with cancer, patients with metastatic cancer have limited therapeutic options after initial lines of therapy.  Understanding tumor biol. has translated into the identification of actionable targets that resulted in therapeutics.  Antibody-drug conjugates (ADC) are capitalizing on this explosion of scientific information.  ADCs allow an antibody to a unique target to be conjugated via an innovative linker, to a highly toxic drug which is delivered to its target.  Sacituzumab govitecan is an ADC that combines the active mol. in irinotecan, SN-38, to an antibody targeting trop2.: In this review, the authors introduce the reader to the ADC sacituzumab govitecan providing the reader with details about its pharmacokinetics, pharmacodynamics, efficacy and safety.  The authors also give their expert anal. about its potential future use.: Sacituzumab govitecan is a novel and well-tolerated therapeutic showing promising results in difficult to treat cancers.  Further studies are underway to optimize the group of patients that would benefit from it.  Given its excellent performance, we are cautiously optimistic it will be approved by the FDA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4PTnZwxC9rVg90H21EOLACvtfcHk0lhdyVaB-bBj2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVags7s%253D&md5=e2a9aeb979d52eca095bd455aa73667b</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1080%2F14712598.2017.1331214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14712598.2017.1331214%26sid%3Dliteratum%253Aachs%26aulast%3DSahota%26aufirst%3DS.%26aulast%3DVahdat%26aufirst%3DL.%2BT.%26atitle%3DSacituzumab%2520govitecan%253A%2520an%2520antibody%25E2%2580%2593drug%2520conjugate%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2017%26volume%3D17%26issue%3D8%26spage%3D1027%26epage%3D1031%26doi%3D10.1080%2F14712598.2017.1331214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span> <span> </span><span class="NLM_article-title">Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody–drug conjugate (ADC)</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">22496</span>– <span class="NLM_lpage">22512</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=10.18632%2Foncotarget.4318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=26101915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;key=1%3ACAS%3A280%3ADC%252BC2MbmtVarsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=22496-22512&issue=26&author=D.+M.+Goldenbergauthor=T.+M.+Cardilloauthor=S.+V.+Govindanauthor=E.+A.+Rossiauthor=R.+M.+Sharkey&title=Trop-2+is+a+novel+target+for+solid+cancer+therapy+with+sacituzumab+govitecan+%28IMMU-132%29%2C+an+antibody%E2%80%93drug+conjugate+%28ADC%29&doi=10.18632%2Foncotarget.4318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)</span></div><div class="casAuthors">Goldenberg David M; Cardillo Thomas M; Govindan Serengulam V; Rossi Edmund A; Sharkey Robert M</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">22496-512</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers.  The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody.  In vitro and in vivo studies show enhanced efficacy, while there is a gradual release of SN-38 that contributes to the overall effect.  IMMU-132 is most efficacious at a high drug:antibody ratio (DAR) of 7.6:1, which does not affect binding and pharmacokinetics.  It targets up to 136-fold more SN-38 to a human cancer xenograft than irinotecan, SN-38's prodrug.  IMMU-132 delivers SN-38 in its most active, non-glucuronidated form, which may explain the lower frequency of severe diarrhea than with irinotecan.  Thus, this ADC, carrying a moderately-toxic drug targeting Trop-2 represents a novel cancer therapeutic that is showing promising activity in patients with several metastatic cancer types, including triple-negative breast cancer, non-small-cell and small-cell lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_AS8-S1EVm3RxY89Cm6SyfW6udTcc2ebuxivuMV0gerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbmtVarsA%253D%253D&md5=df2f5d058386096fad912f53659cb15c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4318%26sid%3Dliteratum%253Aachs%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DCardillo%26aufirst%3DT.%2BM.%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DRossi%26aufirst%3DE.%2BA.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26atitle%3DTrop-2%2520is%2520a%2520novel%2520target%2520for%2520solid%2520cancer%2520therapy%2520with%2520sacituzumab%2520govitecan%2520%2528IMMU-132%2529%252C%2520an%2520antibody%25E2%2580%2593drug%2520conjugate%2520%2528ADC%2529%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D26%26spage%3D22496%26epage%3D22512%26doi%3D10.18632%2Foncotarget.4318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01530&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01530%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-1%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01530" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991d629e773bf2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
